<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet xmlns="http://www.openarchives.org/OAI/2.0/">
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pseudohypoxia induced by iron chelators preserves working memory performance in aged mice</ArticleTitle>
    <FirstPage LZero="delete">11550</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Iwasaki</LastName>
        <Affiliation>Health Service Section, Environment Health &amp; Safety Intelligence Department, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonari</FirstName>
        <LastName>Kasai</LastName>
        <Affiliation>Department of Applied Energy, Graduate School of Engineering, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiho</FirstName>
        <LastName>Komaki</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pseudohypoxia refers to a physiological condition wherein hypoxia-inducible factor (HIF) is pharmacologically upregulated under normoxia, thereby modulating immune responses. We hypothesized that pseudohypoxia, induced by iron chelators, may similarly potentiate systemic immune responses in aged mice, concurrently triggering neuro-regenerative signaling pathways and enhancing cognitive performance. In this study, aged mice (43–48 weeks old) were orally administered two iron chelators, Super Polyphenol 10 (SP10) or Roxadustat, to induce a pseudohypoxia. An 8-week oral regimen of SP10 and Roxadustat significantly preserved working memory, as assessed by the Y-maze test (YMT). White blood cell counts and hippocampal volume, as assessed by magnetic resonance imaging (MRI), were elevated in the treatment groups relative to controls. Pseudohypoxia induced by SP10 tended to enhance neuro-regenerative signaling, specifically involving the Tau and JNK pathways, and potentially modulated Doublecortin (DCX) expression, although statistical significance was limited by sample size. Importantly, inflammatory markers, such as ionized calcium-binding adapter molecule 1 (Iba1) and glial fibrillary acidic protein (GFAP), were not elevated by treatment. Collectively, these findings suggest that pseudohypoxia induced by iron chelators preserves working memory performance accompanied by leukocytosis, without concomitant neuroinflammation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Hypoxia-inducible factor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Working memory</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hippocampus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Iron</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>27</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Aerobic Exercise Attenuates Epidermal Hyperplasia in an Obesity-Associated Psoriasiform Dermatitis Model</ArticleTitle>
    <FirstPage LZero="delete">2308</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daiki</FirstName>
        <LastName>Takezaki</LastName>
        <Affiliation>Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuma</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Immunology and Molecular Genetics, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuyasu</FirstName>
        <LastName>Baba</LastName>
        <Affiliation>Department of Immunology and Molecular Genetics, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Iseki</LastName>
        <Affiliation>Department of Immunology and Molecular Genetics, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Kawakami</LastName>
        <Affiliation>Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Shiomi</LastName>
        <Affiliation>Department of Pathology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Mukai</LastName>
        <Affiliation>Department of Immunology and Molecular Genetics, Kawasaki Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Obesity is an important risk factor for psoriasis, and clinical studies indicate that exercise interventions can improve disease severity. However, the mechanisms by which exercise influences psoriatic pathogenesis remain insufficiently understood. To investigate the effects of aerobic exercise on obesity-associated psoriasis, wild-type mice were fed a high-fat diet (HFD) for 7 weeks to induce obesity and subsequently underwent moderate-intensity treadmill running for 3 weeks. Psoriasiform dermatitis was induced by daily topical application of imiquimod (IMQ) to the skin for five consecutive days. HFD increased body weight, epididymal fat mass, and serum cholesterol. HFD-fed mice developed more severe IMQ-induced psoriatic skin changes compared with normal diet-fed mice. Treadmill exercise modestly reduced body weight gain and attenuated epidermal hyperplasia in HFD-fed mice. In contrast, inflammatory cytokine expression, including Tnfa, Il17a, and Il23a, showed modest increases in the skin of HFD-fed exercised mice, which did not parallel the improvement in epidermal hyperplasia. Overall, these findings indicate that while obesity exacerbates psoriasiform dermatitis, aerobic exercise ameliorates epidermal hyperplasia in obese mice without corresponding changes in inflammatory cytokine expression in the skin, suggesting that exercise may influence psoriatic skin changes through multiple metabolic and immunological pathways.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">psoriasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">obesity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aerobic exercise</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">imiquimod</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">high-fat diet</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Pharmaceutical Society of Japan</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-6158</Issn>
      <Volume>49</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Functional Transport Properties of Human Zinc Transporter 1: Kinetics and pH-Dependency</ArticleTitle>
    <FirstPage LZero="delete">364</FirstPage>
    <LastPage>370</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuma</FirstName>
        <LastName>Yoshioka</LastName>
        <Affiliation>Department of Molecular Membrane Biology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaaki</FirstName>
        <LastName>Miyaji</LastName>
        <Affiliation>Department of Molecular Membrane Biology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Intracellular zinc (Zn2+) homeostasis is essential for physiological and pathological processes and is strictly regulated by Zn2+ transporters. Zinc transporter 1 (ZnT1) is a ubiquitously expressed plasma membrane-localized Zn transporter that exports Zn2+ from the cytoplasm to the extracellular space. However, the functional transport properties regarding kinetics and driving forces of ZnT1 remain debatable. In this study, we established a cell-free proteoliposome assay system and demonstrated that ZnT1 transports Zn2+ with high affinity in pH-dependent and pH-independent manners. The Km and Vmax of pH-dependent Zn2+ transport were 0.40 μM and 15.13 nmol/min/mg protein, and those of pH-independent Zn2+ transport were 0.52 μM and 8.88 nmol/min/mg protein (low concentrations of Zn2+), 3.02 μM and 17.59 nmol/min/mg protein (high concentrations of Zn2+), respectively, suggesting biphasic kinetic components of Zn2+ transport. Even without pH gradient formation, ZnT1 exhibits potent Zn2+ transport activity. In pH dependency, Zn2+ transport activity was higher at an inside pH of 6.0 than at 6.5–7.5 for proteoliposomes, despite the same ΔpH of 0.5–1.5. The Zn2+ transport activity decreased at an outside pH of 8.0, despite an increase in ΔpH. Although previous studies have proposed that ZnT1-mediated Zn2+ transport activity is driven by a calcium (Ca2+) gradient and not by a pH gradient, Ca2+ does not enhance Zn2+ transport activity in the presence or absence of a pH gradient. These results strongly suggest that ZnT1 protein transports Zn2+ optimally at a specific pH and exports excess intracellular Zn2+ even without ΔpH.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">zinc transporter 1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SLC30A1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">zinc</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pH</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">proteoliposome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>27</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>CXCR2-Dependent Infiltration of Tumor-Associated Neutrophils Is Linked to Enhanced CD8+ T Cell Effector Function and Reduced Lung Metastasis in 4T1 Breast Cancer</ArticleTitle>
    <FirstPage LZero="delete">3143</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tiantian</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teizo</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miao</FirstName>
        <LastName>Tian</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gakushi</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chunning</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Triple-negative breast cancer (TNBC) is characterized by prominent neutrophil infiltration; however, its significance remains controversial. Here, we investigated the role of neutrophil chemoattractant receptors in TNBC progression and metastasis. In contrast to wild-type (WT), Fpr1−/−, and Fpr2−/− mice, neutrophils were almost completely absent in 4T1 tumors from Cxcr2−/− mice, indicating a dominant role for CXCR2 in the recruitment of tumor-associated neutrophils, leading us to use Cxcr2−/− mice for further studies. Primary tumor growth was comparable between WT and Cxcr2−/− mice, whereas lung metastasis was significantly increased in Cxcr2−/− mice, with reduced expression of inflammatory cytokines, chemokines and cytotoxic molecules, including granzyme B and perforin, in primary tumors and metastatic lungs of Cxcr2−/− mice. In vitro, WT, but not Cxcr2−/−, neutrophils enhanced CD8+ T cell activation, partly via ICAM-1, and directly induced tumor cell death, supporting their anti-tumor function. To assess clinical relevance, transcriptomic data were analyzed. High neutrophil infiltration combined with elevated CXCR2 expression, and to a lesser extent CXCR1 expression, was associated with improved prognosis in patients with basal-like BC that largely overlaps with TNBC. Collectively, these findings suggest that CXCR2-mediated neutrophil recruitment exerts protective, anti-tumor effects and may represent a new prognostic marker for TNBC patients.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">breast cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neutrophils</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CD8+ T cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chemokines</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chemokine receptors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor microenvironment</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0309-0167</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinicopathological and transcriptomic profiles of 101 patients with diffuse large B-cell lymphoma/high-grade B-cell lymphoma with double-hit MYC and BCL2 or BCL6 and triple hit</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Miyaoka</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joaquim</FirstName>
        <LastName>Carreras</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yara Yukie</FirstName>
        <LastName>Kikuti</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruka</FirstName>
        <LastName>Ikoma</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Nagase</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Pathology, School of Medicine Tokai University  Isehara Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Orita</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Hematology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rika</FirstName>
        <LastName>Sakai</LastName>
        <Affiliation>Department of Medical Oncology, Kanagawa Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuharu</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Midori Filiz</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Tsukasaki</LastName>
        <Affiliation>Department of Hematology, International Medical Center, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuji</FirstName>
        <LastName>Momose</LastName>
        <Affiliation>Department of Pathology, Saitama Medical Center, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Kameoka</LastName>
        <Affiliation>Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Hematology, Osaka City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Satou</LastName>
        <Affiliation>Department of Surgical Pathology, Aichi Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiichi</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Center for Clinical Pathology, Fujita Health University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Oishi</LastName>
        <Affiliation>Department of Pathology, University of Yamanashi</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akio</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Hematology, NHO Shibukawa Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Division of Hematology, Kawasaki Municipal Kawasaki Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Masugi</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aims: Diffuse large B-cell lymphoma/high-grade B-cell lymphoma (DLBCL/HGBCL) with MYC and BCL2 rearrangements (double-hit lymphoma with BCL2, DHL-BCL2) is a mature aggressive B-cell lymphoma that also includes concurrent triple hit with BCL6 translocation (TH). DHL with MYC and BCL6 (DH-BCL6) can also occur. The differences among these three DLBCL/HGBCL subtypes have not yet been definitively determined.&lt;br&gt;
Methods and Results: This study characterized the clinicopathological features and transcriptomic profiles of a series of 101 cases of DLBCL/HGBCL that were subclassified according to MYC, BCL2 and BCL6 FISH data, including cell-of-origin (COO)-like, molecular high-grade (MHG)-like and double-hit/dark-zone (DHIT/DZsig)-like signatures. DLBCL/HGBCL-DH-BCL2 was characterized by higher HGBCL morphology, CD10 positivity, GCB Hans's, GCB COO and MHG molecular subtype. DLBCL/HGBCL-TH had higher LDH levels and worse overall survival. DLBCL/HGBCL-DH-BCL6 had higher MUM1 expression, non-GCB Hans', ABC/Unclassified COO, non-MHG and low DHIT/DZ signatures. Transcriptomic analysis showed that DLBCL/HGBCL-DH-BCL2 and DLBCL/HGBCL-TH were close but separated from DLBCL/HGBCL-DH-BCL6. Gene set enrichment analysis (GSEA) revealed different levels of enrichment between the subtypes.&lt;br&gt;
Conclusions: DLBCL/HGBCL-DH-BCL6 differs from the DLBCL/HGBCL-DH-BCL2, and the DLBCL/HGBCL-TH is associated with the worst survival. Analysis of all three genes of MYC, BCL2 and BCL6 is recommended in the context of DLBCL/HGBCL diagnosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">BCL2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">BCL6</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">high-grade B-cell lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">molecular profile</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MYC</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rearrangements</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2688-4046</Issn>
      <Volume>6</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>PPy‐Coated Wire Actuators for the Micromechanostimulation of Cells: Fabrication and Characterization</ArticleTitle>
    <FirstPage LZero="delete">e202500639</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Amaia B.</FirstName>
        <LastName>Ortega‐Santos</LastName>
        <Affiliation>Sensor and Actuator Systems, Department of Physics Chemistry and Biology (IFM), Linköping University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Hayano</LastName>
        <Affiliation>Department of Orthodontics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emilio Satoshi</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Advanced Research Center for Oral and Craniofacial Sciences Dental School, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jose G.</FirstName>
        <LastName>Martínez</LastName>
        <Affiliation>Sensor and Actuator Systems, Department of Physics Chemistry and Biology (IFM), Linköping University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kamioka</LastName>
        <Affiliation>Department of Orthodontics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Edwin W. H.</FirstName>
        <LastName>Jager</LastName>
        <Affiliation>Sensor and Actuator Systems, Department of Physics Chemistry and Biology (IFM), Linköping University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cellular mechanotransduction signals play a crucial role in physiological and pathological conditions, including skeletal disorders. Although various systems exist to mechanically stimulate cultured cells, most are constrained by incubator incompatibility, limited physiological relevance, nonuniform stimulation, or complexity. The objective of this article is to develop and validate a compact, incubator-compatible tool capable of delivering localized and physiologically relevant mechanical stimulation to small cell populations. Here, we introduce a polypyrrole-based wire-shaped microactuator designed to induce localized mechanical stress to adjacent cells. These wire-shaped microactuators are biocompatible, easy-to-use, and compact for use within standard in vitro cell culture systems. Using a noncontact optical method, we characterize the actuation of polypyrrole-coated wires in an aqueous NaDBS electrolyte, showing radial expansion of 1.5–8 µm depending on the deposited polypyrrole film thickness, comparable to cellular dimensions. Next, the actuation is confirmed to be robust and stable to use in cell culture media at physiological temperature. To evaluate biological relevance, osteoblastic KUSA-A1 cells are mechanically stimulated inside the incubator and transcriptomic changes are assessed. Mechanical stimulation resulted in upregulation of genes previously associated with mechanotransduction, including Fos and Fosb. Additionally, several uncharacterized long noncoding RNAs are differentially expressed, suggesting potential novel players in the mechanotransduction pathway.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">conducting polymers</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mechanotransduction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">osteoblasts</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">polypyrrole</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">RNA sequencing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">soft-microactuators</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0923-1811</Issn>
      <Volume>119</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Big data-driven target identification by machine learning: DRD2 as a therapeutic target for psoriasis</ArticleTitle>
    <FirstPage LZero="delete">9</FirstPage>
    <LastPage>17</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Sakai</LastName>
        <Affiliation>Department of Dermatology, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryusuke</FirstName>
        <LastName>Sawada</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Otoha</FirstName>
        <LastName>Ichinose</LastName>
        <Affiliation>Department of Bioscience and Bioinformatics, Faculty of Computer Science and Systems Engineering, Kyushu Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Terabayashi</LastName>
        <Affiliation>Department of Pharmacology, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaka</FirstName>
        <LastName>Hatano</LastName>
        <Affiliation>Department of Dermatology, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Yamanishi</LastName>
        <Affiliation>Department of Complex Systems Science, Graduate School of Informatics, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshimasa</FirstName>
        <LastName>Ishizaki</LastName>
        <Affiliation>Department of Pharmacology, Faculty of Medicine, Oita University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: The development of medical treatments has traditionally relied on researchers leveraging scientific knowledge to hypothesize disease mechanisms and identify therapeutic agents. However, the depletion of novel therapeutic targets has become a significant challenge, resulting in stagnation within pharmaceutical research.&lt;br&gt;
Objective: To address the scarcity of therapeutic targets, we developed a machine learning (ML)-based system capable of predicting therapeutic target molecules for diseases. To validate its utility, we applied this system to psoriasis, aiming to identify novel treatment strategies.&lt;br&gt;
Methods: Our approach utilized a large clinical database to calculate reporting odds ratios for all drugs associated with the prevention of diseases of interest. We identified target proteins by analyzing large chemical structure databases to discover proteins commonly associated with preventive drug candidates. Experimental validation was conducted by administering a predicted therapeutic candidate in an imiquimod-induced psoriasis mouse model.&lt;br&gt;
Results: The ML-based predictions identified drugs for Parkinson’s disease as potential preventive candidates for psoriasis. Further analysis highlighted dopamine receptor D2 (DRD2) as a therapeutic target. Administration of a DRD2 agonist alleviated psoriasis symptoms in mice, evidenced by the downregulation of mRNA expression in the IL-17 pathway and reduced serum tumor necrosis factor-α levels.&lt;br&gt;
Conclusion: This study demonstrates the utility of a novel ML-based system for identifying therapeutic targets, as shown by its successful application in uncovering the role of DRD2 in psoriasis. Beyond psoriasis, this system offers significant potential for exploring pathological mechanisms and discovering therapeutic targets across various diseases.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">artificial intelligence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">big data</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">machine learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dopamine receptor D2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psoriasis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2398-8835</Issn>
      <Volume>9</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of Overload on Imiquimod‐Induced Psoriasis Model Mice: A Basic Experimental Study</ArticleTitle>
    <FirstPage LZero="delete">e72040</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomoki</FirstName>
        <LastName>Furutani</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry, and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asahi</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Okayama University Medical School Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Mashima</LastName>
        <Affiliation>Okayama University Medical School Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsumi</FirstName>
        <LastName>Yukihiro</LastName>
        <Affiliation>Okayama University Medical School Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoki</FirstName>
        <LastName>Kusakabe</LastName>
        <Affiliation>Okayama University Medical School Faculty of Medicine Okayama Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Nakamichi</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aki</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Locomotive Pain Center, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Aim: Psoriasis is a skin disorder complicated by arthritis and enthesitis. The cytokines interleukin (IL)-17, IL-23, and tumor necrosis factor (TNF)-α are reportedly key effectors of psoriasis. Additionally, gamma delta (γδ) T cells exacerbate inflammation by producing inflammatory cytokines such as IL-17 and TNF-α. However, details regarding the mechanisms linking pathogenesis and mechanical stress remain unclear. This study aimed to investigate the effect of strenuous exercise on the pathology of psoriasis using mouse models of imiquimod (IMQ)-induced psoriasis.&lt;br&gt;
Methods: Twenty mice were randomly assigned to four groups: IMQ − TRED− (control), IMQ − TRED+ (treadmill running mice), IMQ + TRED− group (IMQ treated mice), and IMQ + TRED+ group (IMQ treated and treadmill running mice). The tissue sections from back skin and thymus were immunostained with antibodies against IL-17, IL-23, and γδ T cells. Shoulder sections were stained using hematoxylin and eosin, and Toluidine Blue and Picrosirius Red. Additionally, the shoulder tissue sections were immunostained with antibodies against TNF-α and matrix metalloproteinase (MMP)-13. Serum cytokine level was measured to evaluate systemic inflammation.&lt;br&gt;
Results: Strenuous exercise exacerbated pathological changes associated with psoriasis, including increased γδ T cell infiltration and upregulated IL-17 and IL-23 expression in the skin, as well as enhanced γδ T cell development and IL-17 expression in the thymus. Although strenuous exercise did not further worsen the modified PASI scores, histological and immunological markers of inflammation were significantly enhanced. Serum levels of TNF-α and IL-17 were significantly elevated in IMQ-induced psoriasis model mice. Moreover, pathological changes induced by strenuous exercise were observed in the enthesis, including angiogenesis and upregulated expression of TNF-α and MMP-13.&lt;br&gt;
Conclusion: This study revealed that strenuous exercise exacerbates pathological changes in IMQ-induced psoriasis model mice.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">enthesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psoriasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">strenuous exercise</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2666-6065</Issn>
      <Volume>67</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Alcohol consumption, smoking, and the implications of their cessations for field carcinogenesis in the esophagus: a 10-year prospective cohort study</ArticleTitle>
    <FirstPage LZero="delete">101798</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Chikatoshi</FirstName>
        <LastName>Katada</LastName>
        <Affiliation>Department of Medical Oncology, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuji</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Health Promotion, National Institute of Public Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonori</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuaki</FirstName>
        <LastName>Furue</LastName>
        <Affiliation>Department of Endoscopy, Saitama Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhisa</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Ishido</LastName>
        <Affiliation>Department of Gastroenterology, Kitasato University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Division of Endoscopy, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyoshi</FirstName>
        <LastName>Nakanishi</LastName>
        <Affiliation>Department of Gastroenterology, Ishikawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Koike</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Tamaoki</LastName>
        <Affiliation>Department of Medical Oncology, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noboru</FirstName>
        <LastName>Kawata</LastName>
        <Affiliation>Division of Endoscopy, Shizuoka Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Hirao</LastName>
        <Affiliation>Department of Surgery, NHO Osaka National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiro</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Ogata</LastName>
        <Affiliation>Department of Gastrointestinal Surgery, Kanagawa Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Katagiri</LastName>
        <Affiliation>Division of Gastroenterology, Department of Medicine, Showa Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takenori</FirstName>
        <LastName>Yamanouchi</LastName>
        <Affiliation>Department of Gastroenterology, Kumamoto Regional Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Kiyokawa</LastName>
        <Affiliation>Department of Gastroenterology, St. Marianna University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Kawakubo</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maki</FirstName>
        <LastName>Konno</LastName>
        <Affiliation>Department of Gastroenterology, Tochigi Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Medical Oncology, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Medical Oncology, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tai</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Surgery, Kawasaki Municipal Kawasaki Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadakazu</FirstName>
        <LastName>Shimoda</LastName>
        <Affiliation>Department of Diagnostic Pathology, Shizuoka Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Ochiai</LastName>
        <Affiliation>Exploratory Oncology Research and Clinicai Trial Center, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Molecular-Targeting Prevention, Kyoto Prefectural University of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Clinical Research Unit, National Hospital Organization Kurihama Medical and Addiction Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Muto</LastName>
        <Affiliation>Department of Medical Oncology, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Alcohol and tobacco are established carcinogens, which promote field carcinogenesis for esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the long-term effects of alcohol and tobacco cessations, and background mucosal status, on risk for metachronous ESCC (mESCC) after endoscopic resection (ER).&lt;br&gt;
Methods This was a multicentre prospective cohort study of patients with intramucosal ESCC treated by ER. All participants received structured education on cessation, and underwent regular endoscopic surveillance. Patients were stratified by Lugol-voiding lesion (LVL) grade (A: none, B: 1–9, C: ≥10). The impacts of alcohol and smoking cessation on field carcinogenesis were assessed.&lt;br&gt;
Findings Among 331 enrolled patients, the median follow-up was 120 months (range: 1.3–176.9). The cumulative incidences of mESCC were 10.4%, 27.2%, and 61.8% in grades A, B, and C, respectively. An increment of 1 unit (22 g ethanol) of alcohol consumption and higher LVL grade independently increased the risk for mESCC. Alcohol or smoking cessation reduced this risk (hazard ratio [HR] 0.52, 95% confidence interval [CI]: 0.31–0.88; HR 0.44, 95% CI: 0.25–0.78, respectively), and combined cessation had the greatest impact (HR 0.21, 95% CI: 0.07–0.65). Complete cessation, rather than partial reduction, was necessary to achieve meaningful risk reduction.&lt;br&gt;
Interpretation Alcohol and tobacco exposure, and a large number of LVL, are major determinants of mESCC. Complete cessation markedly reduces risk, underscoring the importance of behavioural interventions for secondary prevention of field carcinogenesis after ER.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Esophageal squamous cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Field carcinogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metachronous cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Alcohol</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tobacco</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lugol-voiding lesion</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1478-811X</Issn>
      <Volume>24</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>MMP-3 cleavage of Lamin A induces pro-migratory nuclear deformity, nucleophagy, and their autophagic secretion with extracellular vesicles in metastatic cancer</ArticleTitle>
    <FirstPage LZero="delete">146</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Eguchi</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eman A.</FirstName>
        <LastName>Taha</LastName>
        <Affiliation>Department of Biochemistry, Faculty of Science, Ain Shams University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vikas</FirstName>
        <LastName>Tiwari</LastName>
        <Affiliation>Council of Scientific &amp; Industrial Research-Indian Institute of Toxicological Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuki</FirstName>
        <LastName>Takebe</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lizi</FirstName>
        <LastName>Xing</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiharu</FirstName>
        <LastName>Sogawa</LastName>
        <Affiliation>Department of Food and Health Sciences, Faculty of Environmental Studies, Hiroshima Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kuniaki</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Stuart K.</FirstName>
        <LastName>Calderwood</LastName>
        <Affiliation>Division of Molecular and Cellular Biology, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases that cleave a plethora of substrates, including components of the extracellular matrix and cell-surface-associated proteins, as well as intracellular targets. MMPs have also been found in extracellular vesicles (EVs), such as exosomes. MMP-3 promotes tumor growth, epithelial-to-mesenchymal transition, genome instability, migration, invasion, and metastasis of cancer cells, and nuclear MMP-3 controls gene transcription. Intranuclear proteolysis by MMPs may significantly alter cancer progression. However, the nuclear substrates of MMP-3 have not been well investigated. In this study, we performed proteomic analyses to identify the nuclear substrates and EV proteins regulated by MMP-3. While rabidly metastatic colon cancer (LuM1) three-dimensionally cultured tumoroids secreted EVs containing 30 protein types, including Lamin A (LMNA), MMP-3, fibronectin (FN1), HSPA8 (Hsc70), β-actin (ACTB), and vimentin (VIM), CRISPR/Cas9-based knockout of MMP-3 reduced the secretion of these proteins in EVs. Notably, EV-bound cleaved Lamin secretion was confirmed by immunoelectron microscopy. Also, MMP-3 formed proteolytic dimers via its hemopexin-like repeat domains in nuclei. Many nuclear MMP-3-binding proteins, including Lamin A/C, histones, topoisomerases, and hnRNPs, were screened by co-immunoprecipitation followed by proteomics. Proteolytic MMP-3 overexpression generated a C-terminal 30-kDa fragment of Lamin A, whose cleavage site was defined via structural analysis. MMP-3 digestion of Lamin A induced nuclear deformity (atypia) required for cell migration in confined space. The cleaved Lamin A and MMP-3 were transported with autophagosomes (LC3B+), nucleophagosomes, and amphisomes (CD63 + LC3B+) and co-secreted with EVs. Proteolytic MMP-3 also induced nuclear speckles of Lamin A, suggesting their roles in transcription and splicing. Clinical analysis revealed that high expressions of MMP3 and LMNA were significantly seen in head and neck squamous cell carcinoma (HNSC) than in the other 16 cancer types, and predicted poor prognosis of patients suffering from HNSC, pancreatic, rectum and lung adenocarcinomas at specific stages. Immunohistochemistry revealed that nuclear MMP-3 and cleaved Lamin were significantly higher expressed in stage IV metastatic HNSC cases than in stage I non-metastatic cases. Taken together, MMP3-cleavage of Lamin A induces nuclear deformity, nucleophagy, and their autophagic co-secretion with EVs in metastatic cancer. Also, high expression of MMP-3 and secretion of Lamin A can predict poor prognosis in multiple cancer types at specific stages.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Lamin A (LMNA)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Matrix metalloprotease (MMP)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proteolysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Extracellular vesicle (EV)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Exosome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Autophagy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Amphisome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proteome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nuclear deformity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Migration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metastatic cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Head and neck squamous cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Colorectal cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>JMIR Publications Inc.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2369-3762</Issn>
      <Volume>12</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prescription Support Practice for Pharmacy Students: Pre-Post Educational Intervention Study</ArticleTitle>
    <FirstPage LZero="delete">e79545</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fuka</FirstName>
        <LastName>Aizawa</LastName>
        <Affiliation>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Yagi</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Higashionna</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shimon</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuaki</FirstName>
        <LastName>Shinomiya</LastName>
        <Affiliation>Department of Pharmaceutical Care and Clinical Pharmacy, Tokushima Bunri University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Niimura</LastName>
        <Affiliation>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuhiro</FirstName>
        <LastName>Goda</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Ishizawa</LastName>
        <Affiliation>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: In the field of team-based care, pharmacists are vital for optimizing medication therapy. However, many medical professionals lack the opportunity to learn how to propose prescription changes with precision.&lt;br&gt;
Objective: This study aimed to address this knowledge gap by developing and assessing a new educational program for pharmacy students focused on prescription support and interprofessional collaboration.&lt;br&gt;
Methods: We recruited 191 fifth-year pharmaceutical students during the 2022‐2024 academic years. The program featured a 7-day intensive curriculum that included learning how to assist with prescriptions, analyzing clinical data, and engaging in role-playing exercises. A web-based questionnaire and a paper test were used to evaluate students’ awareness and knowledge both before and after the program. Statistical analyses were performed to verify the significance of changes; we utilized the Wilcoxon signed-rank test for the ordinal data derived from the specific behavioral objectives and 2-tailed paired t tests for the interval data from the knowledge tests. The magnitude of change was quantified using r for Wilcoxon tests and Cohen dz for 2-tailed t tests, with 95% CI calculated to ensure the stability and reliability of the observed results.&lt;br&gt;
Results: Analysis of the primary outcome specific behavioral objectives revealed statistically significant effects across all items (Wilcoxon signed-rank test; P&lt;.001). Effect sizes (r=0.505‐0.835) ranged from moderate to large, with particularly large effects observed in identifying contents issue (r=0.835, 95% CI 0.126-0.330; P&lt;.001). Knowledge test scores showed significant improvement in the following 3 subjects: pharmacology (r=−0.504, 95% CI –0.215 to 0.127; P&lt;.001), organic chemistry (r=0.254, 95% CI –0.148 to –0.193; P=.004), and communication (r=0.221, 95% CI –0.151 to –0.190; P=.01). No significant changes were observed in pathology or pharmacokinetics.&lt;br&gt;
Conclusions: This program provides strong evidence that practical, hands-on learning with hospital pharmacists helps improve pharmacy students’ professional skills and optimize pharmaceutical therapies in interprofessional care. By teaching pharmacists to effectively propose prescription changes, the program equips them to become integral members of interprofessional care, ultimately leading to optimized pharmaceutical care for patients.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">academic detailing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pharmaceutical clinical practice</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prescription support</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">professional education</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Interprofessional care</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1462-8910</Issn>
      <Volume>27</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>D3 lymph node dissection in colon cancer patients aged 90 years and over: Is it justified? A multi‐institutional retrospective study</ArticleTitle>
    <FirstPage LZero="delete">e70269</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoe</FirstName>
        <LastName>Takanaga</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Inada</LastName>
        <Affiliation>Department of Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Toshima</LastName>
        <Affiliation>Department of Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Ohtani</LastName>
        <Affiliation>Department of Surgery, Saiseikai Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Setouchi Colorectal Neoplasm Registration study group collaborators</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aim: The oncological benefit of D3 lymph node dissection (D3 LND) for colon cancer in patients aged ≥90 years remains unclear. This study aimed to evaluate the impact of D3 LND on outcomes in this specific, vulnerable population.&lt;br&gt;
Method: This retrospective cohort study evaluated 166 patients aged ≥90 years with pathological Stages II–III colon cancer undergoing non-D3 or D3 LND from a multicentre database (2011–2022). Postoperative complications, overall survival and cancer-specific survival were compared between LND groups using propensity score-weighted analyses.&lt;br&gt;
Results: D3 LND group had significantly more females and laparoscopic procedures. Operation time was longer, and blood loss was lower in the D3 LND group. Postoperative complications and severe complications were significantly fewer, and postoperative hospital stay was shorter in the D3 LND group. The number of harvested lymph nodes and distal margin was significantly higher in the D3 group. While unadjusted analysis showed better overall survival with D3 LND (p &lt; 0.001), adjusted cancer-specific survival showed no significant difference (p = 0.10). Adjusted mortality risk was significantly higher in the non-D3 group (p = 0.001).&lt;br&gt;
Conclusion: In nonagenarian colon cancer patients, D3 LND is safe and feasible without increasing complications, but lacks survival benefit. Careful consideration is warranted, and high-quality D2 LND must be consistently ensured when limited surgery is chosen.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">colon cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lymph node dissection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nonagenarian</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">postoperative complication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">survival benefit</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Severe Anemia Caused by a Colorectal Lipoma With Central Erosions: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e85768</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ko</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Colorectal lipomas are benign tumors that are often asymptomatic and discovered incidentally. In most cases, they can be managed conservatively with observation. We report the case of a man in his 70s with a colorectal lipoma located in the cecum. An investigation into his severe anemia led to the suspicion that the cecal lipoma was the underlying cause. An ileocecal resection was performed. Erosions were observed at the center of the lipoma. Although small colorectal lipomas are generally asymptomatic and rarely cause anemia, periodic endoscopic examinations are recommended. These lesions should be considered in the differential diagnosis of lower gastrointestinal bleeding.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bleeding lipoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">colorectal lipoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">laparoscopic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mucosal erosion</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1435-2451</Issn>
      <Volume>411</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Surgical outcomes and patient selection in nonagenarians with colon cancer: a comparative multi-institutional study of laparoscopic and open approaches</ArticleTitle>
    <FirstPage LZero="delete">21</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoe</FirstName>
        <LastName>Takanaga</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Inada</LastName>
        <Affiliation>Department of Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Toshima</LastName>
        <Affiliation>Department of Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Ohtani</LastName>
        <Affiliation>Department of Surgery, Saiseikai Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoto</FirstName>
        <LastName>Hori</LastName>
        <Affiliation>Department of Surgery, Tottori Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaoru</FirstName>
        <LastName>Shigemitsu</LastName>
        <Affiliation>Department of Surgery, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sumiharu</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Surgery, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsushi</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Surgery, Kobe Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Department of Surgery, Onomichi City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuji</FirstName>
        <LastName>Nobuhisa</LastName>
        <Affiliation>Department of Surgery, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumitaka</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Surgery, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Umeoka</LastName>
        <Affiliation>Department of Surgery, Matsuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Setouchi Colorectal Neoplasm Registration study group collaborators</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose The appropriate surgical approach for colon cancer (CC) in nonagenarian patients remains a subject of clinical debate. This study aimed to compare the short-term outcomes of laparoscopic (Lap) versus open (Open) surgery in patients aged ≥ 90 years with resectable colon cancer.&lt;br&gt;
Methods This multi-institutional retrospective cohort study included oldest-old patientswith pathological Stage II/III CC who underwent elective surgery at 15 hospitals between 2011 and 2022. Patients with rectal cancer, Stage 0/I/IV disease, or emergency surgery were excluded. To address selection bias, inverse-probability-weighted regression adjustment and stabilized inverse probability of treatment weighting (sIPTW) were applied. The primary outcome was postoperative complications; secondary outcomes included overall survival (OS).&lt;br&gt;
Results Median age was 92 years in both groups. Before adjustment, the Lap group had a higher proportion of female patients (p = 0.038) and lower ASA scores (p = 0.01). Laparoscopic surgery was associated with a significantly longer operative time (220 vs. 171 min, p = 0.046) but less intraoperative blood loss (10 vs. 78 mL, p &lt; 0.01). Postoperative complication rates were comparable (Lap: 31.8%, Open: 33.8%), while the Lap group had a significantly shorter hospital stay (13 vs. 17 days, p &lt; 0.01). D3 lymph node dissection was more frequently performed in the Lap group (p &lt; 0.01). After sIPTW, overall survival did not differ significantly between groups (p = 0.61).&lt;br&gt;
Conclusion Both laparoscopic and open surgery are feasible options for selected nonagenarians with colon cancer. Laparoscopic surgery may offer benefits in terms of reduced blood loss and shorter hospitalization, despite longer operative times. Careful patient selection considering frailty and comorbidities is essential in determining the most appropriate surgical approach.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Oldest-old patients</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Colon cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Laparoscopic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Surgical outcome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Overall survival</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0309-0167</Issn>
      <Volume>88</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Claudin-18 expression in gastric type adenocarcinoma and HPV-associated adenocarcinoma of the uterine cervix</ArticleTitle>
    <FirstPage LZero="delete">1003</FirstPage>
    <LastPage>1015</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nobuko</FirstName>
        <LastName>Yasutake</LastName>
        <Affiliation>Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Yokawa</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry &amp;amp; Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry &amp;amp; Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Riri</FirstName>
        <LastName>Mishima</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry &amp;amp; Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Misato</FirstName>
        <LastName>Komamizu</LastName>
        <Affiliation>Department of Gynecology and Obstetrics, Graduate School of Medical Sciences Kyushu University  Fukuoka Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Kuga</LastName>
        <Affiliation>Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rina</FirstName>
        <LastName>Jiromaru</LastName>
        <Affiliation>Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichiro</FirstName>
        <LastName>Kawatoko</LastName>
        <Affiliation>Department of Medicine and Clinical Science, Kyushu University Beppu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenzo</FirstName>
        <LastName>Sonoda</LastName>
        <Affiliation>Department of Gynecology, Kyushu University Beppu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Yahata</LastName>
        <Affiliation>Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoko</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinao</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry &amp;amp; Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aims: Claudin-18 (CLDN18) is both a marker for the gastric phenotype and a therapeutic target. However, little is known about its immunoexpression in endocervical adenocarcinomas (ECAs), particularly as detected using the clone 43-14A antibody, or about the gene expression of its isoforms in ECAs.&lt;br&gt;
Methods and results: We examined CLDN18, HIK1083, p16 and Rb expression by immunohistochemistry and high-risk human papillomavirus (HR-HPV) mRNA by in situ hybridization (ISH) in 121 ECAs, including 35 HPV-independent adenocarcinomas (gastric type [GAS], n = 24; non-GAS, n = 11) and 86 HPV-associated ECAs. We also analysed mRNA expression of the CLDN18.1 (lung type) and CLDN18.2 (gastric type) isoforms by quantitative polymerase chain reaction (qPCR) in selected cases. CLDN18 positivity was detected in 8/24 (33%) GASs, 0/11 (0%) non-GASs and 2/86 (2%) HPV-associated ECAs, with positivity defined as staining in ≥75% of tumour cells, as in gastric cancer. When a 5% cut-off was used, CLDN18 positivity was detected in 22/24 (92%) GASs, 0/11 (0%) non-GASs and 6/86 (7%) HPV-associated ECAs; CLDN18 expression was thus significantly associated with GAS histology (P &lt; 0.0001). Among the 6 cases of HPV-associated ECAs with CLDN18 expression (ranging from 5% to 80%), the histological patterns included a mix of usual and mucinous features in 4 cases, pure usual type in 1 and villoglandular variant in 1. Otherwise features such as p16 overexpression and the Rb partial loss pattern were consistent with those of HPV-associated ECAs. Six of 22 (27%) CLDN18-positive GASs were also positive for p16, but their other features—such as CLDN18 expression and the Rb preserved pattern—were the same as in p16 negative GASs. Expression of CLDN18.2 mRNA but not CLDN18.1 mRNA was confirmed in both GASs and HPV-associated ECAs.&lt;br&gt;
Conclusions: CLDN18 (43-14A) emerged as a potential diagnostic and therapeutic marker for GAS. A minor subset of HPV-associated ECAs also can be immunoreactive for CLDN18 and express CLDN18.2 mRNA, suggesting divergent gastric phenotypic differentiation. The caution is that GAS and HPV-associated ECAs can share overlapping histological features and similar expression of CLDN18 and p16.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">claudin-18</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endocervical adenocarcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric type</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">human papillomavirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">p16</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Challenge of Diagnosing Scirrhous Gastric Cancer by Endoscopic Biopsy: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e87334</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Internal Medicine, Clinic IkedaDepartment of Internal Medicine, Clinic Ikeda</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Yoshino</LastName>
        <Affiliation>Department of Pathology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobumasa</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Internal Medicine, Clinic Ikeda</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Scirrhous gastric cancer, also known as linitis plastica, is a rare and aggressive subtype of gastric carcinoma that poses significant diagnostic challenges due to its submucosal infiltration and often normal-appearing mucosa. We report a case involving a 30-year-old Japanese woman who presented with a six-month history of epigastric pain and postprandial vomiting. Initial endoscopic examination revealed erythema and mucosal swelling, with limited antral distensibility and resistance during duodenal intubation. Despite 12 mucosal biopsies, histopathological examination revealed no evidence of malignancy. Given the strong clinical and endoscopic suspicion of scirrhous gastric cancer, additional deep sections and immunohistochemical staining were performed. These revealed scattered signet-ring cell carcinoma and poorly differentiated adenocarcinoma, with positive immunostaining for p53 and Ki67. The patient underwent total gastrectomy, and the diagnosis of scirrhous gastric cancer was confirmed on the resected specimen. This case highlights the importance of a high index of clinical suspicion, close collaboration between endoscopists and pathologists, and the utility of ancillary diagnostic tools, such as immunohistochemistry, in identifying subepithelial gastric malignancies that may be missed on conventional biopsy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">endoscopic biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophagogastroduodenoscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immunohistochemistry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">linitis plastica</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">scirrhous gastric cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1345-2630</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tabtoxin biosynthetic gene cluster in Pseudomonas syringae pv. tabaci 6605 genomic island 1 (GI-1Pta6605) is required for severe disease symptoms</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kotomi</FirstName>
        <LastName>Kunishi</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norika</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidenori</FirstName>
        <LastName>Matsui</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanami</FirstName>
        <LastName>Sakata</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiteru</FirstName>
        <LastName>Noutoshi</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Ichinose</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>One of the genomic islands in Pseudomonas syringae pv. tabaci 6605 (GI-1Pta6605) has been identified as a pathogenicity island required for virulence because the deletion almost completely eliminated disease symptoms in inoculation tests at 4 × 105 CFU/ml. GI-1Pta6605 contains four cargo regions (CRs) named CR-1 to CR-4. The ∆CR-4 mutant did not produce tabtoxin like ∆GI-1 and disease symptoms did not develop in tobacco. However, it grew, although to a lesser extent than the wild-type strain. These results indicate that the tabtoxin biosynthetic gene cluster in GI-1 is required for virulence but not for establishment of compatibility.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">GI-1Pta6605</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pathogenicity island</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pseudomonas syringae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tabtoxin</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1757-2215</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pan-cancer profiling links C1orf50 to DNA repair and immune modulation in ovarian cancer</ArticleTitle>
    <FirstPage LZero="delete">13</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Anna</FirstName>
        <LastName>Rogachevskaya</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Ohtsu</LastName>
        <Affiliation>Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vanessa D.</FirstName>
        <LastName>Chin</LastName>
        <Affiliation>UMass Chan Medical School, UMass Memorial Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tirso</FirstName>
        <LastName>Peña</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Arai</LastName>
        <Affiliation>Department of Urology, Gunma University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Fujimura</LastName>
        <Affiliation>Department of Molecular Physiology, Faculty of Medicine, Graduate School of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background C1orf50 encodes a small, evolutionarily conserved protein, the function of which remains unclear. Its significance across various human cancers, particularly its specific role in ovarian cancer within an immunogenomic context, is not yet fully understood. Utilizing The Cancer Genome Atlas and single-cell RNA sequencing (scRNA-seq) public datasets, we conducted a comprehensive profiling of C1orf50 across multiple cancer types, with a particular focus on ovarian cancer, to investigate its associations with copy-number status, genomic instability, tumor programs, and the immune microenvironment.&lt;br&gt;
Results Across cancer types, copy-number gain or amplification of C1orf50 was most frequent in ovarian cancer and closely tracked with higher messenger RNA levels. Higher C1orf50 expression was associated with a greater tumor mutational burden and homologous recombination deficiency, as indicated by gene-set patterns that suggested heightened cell-cycle and cellular stress responses accompanied by reduced oxidative phosphorylation, enrichment of regulatory T cells, and depletion of resting memory CD4 T cells. In ovarian cancer, focal events at chromosome 1p34.2 were accompanied by stepwise increases in C1orf50 expression by clinical stage and were linked to higher tumor mutational burden, homologous recombination deficiency, and greater loss of heterozygosity, together with more frequent gene alterations in BRCA1 or BRCA2. Immune composition clustered into profiles consistent with an immunosuppressive context in tumors with higher C1orf50 expression. The scRNA-seq data further revealed that cancer cells enhanced immune-suppressive interactions with various immune cell populations and diminished antigen-presentation signals. Analyses of genomic instability in ovarian cancer suggested mutational processes compatible with base-substitution patterns associated with cytidine deaminase activity and with insertion-deletion patterns characteristic of homologous recombination failure, while transcript-level patterns pointed to a broad downshift of canonical DNA repair activity with apparent compensatory adjustments in related pathways rather than a uniform change in any single pathway.&lt;br&gt;
Conclusions The overexpression of C1orf50 characterizes an aggressive immunogenomic phenotype in ovarian cancer, distinguished by genomic instability, impaired DNA repair mechanisms, and extensive immunosuppression. These findings indicate that C1orf50 warrants consideration as a potential biomarker and a prospective target for therapeutic investigation. Furthermore, they advocate for the progression to prospective validation and functional studies to ascertain its clinical significance.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">C1orf50</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pan-cancer analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DNA repair</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gene expression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tumor microenvironment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune evasion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Single-cell RNA-seq</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2589-5370</Issn>
      <Volume>80</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial</ArticleTitle>
    <FirstPage LZero="delete">103078</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Shimada</LastName>
        <Affiliation>Department of Hematology and Oncology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoko</FirstName>
        <LastName>Yamaguchi</LastName>
        <Affiliation>Department of Hematological Malignancies, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yachiyo</FirstName>
        <LastName>Kuwatsuka</LastName>
        <Affiliation>Department of Advanced Medicine, Nagoya University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Matsue</LastName>
        <Affiliation>Division of Hematology/Oncology, Internal Medicine, Kameda Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keijiro</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Hematology, Nagano Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Kusumoto</LastName>
        <Affiliation>Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirokazu</FirstName>
        <LastName>Nagai</LastName>
        <Affiliation>Department of Hematology, National Hospital Organization Nagoya Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Takizawa</LastName>
        <Affiliation>Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Fukuhara</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Tohoku University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Nagafuji</LastName>
        <Affiliation>Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Miyazaki</LastName>
        <Affiliation>Department of Hematology and Oncology, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiichi</FirstName>
        <LastName>Ohtsuka</LastName>
        <Affiliation>Department of Hematology, Oita Prefectural Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akinao</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Hematology, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasumasa</FirstName>
        <LastName>Sugita</LastName>
        <Affiliation>Department of Hematology, Oami Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiki</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Hematology and Oncology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Kayukawa</LastName>
        <Affiliation>Department of Clinical Oncology, Nagoya Memorial Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Wake</LastName>
        <Affiliation>Department of Hematology, Toranomon Hospital Kajigaya</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukio</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Department of Internal Medicine, Toyama Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Meguro</LastName>
        <Affiliation>Division of Hematology, Tochigi Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Kin</LastName>
        <Affiliation>Department of Hematology, Daini Osaka Police Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Minami</LastName>
        <Affiliation>Department of Hematology, National Cancer Center Hospital East</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daigo</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Hematology, Hokkaido University Faculty of Medicine, Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Division of Hematology, Ichinomiya Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoko</FirstName>
        <LastName>Shimada</LastName>
        <Affiliation>Department of Pathology and Clinical Laboratories, Nagoya University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasufumi</FirstName>
        <LastName>Masaki</LastName>
        <Affiliation>Department of Hematology and Immunology, Kanazawa Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masataka</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Hematology, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Atsuta</LastName>
        <Affiliation>Japanese Data Center for Hematopoietic Cell Transplantation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Kiyoi</LastName>
        <Affiliation>Department of Hematology and Oncology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ritsuro</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of HSCT Data Management and Biostatistics, Nagoya University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeo</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pathology and Clinical Laboratories, Nagoya University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Kinoshita</LastName>
        <Affiliation>Department of Hematology and Cell Therapy, Aichi Cancer Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma for which prognosis is typically poor without a timely diagnosis. To explore the safety and efficacy of standard chemotherapy combined with central nervous system (CNS)-directed therapy, we conducted a multicentre, single-arm, phase 2 trial in untreated IVLBCL patients without CNS involvement at diagnosis (PRIMEUR-IVL). In the primary analysis, the PRIMEUR-IVL study demonstrated 2-year progression-free survival (PFS) of 76% and 2-year overall survival (OS) of 92% with a low incidence (3%) of secondary CNS involvement (sCNSi).&lt;br&gt;
Methods We present a prespecified final analysis of the PRIMEUR-IVL study including 5-year PFS, OS and cumulative incidence of sCNSi. Participants were enrolled between June 2011 and July 2016, and the data cutoff date for the final analysis was 16 November 2021. The trial was registered in the UMIN Clinical Trial Registry (UMIN000005707) and the Japan Registry of Clinical Trials (jRCTs041180165).&lt;br&gt;
Findings With a median follow-up of 7.1 years (interquartile range 5.6–8.7), 5-year PFS in all 37 eligible patients was 68% (95% confidence interval [CI] 50%–80%) and OS was 78% (95% CI 61%–89%). No additional sCNSi was observed after the primary analysis. Severe adverse events after the primary analysis were grade 4 neutropenia (n = 1) and grade 4 myelodysplastic syndrome that did not require specific treatment (n = 1). Eight deaths occurred during the observation period after enrolment, due to primary disease (n = 6), sepsis (n = 1) and unknown sudden death (n = 1).&lt;br&gt;
Interpretation Long-term follow-up data demonstrated durable response for PFS and OS, and low cumulative incidence of sCNSi, indicating the efficacy of standard chemotherapy combined with CNS-directed therapy for untreated IVLBCL patients.&lt;br&gt;
Funding This study received financial support from the Japan Agency for Medical Research and Development, Center for Supporting Hematology-Oncology Studies, and National Cancer Center.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Central nervous system-directed therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Intravascular large B-Cell lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">R-CHOP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Secondary central nervous system involvement</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>64</Volume>
      <Issue>14</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Myeloid Sarcoma in the Small Intestine</ArticleTitle>
    <FirstPage LZero="delete">2155</FirstPage>
    <LastPage>2159</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Kamio</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichiro</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsunori</FirstName>
        <LastName>Matsueda</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Kametaka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Myeloid sarcoma is a rare extramedullary tumor of immature myeloid cells that is often associated with acute myeloid leukemia (AML). We herein report an 81-year-old man who presented with intestinal obstruction due to myeloid sarcoma of the small intestine. Diagnostic challenges were overcome using double-balloon enteroscopy and a biopsy, which confirmed the diagnosis of myeloid sarcoma. The patient subsequently developed AML but responded well to chemotherapy. This case underscores the importance of considering myeloid sarcoma in the differential diagnosis of small-bowel tumors. Highlighting the significance of a histological analysis, even in patients presenting with small bowel obstruction, the early diagnosis and treatment are crucial for improving outcomes, particularly in patients without a history of hematologic malignancies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">acute myeloid leukemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">double-balloon enteroscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">myeloid sarcoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">small intestine</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pseudoachalasia Due to Malignant Pleural Mesothelioma Involving the Esophagus</ArticleTitle>
    <FirstPage LZero="delete">e84161</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Manami</FirstName>
        <LastName>Honda</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We report a rare case of pseudoachalasia secondary to malignant pleural mesothelioma involving the esophagus. A 66-year-old man presented with progressive dysphagia, weight loss, and postprandial hiccups. Endoscopic examination showed esophageal dilation with luminal narrowing at the esophagogastric junction, but no mucosal abnormalities. Computed tomography revealed an irregular-shaped mass extending from the peri-esophagogastric junction to the retroperitoneum, accompanied by pleural effusion, right-sided hydronephrosis, and multiple hepatic lesions. Endoscopic ultrasound-guided fine-needle aspiration from the mass lesion through the esophageal lumen revealed epithelioid malignant mesothelioma. This case highlights the importance of considering malignant mesothelioma in the differential diagnosis of pseudoachalasia, particularly when imaging reveals extrinsic esophageal compression without mucosal lesions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">endoscopic ultrasound-guided fine-needle aspiration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophageal diseases</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophagogastroduodenoscopy (egd)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">malignant mesothelioma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pseudoachalasia</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Gastrointestinal Stromal Tumors in the Stomach With Tumor Growth and Hemorrhage During Conservative Management: A Report of Two Cases</ArticleTitle>
    <FirstPage LZero="delete">e82046</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Gastrointestinal stromal tumors (GISTs) are often detected incidentally during esophagogastroduodenoscopy. Although surgical resection is the standard treatment for GISTs, patients with significant comorbidities may not be eligible for surgery and are managed conservatively. Herein, we report two cases of gastric GISTs that were initially observed during the management of other comorbidities but subsequently became enlarged, resulting in gastrointestinal bleeding. These cases highlight the potential risks of tumor progression and bleeding in patients undergoing conservative management.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">conservative management</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric subepithelial lesion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastrointestinal bleeding</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastrointestinal stromal tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor growth</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1865-7257</Issn>
      <Volume>18</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Microsatellite-high intrahepatic cholangiocarcinoma with favorable treatment outcome using pembrolizumab</ArticleTitle>
    <FirstPage LZero="delete">363</FirstPage>
    <LastPage>368</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Horiguchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironari</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosaku</FirstName>
        <LastName>Morimoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Terasawa</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Intrahepatic cholangiocarcinoma has a poor prognosis. In unresectable cases, the survival period is short despite combination therapy with cytotoxic anticancer agents and immune checkpoint inhibitors. The usefulness of immune checkpoint inhibitors against malignant tumors with microsatellite instability-high (MSI-H) mutations was shown in the KEYNOTE158 study; however, data for intrahepatic cholangiocarcinoma are insufficient. In the present case, a 65-year-old man with intrahepatic cholangiocarcinoma and lymph node metastasis could not be treated with a combination of gemcitabine, CDDP, and S-1. A comprehensive cancer genomic profiling (CGP) test showed MLH1 pathogenic mutation and MSI-H. When pembrolizumab was administered, the tumor shrinkage effect was rapidly observed, which was sustained even after 30 months. No pathogenic mutations were observed in the germline test, and MSI-high was considered to be due to the MLH1 pathogenic mutation occurring sporadically in somatic cells. MSI-H intrahepatic cholangiocarcinoma is extremely rare. However, because pembrolizumab is expected to be effective, CGP testing should be actively performed.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Microsatellite instability (MSI)-high</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tumor mutation burden (TMB)-high</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Intrahepatic cholangiocarcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Comprehensive genome profiling</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Gastric Metastasis of Renal Cell Carcinoma Initially Diagnosed by Esophagogastroduodenoscopy</ArticleTitle>
    <FirstPage LZero="delete">e79651</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Kamio</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichiro</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Here, we report a rare case of renal cell carcinoma (RCC) initially detected as a gastric metastasis. A 58-year-old man with epigastric discomfort underwent esophagogastroduodenoscopy, which revealed a reddish semi-pedunculated lesion with a whitish coating. Biopsy and imaging confirmed clear cell RCC metastasis. Contrast-enhanced computed tomography (CT) revealed a primary renal tumor with pancreatic and lymph node metastases. Despite chemotherapy treatment, the patient died after 10 months. Gastric metastases from RCC, although rare, should be considered in highly vascular gastric lesions with white coatings. Clinicians must be vigilant for metastatic diseases with atypical gastric findings.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">clear renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophagogastroduodenoscopy (egd)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">metastatic tumor, renal cell carcinoma (rcc)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6694</Issn>
      <Volume>18</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Antigen Remodeling in Colorectal Cancer: How Radiotherapy and Chemotherapy Enhance Immunotherapy Responsiveness</ArticleTitle>
    <FirstPage LZero="delete">715</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Moriwake</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Kayano</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Colorectal cancer (CRC) is traditionally considered a “cold tumor” characterized by low immunogenicity and limited responsiveness to immune checkpoint inhibitors (ICIs). However, recent findings reveal that cytotoxic modalities can reprogram this immunologically inert landscape. This review integrates these evolving concepts to guide the optimization of future treatments. Radiotherapy induces extensive DNA double-strand breaks, which may generate de novo mutations through error-prone repair while simultaneously exposing cryptic antigens via increased transcriptional instability, alternative splicing, and enhanced proteasomal processing. Chemoradiation also amplifies epigenetic and epitranscriptomic sources of neoepitope diversity, including RNA editing and stress-induced splicing alterations, expanding the immunopeptidome beyond canonical mutation-driven neoantigens. These changes collectively enhance antigen presentation and facilitate T-cell priming. Chemotherapy further reduces immunosuppressive cell populations and promotes dendritic cell activation, creating a permissive milieu for subsequent immune engagement. Clinically, the VOLTAGE studies demonstrated that long-course chemoradiotherapy can sensitize even mismatch repair–proficient rectal cancers to PD-1 blockade, yielding clinically meaningful pathological responses. In contrast, mismatch repair–deficient rectal tumors may respond completely to ICIs alone. Short-course radiotherapy combined with chemotherapy and ICIs has also shown encouraging activity in the setting of total neoadjuvant therapy. Collectively, these findings support a paradigm in which radiotherapy, chemotherapy, and epigenetic/epitranscriptomic alterations—including RNA editing—act as potent modulators of tumor antigenicity. By expanding the neoantigen repertoire and reshaping the tumor microenvironment, these strategies can transform CRC from a cold tumor into one that is increasingly responsive to immunotherapy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immunotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neoantigens</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Ovid Technologies (Wolters Kluwer Health)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1743-9159</Issn>
      <Volume>112</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Total thymectomy is oncologically superior to partial thymectomy in patients with thymic carcinoma: insights from a multicenter real-world data analysis</ArticleTitle>
    <FirstPage LZero="delete">2301</FirstPage>
    <LastPage>2310</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikio</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center of Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Habu</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Suzawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromasa</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mototsugu</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Kurosaki</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eisuke</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsurou</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiya</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makio</FirstName>
        <LastName>Hayama</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Tao</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaomi</FirstName>
        <LastName>Yamane</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Inokawa</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Hirami</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Washio</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiko</FirstName>
        <LastName>Misao</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshifumi</FirstName>
        <LastName>Sano</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Kawamata</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Although total thymectomy has been the standard surgical approach for thymic epithelial tumors, an increasing number of recent reports suggest that partial thymectomy for early-stage thymomas may yield outcomes comparable to those of total thymectomy. However, whether partial thymectomy is a viable alternative for thymic carcinoma remains unclear.&lt;br&gt;
Materials and methods: A total of 106 patients with thymic carcinoma underwent curative intended resection at 19 institutions between January 2010 and December 2021. Excluding 14 patients with incomplete resection, 92 patients with thymic carcinoma who underwent total (n = 73) or partial thymectomy (n = 19) were compared. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using Kaplan–Meier curves and Cox proportional hazard models. Overlap weighting was applied to adjust for potential confounding factors.&lt;br&gt;
Results: Among patients with clinical stage I disease, 79.3% were upstaged to stage II or higher postoperatively. Unadjusted analyses revealed no statistically significant differences in OS and RFS between the total and partial thymectomy groups, although a trend toward poorer outcomes in the partial thymectomy group was observed. After overlap weighting, partial thymectomy was associated with significantly poorer OS (P = 0.0027) and higher recurrence risk (P &lt; 0.0001). Early postoperative recurrence occurred more frequently in the partial thymectomy group.&lt;br&gt;
Conclusion: Partial thymectomy was associated with significantly worse survival and recurrence outcomes in thymic carcinoma. Given the limitations of preoperative diagnosis, total thymectomy should remain the preferred surgical approach for undiagnosed thymic epithelial tumors to achieve optimal oncologic control and minimize the risk of recurrence.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">partial thymectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">real-world data analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">retrospective comparative cohort study</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thymic carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thymic epithelial tumors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">total thymectomy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effective Treatment of Advanced Hepatocellular Carcinoma with Extensive Peritoneal Dissemination Using Lenvatinib</ArticleTitle>
    <FirstPage LZero="delete">69</FirstPage>
    <LastPage>74</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Wakatsuki</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Ueno</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaomi</FirstName>
        <LastName>Namba</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yorito</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Okabayashi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70075</ArticleId>
    </ArticleIdList>
    <Abstract>Patients with hepatocellular carcinoma (HCC) and extensive peritoneal dissemination generally have a poor prognosis and are often resistant to systemic therapy. We report the case of a 47-year-old woman with HCC and massive peritoneal dissemination who presented with malignant ascites requiring repeated cell-free and concentrated ascites reinfusion therapy and peritoneovenous shunt placement, as well as malignant pleural effusion requiring pleurodesis. Combined immunotherapy with durvalumab/tremelimumab was initiated;however, disease progression was observed after three treatment courses, prompting a switch to lenvatinib therapy. Two months after initiation of lenvatinib, CT imaging demonstrated complete disappearance of arterial enhancement in the primary hepatic lesion, along with reduction in the size of peritoneal dissemination nodules. Thirteen months after switching to lenvatinib (16 months after the initial diagnosis), the alpha-fetoprotein level continued to decrease, and the disease remained stable under treatment. Despite the extremely high tumor burden, lenvatinib achieved disease stabilization and symptomatic improvement.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">diagnostic laparoscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hepatocellular carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peritoneal dissemination</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lenvatinib</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2950-3299</Issn>
      <Volume>33</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Collagen depletion by pirfenidone enhances antitumor effect of oncolytic adenovirus against peritoneal metastases of gastric cancer</ArticleTitle>
    <FirstPage LZero="delete">201045</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Okura</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Mikane</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiko</FirstName>
        <LastName>Kanaya</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ema</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Une</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Ohtsuka</LastName>
        <Affiliation>Laboratory of Fundamental Oncology, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rieko</FirstName>
        <LastName>Ohki</LastName>
        <Affiliation>Laboratory of Fundamental Oncology, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Urata</LastName>
        <Affiliation> Oncolys BioPharma, Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cancer-associated fibroblasts (CAFs) play a crucial role in collagen accumulation, which develops and promotes peritoneal metastasis (PM) in gastric cancer (GC). In addition, the abundant stromal collagens in the tumor microenvironment function as a physical barrier against penetration of antitumor drugs and oncolytic viruses. This study investigated whether collagen depletion by pirfenidone (PFD), an antifibrotic drug, enhances the antitumor effects of oncolytic adenoviruses. Analysis of the clinical samples revealed a significant association of high expression of collagen 1 and α-smooth muscle actin (α-SMA) with PM development and poor prognosis of advanced GC. Human and murine GC cells enhanced collagen production by fibroblasts, which was suppressed by PFD. Abundant fibroblasts and collagen inhibited the penetration of OBP-702, which reduced the antitumor effects of OBP-702 in the spheroid model. Intraperitoneal co-injection of GC cells and fibroblasts promoted the development of collagen-rich PM and reduced the antitumor effects of OBP-702 in vivo model. PFD suppressed collagen production in PM and improved viral penetration into the tumors, which enhanced the antitumor effects of OBP-702 against PM of GC. Collagen depletion by PFD enhances the penetration of OBP-702 into PM of GC, in turn enhancing the antitumor effects of OBP-702 against PM of GC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">MT: Regular Issue</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oncolytic virotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peritoneal metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">collagen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pirfenidone</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Central Serous Chorioretinopathy in Parallel With Onset and Relapses of Minimal Change Nephrotic Syndrome: A 28-Year Case Follow-Up</ArticleTitle>
    <FirstPage LZero="delete">e102426</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Central serous chorioretinopathy is an idiopathic disease that manifests as one or several localized, small, dome-shaped serous retinal detachments on fundus examination. The pathophysiology involves fluid leakage from the choroidal capillaries, known as the choriocapillaris, into the subretinal space through sites of damage in the retinal pigment epithelium. This case report discusses the underlying causes of central serous chorioretinopathy-like findings in minimal change nephrotic syndrome.&lt;br&gt;
&lt;br&gt;
The patient was a 33-year-old woman who developed nephrotic syndrome that was confirmed to be minimal change disease by renal biopsy. She experienced two major relapses of nephrotic syndrome at the ages of 36 and 41 years. She also had a minor relapse at the age of 37 years, five months after the first major relapse at the age of 36 years, as well as four additional minor relapses at the ages of 44, 46, 50, and 51 years. The onset of central serous chorioretinopathy-like manifestations, which were localized to the left eye, occurred three months after the initial onset of nephrotic syndrome at the age of 33 years. Two subsequent episodes of relapse of central serous chorioretinopathy-like manifestations were observed in both eyes at intervals of five months and one month, respectively, after major relapses of nephrotic syndrome at the ages of 36 and 41 years. Thereafter, she did not develop further central serous chorioretinopathy-like manifestations.&lt;br&gt;
&lt;br&gt;
She discontinued oral prednisolone at the age of 54 years and experienced no further relapses of nephrotic syndrome through her latest visit at the age of 61 years. She maintained normal renal function and good visual acuity in both eyes. The long-term, consistent temporal association between episodes of central serous chorioretinopathy and the onset and relapses of minimal change nephrotic syndrome is strongly supported by longitudinal clinical observations spanning 28 years. This parallel course suggests a possible shared pathophysiological mechanism or common triggering factors underlying both diseases.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">central serous chorioretinopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">corticosteroid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cyclosporine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fluorescein angiography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">minimal change disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">minimal change nephrotic syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">photoreceptor ellipsoid zone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">renal biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">steroid-induced retinal pigment epitheliopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">steroid pulse therapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>China Anti-cancer Association</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2095-3941</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>SPRED2 suppresses the stemness of hepatocellular carcinoma through the p53/miR-506-3p/KLF4 pathway</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tong</FirstName>
        <LastName>Gao</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachio</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aye</FirstName>
        <LastName>Moh-Moh-Aung</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tianyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teizo</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: We previously reported that endogenous Sprouty-related, EVH1 domain-containing protein 2 (SPRED2), an inhibitor of the Ras/Raf/ERK-MAPK pathway, controls hepatocellular carcinoma (HCC) cell stemness by downregulating the expression of pluripotency factors, such as Nanog, c-Myc, and KLF4, in an ERK-dependent fashion. However, the exact mechanisms by which SPRED2 regulates HCC cell stemness have not been established.&lt;br&gt;
Methods: Three human HCC cell lines [HepG2 (parental and SPRED2-deficient), HLE, and Hep3B] were used. Cells were transfected to downregulate or overexpress proteins. Western blot and RT-qPCR were used to evaluate the level of protein and mRNA expression. Co-immunoprecipitation and ChIP-qPCR were used to examine protein-protein interactions and the activation of gene transcription. Clinical HCC tissues were also used to validate in vitro data.&lt;br&gt;
Results: KLF4 was identified as the major pluripotency factor responsible for SPRED2-mediated downregulation of HCC cell stemness and KLF4 expression was regulated by miR-506-3p. SPRED2 formed a protein complex with the tumor suppressor (p53) and upregulated miR-506 gene transcription by binding to the promoter region, resulting in subsequent downregulation of KLF4 mRNA expression. There was a negative correlation between KLF4 expression and miR-506-3p and a positive correlation between miR-506-3p expression and SPRED2 in human HCC samples, highlighting the relevance of the study findings.&lt;br&gt;
Conclusions: The current study revealed a novel SPRED2/p53/miR-506-3p/KLF4 axis through which SPRED2 contributes to the suppression of HCC cell stemness and provides a potential new target to prevent HCC progression.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">SPRED2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">p53</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">KLF4</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">miR-506-3p</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stemness</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1873-149X</Issn>
      <Volume>33</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Bridging the Gap Between Static Histology and Dynamic Organ-on-a-Chip Models</ArticleTitle>
    <FirstPage LZero="delete">10</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Zheyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiji</FirstName>
        <LastName>Naruse</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>For more than a century, pathology has served as a cornerstone of modern medicine, relying primarily on static microscopic assessment of tissue morphology—such as H&amp;E staining—which remains the “gold standard” for disease diagnosis. However, this conventional paradigm provides only a snapshot of disease states and often fails to capture their dynamic evolution and complex functional mechanisms. Moreover, animal models are constrained by marked interspecies differences, creating a persistent gap in translational research. To overcome these limitations, we propose the concept of New Pathophysiology, a research framework that transcends purely morphological descriptions and aims to resolve functional dynamics in real time. This approach integrates Organ-on-a-Chip (OOC) technology, multi-omics analyses, and artificial intelligence to reconstruct the entire course of disease initiation and to enable personalized medicine. In this review, we first outline the foundations and limitations of traditional pathology and animal models. We then systematically summarize more than one hundred existing OOC disease models across multiple organs—including the kidney, liver, and brain. Finally, we elaborate on how OOC technologies are reshaping the study of key pathological processes such as inflammation, metabolic dysregulation, and fibrosis by converting them into dynamic, mechanistic disease models, and we propose future perspectives in the field. This review adopts a relatively uncommon classification strategy based on pathological mechanisms (mechanism-based), rather than organ-based categorization, allowing readers to recognize shared principles underlying different diseases. Moreover, the focus of this work is not on emphasizing iteration or replacement of existing approaches, but on preserving past achievements from a historical perspective, with an emphasis on overcoming current limitations and enabling new advances.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">new pathophysiology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">organ-on-a-chip/OOC</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dynamic disease modeling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">histopathology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">large-model analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">personalized medicine</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Baishideng Publishing Group Inc.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1948-5190</Issn>
      <Volume>17</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Endoscopic features of oral and pharyngolaryngeal papillomas and their role in distinguishing squamous cell carcinoma</ArticleTitle>
    <FirstPage LZero="delete">110594</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyasu</FirstName>
        <LastName>Kono</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiro</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>BACKGROUND&lt;br&gt;
Oral and pharyngolaryngeal papillomas are occasionally detected during esophagogastroduodenoscopy. However, their endoscopic features have not been sufficiently investigated.&lt;br&gt;
AIM&lt;br&gt;
To distinguish oral and pharyngolaryngeal papillomas from elevated squamous carcinomas, this study examined their endoscopic features.&lt;br&gt;
METHODS&lt;br&gt;
Forty-seven patients with oral or pharyngeal papilloma participated in this study. The endoscopic characteristics of papillomas were identified by focusing on narrowband and blue laser imaging representations.&lt;br&gt;
RESULTS&lt;br&gt;
Papillomas were classified into three patterns based on their endoscopic features: Salmon roe-like polyps, polyps without capillary transparency, and pinecone-like polyps, with salmon roe-like polyps most prevalent (48.9%). We subsequently analyzed features differentiating papillomas and squamous cell carcinomas in the same region and found that squamous cell carcinomas exhibited at least one of the following three features: Uneven or absent lobulated structure, irregular morphology of capillaries, and coexistence of flat lesions. In contrast, papillomas displayed a uniform lobulated structure, homogeneous or non-visible capillaries, and an absence of flat components. When any of these characteristics were present, two endoscopic specialists evaluated the lesions for the diagnosis of squamous cell carcinoma, with sensitivities of 100% and 97.6% and specificities of 68.9% and 93.3%.&lt;br&gt;
CONCLUSION&lt;br&gt;
Understanding distinct endoscopic patterns of oropharyngeal papillomas and squamous cell carcinomas provides valuable guidance to endoscopists performing esophagogastroduodenoscopy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Esophagogastroduodenoscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Human papillomavirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Laryngeal polyp</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Papilloma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pharyngeal polyp</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society of Clinical Oncology (ASCO)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2473-4276</Issn>
      <Volume>9</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Development and Validation of an Ipsilateral Breast Tumor Recurrence Risk Estimation Tool Incorporating Real-World Data and Evidence From Meta-Analyses: A Retrospective Multicenter Cohort Study</ArticleTitle>
    <FirstPage LZero="delete">e2500182</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasuaki</FirstName>
        <LastName>Sagara</LastName>
        <Affiliation>Department of Breast and Thyroid Surgical Oncology, Hakuaikai Sagara Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Breast Surgical Oncology, St Luke's International Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuri</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Breast Surgical Oncology, The Cancer Institute Hospital of JFCR</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Ishitobi</LastName>
        <Affiliation>Department of Breast Surgery, Osaka Habikino Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Radiation Oncology and Image-Applied Therapy, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Tsukioki</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Takada</LastName>
        <Affiliation>Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuri</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Medical Statistics, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomo</FirstName>
        <LastName>Osako</LastName>
        <Affiliation>Division of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiko</FirstName>
        <LastName>Sakai</LastName>
        <Affiliation>Department of Breast Surgical Oncology, The Cancer Institute Hospital of JFCR</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Ipsilateral breast tumor recurrence (IBTR) remains a critical concern for patients undergoing breast-conserving surgery (BCS). Reliable risk estimation tools for IBTR risk can support personalized surgical and adjuvant treatment decisions, especially in the era of evolving systemic therapies. We aimed to develop and validate models to estimate IBTR risk.&lt;br&gt;
Patients and Methods This multicenter retrospective cohort study included 8,938 women who underwent partial mastectomy for invasive breast cancer between 2008 and 2017. Prediction models were developed using Cox proportional hazards regression and validated via bootstrap resampling. Model performance was assessed using Harrell's C-index, Brier scores, calibration plots, and goodness-of-fit tests.&lt;br&gt;
Results During a median follow-up of 9.0 years (IQR, 6.6-10.9), IBTR occurred in 320 patients (3.6%). The initial model, based on variables from Sanghani et al, achieved a Harrell's C-index of 0.74. Incorporating hormonal receptor status, human epidermal growth factor receptor 2 status, radiotherapy, and targeted therapy as predictors reduced the C-index to 0.65, despite their clinical relevance. Importantly, the inclusion of these factors improved calibration, demonstrating better alignment between predicted and observed IBTR probabilities. Although the hazard ratios (HRs) for radiotherapy aligned with the Early Breast Cancer Trialists’ Collaborative Group meta-analyses (MA), those for chemotherapy and endocrine therapy showed slight differences. Therefore, HRs from the MA were used to represent treatment effects in our model.&lt;br&gt;
Conclusion We have developed and internally validated a new risk estimation model for IBTR using Cox regression and bootstrap methods. A Web-based risk estimation tool is now available to facilitate individualized risk assessment and treatment planning.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0014-4800</Issn>
      <Volume>145</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Assessing the role of folate syntrophy and folate cross-feeding in the pathobiology of infectious-inflamed milieu caused by Fusobacterium nucleatum</ArticleTitle>
    <FirstPage LZero="delete">105021</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Darab</FirstName>
        <LastName>Ghadimi</LastName>
        <Affiliation>Department of Microbiology and Biotechnology, Max Rubner-Institut</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sophia</FirstName>
        <LastName>Blömer</LastName>
        <Affiliation>Faculty of Medicine, Christian-Albrechts-University of Kiel</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aysel</FirstName>
        <LastName>Şahin Kaya</LastName>
        <Affiliation>Department of Nutrition and Dietetics, Faculty of Health Sciences, Antalya Bilim University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sandra</FirstName>
        <LastName>Krüger</LastName>
        <Affiliation>Institute of Pathology, Kiel University, University Hospital, Schleswig-Holstein</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Christoph</FirstName>
        <LastName>Röcken</LastName>
        <Affiliation>Institute of Pathology, Kiel University, University Hospital, Schleswig-Holstein</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Heiner</FirstName>
        <LastName>Schäfer</LastName>
        <Affiliation>Laboratory of Molecular Gastroenterology &amp; Hepatology, Christian-Albrechts-University &amp; UKSH Campus Kiel</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jumpei</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Bacteriology, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigenobu</FirstName>
        <LastName>Matsuzaki</LastName>
        <Affiliation>Department of Medical Laboratory Science, Faculty of Health Sciences, Kochi Gakuen University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wilhelm</FirstName>
        <LastName>Bockelmann</LastName>
        <Affiliation>Department of Microbiology and Biotechnology, Max Rubner-Institut</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Diet and nutrition affect almost every biological process, including multiple chronic diseases, diabetes, and some cancers. However, there are still significant gaps in our understanding of the importance of nutrition and healthy diets in syntrophy with respect to cross-feeding of the microbe-microbe and the microbe-host in the pathobiology of the infectious-inflamed intestinal milieu caused by anaerobic opportunistic bacteria such as Fusobacterium nucleatum (F. nucleatum). We examined the immune outcomes of three-member folate syntrophy and cross-feeding between F. nucleatum bacteria, endogenous folate-producing gut bacteria, and host cells at the host-pathogen interface using a triple co-culture model. T84, THP-1, and Huh7 cells were inoculated with F. nucleatum for 6 h in regular DMEM, DMEM with 9.5 μM folic acid, or with/without a mixture of Bifidobacterium longum subsp. infantis (B. infantis) and Escherichia coli Nissle 1917 (EcN). Cytokine secretion, cometabolite levels (ammonia, indoles), cell viability, and barrier integrity were assessed. F. nucleatum-induced folate depletion was associated with increased IL-1β and IL-6 and decreased IL-22, along with reduced transepithelial electrical resistance (TEER) and cell viability in T84 cells. Folate supplementation mitigated these effects. The mixture of B. infantis and EcN reduced F. nucleatum-induced pro-inflammatory cytokines, increased IL-22, and improved TEER and cell viability. These protective effects were enhanced by the addition of folate. F. nucleatum also elevated ammonia and reduced indoles, effects reversed by B. infantis and EcN. In addition to the intrinsic pathogenicity of harmful bacteria, folate deprivation, microbe–microbe folate syntrophy, and microbe–host folate cross-feeding contribute to the pathobiology of anaerobic opportunistic bacteria and influence the physiological fate of host cells. A combination of B. infantis and EcN modulates the infectious-inflamed interface through a cytoprotective effect and mechanical competitive extrusion of pathogenic F. nucleatum. These results provide potential insights into the mechanisms of early-onset colorectal cancer, and evidently, require future studies using patient-derived organoids and in vivo systems to improve clinical relevance.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Nutrition</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metaflammation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Folate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cytokines</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Host cells</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-321X</Issn>
      <Volume>31</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical and molecular characteristics of urinary catheter-associated Pseudomonas aeruginosa prostatic infection: A case series of four postoperative nosocomial infections</ArticleTitle>
    <FirstPage LZero="delete">102853</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Sano</LastName>
        <Affiliation>Laboratory of Veterinary Public Health, School of Veterinary Medicine and Animal Sciences, Kitasato University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashige</FirstName>
        <LastName>Kashimoto</LastName>
        <Affiliation>Laboratory of Veterinary Public Health, School of Veterinary Medicine and Animal Sciences, Kitasato University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pseudomonas aeruginosa is a causative pathogen of nosocomial catheter-associated urinary tract infections (CAUTI), but prostate involvement, including prostatitis and prostatic abscess, is rare. The clinical characteristics of P. aeruginosa-associated CAUTI with prostatic lesions, as well as the contribution of genetic backgrounds remain unclear. We describe four cases of urinary catheter-associated prostatic infection caused by P. aeruginosa following postoperative catheterization. All patients developed fever within 10 days after surgery, and three of the four patients developed bacteremia. Three patients were diagnosed with prostatic abscess by contrast-enhanced computed tomography or magnetic resonance imaging, while one case presented with prostatitis without abscess formation. Prostate-specific antigen levels were elevated over 20 ng/mL in all three measured cases. All patients were treated successfully with prolonged antibiotic therapy (28–39 days) without surgical drainage. Notably, all three abscess cases were successfully managed with fluoroquinolone-based combination therapy, highlighting its potential role in the management of prostatic abscesses. Three of four isolates were submitted for molecular investigations. All isolates harbored exoT and exoY, whereas exoU was absent. Biofilm-associated genes were detected in two cases, but not in the remaining case. Our findings suggested that P. aeruginosa strains carrying T3SS genes (exoT and exoY) potentially develop prostatic infections, independent of biofilm-associated genes. Host and iatrogenic factors, such as catheter manipulation, may play more critical roles in the development of prostatic pathology than strain-specific determinants. Assessment of prostate-specific antigen levels and early imaging may facilitate appropriate diagnosis and effective management when P. aeruginosa is detected as a cause of CAUTI.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Pseudomonas aeruginosa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Catheter-associated urinary tract infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Prostatic abscess</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Type III secretion system</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1758-5902</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Procedural Transhiatal Approach for the Thoracic Para‐Aortic Lymph Node: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e70066</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushige</FirstName>
        <LastName>Takeda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hijiri</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kento</FirstName>
        <LastName>Kawasaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyoshi</FirstName>
        <LastName>Kunitomo</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoaki</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The thoracic posterior para-aortic lymph node (TPAN) is classified as an extra-regional lymph node in esophageal cancer, with metastasis indicating poor prognosis. However, some cases with suspected TPAN metastasis may benefit from esophagectomy with lymph node dissection, including TPAN. This report presents the case of a 58-year-old man with upper thoracic esophageal squamous cell carcinoma and suspected simultaneous TPAN metastasis who underwent neoadjuvant chemotherapy followed by thoracoscopic subtotal esophagectomy and procedural transhiatal TPAN dissection. This transhiatal approach provided direct access to the lymph node without additional thoracic incisions, ensuring safe resection in coordination with the assistant and following anatomical landmarks systematically. Pathological examination showed a false-positive TPAN finding, though the patient later developed distant recurrence. Compared with conventional approaches, this transhiatal technique allows for procedural and reproducible lymphadenectomy while minimizing respiratory burden. This case highlights the feasibility of a transhiatal approach for TPAN dissection.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">112aoP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophageal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thoracic posterior para-aortic lymph node</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2772-5723</Issn>
      <Volume>5</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Feasibility and Diagnostic Utility of Mucosal T-Cell Flow Cytometry for Intestinal Graft-Versus-Host Disease</ArticleTitle>
    <FirstPage LZero="delete">100820</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mai</FirstName>
        <LastName>Hiramatsu</LastName>
        <Affiliation>Division of Medical Support, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Araki</FirstName>
        <LastName>Hirabata</LastName>
        <Affiliation>Division of Medical Support, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahide</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Division of Medical Support, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Aims: Timely diagnosis of intestinal complications after hematopoietic stem cell transplantation (HSCT), including graft-versus-host disease (GVHD), transplant-associated thrombotic microangiopathy, and cytomegalovirus infection, is essential for appropriate management. This study evaluated whether mucosal T-cell profiling from endoscopic biopsies could support the diagnosis of these post-transplant conditions.&lt;br&gt;
Methods: We prospectively analyzed 58 intestinal biopsy specimens from 21 post-HSCT patients. Paired samples were obtained from the stomach and duodenum during upper endoscopy and from the ileum and large intestine during colonoscopy. Lymphocytes were isolated from each specimen and analyzed using flow cytometry. These data were integrated with those of a previously collected cohort (35 patients, 51 samples) for comparative immunophenotypic analysis across histologically defined groups.&lt;br&gt;
Results: Duodenal biopsies yielded more lymphocytes than did gastric biopsies (mean ± standard deviation: 532 ± 823 vs 233 ± 392 cells; P = .070), with comparable yields between the ileum and colon. Among 41 evaluable cases, the CD56+:CD3+ ratio was significantly lower in patients with GVHD (5.5 ± 2.2%) than in those with nonspecific or no inflammation (28.4 ± 16.3%; P = .006). A cutoff value of &lt;11% provided 85.7% sensitivity and 83.3% specificity for diagnosing GVHD (area under the curve = 0.91).&lt;br&gt;
Conclusion: Mucosal T-cell profiling using endoscopic biopsies is feasible and may aid in the diagnosis of GVHD after HSCT. A decreased CD56+:CD3+ ratio is a promising marker for distinguishing GVHD from other post-transplant intestinal conditions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cytomegalovirus infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">flow cytometry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">graft-versus-host disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hematopoietic stem cell transplantation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">T lymphocytes</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Clinical Investigation</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2379-3708</Issn>
      <Volume>10</Volume>
      <Issue>24</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Enhancement of drug delivery through fibroblast activation protein–targeted near-infrared photoimmunotherapy</ArticleTitle>
    <FirstPage LZero="delete">e195776</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Seitaro</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tasuku</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushige</FirstName>
        <LastName>Takeda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hijiri</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kento</FirstName>
        <LastName>Kawasaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyoshi</FirstName>
        <LastName>Kunitomo</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Akai</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruki</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Nishiwaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Kashima</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Shirakawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Peter L.</FirstName>
        <LastName>Choyke</LastName>
        <Affiliation>Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisataka</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The tumor microenvironment plays a key role in cancer progression and therapy resistance, with cancer-associated fibroblasts (CAFs) contributing to desmoplasia, extracellular matrix (ECM) remodeling, and elevated interstitial fluid pressure, all of which hinder drug delivery. We investigated fibroblast activation protein–targeted (FAP-targeted) near-infrared photoimmunotherapy (NIR-PIT) as a strategy to improve drug penetration in CAF-rich tumors. In clinical esophageal cancer samples, FAP expression strongly correlated with increased collagen I, hyaluronic acid, and microvascular collapse. CAF-rich 3D spheroids demonstrated elevated ECM deposition and significantly impaired drug uptake compared with CAF-poor models. FAP-targeted NIR-PIT selectively reduced CAFs, reduced ECM components, and restored drug permeability. In vivo, FAP-targeted NIR-PIT enhanced the accumulation of panitumumab and Abraxane in CAF-rich tumors and improved antitumor efficacy when combined with chemotherapy. These findings highlight FAP-targeted NIR-PIT as a promising therapeutic approach to remodel the tumor stroma and overcome drug resistance in desmoplastic solid tumors.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1347-9032</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG-TOP2 Study</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kayoko</FirstName>
        <LastName>Tao</LastName>
        <Affiliation>Department of Pediatrics, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takako</FirstName>
        <LastName>Yoshioka</LastName>
        <Affiliation>Department of Pathology, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miho</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Childhood Cancer Data Management, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Komatsu</LastName>
        <Affiliation>Department of Pediatrics, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Tsujimoto</LastName>
        <Affiliation>Department of Pediatrics, Yokohama City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Pediatrics, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Tanimura</LastName>
        <Affiliation>Department of Pediatrics, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minako</FirstName>
        <LastName>Sugiyama</LastName>
        <Affiliation>Department of Pediatrics, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Sekiguchi</LastName>
        <Affiliation>Department of Pediatrics, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Pediatrics, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Yatabe</LastName>
        <Affiliation>Department of Diagnostic Pathology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Diagnostic Pathology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Okita</LastName>
        <Affiliation>Department of Pathology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Hirato</LastName>
        <Affiliation>Department of Pathology, Public Tomioka General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Kohashi</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukichi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Kanagawa Children's Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kohsaka</LastName>
        <Affiliation>Division of Cellular Signaling, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Department of Clinical Genomics, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kuniko</FirstName>
        <LastName>Sunami</LastName>
        <Affiliation>Department of Laboratory Medicine, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Genetic Medicine and Services, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Tsutsumi</LastName>
        <Affiliation>Genome Science &amp; Medicine Division, Research Center of Advanced Science and Technology, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Aburatani</LastName>
        <Affiliation>Genome Science &amp; Medicine Division, Research Center of Advanced Science and Technology, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyoshi</FirstName>
        <LastName>Koh</LastName>
        <Affiliation>Department of Hematology and Oncology, Saitama Children's Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Hirayama</LastName>
        <Affiliation>Department of Pediatrics, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Karakawa</LastName>
        <Affiliation>Department of Pediatrics, Hiroshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukayo</FirstName>
        <LastName>Terashita</LastName>
        <Affiliation>Department of Pediatrics, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Fujisaki</LastName>
        <Affiliation>Department of Pediatric Hematology and Oncology, Osaka City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Yagi</LastName>
        <Affiliation>Okinawa Prefectural Nanbu Medical Center &amp; Children's Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Yoneda</LastName>
        <Affiliation>Department of Pediatric Surgery, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Mochizuki</LastName>
        <Affiliation>Department of Pediatrics, National Center for Global Health and Medicine, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Shichino</LastName>
        <Affiliation>Department of Pediatrics, National Center for Global Health and Medicine, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Hematology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Takimoto</LastName>
        <Affiliation>Department of Childhood Cancer Data Management, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Ichimura</LastName>
        <Affiliation>Department of Pathology, Kyorin University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chitose</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Pediatrics, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kimikazu</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Children's Cancer Center National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation>Department of Clinical Genomics, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Pediatrics, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>To develop an optimized genomic medicine platform for pediatric cancers, a nationwide cancer genome profiling project was conducted from January 2022 to February 2023 in collaboration with the Japan Children's Cancer Group. This prospective observational study analyzed matched blood and FFPE tumor samples from patients aged 0–29 years with solid tumors. Genomic analysis used the TOP2 hybrid capture–enrichment system, targeting 737 and 455 genes in the DNA and RNA panels, along with allele-specific genome copy number alterations. A total of 210 patients from 50 institutions were enrolled across Japan (median age, 8 years; range, 0–25). Of these, 154 (77%) were enrolled at diagnosis or during/after initial treatment and 56 (27%) at disease progression or relapse. The TOP2 findings had great benefits in clarifying the diagnosis of pediatric solid tumors. Among the 204 patients with genomic results, 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%), respectively. Oncogenic fusions were noted in 45 (23%) patients. A copy number alteration was identified in at least one genomic region in 170 (83%) patients. Two patients exhibited a high tumor mutation burden. Seventeen (8%) patients harbored a germline pathogenic/likely pathogenic variant in cancer-predisposing genes. This study highlighted the feasibility of implementing a nationwide precision medicine platform and the clinical utility of the TOP2 system for pediatric cancers. The results support the integration of genomic data into the standard clinical care of pediatric patients with cancer, both at diagnosis and at relapse.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">genomic medicine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">integrative diagnosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">molecularly targeted therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">multigene panel</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pediatric cancers</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2467-981X</Issn>
      <Volume>10</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Favorable outcomes of epilepsy with gait-induced seizures after resection of the unilateral supplementary motor area</ArticleTitle>
    <FirstPage LZero="delete">489</FirstPage>
    <LastPage>492</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Kodama</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoto</FirstName>
        <LastName>Kunii</LastName>
        <Affiliation>Department of Neurosurgery, Jichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Shirota</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takusei</FirstName>
        <LastName>Chou</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizuho</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seijiro</FirstName>
        <LastName>Shimada</LastName>
        <Affiliation>Department of Neurosurgery, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Meiko</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masako</FirstName>
        <LastName>Ikemura</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Neuropahtology (Brain Bank for Aging Research), Tokyo Metropoliran Institute for Geriatrics and Gerontology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Akamatsu</LastName>
        <Affiliation>Department of Neurology, International University of Health and Walfare Narita Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taira</FirstName>
        <LastName>Uehara</LastName>
        <Affiliation>Department of Neurology, International University of Health and Walfare Narita Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhito</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Neurosurgery, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Gait-induced seizures are a rare manifestation of reflex epilepsy. Pathophysiology of this phenomenon has not been fully understood.&lt;br&gt;
Case presentation: A 28-year-old woman presented with a long history of “falls” following paroxysmal bilateral leg stiffness triggered by walking. Scalp electroencephalogram (EEG) revealed low-amplitude rhythmic beta activity, maximal at the Cz electrode, during these events. Magnetoencephalography demonstrated repetitive sharp waves source-localized to the right primary motor cortex. Multiple anti-seizure medications failed to improve her symptoms; however, the clinical manifestation was consistent with epilepsy with gait-induced seizures. Intracranial subdural EEG recording was performed and confirmed ictal activity originating from the right supplementary motor area. Resection of this area resulted in complete resolution of her symptoms.&lt;br&gt;
Discussion: This is the first reported case of successful resective surgery for epilepsy with gait-induced seizure. Brain networks involving cortical regions responsible for the initiation or execution of walking presumably played a key role in the generation of gait-induced seizures. Careful assessment using non-invasive neurophysiological studies facilitated accurate diagnosis, successful intracranial recordings, and effective resective surgery.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Reflex epilepsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Intracranial electroencephalogram (EEG)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Electrocorticogram</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">magnetoencephalogram (MEG)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SMA</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Informa UK Limited</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2167-8421</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Novel in-frame duplication variant of SOD1 in a Japanese family with familial amyotrophic lateral sclerosis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Nakajima</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroya</FirstName>
        <LastName>Naruse</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Riku</LastName>
        <Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitsugu</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shimon</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Pathology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Moro</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Kotsuki</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Nagai</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin-ichi</FirstName>
        <LastName>Tokushige</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Uchibori</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chizuko</FirstName>
        <LastName>Oishi</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yabata</LastName>
        <Affiliation>Department of Neurology, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Urushitani</LastName>
        <Affiliation>Department of Neurology, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Iwasaki</LastName>
        <Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yaeko</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: To analyze the cases of a family with a novel in-frame duplication variant (NM_000454.5:c.357_357 + 2dup, p.Val120dup) of SOD1 and a structural model of the mutated SOD1 protein. Methods: The clinical profiles of three patients in the family were analyzed, including the neuropathological findings of the proband’s mother. Genetic analyses were conducted for three patients. cDNA and in silico structural analyses were performed to evaluate the effects of duplication variants on the structure of SOD1. Results: The clinical features of the patients included predominant involvement of the lower motor neurons, asymmetric onset of motor symptoms in the lower limbs, and a relatively rapid progression of muscular weakness and respiratory insufficiency. Neuropathological findings revealed severe loss of spinal cord motor neurons, and immunohistochemistry using an anti-misfolded SOD1 antibody revealed aggregates in the spinal cord. Genetic analyses revealed a c.357_357 + 2dup at the exon 4–intron 4 boundary of SOD1 in three patients. cDNA analysis of the proband suggested the presence of a valine (p.Val120dup) duplication in the heterozygous state, and the SOD1 transcript level showed no significant differences from those of healthy controls. In silico structural analyses predicted that p.Val120dup could affect the structure of the β-barrels and copper ion binding site of SOD1, suggesting an abnormal conformation of SOD1 that is predicted to interfere with the binding of copper ions. Conclusion: We identified a novel in-frame duplication variant in the C-terminus of β7 of SOD1. This genotype–structure–phenotype study of SOD1 provides valuable insights into disease-causing mechanisms.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Familial amyotrophic lateral sclerosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SOD1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">in-frame duplication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">protein structure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">misfolded protein</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>MRI Images of a Case of Adenocarcinoma, Human Papillomavirus-Independent, Mesonephric Type, of the Uterine Cervix</ArticleTitle>
    <FirstPage LZero="delete">463</FirstPage>
    <LastPage>468</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yudai</FirstName>
        <LastName>Asano</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chika</FirstName>
        <LastName>Nishihara</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Kitayama</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanako</FirstName>
        <LastName>Okawa</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoko</FirstName>
        <LastName>Makimoto</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiyo</FirstName>
        <LastName>Higaki</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuhide</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hanako</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoyuki</FirstName>
        <LastName>Ida</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yanai</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Hiraki</LastName>
        <Affiliation>Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69850</ArticleId>
    </ArticleIdList>
    <Abstract>We present a case of a woman in her 70s who was diagnosed with mesonephric adenocarcinoma of the uterine cervix, following biopsy and surgery. Preoperative MRI revealed a 7-cm, well-defined circumferential cervical mass with left lateral wall predominance, bulging into the uterine cavity and vagina. The lesion showed intermediate signal intensity on T2-weighted images, diffusion restriction, and early contrast enhancement weaker than that of the myometrium, followed by washout on contrast-enhanced imaging. The circumferential growth pattern with the lateral wall predominance and its imaging characteristics may suggest this rare entity be routinely included in the differential diagnosis of cervical cancers.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">mesonephric adenocarcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cervical cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MRI imaging characteristics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HPV-independent adenocarcinoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Exacerbation of Proteinuria in a Patient with Behçet’s Disease and IgA Nephropathy Following Colchicine Discontinuation</ArticleTitle>
    <FirstPage LZero="delete">457</FirstPage>
    <LastPage>461</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomohiko</FirstName>
        <LastName>Asakawa</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimasa</FirstName>
        <LastName>Sakurabu</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Onishi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsumi</FirstName>
        <LastName>Matsuoka-Uchiyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidemi</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoko</FirstName>
        <LastName>Umebayashi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rika</FirstName>
        <LastName>Takemoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69849</ArticleId>
    </ArticleIdList>
    <Abstract>This case involves a 23-year-old male who was diagnosed with Behçet’s disease 5 years ago and managed with colchicine. Two months ago, he underwent renal biopsy due to abnormal urinalysis and kidney dysfunction, leading to a diagnosis of IgA nephropathy. He subsequently underwent tonsillectomy followed by glucocorticoid pulse therapy. However, after the tonsillectomy, discontinuing colchicine led to increased proteinuria, despite the glucocorticoid pulse therapy. Upon reintroducing colchicine, urinary protein excretion decreased, achieving incomplete remission. These findings suggest that colchicine may be effective in decreasing proteinuria in patients with Behçet’s disease complicated by IgA nephropathy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Behçet’s disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">IgA nephropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">colchicine</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2399-3642</Issn>
      <Volume>8</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Single-cell and spatial transcriptomic characterization of pulmonary pleomorphic carcinoma</ArticleTitle>
    <FirstPage LZero="delete">1773</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Ohki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Hisamatsu</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Ishimura</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryunosuke</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Higashihara</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiro</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Yoshichika</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiaki</FirstName>
        <LastName>Mukohara</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mao</FirstName>
        <LastName>Yoshikawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuma</FirstName>
        <LastName>Fukumoto</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Suzawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuaki</FirstName>
        <LastName>Tomioka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaroh</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikio</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiichiro</FirstName>
        <LastName>Sugimoto</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pulmonary pleomorphic carcinoma (PPC) is a rare subtype of lung cancer that comprises both epithelial and sarcomatoid components. The molecular basis of PPC, including the cellular dynamics of its components, remains largely unknown. To elucidate potential therapeutic targets for PPC, we perform a multi-omics analysis incorporating digital spatial profiling and single-cell RNA sequencing (scRNA-seq). PPC exhibits diverse driver gene alterations, including MET exon 14 skipping mutation (METex14) and ALK fusion. In spatial transcriptomics, MET gene and protein are overexpressed exclusively within the epithelial component and not in the sarcomatoid component, even in patients harboring METex14. Epithelial-mesenchymal transition (EMT)-related transcriptional changes, along with extracellular matrix (ECM) remodeling between the epithelial and sarcomatoid components, are observed. scRNA-seq identifies cell populations within the epithelial component that contribute to the malignant transformation and differentiation of the sarcomatoid component. They are characterized by an intermediate EMT state with ECM remodeling signature, suggesting their potential as novel therapeutic targets for PPC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2468-2942</Issn>
      <Volume>45</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Neoadjuvant FOLFOXIRI for locally advanced rectal cancer: A retrospective analysis focusing on long-term anal preservation</ArticleTitle>
    <FirstPage LZero="delete">101049</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiko</FirstName>
        <LastName>Kanaya</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>To investigate the safety and efficacy of FOLFOXIRI as neoadjuvant chemotherapy (NAC) for locally advanced rectal cancer (LARC). The outcomes of preoperative and perioperative treatments, as well as long-term outcomes, were retrospectively compared between 26 patients who underwent FOLFOXIRI as NAC for LARC with cT3–4 and/or N+ at our institute between 2015 and 2022, and 31 patients with LARC who underwent neoadjuvant chemoradiotherapy (CAPOX-RT) at our institute between 2011 and 2022. Grade 3 or higher adverse events due to neoadjuvant treatment were significantly more common in the FOLFOXIRI group (11 cases, 42.3 %) than in the CAPOX-RT group (3 cases, 9.7 %), and most of these were neutropenia. Based on the postoperative pathological findings, the complete response rate was significantly lower in the FOLFOXIRI group (1 case, 3.8 %) than in the CAPOX-RT group (7 cases, 22.6 %), but there were no significant differences in the R0 resection rate, survival rate, or relapse-free survival rate. In the CAPOX-RT group, 17 patients (54.8 %) had anal preservation, and during the observation period, 4 patients required stoma construction due to loss of anal function in the late stage. In contrast, in the FOLFOXIRI group, there were no cases of loss of anal function among the 20 patients (76.9 %) who had anal preservation. FOLFOXIRI as NAC requires caution regarding hematological toxicity, but it can be an effective treatment option for patients with LARC who wish to preserve their anus.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Locally advanced rectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Neoadjuvant chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">FOLFOXIRI</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Late pelvic toxicity</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1424-3903</Issn>
      <Volume>25</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficacy of diagnosing intraductal papillary mucinous neoplasm with mural nodules by contrast-enhanced endoscopic ultrasound using time–intensity curve analysis with a new support program: A multicenter retrospective study (with video)</ArticleTitle>
    <FirstPage LZero="delete">1103</FirstPage>
    <LastPage>1108</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Saragai</LastName>
        <Affiliation>Department of Internal Medicine, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuneyoshi</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Internal Medicine, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Ueki</LastName>
        <Affiliation>Department of Internal Medicine, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Harada</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nao</FirstName>
        <LastName>Hattori</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taisuke</FirstName>
        <LastName>Obata</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Terasawa</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Horiguchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Tsutsumi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Uemoto</LastName>
        <Affiliation>Business Strategy Division, Ryobi Systems Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayoshi</FirstName>
        <LastName>Tanimoto</LastName>
        <Affiliation>Business Strategy Division, Ryobi Systems Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akimitsu</FirstName>
        <LastName>Ohto</LastName>
        <Affiliation>Business Strategy Division, Ryobi Systems Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/objectives: Preoperative diagnosis of the pathological grade of intraductal papillary mucinous neoplasms (IPMN) is challenging. This study aimed to evaluate the accuracy of contrast-enhanced endoscopic ultrasound (CE-EUS) using time–intensity curve (TIC) analysis with a newly developed support program to differentiate between low-grade dysplasia (LGD) and high-grade dysplasia (HGD)/invasive carcinoma (IC) in IPMN.&lt;br&gt;
Methods: This study retrospectively analyzed 32 patients who underwent CE-EUS using the support program for TIC analysis and IPMN resection (LGD: 17, HGD/IC: 15) at two medical centers. The TIC parameters of mural nodules (MN) were compared between the LGD and HGD/IC groups, and the diagnostic accuracies of the TIC parameters were evaluated.&lt;br&gt;
Results: The MN/pancreatic parenchyma contrast ratio was significantly higher in the HGD/IC group than in the LGD group (1.53 vs. 0.99; P &lt; 0.0001), and the diagnostic abilities of the contrast ratio were as follows: sensitivity, 67 %; specificity, 100 %; and accuracy, 84 %. There were no differences in the echo intensity reduction rate of the MNs between the two groups (HGD/IC, 61.6 vs. 61.2, 0.99; P = 0.421), and the diagnostic abilities of the reduction rate were as follows: sensitivity, 93 %; specificity, 41 %; and accuracy, 66 %.&lt;br&gt;
Conclusions: The contrast ratio calculated using TIC analysis with the support program is potentially useful for differentiating between IPMNs with LGD and those with HGD/IC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Endoscopic ultrasonography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pancreatic intraductal papillary mucinous neoplasm</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Neoplasm grading</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Contrast agent</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>64</Volume>
      <Issue>23</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Remarkable Efficacy of Capmatinib in a Patient with Cancer of Unknown Primary with MET Amplification</ArticleTitle>
    <FirstPage LZero="delete">3460</FirstPage>
    <LastPage>3464</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takaaki</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Makimoto</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Sumii</LastName>
        <Affiliation>Department of General Internal Medicine, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rika</FirstName>
        <LastName>Omote</LastName>
        <Affiliation>Department of Pathology, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yayoi</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Clinical Research Support Office, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Ichihara</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Tabata</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This case report describes a 70-year-old female with cancer of unknown primary origin (CUP) who exhibited multiple distant lymph node metastases. Despite conventional chemotherapy (carboplatin and paclitaxel) and immunotherapy (nivolumab), disease progression was noted. Genomic profiling revealed MET amplification, leading to the administration of capmatinib, a selective MET tyrosine kinase inhibitor. The patient experienced substantial tumor reduction with dose adjustments due to adverse effects, indicating the potential efficacy of capmatinib in treating CUP with MET amplification.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">MET amplification</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">capmatinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MET inhibitors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cancer of unknown primary</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MET exon 14 skipping</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0167-4889</Issn>
      <Volume>1873</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>SPRED2 controls the severity of cisplatin-induced acute kidney injury by inhibiting ERK activation and TNFα production in mice</ArticleTitle>
    <FirstPage LZero="delete">120091</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Xu</FirstName>
        <LastName>Yang</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jiali</FirstName>
        <LastName>He</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tong</FirstName>
        <LastName>Gao</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Steven L.</FirstName>
        <LastName>Kunkel</LastName>
        <Affiliation>Department of Pathology, University of Michigan Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teizo</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cisplatin is an effective chemotherapeutic agent used to treat solid tumors, but its clinical use is limited by acute kidney injury (AKI), in which ERK signaling plays a crucial role. Here, we investigated whether Sprouty-related EVH1 domain-containing protein 2 (SPRED2), an endogenous inhibitor of the Ras/Raf/ERK pathway, protects against cisplatin-induced AKI. Spred2−/− mice showed more severe renal injury and stronger ERK activation than wild-type (WT) mice, whereas pretreatment with the MEK inhibitor U0126 markedly attenuated the injury. In HK-2 cells (proximal tubular cells), SPRED2 knockdown enhanced cisplatin-induced apoptosis and caspase-3 activation, accompanied by decreased Bcl-2 expression. Spred2−/− kidneys displayed increased macrophage infiltration and elevated Tnfα, Il1b, and Ccl2 expression. Neutralization of TNFα with anti-TNFα antibody ameliorated renal injury and reduced the levels of Il1b and Ccl2 mRNA in Spred2−/− mice. In vitro, TNFα slightly decreased the viability of control and SPRED2 knockdown HK-2 cells without cisplatin treatment, but the decreased viability was augmented in SPRED2 knockdown cells by cisplatin. Immunohistochemistry revealed that macrophages were the predominant TNFα-positive cell population. Bone marrow–derived macrophages from Spred2−/− mice produced higher levels of TNFα in response to cisplatin compared with control cells, and this increase was markedly suppressed by U0126.&lt;br&gt;
These findings indicate that endogenous SPRED2 protects kidneys from cisplatin-induced AKI by limiting ERK activation, tubular apoptosis, and TNFα-mediated inflammation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cisplatin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ERK</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Macrophage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SPRED2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TNFα</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1865-7257</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Avoiding splenectomy in splenic sclerosing angiomatoid nodular transformation through endoscopic ultrasound-guided tissue acquisition: a 36-month follow-up case report</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takaki</FirstName>
        <LastName>Okuyama</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosaku</FirstName>
        <LastName>Morimoto</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayoshi</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Pathology, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Satomi</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Takei</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Takenaka</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A 48-mm splenic mass was incidentally discovered in a 78-year-old man upon computed tomography. Follow-up imaging at 12 months revealed enlargement to 60 mm, prompting endoscopic ultrasound-guided tissue acquisition with a 22-gauge needle. Histopathological analysis confirmed that it was a sclerosing angiomatoid nodular transformation. The patient was asymptomatic and had no hematologic abnormalities; therefore, splenectomy was not performed. After biopsy, the lesion regressed from 60 mm to 46 mm, possibly owing to hematoma formation or vascular disruption, and remained stable during 36 months of follow-up. Although splenectomy has been performed in most reported cases of sclerosing angiomatoid nodular transformation because of diagnostic uncertainty, a few recent reports have demonstrated that sclerosing angiomatoid nodular transformation can be diagnosed by endoscopic ultrasound-guided tissue acquisition, thereby avoiding splenectomy. This case highlights the diagnostic utility of endoscopic ultrasound-guided tissue acquisition and supports spleen-preserving management for biopsy-proven sclerosing angiomatoid nodular transformation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Sclerosing angiomatoid nodular transformation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Spleen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Endoscopic ultrasound-guided tissue acquisition</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Conservative management</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Biopsy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1433-7398</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A rare case of supratentorial ependymosarcoma harboring ZFTA::RELA fusion</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuki</FirstName>
        <LastName>Suruga</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaishi</FirstName>
        <LastName>Satomi</LastName>
        <Affiliation>Department of Pathology, Faculty of Medicine, Kyorin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiko</FirstName>
        <LastName>Hattori</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Kurozumi</LastName>
        <Affiliation>Department of Neurosurgery, Hamamatsu University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sumihito</FirstName>
        <LastName>Nobusawa</LastName>
        <Affiliation>Department of Human Pathology, Gunma University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Hirato</LastName>
        <Affiliation>Department of Pathology, Public Tomioka General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yanai</LastName>
        <Affiliation>Department of Pathology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Washio</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Ichimura</LastName>
        <Affiliation>Department of Pathology, Faculty of Medicine, Kyorin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomotsugu</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation>Department of Neurosurgery, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Ependymosarcoma is an exceedingly rare variant of ependymoma characterized by a mixture of ependymomatous and sarcomatous components. We report a case of supratentorial ependymosarcoma harboring a ZFTA::RELA fusion in a 10-year-old girl. Histologically, the tumor comprised an ependymomatous component resembling clear cell ependymoma and a sarcomatous component. ZFTA::RELA fusion was confirmed in both components. Genome-wide methylation profiling classified both components as supratentorial ependymoma, ZFTA fusion–positive by the German Cancer Research Center (DKFZ) CNS tumor classifier v12b8. However, their copy number alteration profiles were distinct. The ependymomatous component exhibited a gain of chromosome 1q and a loss of chromosomes 1p, 9, and 19q, while the sarcomatous component showed a loss of chromosome 14. These findings suggest that both components may have differentiated from a common precursor despite their distinct morphologies. The patient underwent gross total resection followed by adjuvant chemoradiotherapy and remains recurrence-free eight years post-treatment. Further investigation of additional cases is warranted to better understand the pathogenesis of this rare tumor.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Ependymoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Ependymosarcoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ZFTA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">RELA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Methylation profiling</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Risk Stratification for the Prediction of Skeletal-Related Events in Patients With Bone Metastases From Non-small Cell Lung Cancer</ArticleTitle>
    <FirstPage LZero="delete">e95808</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Orthopedic Surgery, Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Skeletal-related events (SREs) frequently occur in patients with bone metastases from non-small cell lung cancer (NSCLC). This study aimed to identify risk factors for SREs in patients with NSCLC. Based on these factors, we also aimed to stratify patients into subgroups to facilitate the assessment of SRE risk. This retrospective analysis used medical records of 139 patients with NSCLC bone metastases who received treatment at our institution between 2011 and 2014. The incidence of SREs was assessed, and SRE-free survival was analyzed using the Kaplan-Meier method. Clinical information collected at registration was assessed to identify factors associated with the onset of SREs within six months. Univariate analysis was performed using Fisher’s exact test, and multivariate analysis was performed using Cox regression. Of the 139 patients, 36 (26%) developed SREs after registration. The SRE-free survival rates were 80% and 64% at 6 and 12 months, respectively. The univariate and multivariate analyses revealed that the absence of epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangement (hazard ratio (HR): 4.51, 95% confidence interval (CI): 1.32-15.7, p = 0.017) and a lactate dehydrogenase (LDH) level ≥400 U/L (HR: 8.08, 95% CI: 1.78-36.6, p = 0.0067) were risk factors for SRE presentation within six months. Patients were classified into the following three subgroups: with EGFR mutation or ALK rearrangement and LDH level &lt;400 U/L; without EGFR mutation or ALK rearrangement and LDH level &lt;400 U/L; with/without EGFR mutation or ALK rearrangement and LDH level ≥400 U/L. The corresponding six-month SRE-free survival rates were 92%, 69%, and 34%, respectively, showing significant differences (p &lt; 0.001). Close monitoring is recommended for patients with LDH levels ≥400 U/L in daily clinical practice, particularly with the help of the proficiency of orthopedic and radiological experts, to prevent complications such as pathological fractures and paraplegia.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anaplastic lymphoma kinase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bone metastases</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">epidermal growth factor receptor-tyrosine kinase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lactate dehydrogenase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">non-small cell lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">skeletal related events</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>High Prevalence of MYD88 and CD79B Mutations in Primary Sinonasal Diffuse Large B-Cell Lymphoma: Identification of an MCD-like Subtype</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">FANGLI</FirstName>
        <LastName>PENG</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1320-5358</Issn>
      <Volume>30</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Case of IgA Nephropathy With Membranoproliferative Glomerulonephritis-Like Features Miyu Kanazawa, </ArticleTitle>
    <FirstPage LZero="delete">e70057</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Miyu</FirstName>
        <LastName>Kanazawa</LastName>
        <Affiliation>Okayama University Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoya</FirstName>
        <LastName>Aoki</LastName>
        <Affiliation>Okayama University Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mihiro</FirstName>
        <LastName>Sue</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromasa</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naruhiko</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Nakanoh</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A 73-year-old man was referred due to the onset of nephrotic-range proteinuria. He had been diagnosed with rheumatoid arthritis 18 years prior and had achieved remission with treatment, including methotrexate and janus kinase (JAK) inhibitor. Although routine follow-ups had not revealed any urinary abnormalities, subsequent tests detected proteinuria and hematuria in the absence of infection or other symptoms. As the urinary abnormalities persisted, with a serum albumin decrease and proteinuria measuring 5.7 g/day, indicating nephrotic syndrome, the patient was referred to our hospital for further evaluation, and a renal biopsy was performed. Light microscopy revealed mesangial cell proliferation, endocapillary proliferation and double-contoured basement membranes. Immunofluorescence microscopy showed IgA-dominant deposits in both mesangial areas and glomerular capillary walls. Transmission electron microscopy demonstrated electron-dense deposits in the mesangium and subendothelial regions, leading to the diagnosis of membranoproliferative glomerulonephritis (MPGN)-type IgA nephropathy. Immunostaining with the Gd-IgA1 (galactose-deficient IgA1)-specific antibody (KM55) was positive, consistent with the diagnosis. Following the initiation of steroid therapy, proteinuria rapidly decreased, achieving complete remission within 5 months. IgA nephropathy with MPGN-like features often presents as nephrotic syndrome, differing from the typical pathological and clinical presentation of IgA nephropathy, making differentiation from secondary MPGN and other diseases sometimes challenging. This case suggests that KM55 staining may offer additional information in differentiating atypical IgA nephropathy with non-classical pathological features.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Gd-IgA1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">IgA nephropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">membranoproliferative glomerulonephritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nephrotic syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rheumatoid arthritis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0929-1903</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>p53-armed oncolytic adenovirus induces apoptosis in pancreatic cancer-associated stellate cells via macropinocytosis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takeyoshi</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Nagai</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Kajiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoyuki</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuzo</FirstName>
        <LastName>Umeda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyoshi Y.</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Okayama University Graduate School of Interdisciplinary Science and Engineering in Health Systems</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsunobu R.</FirstName>
        <LastName>Kano</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Okayama University Graduate School of Interdisciplinary Science and Engineering in Health Systems</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Masamune</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Urata</LastName>
        <Affiliation>Oncolys BioPharma, Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pancreatic ductal adenocarcinoma (PDAC)-associated pancreatic stellate cells (PSCs) promote PDAC tumor progression. Notably, PDAC tumors display enhanced macropinocytosis, resulting in enhanced uptake of extracellular particles, including nutrients and viruses. We previously demonstrated the therapeutic potential of telomerase-specific oncolytic adenoviruses OBP-301 and p53-armed OBP-702 against human PDAC cells. However, it remains unclear whether macropinocytosis promotes the virus sensitivity of PDAC-associated PSCs. Here, we show that PSCs activated by human PDAC cells (Panc-1 and BxPC-3) exhibit enhanced sensitivity to wild-type and oncolytic adenoviruses via enhanced macropinocytosis. The virus sensitivity of PSCs was analyzed for the infectivity, replication, and cytopathic activity of wild-type and oncolytic adenoviruses. PDAC-associated PSCs were more sensitive to wild-type and oncolytic adenoviruses than were control PSCs; this sensitivity was mediated by activation of macropinocytosis. In three-dimensional (3D) culture models, p53-armed OBP-702 decreased the viability of PDAC-associated PSCs more strongly than did non-armed OBP-301, reflecting induction of p53-mediated apoptosis. Co-inoculation of PSCs enhanced the growth of PDAC tumors, an effect that was attenuated by OBP-702-mediated p53 activation in the tumor stroma. Our results suggest that p53-armed oncolytic adenovirus OBP-702 eliminates PDAC-associated PSCs via enhancement of macropinocytosis-mediated virus entry and induction of p53-mediated apoptosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2073-4409</Issn>
      <Volume>14</Volume>
      <Issue>18</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effect of Oral Peritumoral Tissue on Infiltration and Differentiation of Tumor-Associated Macrophages in Oral Squamous Cell Carcinoma</ArticleTitle>
    <FirstPage LZero="delete">1481</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tianyan</FirstName>
        <LastName>Piao</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyofumi</FirstName>
        <LastName>Takabatake</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuma</FirstName>
        <LastName>Arashima</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yulu</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Htoo Shwe</FirstName>
        <LastName>Eain</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yamin</FirstName>
        <LastName>Soe</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zin Zin</FirstName>
        <LastName>Min</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The recruitment of tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) of oral squamous carcinoma (OSCC) affects significant cancer invasion; however, in the normal host tissue that is located in the cancer’s surrounding area, this is poorly investigated. In this study, we examined the impact of gingival connective tissue cells (GCTCs) and periodontal ligament cells (PDLCs), which are involved in the invasive pathway of OSCC, on oral cancer invasion via TAMs recruitment. Transwell (migration) assays were used to examine the effects of GCTCs and PDLCs on the migration of macrophages, which indicated that the interaction between GCTCs and HSC-2/HSC-3 (human oral squamous cell carcinoma cell line) promoted the recruitment of macrophages, whereas the interaction between PDLCs was inhibited. An indirect co-culture was then used to examine the effects of GCTCs and PDLCs on the differentiation of macrophages, which indicated that the interaction between GCTCs enhanced their ability to transform into M2-type macrophages. Furthermore, the effects of GCTCs and PDLCs on the recruitment of CD45(+) monocytes, F4/80(+) M0 macrophages, iNOS(+) M1 macrophages, and CD163(+) M2 TAMs were assayed by immunohistochemistry. The results revealed that the interaction between GCTCs and HSC-2/HSC-3 promoted the infiltration of CD45(+) monocytes, F4/80(+) M0 macrophages, and CD163(+) M2 TAMs, whereas the PDLCs inhibited it, while their effect on iNOS(+) M1 macrophages was limited. Collectively, the GCTCs contributed to the infiltration of TAMs into the TME of OSCC cells, whereas the PDLCs exerted an inhibitory effect. These findings suggest a potential regulatory mechanism underlying the progression of OSCC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">oral squamous cell carcinoma (OSCC)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gingival connective tissue cells (GCTCs)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontal ligament cells (PDLCs)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor-associated macrophages (TAMs)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">macrophage polarity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor microenvironment (TME)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6694</Issn>
      <Volume>17</Volume>
      <Issue>17</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Refining the Role of Tumor-Associated Macrophages in Oral Squamous Cell Carcinoma</ArticleTitle>
    <FirstPage LZero="delete">2770</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kiyofumi</FirstName>
        <LastName>Takabatake</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Piao</FirstName>
        <LastName>Tianyan</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuma</FirstName>
        <LastName>Arashima</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Anqi</FirstName>
        <LastName>Chang</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Htoo Shwe</FirstName>
        <LastName>Eain</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yamin</FirstName>
        <LastName>Soe</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zin Zin</FirstName>
        <LastName>Min</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masae</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>In the tumor microenvironment, various immune and stromal cells, such as fibroblasts and vascular endothelial cells, contribute to tumor growth and progression by interacting with cancer cells. Tumor-associated macrophages (TAMs) have attracted attention as major players in the tumor microenvironment. The origin of TAMs is believed to be the infiltration of monocytes derived from bone marrow progenitor cells into tumor tissues and their differentiation into macrophages, whereas tissue-resident macrophages derived from yolk sacs have recently been reported. TAMs infiltrating tumor tissues act in a tumor-promoting manner through immunosuppression, angiogenesis, and the promotion of cancer cell invasion. Reflecting the nature of TAMs, increased TAM invasion and TAM-specific gene expression in tumor tissues may be the new biomarkers for cancer. Moreover, new therapeutic strategies targeting TAMs, such as transformation into immunostimulatory macrophages, suppression of TAM infiltration, and promotion of phagocytosis, are being investigated, and many clinical trials are underway. As the origin and function of TAMs are further elucidated, TAM-targeted therapy is expected to become a new option for the immunotherapy of various cancers, including oral cancers.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">tumor-associated macrophage (TAM)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oral squamous cell carcinoma (OSCC)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">macrophage polarity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">invasion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">carcinogenesis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Ivyspring International Publisher</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1837-9664</Issn>
      <Volume>16</Volume>
      <Issue>14</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>CXCR4 Inhibition Induces Tumor Necrosis by Selectively Targeting the Proliferating Blood Vessels in Oral Squamous Cell Carcinoma</ArticleTitle>
    <FirstPage LZero="delete">4055</FirstPage>
    <LastPage>4070</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yamin</FirstName>
        <LastName>Soe</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Htoo Shwe</FirstName>
        <LastName>Eain</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saori</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Preliminary Examination Room, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">May Wathone</FirstName>
        <LastName>Oo</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zin Zin</FirstName>
        <LastName>Min</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyofumi</FirstName>
        <LastName>Takabatake</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The C-X-C chemokine receptor type 4 (CXCR4) is a G protein-coupled transmembrane receptor that contributes to tumor growth and angiogenesis. While prior studies have primarily focused on CXCR4 expression in cancer cells and its role in metastasis, a few have examined its involvement in tumor-associated vasculature. In this study, we reported for the first time that CXCR4 expression within the tumor vasculature is significantly associated with higher pathological grades of human oral squamous cell carcinoma (OSCC) (p&lt;0.03). A previous study reported that inhibiting CXCR4 with AMD3100 induces tumor cell death and enhances the efficacy of the chemotherapeutic agent cisplatin. These findings suggest that CXCR4 is an important target for cancer treatment. However, the tumor vascular system is known to be heterogeneous within the tumor microenvironment (TME), which may influence the treatment outcomes. Therefore, this study aimed to explore the effect of CXCR4 antagonism on various blood vessels present within the oral squamous cell carcinoma (OSCC) tumor stroma. Although the efficiency of AMD3100 was not significant in MOC cancer cells, necrosis was induced in the TME when applied to a poorly differentiated OSCC model, highlighting the role of the TME. Notably, CXCR4 is found to be highly overlapped with CD105+ angiogenic tumor vessels among various vascular markers. Treatment with AMD3100 leads to a marked reduction in the CD105+ vessels and impairs the maturation of tumor micro-vessels, explaining the cause of observed necrosis. Thus, CXCR4 serves as a promising biomarker in OSCC, and its inhibition with AMD3100 offers the therapeutic potential, particularly in cases with advanced pathological grades.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CXCR4</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor angiogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chemokine receptors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor microenvironment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oral squamous cell carcinoma (OSCC)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">AMD3100</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2470-9239</Issn>
      <Volume>10</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Decreased homovanillic acid and 5‐hydroxyindoleacetic acid levels in the cerebrospinal fluid of patients with Dravet syndrome with parkinsonism</ArticleTitle>
    <FirstPage LZero="delete">965</FirstPage>
    <LastPage>970</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Sugiyama</LastName>
        <Affiliation>Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuko</FirstName>
        <LastName>Katsumoto</LastName>
        <Affiliation>Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Yoneno</LastName>
        <Affiliation>Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Akiyama</LastName>
        <Affiliation>Department of Pediatric Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Komaki</LastName>
        <Affiliation>Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Dravet syndrome (DS) is an early onset, developmental, and epileptic encephalopathy characterized by drug-resistant seizures and multiple comorbidities. It has been reported that in adulthood, it may be accompanied by parkinsonism, but the pathogenesis of this condition remains unclear. We performed dopamine transporter single-photon emission computed tomography (DAT SPECT) and measured monoamine metabolite levels in the cerebrospinal fluid (CSF) in two adult patients with DS who developed parkinsonism around the age of 30 years. DAT SPECT showed no abnormalities in either patient, whereas CSF tests revealed significant decreases in the levels of homovanillic and 5-hydroxyindoleacetic acids. One patient with severe symptoms was treated with levodopa–carbidopa, which improved parkinsonism manifestations. The other patient initiated treatment with a low dose and has been continuing the treatment without any reported side effects. In conclusion, CSF testing can detect a decrease in dopamine synthesis and may be useful in monitoring the efficacy of levodopa treatment in patients with DS and parkinsonism.&lt;br&gt;
Plain Language Summary: Dravet syndrome (DS) is an early onset, developmental, and epileptic encephalopathy. DS can lead to the development of parkinsonism in adulthood, a clinical syndrome characterized by tremor, slowed movements, and rigidity. Although parkinsonism is a significant issue for patients, its underlying pathology has not yet been elucidated. In this study, we confirmed that the levels of monoamine metabolites in the CSF were low in two patients, potentially shedding light on the pathology involved.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">dopamine transporter</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">levodopa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">monoamine metabolites</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">single-photon emission computed tomography</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Bioscientifica</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2052-0573</Issn>
      <Volume>2025</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Adult hypophosphatasia presenting with recurrent acute joint pain</ArticleTitle>
    <FirstPage LZero="delete">e240121</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hayao</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Diabetes and Endocrinology, Shiga General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaaki</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Department of Diabetes and Endocrinology, Shiga General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsubumi</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Sunouchi</LastName>
        <Affiliation>Division of Nephrology and Endocrinology, The University of Tokyo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoko</FirstName>
        <LastName>Hidaka</LastName>
        <Affiliation>Division of Nephrology and Endocrinology, The University of Tokyo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuaki</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Osteoporosis Center, The University of Tokyo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromi</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Department of Genomic Medicine, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidenori</FirstName>
        <LastName>Kawasaki</LastName>
        <Affiliation>Department of Genomic Medicine, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Akiyama</LastName>
        <Affiliation>Department of Child Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsumi</FirstName>
        <LastName>Nakajima</LastName>
        <Affiliation>Department of Diabetes and Endocrinology, Shiga General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Yabe</LastName>
        <Affiliation>Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taizo</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Diabetes and Endocrinology, Shiga General Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Hypophosphatasia (HPP) is a genetic disorder due to pathological variants in ALPL, the gene encoding tissue-nonspecific alkaline phosphatase (ALP). HPP is typically associated with bone-related symptoms, such as bone deformity, fractures and bone pain in children, but can appear in adults with symptoms resembling arthritis. A 22-year-old male experienced repeated and severe sudden attacks of joint pain in the elbows and knees. Magnetic resonance imaging and joint ultrasonography showed joint effusions indicating chronic inflammation. Blood biochemical tests revealed a remarkably low serum ALP level, and repeated examination confirmed a sustained low ALP level; urine phosphoethanolamine, plasma inorganic pyrophosphate and plasma pyridoxal-5′-phosphate levels were elevated, raising concern for HPP. While the patient had no history of premature loss of primary teeth, fragility fractures, muscle weakness or abnormalities in growth, genetic testing revealed a likely pathogenic and a pathogenic heterozygous variant in the ALPL gene, i.e., c.979T&gt;C (p.Phe327Leu) and c.1559del (p.Leu520Argfs), confirming HPP. Additional genetic testing of his parents showed a heterozygous c.1559del variant in his father and a heterozygous c.979T&gt;C variant in his mother. A diagnosis of adult HPP due to compound heterozygous mutations was therefore confirmed. Enzyme replacement therapy with asfotase alfa was then introduced; no attacks of arthralgia occurred in the 1-year period since then. This case highlights the possibility of HPP in adults who present clinically with repeated joint symptoms and low serum ALP levels but without bone-related symptoms.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">hypophosphatasia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">genetic disorders</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bone</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0007-1048</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Ishiyama</LastName>
        <Affiliation>Department of Hematology, Kanazawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahide</FirstName>
        <LastName>Yamazaki</LastName>
        <Affiliation>Department of Internal Medicine, Keiju Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Hematology, Kanazawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoko</FirstName>
        <LastName>Hosono</LastName>
        <Affiliation>Department of Hematology and Oncology, University of Fukui Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Yamaguchi</LastName>
        <Affiliation>Department of Hematology, Nippon Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noboru</FirstName>
        <LastName>Asada</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Tanimoto</LastName>
        <Affiliation>Department of Hematology and Oncology, Japanese Red Cross Fukuoka Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Sugiura</LastName>
        <Affiliation>Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Usuki</LastName>
        <Affiliation>Department of Hematology, NTT Medical Center Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Department of Biostatistics and Health Data Science, Graduate School of Medical Science, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seishi</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Pathology and Tumor Biology, Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuzuru</FirstName>
        <LastName>Kanakura</LastName>
        <Affiliation>Sumitomo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Itaru</FirstName>
        <LastName>Matsumura</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Akashi</LastName>
        <Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Hematology, Kanazawa University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The efficacy of ciclosporin (CsA) to treat transfusion-independent non-severe aplastic anaemia (TI-NSAA) has not yet been systematically evaluated. We conducted a prospective trial in patients with TI-NSAA treated with CsA monotherapy. CsA (3.5 mg/kg/day) was administered to patients with TI-NSAA aged ≥16. The CsA dose was adjusted to maintain a blood CsA level of ≥600 ng/mL at 2 h post-administration. Blood cell counts were assessed after 8, 16 and 52 weeks of therapy. Thirty-two evaluable patients from 21 institutions were enrolled. The median age was 63.5 (range: 16–83) years. At 8 weeks, haematological improvement, with increases in haemoglobin (Hb) ≥1.5 g/dL (haematological improvement in erythrocytes [HI-E]) and platelet count ≥30 × 109/L (haematological improvement in platelets [HI-P]), was observed in 0/25 (0%) and 6/32 (19%) evaluable cases respectively. HI-E and HI-P occurred in 1/25 (4%) and 10/32 (31%) patients at 16 weeks, respectively, and at 52 weeks in 5/25 (20%) and 16/32 (50%) patients respectively. Nine grade 3 adverse events (AEs) occurred in six patients, but there were no grade ≥4 AEs. Ten of the 32 patients experienced grade 2 renal toxicity. Low-dose CsA is effective in TI-NSAA patients and demonstrates minimal renal toxicity. However, at least 16 weeks are necessary to adequately evaluate its efficacy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">ciclosporin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prospective study</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">renal toxicity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transfusion-independent non-severe aplastic anaemia</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0040-8166</Issn>
      <Volume>98</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The vicious cycle between nutrient deficiencies and antibiotic-induced nutrient depletion at the host cell-pathogen interface: Coenzyme Q10 and omega-6 as key molecular players</ArticleTitle>
    <FirstPage LZero="delete">103224</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Darab</FirstName>
        <LastName>Ghadimi</LastName>
        <Affiliation>Department of Microbiology and Biotechnology, Max Rubner-Institut</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sophia</FirstName>
        <LastName>Blömer</LastName>
        <Affiliation>Faculty of Medicine, Christian-Albrechts-University of Kiel</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aysel</FirstName>
        <LastName>Şahi̇n Kaya</LastName>
        <Affiliation>Department of Nutrition and Dietetics, Faculty of Health Sciences, Antalya Bilim University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sandra</FirstName>
        <LastName>Krüger</LastName>
        <Affiliation>Institute of Pathology, Kiel University, University Hospital, Schleswig-Holstein</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Christoph</FirstName>
        <LastName>Röcken</LastName>
        <Affiliation>Institute of Pathology, Kiel University, University Hospital, Schleswig-Holstein</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Heiner</FirstName>
        <LastName>Schäfer</LastName>
        <Affiliation>Laboratory of Molecular Gastroenterology &amp; Hepatology, Christian-Albrechts-University &amp; UKSH Campus Kiel</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jumpei</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Bacteriology, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigenobu</FirstName>
        <LastName>Matsuzaki</LastName>
        <Affiliation>Department of Medical Laboratory Science, Faculty of Health Sciences, Kochi Gakuen University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wilhelm</FirstName>
        <LastName>Bockelmann</LastName>
        <Affiliation>Department of Microbiology and Biotechnology, Max Rubner-Institut</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The increasing prevalence of antibiotic resistance and pathological inflammation underscores the importance of understanding the underlying biochemical and immune processes that govern the host-pathogen interface. Nutrient deficiency, compounded by antibiotic-induced nutrient depletion, forms a vicious cycle of overt inflammation, contributing to bacterial toxin translocation in human inter-organ and intra-organs milieus. Coenzyme Q10 (CoQ10) and omega-6 linoleic acid (LA 18:2ω6) are integral to cellular membrane integrity and immune defense. However, the complex enzymatic steps at the host cell-pathogen interface remain poorly understood. This study is particularly timely, as it explores these knowledge gaps, which can inform the development of nutritional and therapeutic strategies that modulate or target these mechanisms. Using an infectious-inflamed cell co-culture model of the gut-liver axis, we exposed triple cell co-cultures of human intestinal epithelial cells (T84), macrophage-like THP-1 cells, and hepatic cells (Huh7) to linoleic acid-producing Lactobacillus casei (L. casei) and Pseudomonas aeruginosa strain PAO1 (PAO1). The cultures were incubated for 6 h in medium with or without ceftazidime antibiotic. PAO1 and L. casei exerted opposing effects on the secretion of Th1 cytokines IL-1β, IL-6, and the Th 2-type cytokine IL-10. Inoculation with PAO1 decreased CoQ10 and linoleic acid levels compared to uninfected controls. L. casei restored cellular health and biofunctionality impaired by PAO1, indicating its benefit to the host's well-being. The antibiotic ceftazidime exerted dual effects, alleviating PAO1 toxicity while marginally disrupting the beneficial effects of L. casei. Our results show how the vicious cycle of nutrient deficiency and antibiotic-induced nutrient loss reinforces pathological inflammation at the host cell-pathogen interface and highlights the need for more appropriate targeted antibiotic use that preserves essential nutrients like CoQ10 and omega-6 fatty acids. Inflammatory responses driven by opportunistic pathogens and LA-producing bacteria represent opposing immunometabolic pathways that may provide insights into novel approaches for treating infection and reducing antibiotic resistance.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Antibiotics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Coenzyme Q10</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Inflammation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Micronutrients</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oxidative stress</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-9625</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2024 for the clinical practice of hereditary colorectal cancer</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kohji</FirstName>
        <LastName>Tanakaya</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuro</FirstName>
        <LastName>Yamaguchi</LastName>
        <Affiliation>Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiji</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Surgery 1, University of Occupational and Environmental Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Endoscopy Division, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Kumamoto</LastName>
        <Affiliation>Department of Genome Medical Science and Medical Genetics, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuki</FirstName>
        <LastName>Akiyama</LastName>
        <Affiliation>Department of Surgery 1, University of Occupational and Environmental Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Ishimaru</LastName>
        <Affiliation>Division of Gastrointestinal Surgery and Surgical Oncology, Graduate School of Medicine, Ehime University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Gastroenterology and Oncology, Tokushima University Graduate School of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Kawasaki</LastName>
        <Affiliation>College of Nursing, University of Hyogo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keigo</FirstName>
        <LastName>Komine</LastName>
        <Affiliation>Department of Medical Oncology, Tohoku University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Shibata</LastName>
        <Affiliation>Himawari-No-Kai (Sunflower Association), a Patient Advocacy Group for Individuals and Families Affected By Lynch Syndrome</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusaku</FirstName>
        <LastName>Shimamoto</LastName>
        <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Shimodaira</LastName>
        <Affiliation>Division of Medical Oncology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeki</FirstName>
        <LastName>Sekine</LastName>
        <Affiliation>Department of Pathology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akinari</FirstName>
        <LastName>Takao</LastName>
        <Affiliation>Department of Gastroenterology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Misato</FirstName>
        <LastName>Takao</LastName>
        <Affiliation>Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Takamizawa</LastName>
        <Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoji</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Department of Clinical Genetics, Saitama Medical Center, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumitaka</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Department of Surgery, Hiroshima City Hospital Organization Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Chino</LastName>
        <Affiliation>Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hourin</FirstName>
        <LastName>Cho</LastName>
        <Affiliation>Endoscopy Center, Tokyo Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Doi</LastName>
        <Affiliation>Harmony Line (Association for Patients and Families With Familial Adenomatous Polyposis)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Nakajima</LastName>
        <Affiliation>Division of Hereditary Tumors, Department of Genetic Oncology, Osaka International Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakiko</FirstName>
        <LastName>Nakamori</LastName>
        <Affiliation>Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Pediatrics, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiya</FirstName>
        <LastName>Nagasaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Saitama Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Hasumi</LastName>
        <Affiliation>Department of Urology, Yokohama City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kouji</FirstName>
        <LastName>Banno</LastName>
        <Affiliation>Center of Maternal -Fetal/Neonatal Medicine, Hiroshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Hinoi</LastName>
        <Affiliation>Department of Clinical and Molecular Genetics, Hiroshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Fujiyoshi</LastName>
        <Affiliation>Department of Surgery, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Horimatsu</LastName>
        <Affiliation>Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Masuda</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Miguchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Hiroshima Prefectural Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Mizuuchi</LastName>
        <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Miyakura</LastName>
        <Affiliation>Department of Colon and Pelvic Surgery, Cancer Prevention and Genetic Counseling, Tochigi Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michihiro</FirstName>
        <LastName>Mutoh</LastName>
        <Affiliation>Department of Molecular-Targeting Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Yoshioka</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>JA Onomichi General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Koshigaya Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Sakamaki</LastName>
        <Affiliation>Faculty of Health Data Science, Juntendo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michio</FirstName>
        <LastName>Itabashi</LastName>
        <Affiliation>Saiseikai Kazo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyuki</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiro</FirstName>
        <LastName>Tomita</LastName>
        <Affiliation>Division of Cancer Treatment , Toyonaka Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoichi</FirstName>
        <LastName>Ajioka</LastName>
        <Affiliation>Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Approximately 5% of all colorectal cancers have a strong genetic component and are classified as hereditary colorectal cancer (HCRC). Some of the unique features commonly seen in HCRC cases include early age of onset, synchronous/metachronous cancer occurrence, and multiple cancers in other organs. These characteristics require different management approaches, including diagnosis, treatment or surveillance, from those used in the management of sporadic colorectal cancer. Accurate diagnosis of HCRC is essential because it enables targeted surveillance and risk reduction strategies that improve patient outcomes. Recent genetic advances revealed several causative genes for polyposis and non-polyposis syndromes. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) first published guidelines for the management of HCRC in 2012, with subsequent revisions every 4 years. The 2024 update to the JSCCR guidelines for HCRC was developed by meticulously reviewing evidence from systematic reviews and the consensus of the JSCCR HCRC Guidelines Committee, which includes representatives from patient advocacy groups for FAP and Lynch syndrome. These guidelines provide an up-to-date summary of HCRC, along with clinical recommendations for managing FAP and Lynch syndrome.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Hereditary colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Guidelines</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Familial adenomatous polyposis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lynch syndrome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1092-9134</Issn>
      <Volume>81</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The diagnostic utility and frequency of CD56 expression in plasma cell myeloma</ArticleTitle>
    <FirstPage LZero="delete">152587</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Midori</FirstName>
        <LastName>Imai</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asami</FirstName>
        <LastName>Nishikori</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoka</FirstName>
        <LastName>Haratake</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Midori Filiz</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rio</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Syoma</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizuha</FirstName>
        <LastName>Tabe</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yanai</LastName>
        <Affiliation>Department of Diagnostic Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuharu</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Plasma cell myeloma (PCM) is a hematological malignancy characterized by systemic proliferation of neoplastic plasma cells within the bone marrow. Diagnosis requires clinical findings and immunohistochemical staining, including CD138, CD79a, cyclin D1, immunoglobulin κ (Igκ), and λ (Igλ). However, CD79a and cyclin D1 have limited sensitivity and specificity, and Igκ/Igλ assessment is often difficult due to overstaining. Therefore, more reliable antibodies are needed to accurately diagnose PCM. In this study, we examined the diagnostic utility of CD56 expression in PCM. We retrospectively performed immunostaining for CD138, CD56, CD79a, cyclin D1, Igκ, and Igλ in bone marrow samples from 116 patients with PCM.&lt;br&gt;
CD56 expression was observed in 85/116 cases (73.3 %), CD79a was downregulated in 46/116 cases (39.7 %), and cyclin D1 expression was observed in 42/116 cases (36.2 %). The expression of CD56 was significantly higher than that of CD79a and cyclin D1 (both p &lt; 0.001). The combination of two antibodies resulted in the highest detection rate when combining CD56 and CD79a (105/116, 90.5 %), which was significantly higher than the detection rates of CD56 and cyclin D1 (93/116, 80.2 %) and CD79a and cyclin D1 (75/116, 64.7 %) (both p &lt; 0.001). In contrast, lymphoplasmacytic lymphoma and marginal zone lymphoma lacked CD56 and cyclin D1 expression. Furthermore, in cases where light chain restriction was undetectable (11/116, 9.5 %), all could be diagnosed as PCM based on CD56, CD79a, and cyclin D1. Among these, CD56 showed the highest detection rate (8/11, 72.7 %).&lt;br&gt;
These findings highlight CD56 as a helpful marker for PCM diagnosis and support further clinical research.&lt;br&gt;</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Plasma cell myeloma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immunohistochemical staining</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CD56</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1464-6722</Issn>
      <Volume>26</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparative Genomic Analysis Identifies FleQ and GcbB as Virulence-Associated Factors in Pseudomonas syringae pv. tabaci Strains</ArticleTitle>
    <FirstPage LZero="delete">e70168</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Muhammad Taufiq</FirstName>
        <LastName>Hidayat</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Yoshioka</LastName>
        <Affiliation>Faculty of Agriculture, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Asai</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachiko</FirstName>
        <LastName>Masuda</LastName>
        <Affiliation>Center for Sustainable Resource Science, RIKEN-TRIP</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Shirasu</LastName>
        <Affiliation>Center for Sustainable Resource Science, RIKEN-TRIP</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanami</FirstName>
        <LastName>Sakata</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikihiro</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiteru</FirstName>
        <LastName>Noutoshi</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Ichinose</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidenori</FirstName>
        <LastName>Matsui</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pseudomonas syringae pv. tabaci (Pta) is an important plant pathogen, which causes wildfire disease in Nicotiana species. However, the genetic basis underlying strain-level differences in virulence remains largely unresolved. To address this, we performed a comparative genomic analysis between a highly virulent strain Pta6605 and a less virulent strain Pta7375. Despite high overall genome similarity, we identified key single-nucleotide polymorphisms, including premature stop-codon mutations in seven open reading frames in Pta7375. Notably, point mutations in two regulatory genes, such as fleQ, which encodes a transcription factor essential for flagellar biogenesis and biofilm formation, and gcbB, which encodes a GGDEF domain-containing diguanylate cyclase responsible for cyclic dimeric guanosine monophosphate (c-di-GMP) synthesis, were implicated in virulence disparity. Functional analyses using deletion and locus replacement mutants in the Pta6605 background revealed that the disruption of fleQ markedly reduced motility, flagellin production, c-di-GMP accumulation, biofilm formation and virulence level mirroring the Pta7375 phenotype. The gcbB replacement mutant showed reduced disease symptom development, although c-di-GMP levels remained comparable to the Pta6605 wild type. Locus replacement between strains confirmed that a point mutation in fleQ was the primary driver of reduced motility and flagellin expression in Pta7375. These findings indicate that the reduced virulence of Pta7375 is associated with impaired regulation of flagella-related genes and disruption of the FleQ-mediated c-di-GMP signalling, underscoring the value of comparative genomics in disentangling the complex regulatory networks that govern virulence in plant pathogens.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">comparative genomics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cyclic-di- GMP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fleQ</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gcbB</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pseudomonas syringae</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2198-3844</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Viral RNA Silencing Suppressor Modulates Reactive Oxygen Species Levels to Induce the Autophagic Degradation of Dicer‐Like and Argonaute‐Like Proteins</ArticleTitle>
    <FirstPage LZero="delete">e06572</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shiyu</FirstName>
        <LastName>Zhai</LastName>
        <Affiliation>State Key Laboratory of Crop Stress Biology for Arid Areas and College of Plant Protection, Northwest A&amp;F University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tianxing</FirstName>
        <LastName>Pang</LastName>
        <Affiliation>State Key Laboratory of Crop Stress Biology for Arid Areas and College of Plant Protection, Northwest A&amp;F University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiyu</FirstName>
        <LastName>Peng</LastName>
        <Affiliation>State Key Laboratory of Crop Stress Biology for Arid Areas and College of Plant Protection, Northwest A&amp;F University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shenshen</FirstName>
        <LastName>Zou</LastName>
        <Affiliation>Department of Plant Pathology, College of Plant Protection, Shandong Agricultural University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zhiping</FirstName>
        <LastName>Deng</LastName>
        <Affiliation>Institute of Virology and Biotechnology, Zhejiang Academy of Agricultural Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiro</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Institute of Plant Science and Resources (IPSR), Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zhensheng</FirstName>
        <LastName>Kang</LastName>
        <Affiliation>State Key Laboratory of Crop Stress Biology for Arid Areas and College of Plant Protection, Northwest A&amp;F University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ida Bagus</FirstName>
        <LastName>Andika</LastName>
        <Affiliation>State Key Laboratory of Crop Stress Biology for Arid Areas and College of Plant Protection, Northwest A&amp;F University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Liying</FirstName>
        <LastName>Sun</LastName>
        <Affiliation>State Key Laboratory of Crop Stress Biology for Arid Areas and College of Plant Protection, Northwest A&amp;F University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Mounting evidence indicates that viruses exploit elevated reactive oxygen species (ROS) levels to promote replication and pathogenesis, yet the mechanistic underpinnings of this viral strategy remain elusive for many viral systems. This study uncovers a sophisticated viral counter-defense mechanism in the Cryphonectria hypovirus 1 (CHV1)-Fusarium graminearum system, where the viral p29 protein subverts host redox homeostasis to overcome antiviral responses. That p29 directly interacts with and inhibits the enzymatic activity of fungal NAD(P)H-dependent FMN reductase 1 (FMR1), leading to increased ROS accumulation and subsequent autophagy activation is demonstrated. Strikingly, this ROS-induced autophagy selectively targets for degradation two core antiviral RNA silencing components against CHV1 in F. graminearum, Dicer-like 2 (DCL2) and Argonaute-like 1 (AGL1), thereby compromising the host's primary antiviral defense system. Genetic analysis confirms this coordinated hijacking of host machineries, as CHV1 shows enhanced accumulation in the FMR1 knockout and reduced accumulation in autophagy-deficient fungal strains. This work reveals a tripartite interplay among oxidative stress, autophagy, and RNA silencing that CHV1 manipulates through p29 multifunctional activity. These findings provide a model for how viruses coordinately regulate distinct host defense systems to optimize infection.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">argonaute</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">autophagic degradation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cryphonectria hypovirus 1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dicer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">reactive oxygen species</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">RNA silencing suppressor</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2051-5960</Issn>
      <Volume>13</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Rotenone targets midbrain astrocytes to produce glial dysfunction-mediated dopaminergic neurodegeneration</ArticleTitle>
    <FirstPage LZero="delete">234</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ikuko</FirstName>
        <LastName>Miyazaki</LastName>
        <Affiliation>Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nami</FirstName>
        <LastName>Isooka</LastName>
        <Affiliation>Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Kikuoka</LastName>
        <Affiliation>Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Imafuku</LastName>
        <Affiliation>Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Masai</LastName>
        <Affiliation>Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Tomimoto</LastName>
        <Affiliation>Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakiyo</FirstName>
        <LastName>Sakaguchi</LastName>
        <Affiliation>Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiharu</FirstName>
        <LastName>Sogawa</LastName>
        <Affiliation>Department of Food and Health Sciences, Faculty of Environmental Studies, Hiroshima Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Sogawa</LastName>
        <Affiliation>Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihisa</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Pharmacotherapy, School of Pharmacy, Shujitsu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Asanuma</LastName>
        <Affiliation>Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Exposure to pesticides, such as rotenone or paraquat, is an environmental factor that plays an important role in the pathogenesis of Parkinson's disease (PD). Rotenone induces PD-like pathology and is therefore used to develop parkinsonian animal models. Dopaminergic neurotoxicity caused by rotenone has been attributed to the inhibition of mitochondrial complex I, oxidative stress and neuroinflammation; however, the mechanisms underlying selective dopaminergic neurodegeneration by rotenone remain unclear. To resolve this, we focused on glial diversity and examined whether the brain region-specific glial response to rotenone could determine the vulnerability of dopaminergic neurons using primary cultured neurons, astrocytes and microglia from the midbrain and striatum of rat embryos and rotenone-injected PD model mice. Direct neuronal treatment with low-dose rotenone failed to damage dopaminergic neurons. Conversely, rotenone exposure in the presence of midbrain astrocyte and microglia or conditioned media from rotenone-treated midbrain glial cultures containing astrocytes and microglia produced dopaminergic neurotoxicity, but striatal glia did not. Surprisingly, conditioned media from rotenone-treated midbrain astrocytes or microglia monocultures did not affect neuronal survival. We also demonstrated that rotenone targeted midbrain astrocytes prior to microglia to induce dopaminergic neurotoxicity. Rotenone-treated astrocytes produced secreted protein acidic and rich in cysteine (SPARC) extracellularly, which induced microglial proliferation, increase in IL-1β and TNF-α, and NF-κB (p65) nuclear translocation in microglia, resulting in dopaminergic neurodegeneration. In addition, rotenone exposure caused the secretion of NFAT-related inflammatory cytokines and a reduction in the level of an antioxidant metallothionein (MT)-1 from midbrain glia. Furthermore, we observed microglial proliferation and a decrease in the number of MT-positive astrocytes in the substantia nigra, but not the striatum, of low-dose rotenone-injected PD model mice. Our data highlight that rotenone targets midbrain astrocytes, leading to SPARC secretion, which promotes the neurotoxic conversion of microglia and leads to glial dysfunction-mediated dopaminergic neurodegeneration.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Rotenone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Astrocyte</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Microglia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SPARC</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Parkinson's disease</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japan Neurosurgical Society</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2188-4226</Issn>
      <Volume>12</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Endovascular Thrombectomy for Large Vessel Occlusion in a Patient on Venoarterial Extracorporeal Membrane Oxygenation: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">445</FirstPage>
    <LastPage>451</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>EBISUDANI</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masafumi</FirstName>
        <LastName>HIRAMATSU</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>IWASAKI</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>SUGIU</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>HARUMA</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryu</FirstName>
        <LastName>KIMURA</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>KAWAKAMI</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>SOTOME</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>NISHIHARA</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>YUASA</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>TANAKA</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Extracorporeal membrane oxygenation is utilized in the treatment of severe acute cardiac failure and respiratory failure. While it provides the advantage of oxygenating blood through extracorporeal circulation, it also carries risks of intracranial ischemic and hemorrhagic complications due to the continuous presence of artificial materials within the body. We encountered a case in which venoarterial extracorporeal membrane oxygenation was initiated for fulminant myocarditis, and the patient subsequently developed a large vessel occlusion. The diagnosis was confirmed using perfusion computed tomography. A visible thrombus was observed on the arterial cannula of the extracorporeal membrane oxygenation circuit, and the large vessel occlusion was determined to have been caused by thromboembolism. An immediate extracorporeal membrane oxygenation circuit exchange was performed, followed by endovascular thrombectomy. The patient experienced no perioperative complications and achieved a favorable neurological outcome. Endovascular thrombectomy in extracorporeal membrane oxygenation patients requires careful perioperative management and should be promptly performed in eligible cases of thromboembolic events. Furthermore, because patients on extracorporeal membrane oxygenation are often sedated and under intensive systemic management, regular neurological assessments and intracranial monitoring are essential for the early detection of intracranial pathologies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">large vessel occlusion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endovascular thrombectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">extracorporeal membrane oxygenation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mechanical circulatory support</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">case report</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6694</Issn>
      <Volume>17</Volume>
      <Issue>20</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tertiary Lymphoid Structures Are Associated with Favorable Clinical Outcomes and Negatively Correlated with Cancer-Associated Fibroblasts in Esophageal Cancer</ArticleTitle>
    <FirstPage LZero="delete">3351</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomoyoshi</FirstName>
        <LastName>Kunitomo</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Nishiwaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seitaro</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushige</FirstName>
        <LastName>Takeda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hijiri</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kento</FirstName>
        <LastName>Kawasaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Akai</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoaki</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Shirakawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Esophageal cancer remains a highly aggressive malignant tumor with poor prognosis, despite advances in combination therapies and novel immunotherapies. Tertiary lymphoid structures (TLSs), characterized by densely packed CD20+ B cells in a germinal-center-like structure, have recently been recognized as immune-stimulating components within the tumor microenvironment. In contrast, cancer-associated fibroblasts (CAFs) are stromal cells expressing fibroblast-activating protein (FAP) involved in immunosuppression. Methods: In this retrospective study, 124 clinical samples from patients who underwent radical surgery for esophageal cancer at our institute were analyzed. We investigated whether TLSs could serve as a prognostic factor and examined their association with tumor microenvironment factors. Results: The presence of TLSs was an independent prognostic factor for overall and progression-free survival in multivariate analyses. A high level of TLS formation correlated with better nutritional status, fewer M2 macrophages, and greater plasma cell infiltration. Additionally, little TLS formation was observed in areas with abundant CAFs, and quantitative analyses revealed a significant negative correlation between TLSs and CAFs. Conclusions: TLSs enhance antitumor immunity via macrophages and plasma cells and can be a valuable prognostic indicator in patients undergoing surgery for esophageal cancer. Targeting CAFs may prove to be a promising therapeutic strategy to enhance tumor-immunity-related TLSs.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">tertiary lymphoid structures (TLSs)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cancer-associated fibroblasts (CAFs)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophageal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor microenvironment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prognosis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Histopathological Study of Regenerative Endodontic Therapy on an Immature Mandibular Second Premolar With Pulp Necrosis: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e95647</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hidefumi</FirstName>
        <LastName>Sako</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Pathophysiology - Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Shinoda-Ito</LastName>
        <Affiliation>Department of Pathophysiology - Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyofumi</FirstName>
        <LastName>Takabatake</LastName>
        <Affiliation>Department of Oral Pathology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Takashiba</LastName>
        <Affiliation>Department of Pathophysiology - Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Regenerative endodontic therapy (revascularization) for immature permanent teeth with pulp necrosis and/or apical periodontitis is an effective treatment to promote root maturation. Previous histological studies have reported the formation of cementoid or osteoid tissue and periodontal ligament-like tissue within the root canals. This case report presents the histopathological findings of a human immature permanent tooth with pulp necrosis following revascularization.&lt;br&gt;
&lt;br&gt;
A 11-year-old male patient presented with tenderness on biting and the formation of a sinus tract in the mandibular right second premolar (tooth #29), diagnosed as pulp necrosis with symptomatic apical periodontitis. Revascularization was performed using calcium hydroxide as an intracanal medicament, with reference to the American Association of Endodontists (AAE) 2018 Position Paper on Regenerative Endodontics. At the 12-month follow-up, radiographs showed thickening of the canal walls, apical narrowing, root elongation, and recovery of pulp sensibility. The tooth was later extracted for orthodontic reasons at 42 months and processed for histological examination.&lt;br&gt;
&lt;br&gt;
Histological evaluation revealed cementum-like hard tissue continuous with the existing dentin in the apical region, suggesting apical closure. In contrast, the coronal portion showed less mature cementum-like tissue accompanied by loose connective tissue and neovascularization. These findings indicate that revascularization with calcium hydroxide can induce the formation of cementum-like and dentin-like tissues with vascular regeneration in immature permanent teeth with pulp necrosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">calcium hydroxide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immature permanent teeth</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pulp necrosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">regenerative endodontic therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">revascularization</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>International Institute of Anticancer Research</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1109-6535</Issn>
      <Volume>22</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>C1orf50 Accelerates Epithelial-Mesenchymal Transition and the Cell Cycle of Hepatocellular Carcinoma</ArticleTitle>
    <FirstPage LZero="delete">836</FirstPage>
    <LastPage>849</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">ATSUSHI</FirstName>
        <LastName>TANAKA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">YUSUKE</FirstName>
        <LastName>OTANI</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MASAKI</FirstName>
        <LastName>MAEKAWA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">ANNA</FirstName>
        <LastName>ROGACHEVSKAYA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TIRSO</FirstName>
        <LastName>PEÑA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">VANESSA D.</FirstName>
        <LastName>CHIN</LastName>
        <Affiliation>UMass Chan Medical School, UMass Memorial Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SHINICHI</FirstName>
        <LastName>TOYOOKA</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MICHAEL H.</FirstName>
        <LastName>ROEHRL</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">ATSUSHI</FirstName>
        <LastName>FUJIMURA</LastName>
        <Affiliation>Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Aim: Hepatocellular carcinoma (HCC) is a heterogeneous liver cancer with limited treatment options and a poor prognosis in advanced stages. To identify novel biomarkers and therapeutic targets, we investigated the role of chromosome 1 open reading frame 50 (C1orf50), a gene with a previously uncharacterized function in HCC.&lt;br&gt;
Materials and Methods: We performed a comprehensive transcriptome data analysis of the human hepatocellular carcinoma project from The Cancer Genome Atlas (TCGA) and subsequently validated the oncogenic roles of C1orf50 using HCC cell lines.&lt;br&gt;
Results: Using transcriptomic and clinical data from TCGA, we stratified 355 primary HCC samples based on C1orf50 expression levels. Patients with high C1orf50 expression exhibited significantly shorter overall survival, suggesting its association with aggressive tumor behavior. Differential expression and enrichment analyses revealed that C1orf50-high tumors were enriched in oncogenic pathways, including epithelial-mesenchymal transition (EMT), cell cycle activation, and stemness-related properties. Transcriptional regulatory network analysis detected 456 significantly dysregulated regulons, including ZEB1/2 and E2F2, key drivers of EMT and cell cycle, in the C1orf50-high group. In addition, we observed increased YAP1/TAZ signaling, further linking C1orf50 to stemness and therapeutic resistance. Functional data from CRISPR-based dependency screening suggested that several transcription factors up-regulated in the C1orf50-high state, such as ZBTB11 and CTCE, are essential for the survival of HCC cells. These findings indicate potential therapeutic vulnerabilities and support the rationale for targeting C1orf50-associated pathways.&lt;br&gt;
Conclusion: C1orf50 is a novel biomarker of poor prognosis in HCC and a key regulator of oncogenic features such as EMT, cell cycle progression, and stemness. This study highlights the therapeutic potential of targeting C1orf50-related networks in aggressive subtypes of liver cancer.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">C1orf50</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hepatocellular carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stemness</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cell cycle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">epithelial‑mesenchymal transition</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Primary Lacrimal Sac Diffuse Large B-cell Lymphoma Treated With Local Radiotherapy Alone: A Case With No Relapse After 21 Years of Follow-Up</ArticleTitle>
    <FirstPage LZero="delete">e95411</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Healthcare Science, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuhiro</FirstName>
        <LastName>Takemoto</LastName>
        <Affiliation>Radiotherapy, Himeji Red Cross Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Primary lacrimal sac lymphoma is rare and diagnosed as diffuse large B-cell lymphoma in a predominant histopathological type. Systemic chemotherapy would be the standard of care, but local radiotherapy may be a treatment option toward a localized lesion. The present patient is a 54-year-old otherwise healthy woman with a right lacrimal sac mass, which was proven by excisional biopsy to be diffuse large B-cell lymphoma. Since she did not have any other systemic lesions on gallium scintigraphy and neck-to-abdominal computed tomography scans, which were the standard procedure at that time, she underwent local radiotherapy at 40 Gy. Two years later, at the age of 56 years, she developed radiation retinopathy with macular edema in the right eye and had spotty laser photocoagulation in the nasal half of the fundus. At the age of 57 years, she developed radiation cataract and underwent cataract surgery with intraocular lens implantation in the right eye. At the age of 58 years, the macular edema in the right eye became worse and remained active, resulting in poor visual acuity of 0.1. She thus underwent 25-gauge vitrectomy in the right eye to peel off the adhering posterior vitreous surface, together with the internal limiting membrane, as the standard procedure at that time. The visual acuity in the right eye was elevated to 0.6. She maintained the visual acuity afterward and had no relapse of lymphoma in 21 years from the diagnosis of primary right lacrimal sac diffuse large B-cell lymphoma. Local radiotherapy would still be a treatment option for localized lymphoma lesions such as primary lacrimal sac lymphoma.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">diffuse large b-cell lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">excisional biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lacrimal sac</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">laser photocoagulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">macular edema</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pathology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiation cataract</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiation retinopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vitrectomy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1345-2630</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparative analysis of interactions between five strains of Pseudomonas syringae pv. tabaci and Nicotiana benthamiana</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuna</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Graduate School of Medicine, Science and Technology, Shinshu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Asai</LastName>
        <Affiliation>Graduate School of Environmental, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidenori</FirstName>
        <LastName>Matsui</LastName>
        <Affiliation>Graduate School of Environmental, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Ichinose</LastName>
        <Affiliation>Graduate School of Environmental, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinpei</FirstName>
        <LastName>Katou</LastName>
        <Affiliation>Graduate School of Medicine, Science and Technology, Shinshu University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pseudomonas syringae pv. tabaci 6605 (Pta 6605), the agent of wildfire disease in tobacco, has been used as a model strain for elucidating the virulence mechanisms of Pta. However, the host genes involved in resistance or susceptibility to Pta remain largely unknown. Nicotiana benthamiana is a model plant species in the Solanaceae family and is useful in functional analyses of genes. We herein compared five Pta strains (6605, 6823, 7372, 7375, and 7380) in terms of their phenotypes on medium and interactions with N. benthamiana. Pta 6605 and Pta 6823 showed more active proliferation than the other strains in a high cell density culture. Moreover, Pta 6605 exhibited markedly higher swarming motility than the other strains. In inoculated leaves of N. benthamiana, Pta 6605 and Pta 6823 caused more severe disease symptoms and proliferated to a higher cell density than the other strains. However, Pta 6823 as well as Pta 7372 and Pta 7380 induced the high accumulation of salicylic acid (SA). Moreover, the inoculations of Pta 6823 and Pta 7372 resulted in the upregulation of ethylene biosynthesis genes. On the other hand, Pta 6605 induced neither SA accumulation nor the expression of ethylene biosynthesis genes, and suppressed the expression of jasmonate biosynthesis genes. Moreover, chlorosis was clearly induced in the upper uninoculated leaves of Pta 6605-infected plants. These results suggest that Pta 6605 escapes from or suppresses plant immune systems and, thus, is the most virulent on N. benthamiana among the five strains tested.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Chlorosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nicotiana benthamiana</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Phytohormones</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pseudomonas syringae pv. tabaci</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>26</Volume>
      <Issue>20</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Neurofibromin Encoded by the Neurofibromatosis Type 1 (NF1) Gene Promotes the Membrane Translocation of SPRED2, Thereby Inhibiting the ERK Pathway in Breast Cancer Cells</ArticleTitle>
    <FirstPage LZero="delete">10072</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nang Thee</FirstName>
        <LastName>Su Pwint</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chunning</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tong</FirstName>
        <LastName>Gao</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuze</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakiyo</FirstName>
        <LastName>Sakaguchi</LastName>
        <Affiliation>Department of Cell Biology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teizo</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Neurofibromin (NF) inhibits the RAS/RAF/ERK pathway through its interaction with SPRED1 (Sprouty-related EVH1 domain-containing protein 1). Here, we investigated the functional relationship between NF and SPRED2 in breast cancer (BC). Human BC cell lines were transfected to downregulate or overexpress NF and SPRED2 and subsequently subjected to functional assays. Protein and mRNA levels were analyzed by Western blotting and RT-qPCR, respectively. Protein–protein interactions were examined by immunoprecipitation. Database analyses and immunohistochemistry (IHC) of BC tissues were performed to validate the in vitro findings. Downregulating NF or SPRED2 expression in BC cells enhanced cell proliferation, migration and invasion accompanied by RAF/ERK activation, whereas overexpression produced opposite effects. NF formed a protein complex with SPRED2 and facilitated its translocation to the plasma membrane. By IHC, SPRED2 membrane localization was absent in NF-negative luminal A and triple-negative BC (TNBC) but present in a subset of luminal A BC. By database analyses, both NF1 and SPRED2 mRNA levels were reduced in BC tissues, and luminal A BC patients with high expression of both NF1 and SPRED2 mRNA exhibited improved relapse-free survival. These results suggest a critical role for the NF–SPRED2 axis in BC progression and highlight it as a potential therapeutic target.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">breast cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SPRED2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neurofibromatosis type 1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neurofibromin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">RAS/RAF/ERK</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0929-1903</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>ATPase copper transporting beta contributes to cisplatin resistance as a regulatory factor of extracellular vesicles in head and neck squamous cell carcinoma</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kisho</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Ryumon</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koki</FirstName>
        <LastName>Umemori</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyoichi</FirstName>
        <LastName>Obata</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kunisada</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Okui</LastName>
        <Affiliation>Department of Maxillofacial Diagnostic and Surgical Science, Field of Oral and Maxillofacial Rehabilitation, Graduate School of Medical and Dental Sciences, Kagoshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kuniaki</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fatemeh</FirstName>
        <LastName>Momen-Heravi</LastName>
        <Affiliation>Department of Orofacial Sciences, School of Dentistry, University of California San Francisco</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ibaragi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cisplatin (CDDP) resistance remains a major clinical challenge in the treatment of head and neck squamous cell carcinoma (HNSC). Our group identified ATPase copper transporting beta (ATP7B) as a mediator of CDDP resistance through its role in drug efflux and small extracellular vesicle (sEV) secretion. Herein, we uncovered a novel mechanism by which ATP7B regulates sEV dynamics and the intercellular transmission of CDDP resistance. Using transcriptomic analyses of HNSC datasets, we demonstrate that ATP7B expression correlates with endocytosis- and epithelial-mesenchymal transition (EMT)-related gene sets and with elevated levels of EV-associated proteins. CDDP-resistant HNSC cells exhibited upregulated ATP7B, Rab5/Rab7, and preferentially secreted HSP90- and EpCAM-rich sEVs. These sEVs were leading to increased ATP7B expression and reduced CDDP sensitivity in recipient cells. A pharmacological inhibition of sEV biogenesis with GW4869 suppressed ATP7B and Atox1 expressions, inhibited late endosome maturation, and significantly enhanced CDDP-induced apoptosis in HNSC cells. In vivo, GW4869 reduced the sEV protein content and ATP7B expression in xenograft tumors. These findings establish that ATP7B is a critical modulator of sEV cargo and resistance propagation. Our results highlight a previously unrecognized ATP7B–sEV axis driving chemoresistance and identify sEV inhibition as a promising strategy to overcome therapeutic failure in HNSC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Epstein-Barr Virus-Associated Early Gastric Carcinoma with Lymphoid Stroma Mimicking a Submucosal Tumor: A Typical Case Diagnosed by Endoscopic Resection and Treated by Local Resection with Sentinel Node Navigation</ArticleTitle>
    <FirstPage LZero="delete">399</FirstPage>
    <LastPage>404</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Isozaki</LastName>
        <Affiliation>Department of Surgery, Oomoto Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sasau</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Surgery, Oomoto Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Takama</LastName>
        <Affiliation>Department of Surgery, Oomoto Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Isozaki</LastName>
        <Affiliation>Department of Surgery, Oomoto Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeki</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Department of Surgery, Oomoto Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69442</ArticleId>
    </ArticleIdList>
    <Abstract>Gastric cancer with lymphoid stroma (GCLS) accounts for 1%-7% of gastric cancers; ~80% are Epstein-Barr virus (EBV)-positive. The rate of lymph node metastasis is relatively low, even when an early GCLS has invaded the submucosa. We report an early GCLS with massive submucosal invasion mimicking a submucosal tumor (SMT), diagnosed by endoscopic submucosal resection (ESD) and treated with local resection and sentinel node navigation surgery (SNNS). The patient was a 40-year-old Japanese man. A protruding lesion on the greater curvature of the middle part of his stomach was detected by X-ray, and an endoscopic examination revealed a 2.5-cm protruding tumor covered with a normal mucosa and small ulcers at the apex. ESD was performed for a diagnosis. The pathological diagnosis was lymphoepithelioma-like gastric cancer (GCLS), pT1b(SM2), Ly0, V0, pHM1, pVM1. EBV infection in the cancer cells was confirmed pathologically by EBV-encoded RNA. The local resection was performed using SNNS. The patient has had no recurrence or post-gastrectomy syndrome 4 years postsurgery. EBV-associated early GCLS resembling an SMT is relatively rare, and clinicians need to be aware of this disease. Local resection using SNNS may be a surgical option for GCLS cases with a low rate of lymphatic metastasis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">gastric cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric cancer with lymphoid stroma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lymphoepithelioma-like carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Epstein Barr virus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sentinel node navigation surgery</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Immunoglobulin G4-related Disease Mimicking Portal Vein Tumor Thrombus</ArticleTitle>
    <FirstPage LZero="delete">381</FirstPage>
    <LastPage>385</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Atsunobu</FirstName>
        <LastName>Sakurai</LastName>
        <Affiliation>Department of Radiology, NHO Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Yabuki</LastName>
        <Affiliation>Department of Radiology, NHO Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Aoki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, NHO Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Iseki</LastName>
        <Affiliation>Department of Pathology, NHO Iwakuni Clinical Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69439</ArticleId>
    </ArticleIdList>
    <Abstract>We report the case of a 72-year-old Japanese man with an incidental portal vein mass that was surgically resected and diagnosed as immunoglobulin G4 (IgG4)-related disease. The mass was discovered during an atrial fibrillation examination. The patient had a history of gastric cancer and was also diagnosed with rectal cancer, raising concerns about metastasis. Due to technical challenges, a biopsy was not feasible. Imaging findings suggested portal vein tumor thrombosis, complicating the diagnosis. This case highlights a rare presentation of IgG4-related disease mimicking portal vein tumor thrombus.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">immunoglobulin G4-related disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">inflammatory pseudotumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mass</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">portal vein</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pericarditis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>SAGE Publications</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2352-3727</Issn>
      <Volume>11</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates</ArticleTitle>
    <FirstPage LZero="delete">1</FirstPage>
    <LastPage>13</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Yanagisawa</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jeremy Yuen-Chun</FirstName>
        <LastName>Teoh</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Paweł</FirstName>
        <LastName>Rajwa</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fahad</FirstName>
        <LastName>Quhal</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Benjamin</FirstName>
        <LastName>Pradere</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Marco</FirstName>
        <LastName>Moschini</LastName>
        <Affiliation>Department of Urology, San Raffaele Hospital and Scientific Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shahrokh F.</FirstName>
        <LastName>Shariat</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Miki</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Context: Several phase III randomized controlled trials (RCTs) have shown the importance of perioperative systemic therapy, especially for the efficacy of immune checkpoint inhibitors (ICIs) in both neoadjuvant and adjuvant settings for muscle-invasive bladder cancer (MIBC).&lt;br&gt;
Objective: To synthesize the growing evidence on the efficacy and safety of systemic therapies for MIBC utilizing the data from RCTs.&lt;br&gt;
Evidence acquisition: Three databases and ClinicalTrials.gov were searched in October 2024 for eligible RCTs evaluating oncologic outcomes in MIBC patients treated with systemic therapy. We evaluated pathological complete response (pCR), disease-free survival (DFS), progression-free survival (PFS), event-free survival (EFS), overall survival (OS), and adverse events (AEs).&lt;br&gt;
Evidence synthesis: Thirty-three RCTs (including 14 ongoing trials) were included in this systematic review. Neoadjuvant chemotherapy improved OS compared to radical cystectomy alone. Particularly, the VESPER trial demonstrated that dd-MVAC provided oncological benefits over GC alone in terms of pCR rates, OS (HR: 0.71), and PFS (HR: 0.70). Recently, the NIAGARA trial showed that perioperative durvalumab plus GC outperformed GC alone in terms of pCR rates, OS (HR: 0.75), and EFS (HR: 0.68). Despite the lack of data on overall AE rates in the VESPER trial, differential safety profiles in hematologic toxicity were reported between dd-MVAC and durvalumab plus GC regimens. In the adjuvant setting, no study provided the OS benefit from adjuvant chemotherapy. However, only adjuvant nivolumab had significant DFS and OS benefits compared to placebo.&lt;br&gt;
Conclusions: Neoadjuvant chemotherapy remains the current standard of care for MIBC. Durvalumab shed light on the promising impact of ICIs added to neoadjuvant chemotherapy. Nivolumab is the only ICI recommended as adjuvant therapy in patients who harbored adverse pathologic outcomes. Ongoing trials will provide further information on the impact of combination therapy, including chemotherapy, ICIs, and enfortumab vedotin, in both neoadjuvant and adjuvant settings.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">immune checkpoint inhibitors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">urothelial carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">muscle-invasive</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neoadjuvant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">adjuvant</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>International Institute of Anticancer Research</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0258-851X</Issn>
      <Volume>39</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Accuracy of Contrast-enhanced CT in Diagnosing Small-sized cT3a Renal Cell Carcinoma and Analysis of Factors Predicting Downstaging to pT1</ArticleTitle>
    <FirstPage LZero="delete">2787</FirstPage>
    <LastPage>2793</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">KENSUKE</FirstName>
        <LastName>BEKKU</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">KASUMI</FirstName>
        <LastName>YOSHINAGA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SHOTA</FirstName>
        <LastName>INOUE</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">YOSUKE</FirstName>
        <LastName>MITSUI</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TOMOAKI</FirstName>
        <LastName>YAMANOI</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TATSUSHI</FirstName>
        <LastName>KAWADA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">YUSUKE</FirstName>
        <LastName>TOMINAGA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TAKUYA</FirstName>
        <LastName>SADAHIRA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SATOSHI</FirstName>
        <LastName>KATAYAMA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TAKEHIRO</FirstName>
        <LastName>IWATA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SHINGO</FirstName>
        <LastName>NISHIMURA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">KOHEI</FirstName>
        <LastName>EDAMURA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TOMOKO</FirstName>
        <LastName>KOBAYASHI</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MOTOO</FirstName>
        <LastName>ARAKI</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Aim: This study assessed the accuracy of preoperative contrast-enhanced computed tomography (CECT) scans in staging small-sized, locally advanced (cT3a) renal cell carcinoma (RCC) and identified predictors of pathological downstaging following surgery.&lt;br&gt;
Patients and Methods: Seventy-six patients who underwent radical nephrectomy for cT3aN0M0 RCC with tumors ≤7 cm were analyzed. Preoperative CECT evaluated features such as venous, peritumoral, or renal sinus fat, and urinary tract invasion, predictive values, and concordance index between radiological and pathological findings were calculated for these categories. The study also examined the impact of clinicopathologic factors on downstaging.&lt;br&gt;
Results: Of 76 patients with cT3 RCC, 37% were down-staged to pT1. Down-staged cases had a higher proportion of male patients and non-clear cell carcinoma (86% vs. 58%, 32% vs. 6%; p=0.02, p=0.007, respectively). Multiple cT3a factors were less common in down-staged cases (4% vs. 23%, p=0.04). Non-clear cell carcinoma was significantly associated with downstaging compared to clear cell carcinoma (75% vs. 30%, p=0.006). Multivariate analysis confirmed non-clear cell carcinoma as an independent predictor (odds ratio=8.2, p=0.01). For venous invasion, CECT sensitivity and positive predictive value were high (73.5% and 83.3%, respectively) and the degree of agreement was substantial (κ=0.62).&lt;br&gt;
Conclusion: The accuracy of preoperative CECT was acceptable for detecting venous invasion. The downstaging to pT1 occurred in 37% of cT3a RCC cases in the final pathology, with non-clear cell carcinoma being a significant predictor.&lt;br&gt;</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Contrast‑enhanced CT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">staging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">T3a</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">downstaging</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>64</Volume>
      <Issue>20</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Two Cases of Esophageal Mucosal Damage Observed after Peroral Endoscopic Myotomy for Esophageal Motility Disorders</ArticleTitle>
    <FirstPage LZero="delete">2979</FirstPage>
    <LastPage>2984</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shoichiro</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Kamio</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Satomi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Sakae</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiro</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriaki</FirstName>
        <LastName>Manabe</LastName>
        <Affiliation>Division of Endoscopy and Ultrasonography, Department of Clinical Pathology and Laboratory Medicine, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This report presents two cases of esophageal mucosal damage following peroral endoscopic myotomy (POEM) for esophageal motility disorders. In the first case, delayed perforation and mediastinitis occurred on postoperative day 15 and the patient was treated with endoscopic clipping and antibiotics. In the second case, although no perforation was observed, extensive mucosal injury developed the day after POEM which was successfully managed by fasting and antibiotic therapy. These findings highlight the need for careful patient management to minimize the risks associated with POEM, while maximizing its therapeutic benefits.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">esophagogastroduodenoscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hypercontractile esophagus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">jackhammer esophagus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peroral endoscopic myotomy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Periodontitis associated with Porphyromonas gingivalis infection is a risk factor for infertility through uterine hypertrophy</ArticleTitle>
    <FirstPage LZero="delete">34964</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>Kamei-Nagata</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidefumi</FirstName>
        <LastName>Sako</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyosuke</FirstName>
        <LastName>Sakaida</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masa-aki</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Oral Microbiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Mandai</LastName>
        <Affiliation>Department of Pharmacy, Faculty of Pharmacy, Gifu University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Moyuka</FirstName>
        <LastName>Kubota-Takamori</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiko</FirstName>
        <LastName>Kiyama</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kimito</FirstName>
        <LastName>Hirai</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazu</FirstName>
        <LastName>Takeuchi-Hatanaka</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Shinoda-Ito</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masako</FirstName>
        <LastName>Tai-Tokuzen</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ai</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Center for Reproductive Medicine, Miyake Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Machiko</FirstName>
        <LastName>Kiyokawa</LastName>
        <Affiliation>Center for Reproductive Medicine, Miyake Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomomi</FirstName>
        <LastName>Yamanishi</LastName>
        <Affiliation>Center for Reproductive Medicine, Miyake Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Center for Reproductive Medicine, Miyake Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayuki</FirstName>
        <LastName>Takigawa</LastName>
        <Affiliation>Miyake Hello Dental Clinic, Pediatric Dentistry and Orthodontics</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>The Center for Graduate Medical Education (Dental Division), Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahito</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Center for Reproductive Medicine, Miyake Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Takashiba</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Periodontitis has recently been recognized as a potential risk factor for infertility due to its adverse effect on conception, although the underlying mechanisms remain unclear. This study investigated serum IgG antibody titers against periodontopathogenic bacteria in women with unexplained infertility and investigated how periodontal inflammation affects pregnancy and uterine function using a ligature-induced periodontitis mouse model infected with Porphyromonas gingivalis (Pg). IgG antibody titers against seven periodontopathogenic bacteria strains were measured by ELISA in 76 spontaneously pregnant women and 70 women undergoing infertility treatment. In the in vivo study, periodontitis mice were bred four weeks after periodontitis induction. Birth numbers, newborn weights, and gestation periods were assessed. To evaluate periodontal inflammation, alveolar bone, serum, and uterus was collected before mating. Uterine tissue was evaluated through histological and immunohistochemical staining. Women receiving infertility treatment were significantly older and had higher IgG titers against three Pg strains. Periodontitis mice had fewer births, lower newborn weights, and increased uterine cross-sectional areas. Additionally, elevated estrogen receptor α and progesterone receptor expression levels were observed in endometrial and stromal tissues. These results suggest that periodontitis may cause uterine hypertrophy and hormone receptor changes, potentially impairing pregnancy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Infertility</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Periodontitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Porphyromonas gingivalis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chronic inflammation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Uterus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sex hormone receptor</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1573-7209</Issn>
      <Volume>28</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cancer-associated fibroblast-derived SOD3 enhances lymphangiogenesis to drive metastasis in lung adenocarcinoma</ArticleTitle>
    <FirstPage LZero="delete">51</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">May Wathone</FirstName>
        <LastName>Oo</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Hikita</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoha</FirstName>
        <LastName>Mashima</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Torigata</LastName>
        <Affiliation>School of Medicine, Kobe University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yin Min</FirstName>
        <LastName>Thu</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Habu</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachio</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Suzawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Thoracic Surgery, National Hospital Organization, Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Despite advancements in diagnostic and therapeutic strategies, lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality due to its aggressive metastatic potential. Extracellular superoxide dismutase (SOD3) is an antioxidant enzyme that regulates oxidative stress and is regarded as a tumor suppressor. However, studies have demonstrated that SOD3 can either promote or inhibit cell proliferation and survival in various cancers, and its molecular mechanisms within the tumor microenvironment are poorly understood. In this study, we report a breakthrough in uncovering the role of SOD3 derived from cancer-associated fibroblasts (CAFs) in LUAD. Using LUAD xenograft models co-implanted with SOD3-overexpressing CAFs (CAFSOD3), we observe an aggressive tumor phenotype characterized by increased lymphangiogenesis and lymphatic vessel invasion (LVI) of the tumor. Additionally, LUAD patients with elevated SOD3 levels exhibit a higher incidence of LVI and metastasis. Notably, RNA sequencing of CAFSOD3 reveals that SOD3-mediated VEGF-dependent tumor progression and lymphangiogenesis are up-regulated. Furthermore, single-cell transcriptomic analysis of LUAD clinical samples confirms a strong correlation between SOD3 expression in fibroblasts and characteristics of tumor exacerbation, such as lymphangiogenesis and metastasis. These findings underscore new insights into the role of CAF-derived SOD3 in LUAD progression and highlight its potential as a biomarker and therapeutic target.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cancer-associated fibroblast</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Superoxide dismutase 3</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lymphangiogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Angiogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lung adenocarcinoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>26</Volume>
      <Issue>19</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic</ArticleTitle>
    <FirstPage LZero="delete">9347</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Okumura</LastName>
        <Affiliation>Department of Advanced Cardiovascular Therapeutics, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiya</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Division of Pathology, Saiseikai Fukuoka General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Onoue</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidemichi</FirstName>
        <LastName>Kouzu</LastName>
        <Affiliation>Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Inomata</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by unexplained left ventricular hypertrophy, often resulting from pathogenic variants of sarcomeric protein genes. Conventional treatments, such as the use of beta blockers or calcium channel blockers, focus on symptomatic control but do not address the underlying hypercontractility at the sarcomere level. Recent advances in molecular understanding have led to the development of cardiac myosin inhibitors that directly modulate sarcomeric function by reducing myosin–actin cross-bridge formation and adenosine triphosphatase (ATPase) activity. Mavacamten and aficamten have shown promising results in phase 2 and 3 clinical trials, improving symptoms, exercise capacity, and left ventricular outflow tract gradients in patients with obstructive HCM. This review summarizes the current understanding of HCM pathophysiology, diagnostic strategies, and conventional treatments with a focus on the mechanisms of action of myosin inhibitors, clinical evidence supporting their use, and future directions for improvement. We also discuss their potential applications in non-obstructive HCM and the importance of precision medicine guided by genetic profiling.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">hypertrophic cardiomyopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">myosin inhibitors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sarcomere</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mavacamten</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aficamten</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">heart failure</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6643</Issn>
      <Volume>17</Volume>
      <Issue>18</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Lacticaseibacillus rhamnosus Probio-M9 Alters the Gut Microbiota and Mitigates Pulmonary Hypertension in a Rat Model</ArticleTitle>
    <FirstPage LZero="delete">2927</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Zhixin</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs, Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gaopeng</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyomi</FirstName>
        <LastName>Ohmichi</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kagawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xiaodong</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Feiyan</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs, Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of General Medicine, Kagawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryou</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kagawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Center for Advanced Heart Failure, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Yokota</LastName>
        <Affiliation>Department of General Thoracic Surgery, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zhihong</FirstName>
        <LastName>Sun</LastName>
        <Affiliation>Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs, Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lin Hai</FirstName>
        <LastName>Kurahara</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Intestinal microbiota plays an important role in the progression of pulmonary hypertension (PH). Colostrum-derived Lacticaseibacillus rhamnosus Probio-M9 (Probio-M9) has shown protective effects against inflammation and remodeling. We investigated whether Probio-M9 supplementation could improve the pathology of PH. Methods: The monocrotaline (MCT)-induced PH model rats are created followed by Probio-M9 treatment. Microbiota and pathological analyses were performed to investigate the therapeutic effects of Probio-M9. Results: Probio-M9 significantly suppressed cardiovascular remodeling and reduced mortality in rats. Analysis of the fecal microbiota revealed that Probio-M9 significantly altered the gut microbiota of MCT model rats. Specifically, Alistipes sp009774895 and Duncaniella muris populations increased, whereas Limosilactobacillus reuteri_D, Ligilactobacillus apodeme and Monoglobus sp900542675 decreased compared to those in the MCT group. Focusing on the expression of GPNMB in macrophages and the localization of CD44, we found that the number of these cells increased in the MCT group but significantly decreased with Probio-M9 treatment. In lung tissue from PH patients, more GPNMB-positive macrophages were found than non-PH lungs, and an increase in CD44-positive cells was confirmed in the vicinity of GPNMB. Conclusions: Probio-M9 had a significant impact on the intestinal microbiota and GPNMB/CD44 positive cells in the lungs of PH rats.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">pulmonary artery remodeling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">probiotics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gut microbiota</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">macrophages</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">GPNMB</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CD44</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pharmacokinetics and the effectiveness of pyrogen-free bioabsorbable wet adhesives</ArticleTitle>
    <FirstPage LZero="delete">20056</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Risa</FirstName>
        <LastName>Oshima</LastName>
        <Affiliation>Department of Periodontology, Faculty of Dental Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kumiko</FirstName>
        <LastName>Yoshihara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ko</FirstName>
        <LastName>Nakanishi</LastName>
        <Affiliation>Department of Biomaterials and Bioengineering, Faculty of Dental Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Akasaka</LastName>
        <Affiliation>Department of Biomaterials and Bioengineering, Faculty of Dental Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Shimoji</LastName>
        <Affiliation>Department of Periodontology, Faculty of Dental Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teppei</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Applied Veterinary Science, Faculty of Veterinary Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Okihara</LastName>
        <Affiliation>Division of Applied Chemistry, Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mariko</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Clinical Psychology, School of Clinical Psychology, Kyushu University of Medical and Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikkei</FirstName>
        <LastName>Tamada</LastName>
        <Affiliation>Department of Plastic and Reconstructive Surgery, Tokyo Metropolitan Children’s Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bart</FirstName>
        <LastName>Van Meerbeek</LastName>
        <Affiliation>BIOMAT, Department of Oral Health Sciences, &amp; UZ Leuven, Dentistry, KU Leuven</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsutomu</FirstName>
        <LastName>Sugaya</LastName>
        <Affiliation>Department of Periodontology, Faculty of Dental Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Biomaterials and Bioengineering, Faculty of Dental Medicine, Hokkaido University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Bioabsorbable materials are essential for advanced therapies, including surgical sealing, cell therapy, and drug delivery. Natural bioabsorbable materials, including collagen and hyaluronic acid, have better biocompatibility than synthetic bioabsorbable polymers; however, they are mainly derived from animals, presenting infection risks. Non-animal origin polymers have a lower molecular weight than those of animal origins. Their viscosity increases with increase in molecular weight, making endotoxin removal difficult. Here, using the phosphoryl chloride disposal method, we present a strategy for synthesizing pyrogen-free bioabsorbable adhesives with controlled molecular weight. Phosphopullulan, a polysaccharide derivative, had less than detectable endotoxin levels and controllable average molecular weight of approximately 300,000 to over 1,400,000. Furthermore, it is important to ensure the safety as well as efficacy of bio-implantable materials. We have evaluated the biosafety of polysaccharide derivatives we are developing, and have examined their cell phagocytosis and pharmacokinetics in vitro and in vivo, and have confirmed that they are safe. We have also evaluated their adhesion to wet tissue adhesions and confirmed that they leak less than existing materials.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Phosphopullulan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Polysaccharide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ADME</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Animal study</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Endodontic sealer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0014-4800</Issn>
      <Volume>142</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cross-feeding between beneficial and pathogenic bacteria to utilize eukaryotic host cell-derived sialic acids and bacteriophages shape the pathogen-host interface milieu</ArticleTitle>
    <FirstPage LZero="delete">104967</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Darab</FirstName>
        <LastName>Ghadimi</LastName>
        <Affiliation>Department of Microbiology and Biotechnology, Max Rubner-Institut</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Regina</FirstName>
        <LastName>Fölster-Holst</LastName>
        <Affiliation>Clinic of Dermatology, Venerology und Allergology, University Hospital Schleswig-Holstein</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sophia</FirstName>
        <LastName>Blömer</LastName>
        <Affiliation>Clinic of Dermatology, Venerology und Allergology, University Hospital Schleswig-Holstein</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michael</FirstName>
        <LastName>Ebsen</LastName>
        <Affiliation>Städtisches MVZ Kiel GmbH (Kiel City Hospital), Department of Pathology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Christoph</FirstName>
        <LastName>Röcken</LastName>
        <Affiliation>Institute of Pathology, Kiel University, University Hospital, Schleswig-Holstein</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jumpei</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Bacteriology, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigenobu</FirstName>
        <LastName>Matsuzaki</LastName>
        <Affiliation>Department of Medical Laboratory Science, Faculty of Health Sciences, Kochi Gakuen University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wilhelm</FirstName>
        <LastName>Bockelmann</LastName>
        <Affiliation>Department of Microbiology and Biotechnology, Max Rubner-Institut</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Under an inflamed-intestinal milieu, increased free sialic acids are associated with the overgrowth of some pathogenic bacterial strains. Recently, the protective immunomodulatory activity of gut bacteriophages (phages) has also been highlighted. However, the role of phages in triple reciprocal interactions between pathogenic bacteria, beneficial bacteria, and their host cell sialic acids has not been studied so far. We established a sialidase-explicit model in which beneficial and pathogenic bacteria interact through cross-feeding and competition for free sialic acid using a human triple co-culture cell model incorporating colonocytes (T84 cells), monocytes (THP-1 cells), and hepatocytes (Huh7 cells). Triple co-cultured cells were challenged with Gram-positive Bifidobacterium bifidum (B. bifidum) and Gram-negative Pseudomonas aeruginosa PAO1 (P. a PAO1) in the absence or presence of its KPP22 phage in two different cell culture mediums: 1) standard Dulbecco's Modified Eagle Medium (DMEM) and 2) DMEM with 2,3-dehydro-2-deoxy-N-acetylneuraminic acid (DANA). Changes in physiological, functional, and structural health markers of stimulated cocultured cells were evaluated. The concentrations of sialic acid and pro-inflammatory cytokines in the cell culture supernatants were quantified. P. a PAO1 triggered the release of interleukin 6 and 8 (IL-6 and IL-8), accompanied by increased levels of free sialic acid, reduced viability of co-cultured cells, and disrupted the integrity of the cellular monolayer. These disruptive effects were markedly attenuated by KPP22 phage and B. bifidum. In addition to well-documented differences in the structure and composition of the bacterial cell walls of Gram-negative pathogenic bacteria and bifidobacteria, two distinct factors seem to be pivotal in modulating the pathogen-host interface milieu: (i) the presence of phages and (ii) the utilization of free sialic acids secreted from host cells by bifidobacteria.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Bacterial sialidase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Inflammation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cytokines</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Bifidobacteria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Phages</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1936-5209</Issn>
      <Volume>19</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Oregon Wolfe barley genetic stocks – Research and teaching tools for next generation scientists</ArticleTitle>
    <FirstPage LZero="delete">e70004</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Margaret R.</FirstName>
        <LastName>Krause</LastName>
        <Affiliation>Department of Crop and Soil Science, Oregon State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Juan David</FirstName>
        <LastName>Arbelaez</LastName>
        <Affiliation>Department of Crop Sciences, University of Illinois at Urbana-Champaign</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Åsmund</FirstName>
        <LastName>Asdal</LastName>
        <Affiliation>Nordic Genetic Resource Centre</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ramzi</FirstName>
        <LastName>Belkodja</LastName>
        <Affiliation>CIHEAM-Zaragoza</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nancy</FirstName>
        <LastName>Boury</LastName>
        <Affiliation>Department of Plant Pathology, Entomology, and Microbiology, Iowa State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Victoria C.</FirstName>
        <LastName>Blake</LastName>
        <Affiliation>Department of Plant Sciences and Plant Pathology, Montana State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Patrick J.</FirstName>
        <LastName>Brown</LastName>
        <Affiliation>Department of Plant Sciences, University of California-Davis</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ana</FirstName>
        <LastName>Casas</LastName>
        <Affiliation>Departamento de Genética y Producción Vegetal, Estación Experimental Aula Dei–CSIC</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Luis</FirstName>
        <LastName>Cistué</LastName>
        <Affiliation>Departamento de Genética y Producción Vegetal, Estación Experimental Aula Dei–CSIC</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Alba</FirstName>
        <LastName>Farré‐Martínez</LastName>
        <Affiliation>AGROTECNIO-CERCA Center, Universidad de Lleida</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Scott</FirstName>
        <LastName>Fisk</LastName>
        <Affiliation>Department of Crop and Soil Science, Oregon State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gregory S.</FirstName>
        <LastName>Fuerst</LastName>
        <Affiliation>U.S. Department of Agriculture-Agricultural Research Service, Corn Insects and Crop Genetics Research Unit, Iowa State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Estela</FirstName>
        <LastName>Giménez</LastName>
        <Affiliation>Department of Biotechnology-Plant Biology, School of Agricultural, Food and Biosystems Engineering, Universidad Politécnica de Madrid</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Carla</FirstName>
        <LastName>Guijarro‐Real</LastName>
        <Affiliation>Department of Biotechnology-Plant Biology, School of Agricultural, Food and Biosystems Engineering, Universidad Politécnica de Madrid</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katy</FirstName>
        <LastName>Guthrie</LastName>
        <Affiliation>Department of Agronomy and Plant Genetics, University of Minnesota</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Margaret</FirstName>
        <LastName>Halstead</LastName>
        <Affiliation>Aardevo North America</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Laura</FirstName>
        <LastName>Helgerson</LastName>
        <Affiliation>Department of Crop and Soil Science, Oregon State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Hisano</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ernesto</FirstName>
        <LastName>Igartua</LastName>
        <Affiliation>Departamento de Genética y Producción Vegetal, Estación Experimental Aula Dei–CSIC</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Morten</FirstName>
        <LastName>Lillemo</LastName>
        <Affiliation>Department of Plant Sciences, Norwegian University of Life Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Marina</FirstName>
        <LastName>Martínez‐García</LastName>
        <Affiliation>Department of Biotechnology-Plant Biology, School of Agricultural, Food and Biosystems Engineering, Universidad Politécnica de Madrid</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mariona</FirstName>
        <LastName>Martínez‐Subirà</LastName>
        <Affiliation>AGROTECNIO-CERCA Center, Universidad de Lleida</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susan</FirstName>
        <LastName>McCouch</LastName>
        <Affiliation>Plant Breeding and Genetics Section, School of Integrative Plant Science, Cornell University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Laurie</FirstName>
        <LastName>McGhee</LastName>
        <Affiliation>Colfax-Mingo Community High School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Travis</FirstName>
        <LastName>Nickols</LastName>
        <Affiliation>Department of Crop and Soil Science, Oregon State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nick</FirstName>
        <LastName>Peters</LastName>
        <Affiliation>Department of Plant Pathology, Entomology, and Microbiology, Iowa State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Raymond</FirstName>
        <LastName>Porter</LastName>
        <Affiliation>Haupert Institute for Agricultural Studies, Huntington University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ignacio</FirstName>
        <LastName>Romagosa</LastName>
        <Affiliation>AGROTECNIO-CERCA Center, Universidad de Lleida</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Anja Karine</FirstName>
        <LastName>Ruud</LastName>
        <Affiliation>Department of Plant Sciences, Norwegian University of Life Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Silvio</FirstName>
        <LastName>Salvi</LastName>
        <Affiliation>Department of Agricultural and Food Sciences, University of Bologna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Giuseppe</FirstName>
        <LastName>Sangiorgi</LastName>
        <Affiliation>Department of Agricultural and Food Sciences, University of Bologna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rebekka</FirstName>
        <LastName>Schüller</LastName>
        <Affiliation>Department of Crop Sciences, University of Illinois at Urbana-Champaign</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taner Z.</FirstName>
        <LastName>Sen</LastName>
        <Affiliation>Crop Improvement and Genetics Research Unit, U.S. Department of Agriculture-Agricultural Research Service</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">José Miguel</FirstName>
        <LastName>Soriano</LastName>
        <Affiliation>AGROTECNIO-CERCA Center, Universidad de Lleida</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Robert M.</FirstName>
        <LastName>Stupar</LastName>
        <Affiliation>Department of Agronomy and Plant Genetics, University of Minnesota</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">To‐Chia</FirstName>
        <LastName>Ting</LastName>
        <Affiliation>Agronomy Department, Purdue University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kelly</FirstName>
        <LastName>Vining</LastName>
        <Affiliation>Department of Crop and Soil Science, Oregon State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maria</FirstName>
        <LastName>von Korff</LastName>
        <Affiliation>Institute of Plant Genetics, Heinrich-Heine-Universität Düsseldorf</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Agatha</FirstName>
        <LastName>Walla</LastName>
        <Affiliation>Institute of Plant Genetics, Heinrich-Heine-Universität Düsseldorf</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Diane R.</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Agronomy Department, Purdue University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Robbie</FirstName>
        <LastName>Waugh</LastName>
        <Affiliation>Division of Plant Sciences, School of Life Sciences, University of Dundee</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Roger P.</FirstName>
        <LastName>Wise</LastName>
        <Affiliation>Department of Plant Pathology, Entomology, and Microbiology, Iowa State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Robert</FirstName>
        <LastName>Wolfe</LastName>
        <Affiliation>Agriculture and Agri-Food Canada</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eric</FirstName>
        <LastName>Yao</LastName>
        <Affiliation>Crop Improvement and Genetics Research Unit, U.S. Department of Agriculture-Agricultural Research Service</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Patrick M.</FirstName>
        <LastName>Hayes</LastName>
        <Affiliation>Department of Crop and Soil Science, Oregon State University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The Oregon Wolfe Barley (OWB) mapping population (Reg. no. MP-4, NSL 554937 MAP) is a resource for genetics research and instruction. The OWBs are a set of doubled haploid barley (Hordeum vulgare L.) lines developed at Oregon State University from the F1 of a cross between Dr. Robert Wolfe's dominant and recessive marker stocks. Exhibiting a high level of genetic and phenotypic diversity, the OWBs are used throughout the world as a research tool for barley genetics. To date, these endeavors have led to 56 peer-reviewed publications, as well as three reports in the Barley Genetics Newsletter. At the same time, the OWBs are widely used as an instructor resource at the K–12, undergraduate, graduate, and professional levels. They are currently used at universities and/or institutes in German, Italy, Norway, Spain, and the United States and are currently being developed further for educational use in other countries. Genotype and phenotype data, lesson plans, and seed availability information are available herein and online.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier B.V.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0304-4165</Issn>
      <Volume>1869</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The F54L mutation of Thioredoxin shows protein instability and increased fluctuations of the catalytic center</ArticleTitle>
    <FirstPage LZero="delete">130860</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Baba</LastName>
        <Affiliation>Life Science Research Infrastructure Group, Advanced Photon Technology Division, RIKEN SPring-8 Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Ueno</LastName>
        <Affiliation>Life Science Research Infrastructure Group, Advanced Photon Technology Division, RIKEN SPring-8 Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chika</FirstName>
        <LastName>Ohe</LastName>
        <Affiliation>Life Science Research Infrastructure Group, Advanced Photon Technology Division, RIKEN SPring-8 Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuku</FirstName>
        <LastName>Saji</LastName>
        <Affiliation>Structural Biology Division, Japan Synchrotron Radiation Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachiko</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Structural Biology Division, Japan Synchrotron Radiation Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Life Science Research Infrastructure Group, Advanced Photon Technology Division, RIKEN SPring-8 Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Materials Sciences Research Center, Japan Atomic Energy Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuo</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Neutron Science and Technology Center, Comprehensive Research Organization for Science and Society (CROSS)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mamoru</FirstName>
        <LastName>Ouchida</LastName>
        <Affiliation>Department of Molecular Oncology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Iori</FirstName>
        <LastName>Kawasaki-Ohmori</LastName>
        <Affiliation>Section of Developmental Physiology and Pathology, Faculty of Education, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Takeshita</LastName>
        <Affiliation>Life Science Research Infrastructure Group, Advanced Photon Technology Division, RIKEN SPring-8 Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Thioredoxin is a ubiquitous redox protein that acts as an electron donor via its conserved dithiol motif (C32GPC35), catalyzing dithiol–disulfide exchange to regulate the redox state of target proteins. It supports antioxidant defense via peroxiredoxins, facilitates DNA synthesis by donating electrons to ribonucleotide reductase, and regulates redox-sensitive signaling pathways, including those controlling transcription and apoptosis. Neuronal degeneration and chronic kidney disease have been observed in Txn-F54L mutant rats; however, the details of why the Txn mutation causes these phenomena remain unknown. The present study aimed to elucidate the functional and structural changes caused by the F54L mutation. The Thioredoxin-F54L showed less insulin-reducing activity and more thermosensitivity to denaturation in the body temperature range compared to the wild type. The crystal structure revealed that F54 forms hydrophobic interactions with the surrounding hydrophobic amino acids. In addition, molecular dynamics simulation predicts increased fluctuations around the F54L mutation and a tendency for the distance between residues C32 and C35 at the catalytic center to be widened. The increased distance between residues C32 and C35 of the catalytic center may affect the reducing activity of the enzyme on the substrate. The finding that Thioredoxin-F54L is prone to denaturation at normal body temperature may reduce the normally functioning Thioredoxin. These molecular characteristics of Thioredoxin-F54L may be related to brain and kidney disease development in the Txn-F54L rats.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Txn</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Thioredoxin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Protein instability</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Thermosensitivity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Crystal structure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Molecular dynamics simulation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1071-2690</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>S100A8/A9-MCAM signaling promotes gastric cancer cell progression via ERK-c-Jun activation</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Youyi</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xu</FirstName>
        <LastName>Yang</LastName>
        <Affiliation>Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rie</FirstName>
        <LastName>Kinoshita</LastName>
        <Affiliation>Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nahoko</FirstName>
        <LastName>Tomonobu</LastName>
        <Affiliation>Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bo</FirstName>
        <LastName>Pan</LastName>
        <Affiliation>The First Affiliated Hospital, Zhejiang University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fangping</FirstName>
        <LastName>Wu</LastName>
        <Affiliation>School of Pharmaceutical Sciences, Zhejiang Chinese Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xu</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazumi</FirstName>
        <LastName>Sagayama</LastName>
        <Affiliation>Faculties of Educational and Research Management Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bei</FirstName>
        <LastName>Sun</LastName>
        <Affiliation>Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakiyo</FirstName>
        <LastName>Sakaguchi</LastName>
        <Affiliation>Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>S100 protein family members S100A8 and S100A9 function primarily as a heterodimer complex (S100A8/A9) in vivo. This complex has been implicated in various cancers, including gastric cancer (GC). Recent studies suggest that these proteins play significant roles in tumor progression, inflammation, and metastasis. However, the exact mechanisms by which S100A8/A9 contributes to GC pathogenesis remain unclear. This study investigates the role of S100A8/A9 and its receptor in GC. Immunohistochemical analysis was performed on GC tissue samples to assess the expression of the S100A8/A9 receptor melanoma cell adhesion molecule (MCAM). In vitro transwell migration and invasion assays were used to evaluate the motility and invasiveness of GC cells. Cell proliferation was assessed using a growth assay, and Western blotting (WB) was employed to examine downstream signaling pathways, including ERK and the transcription factor c-Jun, in response to S100A8/A9–MCAM interaction. S100A8/A9 stimulation enhanced both proliferation and migration through MCAM binding in GC cell lines. These cellular events were accompanied by ERK activation and c-Jun induction. Downregulation of MCAM suppressed both ERK phosphorylation and c-Jun expression, highlighting the importance of the S100A8/A9‒MCAM‒ERK‒c-Jun axis in promoting GC progression. These findings indicate that S100A8/A9 contributes to GC progression via MCAM, which activates the ERK‒c-Jun pathway. The S100A8/A9‒signaling axis may represent a novel therapeutic target in GC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Gastric cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">S100 protein</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MCAM</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Inflammation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metastasis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Institute of Mathematical Sciences (AIMS)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2377-9098</Issn>
      <Volume>12</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Biophysical regulation of extracellular matrix in systemic lupus erythematosus</ArticleTitle>
    <FirstPage LZero="delete">412</FirstPage>
    <LastPage>437</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Qiwei</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Qiang</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zhaoyang</FirstName>
        <LastName>Xiao</LastName>
        <Affiliation>Department of Anesthesiology, The Second Affiliated Hospital of Dalian Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiji</FirstName>
        <LastName>NARUSE</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease characterized by immune dysregulation and multi-organ damage. Recent advances have underscored the critical involvement of extracellular matrix (ECM) biophysical properties in shaping immune cell behavior and metabolic states that contribute to disease progression. This review systematically delineates the pathological remodeling of ECM biophysics in SLE, with a focus on their roles in mechanotransduction, immune-metabolic interplay, and organ-specific tissue injury. By integrating current evidence, we highlight how ECM-derived mechanical cues orchestrate aberrant immune responses and propose new perspectives for targeting ECM-immune crosstalk in the development of organ-specific, mechanism-based therapies for SLE.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">systemic lupus erythematosus (SLE)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">extracellular matrix (ECM)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mechanotransduction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mechanism</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immune regulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fibrosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">organ-specific damage</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2077-0383</Issn>
      <Volume>14</Volume>
      <Issue>17</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Evaluation of the Diagnostic Performance of the Brush/Biopsy Rapid On-Site Evaluation (B-ROSE) in Cases of Bile Duct Stricture: A Prospective, Pilot Study</ArticleTitle>
    <FirstPage LZero="delete">6207</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nao</FirstName>
        <LastName>Hattori</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Harada</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taisuke</FirstName>
        <LastName>Obata</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Terasawa</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Tsutsumi</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Horiguchi</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>settingsOrder Article Reprints
Open AccessArticle
Evaluation of the Diagnostic Performance of the Brush/Biopsy Rapid On-Site Evaluation (B-ROSE) in Cases of Bile Duct Stricture: A Prospective, Pilot Study
by Nao Hattori 1,Daisuke Uchida 1,2,*,Kei Harada 1,Ryosuke Sato 1ORCID,Taisuke Obata 1,Akihiro Matsumi 1ORCID,Kazuya Miyamoto 1ORCID,Hiroyuki Terasawa 1ORCID,Yuki Fujii 1,Koichiro Tsutsumi 1ORCID,Shigeru Horiguchi 1,Kazuyuki Matsumoto 1ORCID andMotoyuki Otsuka 1
1
Department of Gastroenterology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
2
Center for Innovative Clinical Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2025, 14(17), 6207; https://doi.org/10.3390/jcm14176207
Submission received: 23 June 2025 / Revised: 21 August 2025 / Accepted: 26 August 2025 / Published: 2 September 2025
(This article belongs to the Section Gastroenterology &amp; Hepatopancreatobiliary Medicine)
Downloadkeyboard_arrow_down Browse Figures Versions Notes
Abstract
Background: Biliary strictures are diagnosed using endoscopic retrograde cholangiopancreatography (ERCP) with brush cytology and biopsy. However, brush cytology shows a sensitivity of 9–56.1% and a diagnostic accuracy of 43–65.4%, while biopsy demonstrates a sensitivity of 48%. Both methods exhibit high specificity but limited sensitivity. While rapid on-site evaluation (ROSE) is effective in endoscopic ultrasound-guided fine needle aspiration (EUS-FNA), its application in ERCP-obtained samples remains underexplored. Methods: This prospective pilot study was conducted at Okayama University Hospital from April 2019 to July 2024. Patients requiring ERCP-guided sampling for bile duct strictures were included. ROSE was applied to brush cytology with up to three additional attempts and to imprint cytology from biopsy samples with up to two attempts. Diagnostic accuracy was assessed based on pathology and clinical course. Results: Among 37 patients (median age: 73 years, add range, and male–female ratio: 27:10), 18 had hilar and 19 had distal bile duct strictures. Brush cytology required one, two, or three attempts in twenty-six, six, and five cases, respectively, whereas biopsy required one or two attempts in thirty-five and two cases, respectively. Among the thirty-seven cases, thirty-five were malignant and two were benign. The B-ROSE group showed a sensitivity, specificity, and accuracy of 71.4%, 100.0%, and 73.0%, respectively, compared to lower accuracy in the conventional group, where single brush cytology attempts yielded a sensitivity of 48.6% and an accuracy of 48.6%, and single biopsy attempts showed a sensitivity of 68.6% and an accuracy of 70.3%. Conclusions: B-ROSE improves diagnostic accuracy, reduces repeat sampling, and minimizes patient burden in ERCP-based diagnosis of bile duct strictures, making it a valuable addition to current diagnostic protocols.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bile duct stricture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ERCP (endoscopic retrograde cholangiopancreatography)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rapid on-site evaluation (ROSE)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">B-ROSE</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Informa UK Limited</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1071-5762</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pseudohypoxia induced by iron chelator activates tumor immune response in lung cancer</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuehua</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manato</FirstName>
        <LastName>Terada</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuze</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teizo</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Hypoxia-inducible factor (HIF) signaling plays a critical role in immune cell function. Pseudohypoxia is characterized as iron-mediated stabilization of HIF-1α under normoxic conditions, which can be induced by iron chelators. This study explored whether iron chelators exert antitumor effects by enhancing tumor immune responses and elucidating the underlying mechanisms. The iron chelators Super–polyphenol 10 (SP10) and Deferoxamine (DFO) were used to create iron-deficient and pseudohypoxia conditions. Pseudohypoxia induced by iron chelators stimulates IL-2 secretion from T cells and from both human and murine nonsmall cell lung cancer (NSCLC) cell lines (A549, PC-3, and LLC). Administration of SP10 reduced tumor growth when LLC tumors were implanted in C57BL/6 mice; however, this was not observed in immunodeficient RAG1-deficient C57BL/6 mice. SP10 itself did not directly inhibit LLC cells proliferation in vitro, suggesting an activation of the tumor immune response. SP10 synergistically enhanced the efficacy of PD-1 antibody therapy in lung cancer by increasing the number of tumor-infiltrating lymphocytes (TILs). In conclusion, iron chelation-induced pseudohypoxia activates tumor immune responses by directly upregulating HIF-1α, augmenting T cell function, and inducing IL-2 secretion from T cells, and cancer cells, thereby amplifying the immune efficacy of the PD-1 antibody in lung cancer treatment.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">iron</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hypoxia-inducible factor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immune checkpoint inhibitors</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prevalence of Streptococcus mutans harboring the cnm gene encoding cell surface protein Cnm in Japanese children</ArticleTitle>
    <FirstPage LZero="delete">27047</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Suehiro</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masatoshi</FirstName>
        <LastName>Otsugu</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Marin</FirstName>
        <LastName>Ochiai</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Misato</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumikazu</FirstName>
        <LastName>Tojo</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Mikasa</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Naka</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiyo</FirstName>
        <LastName>Matsumoto-Nakano</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jinthana</FirstName>
        <LastName>Lapirattanakul</LastName>
        <Affiliation>Department of Oral Microbiology, Faculty of Dentistry, Mahidol University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rena</FirstName>
        <LastName>Okawa</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Nomura</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Dental caries is a highly prevalent infectious disease primarily caused by the pathogenic bacterium Streptococcus mutans, which has also been associated with systemic disease. A 120-kDa collagen-binding protein (Cnm) produced by S. mutans contributes to cardiovascular disease pathogenicity. Few studies have addressed the current prevalence of S. mutans and the cnm gene in Japanese children or examined caries pathology in relation to cnm presence. Here, we investigated the prevalence of S. mutans and the distribution of cnm-positive S. mutans among 490 children who visited two university hospitals in Japan. The caries experience index (dmft/DMFT) was calculated, and the collagen-binding ability of cnm-positive S. mutans strains was assessed. S. mutans was isolated from the oral cavities of 158 patients (36.8%); 10.1% (16/158) harbored cnm-positive S. mutans. When caries experience indices were compared across dentitions, patients harboring cnm-positive strains had significantly higher dmft/DMFT scores than those with cnm-negative strains (P &lt; 0.05). Additionally, a positive correlation was observed between the collagen-binding capacity of cnm-positive S. mutans and the dmft/DMFT score (r = 0.601, P &lt; 0.05). These findings suggest that cnm contributes to caries progression through collagen-mediated adherence to tooth surfaces. The presence of cnm-positive S. mutans may represent a risk factor for increased caries susceptibility in children.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Streptococcus mutans</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Collagen-binding protein</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cnm</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Prevalence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Dental caries</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japanese population</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1865-7257</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Metachronic development of cholangiocarcinoma during treatment for IgG4-related sclerosing cholangitis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kosaku</FirstName>
        <LastName>Morimoto</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaki</FirstName>
        <LastName>Okuyama</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Takei</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Satomi</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Surgery, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Shinoura</LastName>
        <Affiliation>Department of Surgery, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rei</FirstName>
        <LastName>Shibata</LastName>
        <Affiliation>Department of Diagnostic Pathology, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Takenaka</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We report a case of obstructive jaundice due to recurrent distal biliary stricture during 3 years of treatment for immunoglobulin G4 (IgG4)-related sclerosing cholangitis (IgG4-SC) associated with autoimmune pancreatitis. Although a relapse of IgG4-SC was initially suspected, imaging findings, laboratory tests, and histopathological examinations led to the diagnosis of metachronous cholangiocarcinoma. The patient underwent pancreaticoduodenectomy, and no cancer recurrence was noted 6 months postoperatively. Distal cholangiocarcinoma and IgG4-SC remission were observed in the resected specimen. In patients with recurrent biliary strictures during IgG4-SC treatment, comprehensive evaluations are essential because of the risk of disease relapse and development of metachronous cholangiocarcinoma.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Autoimmune pancreatitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">IgG4-related sclerosing cholangitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cholangiocarcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metachronous  carcinogenesis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2692-4609</Issn>
      <Volume>6</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Adequacy evaluation of 22‐gauge needle endoscopic ultrasound‐guided tissue acquisition samples and glass slides preparation for successful comprehensive genomic profiling testing: A single institute experience</ArticleTitle>
    <FirstPage LZero="delete">e70104</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tami</FirstName>
        <LastName>Nagatani</LastName>
        <Affiliation>Clinical Genomic Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoji</FirstName>
        <LastName>Wani</LastName>
        <Affiliation>Department of Pathology, Japanese Red Cross Society, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Takatani</LastName>
        <Affiliation>Department of Internal Medicine, Japanese Red Cross Society, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Fushimi</LastName>
        <Affiliation>Department of Pathology, Japanese Red Cross Society, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Division of Medical Support, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichiro</FirstName>
        <LastName>Hori</LastName>
        <Affiliation>Department of Internal Medicine, Japanese Red Cross Society, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyohei</FirstName>
        <LastName>Kai</LastName>
        <Affiliation>Department of Genetic Medicine, Japanese Red Cross Society, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Clinical Genomic Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Clinical Genomic Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maki</FirstName>
        <LastName>Tanioka</LastName>
        <Affiliation>Clinical Genomic Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Internal Medicine, Japanese Red Cross Society, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Hirasawa</LastName>
        <Affiliation>Clinical Genomic Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: This study aimed to evaluate the successful sequencing rate of Foundation One CDx (F1CDx) using small tissue samples obtained with a 22-gauge needle (22G) through endoscopic ultrasound-guided fine needle acquisition (EUS-TA) and to propose guidelines for tissue quantity evaluation criteria and proper slide preparation in clinical practice.&lt;br&gt;
Methods: Between June 2019 and April 2024, 119 samples of 22G EUS-TA collected for F1CDx testing at Himeji Red Cross Hospital were retrospectively reviewed. Tissue adequacy was only assessed based on tumor cell percentage (≥20%). The procedure stopped when white tissue fragments reached 20 mm during macroscopic on-site evaluation. The specimens were prepared using both ‘tissue preserving sectioning’ to retain tissue within formalin-fixed paraffin-embedded blocks and the ‘thin sectioning matched needle gauge and tissue length’ method with calculation to ensure minimal unstained slides for the 1 mm3 sample volume criterion. Tissue area from HE slides and sample volume were measured, and F1CDx reports were analyzed.&lt;br&gt;
Results: Of 119 samples, 108 (90.8%) were suitable for F1CDx. Excluding the cases not submitted for testing, in the 45 cases where F1CDx was done using 22G EUS-TA samples, eight (17.8%) had a sum of tissue area tissue of 25 mm2 or greater in the HE-stained sample. However, all cases met the F1CDx 1 mm3 volume criterion by submitting &gt; 30 unstained slides per sample. As a result, 43 of 45 cases (95.6%) were successfully analyzable.&lt;br&gt;
Conclusions: The 22G EUS-TA needle is an effective tool for providing the sufficient tissue volume required for F1CDx.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">biliary tract cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">comprehensive genomic profiling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endoscopic ultrasound-guided fine needle aspiration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endoscopic ultrasound-guided fine needle biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pancreatic cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Craniofacial Fibrous Dysplasia to Affect or Not the Optic Nerve in Long-Term Follow-Up of Three Cases</ArticleTitle>
    <FirstPage LZero="delete">e91072</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuhiro</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Department of Otorhinolaryngology, School of Medicine, International University of Health and Welfare</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Fibrous dysplasia of the bone is characterized by immature fibrous bones of trabeculae and fibrovascular proliferation in the medulla. In this study, we report three consecutive patients with craniofacial fibrous dysplasia with or without optic nerve involvement. In Case 1, a 43-year-old man with blurred vision in the right eye at the first visit was well until the age of 54 years, when he came back with symptoms suggestive of paranasal sinusitis. Computed tomography scans disclosed a mucocele in the right sphenoid sinus and thickened bilateral ethmoid, sphenoid, and frontal bones. He underwent an emergency nasal endoscopic surgery to make a drainage opening to the sphenoid and ethmoid sinuses on the right side with incomplete success. The pathology of the resected tissue confirmed fibrous dysplasia. With intravenous antibiotics, he recovered from blepharoptosis, complete ophthalmoplegia, and visual acuity decrease on the right side. He was well until the age of 71 years when he had a self-limiting episode of visual field cloudiness caused by the right sphenoid sinus mucocele. At the age of 75 years, he developed abrupt vision loss to no light perception in the right eye. He underwent an open skull surgery to extirpate the sphenoid mucocele on the right side and died of an unknown cause two years later. In Case 2, a 29-year-old man had a two-week-long headache, and computed tomography scans revealed fibrous dysplasia in the bilateral sphenoid bones. Nasal biopsy at the spheno-ethmoid recess proved a pathological diagnosis of fibrous dysplasia. Goldmann perimetry showed normal visual fields in both eyes. He was followed every year by magnetic resonance imaging to maintain normal visual fields until the latest visit at the age of 41 years. In Case 3, a 12-year-old girl was referred to an ophthalmologist to check her vision. She had been diagnosed with fibrous dysplasia of the left maxillary bone at the age of six years by a dentist. She had a gingival resection on the left maxilla at the age of 15 years and had a left maxillary bone resection at 18 years at another hospital. One month after the resection, Goldmann perimetry showed superior peripheral field depression in the left eye, in contrast with the normal visual field in the right eye. She maintained the visual acuity of 1.5 in both eyes until the last visit at the age of 21 years. In fibrous dysplasia as a rare disease, functional and cosmetic problems, including vision problems, should be considered in a case-based approach.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">computed tomography (ct) scan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">craniofacial bone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fibrous dysplasia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">goldmann perimetry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">magnetic resonance imaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">monostotic</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">optic nerve</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pathology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">visual acuity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">visual field</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2227-9059</Issn>
      <Volume>12</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Development and Characterization of a Three-Dimensional Organotypic In Vitro Oral Cancer Model with Four Co-Cultured Cell Types, Including Patient-Derived Cancer-Associated Fibroblasts</ArticleTitle>
    <FirstPage LZero="delete">2373</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Aizawa</LastName>
        <Affiliation>Division of Biomimetics, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Haga</LastName>
        <Affiliation>Division of Reconstructive Surgery for Oral and Maxillofacial Region, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nagako</FirstName>
        <LastName>Yoshiba</LastName>
        <Affiliation>Department of Oral Health and Welfare, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Witsanu</FirstName>
        <LastName>Yortchan</LastName>
        <Affiliation>Division of Biomimetics, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Takada</LastName>
        <Affiliation>Division of Biomimetics, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rintaro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Division of Biomimetics, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Division of Oral and Maxillofacial Surgery, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Abé</LastName>
        <Affiliation>Division of Oral Pathology, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Division of Oral Pathology, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Yamazaki</LastName>
        <Affiliation>Division of Oral Pathology, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun-ichi</FirstName>
        <LastName>Tanuma</LastName>
        <Affiliation>Division of Oral Pathology, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyo</FirstName>
        <LastName>Igawa</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Tomihara</LastName>
        <Affiliation>Division of Oral and Maxillofacial Surgery, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsaku</FirstName>
        <LastName>Togo</LastName>
        <Affiliation>Department of Respiratory Medicine, Graduate School of Medicine, Juntendo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Izumi</LastName>
        <Affiliation>Division of Biomimetics, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Cancer organoids have emerged as a valuable tool of three-dimensional (3D) cell cultures to investigate tumor heterogeneity and predict tumor behavior and treatment response. We developed a 3D organotypic culture model of oral squamous cell carcinoma (OSCC) to recapitulate the tumor–stromal interface by co-culturing four cell types, including patient-derived cancer-associated fibroblasts (PD-CAFs). Methods: A stainless-steel ring was used twice to create the horizontal positioning of the cancer stroma (adjoining normal oral mucosa connective tissue) and the OSCC layer (surrounding normal oral mucosa epithelial layer). Combined with a structured bi-layered model of the epithelial component and the underlying stroma, this protocol enabled us to construct four distinct portions mimicking the oral cancer tissue arising in the oral mucosa. Results: In this model, α-smooth muscle actin-positive PD-CAFs were localized in close proximity to the OSCC layer, suggesting a crosstalk between them. Furthermore, a linear laminin-γ2 expression was lacking at the interface between the OSCC layer and the underlying stromal layer, indicating the loss of the basement membrane-like structure. Conclusions: Since the specific 3D architecture and polarity mimicking oral cancer in vivo provides a more accurate milieu of the tumor microenvironment (TME), it could be crucial in elucidating oral cancer TME.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">oral cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cancer-associated fibroblasts</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oral mucosa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">patient-derived</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">organotypic culture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">3D in vitro model</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">polarity</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>26</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Possibility of Plasma Membrane Transporters as Drug Targets in Oral Cancers</ArticleTitle>
    <FirstPage LZero="delete">4310</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Chiharu</FirstName>
        <LastName>Sogawa</LastName>
        <Affiliation>Department of Food and Health Sciences, Faculty of Environmental Studies, Hiroshima Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsumitsu</FirstName>
        <LastName>Shimada</LastName>
        <Affiliation>Department of Clinical Phathophysiology, Matsumoto Dental University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Plasma membrane transporters are increasingly recognized as potential drug targets for oral cancer, particularly oral squamous cell carcinoma (OSCC). These transporters play crucial roles in cancer cell metabolism, drug resistance, and the tumor microenvironment, making them attractive targets for therapeutic intervention. Among the two main families of plasma membrane transporters, ATP-binding cassette (ABC) transporters have long been known to be involved in drug efflux and contribute to chemoresistance in cancer cells. On the other hand, solute carriers (SLCs) are also a family of transporters that facilitate the transport of various substrates, including nutrients and drugs, and have recently been shown to contribute to cancer chemosensitivity, metabolism, and proliferation. SLC transporters have been identified as potential cancer biomarkers and therapeutic targets, and their expression profiles suggest that they could be utilized in precision oncology approaches. We summarize previous reports on the expression and role of ABC and SLC transporters in oral cancer and discuss their potential as therapeutic targets.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">SLC transporter</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ABC transporter</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oral cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oral squamous cell carcinoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山大学大学院教育学研究科</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1883-2423</Issn>
      <Volume>189</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>二分脊椎症の病態理解に基づく教育現場での支援</ArticleTitle>
    <FirstPage LZero="delete">67</FirstPage>
    <LastPage>74</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Iori</FirstName>
        <LastName>OHMORI (KAWASAKI)</LastName>
        <Affiliation>Faculty of Education，Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuko</FirstName>
        <LastName>YAMANAKA</LastName>
        <Affiliation>Okayama prefectural Okayama east special needs school</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/bgeou/69238</ArticleId>
    </ArticleIdList>
    <Abstract>　二分脊椎症のある子どもは、症状の個人差が大きく、肢体不自由特別支援学校だけでなく普通学級にも多く在籍している。本研究の目的は，二分脊椎症の病態に基づき、教育現場での支援の在り方について、先行研究の知見をまとめ、教育上の課題をあきらかにすることである。&lt;br&gt;
　二分脊椎症には、下肢の運動障害と感覚障害、排泄障害に加え、水頭症をはじめとした様々な合併症があることから、運動面、生活面、認知面において適切な支援を要する。さらに、思春期以降になると、脊髄係留による疼痛の出現や、歩行能力の低下に注意する必要がある。神経因性膀胱による排尿障害を合併する場合は、清潔間欠導尿を行う。学校生活を楽しいと肯定的に捉えていた子どもたちのほとんどは、清潔間欠導尿を介助無しあるいは一部の介助のみで排尿することができていた。このことから、担任は、身体的、認知的な支援と配慮に加え、多職種と密な連携を取りながら清潔間欠自己導尿を目指した自立活動の指導を進めることと、良好な友人関係を築くための支援を行うことが重要と思われた。</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">二分脊椎症</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">清潔間欠導尿</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">学校生活</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">多職種連携</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>BMJ</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2053-3624</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical impact of combined assessment of myocardial inflammation and fibrosis using myocardial biopsy in patients with dilated cardiomyopathy: a multicentre, retrospective cohort study</ArticleTitle>
    <FirstPage LZero="delete">e003250</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Cardiology, Nagoya City University Graduate School of Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko Ohta</FirstName>
        <LastName>Ogo</LastName>
        <Affiliation>Department of Pathology, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Sugano</LastName>
        <Affiliation>Department of Cardiology, Keiyu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuro</FirstName>
        <LastName>Yokokawa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Fukushima Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromitsu</FirstName>
        <LastName>Kanamori</LastName>
        <Affiliation>Department of Cardiology, Gifu University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Pathology, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiaki</FirstName>
        <LastName>Hiroe</LastName>
        <Affiliation>Department of Cardiology, National Center for Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kinta</FirstName>
        <LastName>Hatakeyama</LastName>
        <Affiliation>Department of Pathology, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hatsue</FirstName>
        <LastName>Ishibashi-Ueda</LastName>
        <Affiliation>Department of Pathology, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Center for Advanced Heart Failure, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaoru</FirstName>
        <LastName>Dohi</LastName>
        <Affiliation>Department of Cardiology and Nephrology, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihisa</FirstName>
        <LastName>Anzai</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Seo</LastName>
        <Affiliation>Department of Cardiology, Nagoya City University Graduate School of Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyoko</FirstName>
        <LastName>Imanaka-Yoshida</LastName>
        <Affiliation>Department of Pathology and Matrix Biology, Mie University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Among patients with dilated cardiomyopathy (DCM), myocardial inflammation and fibrosis are risk factors for poor clinical outcomes. Here, we investigated the combined prognostic value of these two factors, as evaluated using myocardial biopsy samples.&lt;br&gt;
Methods This retrospective and multicentre study included patients with DCM—defined as LVEF of ≤45% and left diastolic diameter of &gt;112% of predicted value, without evidence of secondary or ischaemic cardiomyopathy. In myocardial biopsy samples, inflammatory cells were counted using immunohistochemistry, and Masson’s Trichrome staining was performed to quantify the myocardial fibrosis as collagen area fraction (CAF). Higher myocardial inflammation was defined as leucocytes of ≥14/mm², including ≤4 monocytes/mm², with CD3+ T lymphocytes of≥7/mm². Greater myocardial fibrosis was defined as CAF of&gt;5.9% by the Youden’s index. The primary endpoint was cardiac death or left ventricular assist device implantation.&lt;br&gt;
Results A total of 255 DCM patients were enrolled (average age, 53.1 years; 78% males). Within this cohort, the mean LVEF was 28.0%, mean CAF was 10.7% and median CD3+ cell count was 8.3/mm2. During the median follow-up period of 2688 days, 46 patients met the primary endpoint. Multivariable Cox proportional hazard analyses revealed that CD3+ cell count and CAF were independent determinants of the primary endpoint. Kaplan–Meier analysis showed that patients with both higher myocardial inflammation and greater fibrosis had the worst prognosis (log-rank p&lt;0.001). When myocardial inflammation was graded as one of three degrees: T lymphocytes of &lt;13/mm² (low); 13 of 13.1–23.9/mm² (moderate); and T lymphocytes of ≥24 /mm² (high), patients with moderate inflammation exhibited a superior survival rate when CAF was ≤5.9%, but a worse survival rate when CAF was &gt;5.9%.&lt;br&gt;
Conclusions Having both biopsy-proven higher myocardial inflammation and greater fibrosis predicted the worst clinical prognosis in patients with DCM.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1071-2690</Issn>
      <Volume>60</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>NCF-1 plays a pivotal role in the survival of adenocarcinoma cells of pancreatic and gastric origins</ArticleTitle>
    <FirstPage LZero="delete">1151</FirstPage>
    <LastPage>1159</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Chiemi</FirstName>
        <LastName>Furuya-Ikude</LastName>
        <Affiliation>Division of Tumor Pathology, NIR-PIT Research Institute, Kansai Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akane</FirstName>
        <LastName>Kitta</LastName>
        <Affiliation>Division of Tumor Pathology, NIR-PIT Research Institute, Kansai Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoko</FirstName>
        <LastName>Tomonobu</LastName>
        <Affiliation>Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Kawasaki</LastName>
        <Affiliation>Division of Tumor Pathology, NIR-PIT Research Institute, Kansai Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakiyo</FirstName>
        <LastName>Sakaguchi</LastName>
        <Affiliation>Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eisaku</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Division of Tumor Pathology, NIR-PIT Research Institute, Kansai Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Reactive oxygen species (ROS) play a pivotal biological role in cells, with ROS function differing depending on cellular conditions and the extracellular environment. Notably, ROS act as cytotoxic factors to eliminate infectious pathogens or promote cell death under cellular stress, while also facilitating cell growth (via ROS-sensing pathways) by modifying gene expression. Among ROS-related genes, neutrophil cytosolic factor-1 (NCF-1; p47phox) was identified as a ROS generator in neutrophils. This product is a subunit of a cytosolic NADPH oxidase complex activated in response to pathogens such as bacteria and viruses. NCF-1 has been examined primarily in terms of ROS-production pathways in macrophages and neutrophils; however, the expression of this protein and its biological role in cancer cells remain unclear. Here, we report expression of NCF-1 in pancreatic and gastric cancers, and demonstrate its biological significance in these tumor cells. Abundant expression of NCF-1 was observed in pancreatic adenocarcinoma (PDAC) lines and in patient tissues, as well as in gastric adenocarcinomas. Accumulation of the protein was also detected in the invasive/metastatic foci of these tumors. Unexpectedly, BxPC-3 underwent apoptotic cell death when transfected with a small interfering RNA (siRNA) specific to NCF-1, whereas the cells treated with a control siRNA proliferated in a time-dependent manner. A similar phenomenon was observed in HSC-58, a poorly differentiated gastric adenocarcinoma line. Consequently, the tumor cells highly expressing NCF-1 obtained coincident accumulation of ROS and reduced glutathione (GSH) with expression of glutathione peroxidase 4 (GPX4), a quencher involved in ferroptosis. Unlike the conventional role of ROS as a representative cytotoxic factor, these findings suggest that NCF-1-mediated ROS generation may be required for expansive growth of PDAC and gastric cancers.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">NCF-1 (p47phox)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ROS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tumor growth</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Apoptosis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>63</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Gastric Mucosa-associated Lymphoid Tissue Lymphoma That Relapsed after 11 Years Subsequent to Achieving Complete Remission</ArticleTitle>
    <FirstPage LZero="delete">1697</FirstPage>
    <LastPage>1702</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shoko</FirstName>
        <LastName>Inoo</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiro</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Ootuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A 38-year-old Japanese man was diagnosed with extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue in the stomach (gastric MALT lymphoma). Fluorescence in situ hybridization analysis revealed the absence of t (11;18) (q21;q21) translocation but the presence of extra copies of MALT1, indicating tetrasomy 18. Helicobacter pylori eradication led to complete remission (CR). However, the gastric MALT lymphoma relapsed after 11 years old. This case underscores the need for long-term observation (&gt;10 years) of patients with gastric MALT lymphoma. Further investigation is warranted to elucidate the correlation between trisomy/tetrasomy 18 and the recurrence propensity.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">gastric MALT lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">H. pylori</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">relapse</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>63</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Idiopathic Gastric Antral Ulcers</ArticleTitle>
    <FirstPage LZero="delete">1367</FirstPage>
    <LastPage>1371</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiro</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A Japanese woman presented with gastric antral ulcers accompanied by erosion and edema, demonstrating a chronic pattern of improvement and recurrence for more than six years. The patient had no relevant treatment history, and Helicobacter pylori infection was ruled out. Other potential etiologies contributing to gastric ulcers were eliminated on the basis of endoscopic biopsy and blood laboratory findings. Consequently, the patient was diagnosed with idiopathic gastric antral ulcer. This disease is often overlooked, and the chronological endoscopic images provided in this report can be used as a reference.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">esophagogastroduodenoscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric ulcer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">diopathic ulcer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Helicobacter pylori</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Rare Presentation of Pneumonic-Type Adenocarcinoma Hidden behind Empyema</ArticleTitle>
    <FirstPage LZero="delete">305</FirstPage>
    <LastPage>309</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Senoo</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eito</FirstName>
        <LastName>Niman</LastName>
        <Affiliation>Department of General Thoracic Surgery, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoko</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Takata</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Matsumori</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumika</FirstName>
        <LastName>Murano</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Sugisaki</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rika</FirstName>
        <LastName>Omote</LastName>
        <Affiliation>Department of Diagnostic Pathology, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Ichihara</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of General Thoracic Surgery, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69158</ArticleId>
    </ArticleIdList>
    <Abstract>Pneumonic-type adenocarcinoma (P-ADC) can closely mimic pneumonia. We report a P-ADC initially diagnosed as pneumonia which developed into a pulmonary abscess and empyema. A 50-year-old Japanese male diagnosed with pneumonia, pulmonary abscess, and empyema was administered antibiotics and a chest tube for drainage, which improved his symptoms and blood test results. However, chest computed tomography showed an enlarged infiltrative shadow. The patient underwent bronchoscopy and was diagnosed with an adenocarcinoma. This case highlights the importance of considering P-ADC in differential diagnoses when a pneumonia-like shadow enlarges post-empyema treatment. Diagnostic and clinical tests, e.g., bronchoscopy, should be performed in such cases.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">pneumonic type adenocarcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">empyema</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bronchoscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lung cancer diagnosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cavity formation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pulmonary Calcium Phosphate Cement Embolism After Percutaneous Vertebroplasty for Thoracic Vertebrae Fractures</ArticleTitle>
    <FirstPage LZero="delete">299</FirstPage>
    <LastPage>303</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ruibin</FirstName>
        <LastName>Feng</LastName>
        <Affiliation>Department of Orthopedics, the Ninth Affiliated Hospital of Guangxi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bikang</FirstName>
        <LastName>Zhu</LastName>
        <Affiliation>Department of Orthopedics, the Ninth Affiliated Hospital of Guangxi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Danyun</FirstName>
        <LastName>Wei</LastName>
        <Affiliation>Department of Orthopedics, the Ninth Affiliated Hospital of Guangxi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dingjiao</FirstName>
        <LastName>Zhu</LastName>
        <Affiliation>Department of Radiology, the Ninth Affiliated Hospital of Guangxi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Cairu</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Department of Orthopedics, the Ninth Affiliated Hospital of Guangxi Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69157</ArticleId>
    </ArticleIdList>
    <Abstract>Pulmonary cement embolism (PCE) is a rare but severe complication following percutaneous vertebroplasty (PVP). Calcium phosphate cement (CPC) has emerged as an alternative to traditional materials for vertebral augmentation. There appear to be no established guidelines for managing symptomatic PCE, and there is scarce literature on CPC embolisms. This is a first report of a case of pulmonary CPC embolism following PVP. The patient, a 63-year-old Chinese female, was administered anticoagulant treatment and achieved a satisfactory outcome. Her case highlights the severe potential morbidity associated with CPC leakage and emphasizes the efficacy of anticoagulant treatment for managing pulmonary CPC embolisms.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">percutaneous vertebroplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thoracic vertebrae fracture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">calcium phosphate cement</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pulmonary embolism</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Anterior Uveitis Secondary to an Infected Postoperative Maxillary Cyst</ArticleTitle>
    <FirstPage LZero="delete">283</FirstPage>
    <LastPage>286</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Imamura</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Shiode</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mio</FirstName>
        <LastName>Hosokawa</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Matoba</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kanzaki</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroya</FirstName>
        <LastName>Kindo</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuro</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aya</FirstName>
        <LastName>Murai</LastName>
        <Affiliation>Department of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizuo</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69154</ArticleId>
    </ArticleIdList>
    <Abstract>A 76-year-old man presented with right eyelid swelling and deteriorated vision. Examination revealed anterior uveitis with hypopyon and a visual acuity of 20/2,000 in the right eye, with no abnormalities in the left. Computed tomography revealed enlargement of the right maxillary sinus and internal fluid accumulation, suggesting a postoperative maxillary cyst (POMC). Nasal endoscopic surgery drained the pus by opening the lower wall of the maxillary cyst. Following the procedure, intraocular inflammation resolved, and visual acuity in the right eye improved to 24/20. This is the first reported case of uveitis secondary to POMC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anterior uveitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hypopyon</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">maxillary sinus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">postoperative maxillary cyst</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0387-7604</Issn>
      <Volume>47</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Hypotheses of pathophysiological mechanisms in epileptic encephalopathies: A review</ArticleTitle>
    <FirstPage LZero="delete">104318</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Katsuhiro</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Pediatrics, Asahigawaso Rehabilitation and Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Shibata</LastName>
        <Affiliation>Department of Pediatric Neurology, Okayama University Hospital and Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Tsuchiya</LastName>
        <Affiliation>Department of Pediatric Neurology, Okayama University Hospital and Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mari</FirstName>
        <LastName>Akiyama</LastName>
        <Affiliation>Department of Pediatric Neurology, Okayama University Hospital and Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Akiyama</LastName>
        <Affiliation>Department of Pediatric Neurology, Okayama University Hospital and Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Epileptic encephalopathy (EE) is a serious clinical issue that manifests as part of developmental and epileptic encephalopathy (DEE), particularly in childhood epilepsy. In EE, neurocognitive functions and behavior are impaired by intense epileptiform electroencephalogram (EEG) activity. Hypotheses of pathophysiological mechanisms behind EE are reviewed to contribute to an effective solution for EE.&lt;br&gt;
Review: Current hypotheses are as follows: 1) neuronal dysfunction based on genetic abnormalities that may affect neurocognitive functions and epilepsy separately; 2) impairment of synaptic homeostasis during sleep that may be responsible for DEE/EE with spike-and-wave activation in sleep; 3) abnormal subcortical regulation of the cerebral cortex; 4) abnormal cortical metabolism and hemodynamics with impairment of the neural network including default mode network; 5) neurotransmitter imbalance and disordered neural excitability; 6) the effects of neuroinflammation that may be caused by epileptic seizures and in turn aggravate epileptogenesis; 7) the interaction between physiological and pathological high-frequency EEG activity; etc. The causal relationship between epileptiform EEG activity and neurocognitive dysfunctions is small in DEE based on genetic abnormalities and it is largely unestablished in the other hypothetical mechanisms.&lt;br&gt;
Conclusion: We have not yet found answers to the question of whether the single-central or multiple derangements are present and what seizures and intense epileptiform EEG abnormalities mean in EE. We need to continue our best efforts in both aspects to elucidate the pathophysiological mechanisms of DEE/EE and further develop epilepsy treatment and precision medicine.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Behavior</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Childhood epilepsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cognitive function</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Developmental and epileptic encephalopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Regression</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-7634</Issn>
      <Volume>14</Volume>
      <Issue>15</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Real‐World Data of Comprehensive Cancer Genomic Profiling Tests Performed in the Routine Clinical Setting in Sarcoma</ArticleTitle>
    <FirstPage LZero="delete">e71098</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsunori</FirstName>
        <LastName>Osone</LastName>
        <Affiliation>Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuto</FirstName>
        <LastName>Itano</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Kunisada</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoyuki</FirstName>
        <LastName>Ida</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mashu</FirstName>
        <LastName>Futagawa</LastName>
        <Affiliation>Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsunori</FirstName>
        <LastName>Shimoi</LastName>
        <Affiliation>Department of Medical Oncology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yanai</LastName>
        <Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Hirasawa</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Tabata</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Next-generation sequencing-based comprehensive cancer genomic profiling (CGP) tests are beneficial for refining diagnosis and personalized treatment of various cancers. However, the clinical impact of CGP, as covered by public health insurance in the management of sarcomas, remains unknown. Especially, the data on the utility of the newly emerging dual DNA–RNA panel compared to the conventional DNA-only panel in clinical settings is lacking. Therefore, we evaluated the utility of CGP in routine clinical practice for sarcoma treatment.&lt;br&gt;
Patients and Methods: In this study, three types of DNA panel and one DNA–RNA panel, reimbursed by Japanese public health insurance, were utilized. We detected oncogenic and druggable gene mutations and genotype-matched therapies.&lt;br&gt;
Results: One hundred and thirty-six patients were included in this study. Based on the detection of highly histology-specific translocations in the sequencing results, 2.2% of patients were re-classified. In patients with translocation-related sarcomas, a DNA–RNA panel identified more histology-specific fusion genes than DNA panels (p = 0.0035). Specifically, 86.8% and 39.0% of patients had oncogenic and druggable genomic alterations, respectively. Of these, 9.6% underwent genotype-matched therapy, with a 36.3% response rate and an 81.8% disease control rate. Patients who were administered genomically matched therapy had better overall survival (OS) than those who did not in patients with metastatic or advanced sarcoma with no prior chemotherapy (3-year OS: 83.3% vs. 48.0%, p = 0.42). Patients with TP53 and RB1 mutations had worse OS than those without. Germline findings were detected in 11.0% of the patients, one of whom had a truly germline origin.&lt;br&gt;
Conclusions: This study suggests that publicly reimbursed CGP tests, particularly the dual DNA–RNA panel, could be beneficial for refining diagnostic precision in selected sarcoma subtypes, treatment decisions, detecting the germline findings, and prognosis prediction in routine clinical settings for sarcoma. The implementation of genotype-matched therapies showed favorable clinical outcomes and improved the prognosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">comprehensive genomic profiling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">genotype-matched therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">multiplex gene panel test</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sarcoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0028-0836</Issn>
      <Volume>638</Volume>
      <Issue>8049</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Immune evasion through mitochondrial transfer in the tumour microenvironment</ArticleTitle>
    <FirstPage LZero="delete">225</FirstPage>
    <LastPage>236</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsushige</FirstName>
        <LastName>Kawase</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Nishi</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomofumi</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keizo</FirstName>
        <LastName>Takenaga</LastName>
        <Affiliation>Division of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Inozume</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takamasa</FirstName>
        <LastName>Ishino</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Aki</LastName>
        <Affiliation>Division of Nutriomics and Oncology, RCAST, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jason</FirstName>
        <LastName>Lin</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shusuke</FirstName>
        <LastName>Kawashima</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan Department of Dermatology, Graduate School of Medicine, Chiba University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Nagasaki</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Youki</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichiro</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Makinoshima</LastName>
        <Affiliation>Tsuruoka Metabolomics Laboratory, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makiko</FirstName>
        <LastName>Itami</LastName>
        <Affiliation>Department of Surgical Pathology, Chiba Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasutoshi</FirstName>
        <LastName>Tatsumi</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Suenaga</LastName>
        <Affiliation>Laboratory of Evolutionary Oncology, Chiba Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Morinaga</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Honobe-Tabuchi</LastName>
        <Affiliation>Department of Dermatology, Faculty of Medicine, University of Yamanashi</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Ohnuma</LastName>
        <Affiliation>Department of Dermatology, Faculty of Medicine, University of Yamanashi</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuyoshi</FirstName>
        <LastName>Kawamura</LastName>
        <Affiliation>Department of Dermatology, Faculty of Medicine, University of Yamanashi</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyasu</FirstName>
        <LastName>Umeda</LastName>
        <Affiliation>Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukiko</FirstName>
        <LastName>Kiniwa</LastName>
        <Affiliation>Department of Dermatology, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Ichihara</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun-ichiro</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Diagnostic Pathology, Graduate School of Medicine, Chiba University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toyoyuki</FirstName>
        <LastName>Hanazawa</LastName>
        <Affiliation>Department of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Endocrinological Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Mano</LastName>
        <Affiliation>Division of Cellular Signalling, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuji</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Respirology, Graduate School of Medicine, Chiba University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Osawa</LastName>
        <Affiliation>Division of Nutriomics and Oncology, RCAST, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahito</FirstName>
        <LastName>Kawazu</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cancer cells in the tumour microenvironment use various mechanisms to evade the immune system, particularly T cell attack1. For example, metabolic reprogramming in the tumour microenvironment and mitochondrial dysfunction in tumour-infiltrating lymphocytes (TILs) impair antitumour immune responses2,3,4. However, detailed mechanisms of such processes remain unclear. Here we analyse clinical specimens and identify mitochondrial DNA (mtDNA) mutations in TILs that are shared with cancer cells. Moreover, mitochondria with mtDNA mutations from cancer cells are able to transfer to TILs. Typically, mitochondria in TILs readily undergo mitophagy through reactive oxygen species. However, mitochondria transferred from cancer cells do not undergo mitophagy, which we find is due to mitophagy-inhibitory molecules. These molecules attach to mitochondria and together are transferred to TILs, which results in homoplasmic replacement. T cells that acquire mtDNA mutations from cancer cells exhibit metabolic abnormalities and senescence, with defects in effector functions and memory formation. This in turn leads to impaired antitumour immunity both in vitro and in vivo. Accordingly, the presence of an mtDNA mutation in tumour tissue is a poor prognostic factor for immune checkpoint inhibitors in patients with melanoma or non-small-cell lung cancer. These findings reveal a previously unknown mechanism of cancer immune evasion through mitochondrial transfer and can contribute to the development of future cancer immunotherapies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2475-0328</Issn>
      <Volume>8</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>High risk of multiple gastric cancers in Japanese individuals with Lynch syndrome</ArticleTitle>
    <FirstPage LZero="delete">1008</FirstPage>
    <LastPage>1016</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nobuhiko</FirstName>
        <LastName>Kanaya</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Thijs A.</FirstName>
        <LastName>van Schaik</LastName>
        <Affiliation>Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Aoki</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumiko</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Pathology, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumitaka</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kokichi</FirstName>
        <LastName>Sugano</LastName>
        <Affiliation>Department of Genetic Medicine, Kyoundo Hospital, SSasaki Foundation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiwamu</FirstName>
        <LastName>Akagi</LastName>
        <Affiliation>Division of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyuki</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohji</FirstName>
        <LastName>Tanakaya</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aim: Lynch syndrome (LS) is a dominantly inherited syndrome characterized by an increased risk for LS associated tumors such as colorectal cancer (CRC) and gastric cancer (GC). However, the clinical benefit of surveillance for GC remains unclear while it has already been recommended for CRC. This study aimed to elucidate the clinical features of GC in Japanese individuals with LS, and the risk of developing multiple GCs to build regional-tailored surveillance programs in LS patients with GC.&lt;br&gt;
Methods: Data on Japanese individuals with LS were retrospectively collected from a single institution. The clinical features of GC, including the cumulative risk of multiple GCs, were analyzed.&lt;br&gt;
Results: Among 96 individuals with LS (MLH1/MSH2/MSH6, 75:20:1), 32 GC lesions were detected in 15 individuals with LS (male/female, 11:4). The median age at initial GC diagnosis was 52.7 y (range: 28–71). Histological examination revealed a predominance of intestinal type (19/24: 87.5%). Moreover, the majority of the GC lesions (82%) were determined to have high-frequency of microsatellite instability. The cumulative risk of individuals with LS developing GC at 70 y was 31.3% (MLH1 36.1%, MSH2 18.0%). Notably, the cumulative risk of individuals with LS developing metachronous and/or synchronous GCs at 0, 10 and 20 y after initial diagnosis of GC was 26.7%, 40.7%, and 59.4%, respectively.&lt;br&gt;
Conclusion: Due to a higher risk of developing multiple GCs, intensive surveillance might be especially recommended for Japanese individuals with LS associated initial GC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cumulative risk</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japanese individuals</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lynch syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">multiple gastric cancers</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Spandidos Publications</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2049-9450</Issn>
      <Volume>23</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association of the expression of 5‑FU biomarkers with aging and prognosis in elderly patients with lung cancer treated with S‑1 adjuvant chemotherapy: Follow‑up results of the Setouchi Lung Cancer Group Study 1201</ArticleTitle>
    <FirstPage LZero="delete">79</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Soh</LastName>
        <Affiliation>Department of Thoracic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromasa</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Thoracic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norihito</FirstName>
        <LastName>Okumura</LastName>
        <Affiliation>Department of Thoracic Surgery, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Chest Surgery, Fukushima Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of General Thoracic Surgery, Kawasaki Medical School Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiya</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenicehi</FirstName>
        <LastName>Gemba</LastName>
        <Affiliation>Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Hiroshima 720‑0001, Japan; 8Department of Respiratory Surgery, Japanese Red Cross Nagasaki Genbaku Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Isao</FirstName>
        <LastName>Sano</LastName>
        <Affiliation>Department of Respiratory Surgery, Japanese Red Cross Nagasaki Genbaku Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuji</FirstName>
        <LastName>Fujinaga</LastName>
        <Affiliation>Department of General Thoracic Surgery, National Hospital Organization Nagara Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masafumi</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Department of Surgery and Respiratory Center, Okayama Saiseikai General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Terasaki</LastName>
        <Affiliation>Department of Respiratory Surgery, Saga Medical Center Koseikan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobukazu</FirstName>
        <LastName>Fujimoto</LastName>
        <Affiliation>Department of Medical Oncology and Respiratory Medicine, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Department of Thoracic Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kosaka</LastName>
        <Affiliation>Department of Thoracic Surgery, Shimane Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Inokawa</LastName>
        <Affiliation>Department of Thoracic Surgery, National Hospital Organization Yamaguchi‑Ube Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Thoracic Surgery, Shimonoseki City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshige</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Division of General Thoracic Surgery, Tottori University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Thoracic Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Thoracic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidejiro</FirstName>
        <LastName>Torigoe</LastName>
        <Affiliation>Department of Thoracic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Thoracic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshige</FirstName>
        <LastName>Yoshioka</LastName>
        <Affiliation>Department of Thoracic Oncology, Kansai Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keitaro</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Tokai Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Date</LastName>
        <Affiliation>Department of Thoracic Surgery, Kyoto University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of Thoracic Surgery, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Managing elderly patients presents several challenges because of age‑related declines; however, age should not be the sole determinant for adjuvant treatment decisions in patients with non‑small cell lung cancer (NSCLC). Moreover, age may affect the expression of 5‑fluorouracil (5‑FU) biomarkers. The present study assessed: i) The effect of age on the expression levels of 5‑FU biomarkers by analyzing a public database; and ii) the ability of these biomarkers to predict clinical outcomes in elderly patients with NSCLC who underwent complete resection in the Setouchi Lung Cancer Group Study 1201 (SCLG1201) followed by S‑1 adjuvant chemotherapy. Changes in gene expression levels across age groups were assessed by analyzing The Cancer Genome Atlas (TCGA) database. The expression of 5‑FU biomarkers, including thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase, epidermal growth factor receptor (EGFR) and excision repair cross‑complementation group 1 (ERCC1), were assessed via quantitative reverse‑transcription PCR assays in 89 elderly patients (≥75 years) with NSCLC who received adjuvant chemotherapy with oral fluoropyrimidine prodrug S‑1 in the SLCG1201 trial. TCGA database analysis (n=955) showed that TS expression decreased significantly with aging, especially in the age group ≥75. In the SCLG1201 trial, univariate analysis revealed that EGFR upregulation and TS downregulation were correlated with favorable recurrence‑free survival (RFS) and overall survival (OS), respectively. Multivariate analysis demonstrated that pathological stage was an independent prognostic factor for both RFS and OS. EGFR mutations were associated with upregulation of DPD and EGFR, and downregulation of TS and ERCC1. In conclusion, although pathological stage is an independent prognostic factor for survival, EGFR upregulation and TS downregulation may be a greater predictor of clinical outcomes in elderly patients with NSCLC treated with S‑1 adjuvant chemotherapy. The age‑related decrease in TS expression supports the potential benefit of 5‑FU therapies in elderly patients. Nonetheless, further research is warranted to validate these results.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">non‑small cell lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">elderly patients</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">adjuvant chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">S‑1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EGFR</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">OPRT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ERCC1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DPD</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0003-4975</Issn>
      <Volume>120</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparable Clinical Outcomes Between Segmentectomy and Lobectomy for NSCLC With Unsuspected N1/N2: A Multicenter Real-World Data Study</ArticleTitle>
    <FirstPage LZero="delete">87</FirstPage>
    <LastPage>98</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Ryuko</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikio</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Suzawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Ueno</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiya</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mototsugu</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Inokawa</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiko</FirstName>
        <LastName>Misao</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidejiro</FirstName>
        <LastName>Torigoe</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Washio</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Tao</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Okutani</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makio</FirstName>
        <LastName>Hayama</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Uomoto</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Kurosaki</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Yaginuma</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eito</FirstName>
        <LastName>Niman</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Kawamata</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nishikawa</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Yoshikawa</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuro</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Segmentectomy for lung cancer has been increasingly performed. However, evidence regarding the necessity of additional surgical resection after the diagnosis of unsuspected N1 or N2 lymph node metastasis is limited.&lt;br&gt;
Methods We conducted a multicenter, real-world data study of patients with any clinical T and N0 non-small cell lung cancer (NSCLC) who underwent lobectomy or segmentectomy between 2012 and 2021 and who subsequently received a diagnosis of pathologic N1 or N2 lymph node metastasis. Patients were categorized into lobectomy and segmentectomy groups. We analyzed overall survival (OS), recurrence-free survival (RFS), cumulative recurrence rates, and recurrence patterns using both unadjusted and propensity score–adjusted cohorts.&lt;br&gt;
Results A total of 736 patients were in the lobectomy group, and 70 were in the segmentectomy group. In the unadjusted cohort, segmentectomy-treated patients were older, had a lower preoperative percentage of vital capacity, had smaller tumors, and received less postoperative adjuvant chemotherapy. The 5-year OS was significantly worse in the segmentectomy group (P = .011), with no significant differences in 5-year RFS or cumulative recurrence rates. In the propensity score–adjusted cohort, there were no significant differences in OS, RFS, or recurrence rates; however, the segmentectomy group had a higher rate of local recurrence.&lt;br&gt;
Conclusions In patients with unsuspected N1 or N2 NSCLC, analysis using a cohort adjusted for patient background with propensity scores revealed no differences in OS, RFS, or cumulative recurrence rates between segmentectomy and lobectomy. This finding suggests that additional resection of the remaining segments may not be necessary for these patients. However, the higher rate of local recurrence in the segmentectomy group warrants careful consideration.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1071-2690</Issn>
      <Volume>60</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Enhanced design of pCMViR-TSC plasmid vector for sustainably high cargo gene expression in mammalian cells</ArticleTitle>
    <FirstPage LZero="delete">1215</FirstPage>
    <LastPage>1227</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masakiyo</FirstName>
        <LastName>Sakaguchi</LastName>
        <Affiliation>Department of Cell Biology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rie</FirstName>
        <LastName>Kinoshita</LastName>
        <Affiliation>Department of Cell Biology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nahoko</FirstName>
        <LastName>Tomonobu</LastName>
        <Affiliation>Department of Cell Biology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Sakaguchi</LastName>
        <Affiliation>Department of Microbiology, Tokushima Bunri University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichiro</FirstName>
        <LastName>Futami</LastName>
        <Affiliation>Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Yamauchi</LastName>
        <Affiliation>Department of Biochemistry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Murata</LastName>
        <Affiliation>Department of Cell Biology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken-ichi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Cell Biology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetta</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Cell Biology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuma</FirstName>
        <LastName>Gohara</LastName>
        <Affiliation>Department of Cell Biology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiki</FirstName>
        <LastName>Ochi</LastName>
        <Affiliation>Department of Cell Biology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fan</FirstName>
        <LastName>Jiang</LastName>
        <Affiliation>Department of Cell Biology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ni Luh Gede Yoni</FirstName>
        <LastName>Komalasari</LastName>
        <Affiliation>Faculty of Medicine, Udayana University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Youyi</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">I Made Winarsa</FirstName>
        <LastName>Ruma</LastName>
        <Affiliation>Faculty of Medicine, Udayana University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">I Wayan</FirstName>
        <LastName>Sumardika</LastName>
        <Affiliation>Faculty of Medicine, Udayana University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jin</FirstName>
        <LastName>Zhou</LastName>
        <Affiliation>Medical Oncology Department of Gastrointestinal Tumors, Liaoning Cancer Hospital &amp; Institute, Cancer Hospital of the Dalian University of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Honjo</LastName>
        <Affiliation>Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Futoshi</FirstName>
        <LastName>Kuribayashi</LastName>
        <Affiliation>Department of Biochemistry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazumi</FirstName>
        <LastName>Sagayama</LastName>
        <Affiliation>Organization for Research and Innovation Strategy, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eisaku</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Division of Tumor Pathology, Near InfraRed Photo-Immuno-Therapy Research Institute, Kansai Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Faculty of Science and Technology, Division of Molecular Science, Gunma University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The first-generation pCMViR-TSC, implemented through the promoter sandwich rule, yields 10- to 100-fold higher gene expression than the standard plasmid used with the CMV (cytomegalovirus) or CAG promoter. However, the vector’s shortcomings limit its utility to transient expression only, as it is not suitable for establishing stable transformants in mammalian cells. To overcome this weakness, we here introduce the improved plasmid vector pSAKA-4B, derived from pCMViR-TSC as a second-generation chromosome-insertable vector. This vector facilitates the linear entry of the expression unit into the TTAA site of DNA universally with transposase assistance. The vector is helpful for the indefinite expression of our target gene. The new vector system is proven here to be efficient in establishing stable transformants with a high likelihood of positive clones that exhibit significantly elevated expression levels of the delivered foreign gene. This system, alongside the first-generation vector, is therefore instrumental for diverse basic research endeavors concerning genes, proteins, cells, and animals, and potentially for clinical applications such as gene therapy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Plasmid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gene engineering</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cell culture</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1432-0533</Issn>
      <Volume>150</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Biallelic variants in DNAJC7 cause familial amyotrophic lateral sclerosis with the TDP-43 pathology</ArticleTitle>
    <FirstPage LZero="delete">19</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Yokota</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daiki</FirstName>
        <LastName>Ousaka</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hongming</FirstName>
        <LastName>Sun</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Haraguchi</LastName>
        <Affiliation>Department of Neurology, National Hospital Organisation Minami-Okayama Medical Centre</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ricardo Satoshi</FirstName>
        <LastName>Ota-Elliott</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chika</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohito</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hanae</FirstName>
        <LastName>Nakashima-Yasuda</LastName>
        <Affiliation>Department of Psychiatry, Zikei Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Fukui</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumiko</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Morihara</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Hosono</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seishi</FirstName>
        <LastName>Terada</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Takaki</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the progressive degeneration of motor neurons. ALS pathology primarily involves the failure of protein quality control mechanisms, leading to the accumulation of misfolded proteins, particularly TAR DNA-binding protein 43 (TDP-43). TDP-43 aggregation is a central pathological feature of ALS. Maintaining protein homeostasis is critical and facilitated by heat shock proteins (HSPs), particularly the HSP40 family, which includes co-chaperones such as DNAJC7. Here, we report a family with three siblings affected by ALS who carry a homozygous c.518dupC frameshift variant in DNAJC7, a member of the HSP40 family. All three patients exhibited progressive muscle weakness, limb atrophy, bulbar palsy, and respiratory failure. Pathological examination revealed degeneration of both upper and lower motor neurons, with phosphorylated TDP-43-positive neuronal cytoplasmic inclusions in the frontal and temporal cortices. Immunoblot analysis were consistent with a type B pattern of phosphorylated TDP-43 in the precentral gyrus. Immunohistochemistry and RNA sequencing analyses demonstrated a substantial reduction in DNAJC7 expression at both the protein and RNA levels in affected brain regions. In a TDP-43 cell model, DNAJC7 knockdown impaired the disassembly of TDP-43 following arsenite-induced stress, whereas DNAJC7 overexpression suppressed the assembly and promoted the disassembly of arsenite-induced TDP-43 condensates. Furthermore, in a zebrafish ALS model, dnajc7 knockdown resulted in increased TDP-43 aggregation in motor neurons and reduced survival. To the best of our knowledge, this study provides the first evidence linking biallelic loss-of-function variants in DNAJC7 to familial ALS with TDP-43 pathology.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Amyotrophic lateral sclerosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Heat shock protein</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DNAJC7</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TDP-43</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Live-cell imaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Zebrafish disease model</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Microbiology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2379-5042</Issn>
      <Volume>10</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mycobacterium tuberculosis bacillus induces pyroptosis in human lung fibroblasts</ArticleTitle>
    <FirstPage LZero="delete">e00110-25</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takemasa</FirstName>
        <LastName>Takii</LastName>
        <Affiliation>Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chihiro</FirstName>
        <LastName>Motozono</LastName>
        <Affiliation>Department of Molecular Immunology, Research Institute for Microbial Diseases, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Yamasaki</LastName>
        <Affiliation>Department of Molecular Immunology, Research Institute for Microbial Diseases, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jordi B.</FirstName>
        <LastName>Torrelles</LastName>
        <Affiliation>Texas Biomedical Research Institute and International Center for the Advancement of Research &amp; Education (I•CARE)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joanne</FirstName>
        <LastName>Turner</LastName>
        <Affiliation>Texas Biomedical Research Institute and International Center for the Advancement of Research &amp; Education (I•CARE)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aoi</FirstName>
        <LastName>Kimishima</LastName>
        <Affiliation>Laboratory of Applied Microbial Chemistry, Ōmura Satoshi Memorial Institute, Kitasato University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukihiro</FirstName>
        <LastName>Asami</LastName>
        <Affiliation>Laboratory of Applied Microbial Chemistry, Ōmura Satoshi Memorial Institute, Kitasato University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Oral Microbiology, Graduate School of Medicine, Density and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeaki</FirstName>
        <LastName>Hida</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Cell Signaling, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kikuo</FirstName>
        <LastName>Onozaki</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We previously reported that live, but not dead, virulent Mycobacterium tuberculosis (Mtb) H37Rv bacilli induce cell death in human lung fibroblast cell lines, MRC-5, MRC-9, and TIG-1. Here, using two distinct Mtb strains from two different lineages (HN878 lineage 2 and H37Rv lineage 4), we confirmed cell death at day 2 after infection with a device that measures cell growth/cytotoxicity in real time (Maestro-Z [AXION]). Mtb bacilli uptake by the fibroblast was confirmed with a transmission electron microscope on day 2. Expressions of inflammatory cytokines and interleukin (IL)−1β, IL-6, and IL-8 were observed when exposed to live, but not dead bacteria. The cell death of fibroblasts induced by both Mtb strains tested was prevented by caspase-1/4 and NLRP3 inflammasome inhibitors, but not by caspase-3 and caspase-9 inhibitors. Therefore, we classified the fibroblast cell death by Mtb infection as pyroptosis. To investigate the biological and pathological relevance of fibroblast cell death by Mtb infection, we performed dual RNA-Seq analysis on Mtb within fibroblasts and Mtb-infected fibroblasts at day 2. In Mtb bacilli tcrR, secE2, ahpD, and mazF8 genes were highly induced during infection. These genes play roles in survival in a hypoxic environment, production of a calcium-binding protein-inducing cytokine, and regulation of transcription in a toxin-antitoxin system. The gene expressions of IL-1β, IL-6, and IL-8, caspase-4, and NLRP3, but not of caspase-3 and caspase-9, were augmented in Mtb bacilli-infected fibroblasts. Taken together, our study suggests that Mtb bacilli attempt to survive in lung fibroblasts and that pyroptosis of the host fibroblasts activates the immune system against the infection.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Mycobacterium tuberculosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pyroptosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">caspase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">RNA-Seq</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cytokine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fibroblasts</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2304-6767</Issn>
      <Volume>12</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Coronal Cementum and Reduced Enamel Epithelium on Occlusal Surface of Impacted Wisdom Tooth in a Human</ArticleTitle>
    <FirstPage LZero="delete">348</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Naohiro</FirstName>
        <LastName>Horie</LastName>
        <Affiliation>Division of Reconstructive Surgery for Oral and Maxillofacial Region, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaru</FirstName>
        <LastName>Murata</LastName>
        <Affiliation>Division of Regenerative Medicine, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhito</FirstName>
        <LastName>Minamida</LastName>
        <Affiliation>Division of Oral and Maxillofacial Surgery, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Nagayasu</LastName>
        <Affiliation>Division of Oral and Maxillofacial Surgery, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Shimo</LastName>
        <Affiliation>Division of Reconstructive Surgery for Oral and Maxillofacial Region, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Akazawa</LastName>
        <Affiliation>Industrial Technology and Environment Research Development, Hokkaido Research Organization</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetsugu</FirstName>
        <LastName>Tsujigiwa</LastName>
        <Affiliation>Department of Life Science, Faculty of Science, Okayama University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Youssef</FirstName>
        <LastName>Haikel</LastName>
        <Affiliation>Department of Biomaterials and Bioengineering, Institut National de la Santé et de la Recherche médicale Unité Mixte de Recherche (INSERM UMR) _S 1121, University of Strasbourg</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: There is only limited research on the coronal cementum of a tooth, and the mechanisms of its forming process are not well-defined. This report presents a coronal cementum on the occlusal surfaces of enamel in an impacted wisdom tooth in a human, which is not nearly the cervical portion. Materials and Methods: The tooth (Tooth #1) was derived from a 46-year-old female. Histological analysis, including hematoxylin and eosin (HE) and toluidine blue (TB) staining, and Scanning Electron Microscopy and Energy Dispersive X-ray Spectrometer (SEM-EDS) analysis of the extracted tooth were conducted. Radiographic examination showed that Tooth #1 was horizontally impacted in the maxilla and had the apex of a single root placed between the buccal and palatal roots of Tooth #2. Results: Coronal cementum was distributed widely on the enamel, and reduced enamel epithelium was also found with enamel matrix proteins histologically. The formation of acellular cementum was observed to be more predominant than that of the cellular cementum in Tooth #1. SEM showed that the occlusal cementum connected directly with enamel. Calcium mapping revealed an almost similar occlusal cementum and enamel. In addition, the spectrum of elements in coronal cementum resembled the primary cementum according to SEM-EDS. Discussion: Thus, coronal cementogenesis in impacted human teeth might be related to the existence of reduced enamel epithelium.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">coronal cementum</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">human</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">reduced epithelium</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">impacted tooth</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0168-0102</Issn>
      <Volume>218</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Alteration of perineuronal nets and parvalbumin interneurons in prefrontal cortex and hippocampus, and correlation with blood corticosterone in activity-based anorexia model mice</ArticleTitle>
    <FirstPage LZero="delete">104922</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hoang Duy</FirstName>
        <LastName>Nguyen</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruko</FirstName>
        <LastName>Miyazaki</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ziyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Takaki</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshitaka</FirstName>
        <LastName>Oohashi</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Anorexia nervosa (AN) is an eating disorder characterized by restricted energy intake, severely underweight status, and frequent hyperactivity. Previous research has shown structural and functional alterations in the medial prefrontal cortex (mPFC) and hippocampus of AN patients. To investigate the pathological mechanism of AN, we analyzed the expression and distribution of parvalbumin (PV) interneurons and perineuronal nets (PNNs), which are implicated in the pathology of neuropsychiatric disorders, in the mPFC and hippocampus dorsal (HPCd) and ventral (HPCv) using an activity-based anorexia (ABA) mouse model. We found that PNN expression and density increased in the mPFC, with minor alterations in the HPCd and HPCv of ABA mice. The expression and distribution of PV neurons were unchanged in the brains of ABA mice, except for a regional decrease in PV-expressing neuron density in the HPCd. Co-localization analysis showed an increased number of PNNs enwrapping PV-negative neurons in the mPFC of ABA mice. Furthermore, the upregulation of PNN expression in the mPFC was positively correlated with elevated blood corticosterone levels, a well-known stress indicator, in ABA mice. Our findings suggest that the increased expression and distribution of PNNs surrounding PV-negative neurons in the mPFC may indicate the pathological mechanisms of AN.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anorexia nervosa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">activity-based anorexia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">perineuronal nets</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">parvalbumin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">corticosterone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prefrontal cortex</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hippocampus</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2692-4609</Issn>
      <Volume>6</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Case of Gastric Atypical Lipomatous Tumor/Well‐Differentiated Liposarcoma With Endoscopic Morphological Changes</ArticleTitle>
    <FirstPage LZero="delete">e70146</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Rika</FirstName>
        <LastName>Omote</LastName>
        <Affiliation>Department of Diagnostic Pathology, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shizuma</FirstName>
        <LastName>Omote</LastName>
        <Affiliation>Department of Internal Medicine, Fukuyama Minami Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Sonobe</LastName>
        <Affiliation>Department of Diagnostic Pathology, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Surgery, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Toyokawa</LastName>
        <Affiliation>Department of Gastroenterology, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Surgery, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yanai</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaru</FirstName>
        <LastName>Inagaki</LastName>
        <Affiliation>Department of Surgery, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Atypical lipomatous tumor/well-differentiated liposarcoma is a locally aggressive mesenchymal neoplasm composed of adipocytes and stromal cells. Gastric cases are exceedingly rare, and their malignant potential remains unclear. We report a case of a woman in her 60s who was found to have multiple submucosal tumor-like lesions of the stomach. Over time, the tumors increased in size, requiring a laparoscopic partial gastrectomy. Histological examination revealed a tumor composed of both fatty tissue and fibrous stroma with nuclear atypia. Immunohistochemistry showed positivity for CDK4 and MDM2, and fluorescence in situ hybridization confirmed MDM2 amplification, leading to a diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma. This case presented an unusual gastric manifestation, with multiple submucosal tumor-like lesions on endoscopy and exhibiting progressive morphological changes over several years.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">atypical lipomatous tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CDK4</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MDM2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stomach</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">well-differentiated liposarcoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0169-5002</Issn>
      <Volume>199</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Real-world status of multimodal treatment of Stage IIIA-N2 non-small cell lung cancer in Japan: Results from the SOLUTION study, a non-interventional, multicenter cohort study</ArticleTitle>
    <FirstPage LZero="delete">108027</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hidehito</FirstName>
        <LastName>Horinouchi</LastName>
        <Affiliation>Department of Thoracic Oncology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruyasu</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Department of Thoracic Oncology, Shizuoka Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyuki</FirstName>
        <LastName>Harada</LastName>
        <Affiliation>Division of Radiation Therapy, Shizuoka Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomotaka</FirstName>
        <LastName>Sobue</LastName>
        <Affiliation>Division of Environmental Medicine and Population Sciences, Graduate School of Medicine, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Himeji Medical Cente</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Atagi</LastName>
        <Affiliation>Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Kozuki</LastName>
        <Affiliation>Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaaki</FirstName>
        <LastName>Tokito</LastName>
        <Affiliation>Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Oizumi</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Seike</LastName>
        <Affiliation>Department of Pulmonary Medicine and Oncology, Nippon Medical School Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Mio</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Kyoto Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Sone</LastName>
        <Affiliation>Department of Respiratory Medicine, Kanazawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikako</FirstName>
        <LastName>Iwao</LastName>
        <Affiliation>Department of Medical, AstraZeneca K.K.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Iwane</LastName>
        <Affiliation>Department of Medical, AstraZeneca K.K.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Koto</LastName>
        <Affiliation>Department of Medical, AstraZeneca K.K.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Thoracic Surgery, National Cancer Center Hospital East</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: There is limited consensus on resectability criteria for Stage IIIA-N2 non-small cell lung cancer (NSCLC). We examined the patient characteristics, N2 status, treatment decisions, and clinical outcomes according to the treatment modality for Stage IIIA-N2 NSCLC in Japan.&lt;br&gt;
Materials and methods: Patients with Stage IIIA-N2 NSCLC in Japan were consecutively registered in the SOLUTION study between 2013 and 2014. Patients were divided according to treatment (chemoradiotherapy [CRT], surgery + perioperative therapy [neoadjuvant and/or adjuvant therapy], surgery alone). Demographic characteristics, N2 status (number and morphological features), pathological information, and treatments were analyzed descriptively. Overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) were estimated using the Kaplan–Meier method.&lt;br&gt;
Results: Of 227 patients registered, 133 underwent CRT, 56 underwent surgery + perioperative therapy, and 38 underwent surgery alone. The physicians reported the following reasons for unresectability for 116 of 133 CRT patients: large number of metastatic lymph nodes (70.7 %), extranodal infiltration (25.0 %), poor surgical tolerance (19.0 %), or other reasons (18.1 %). CRT was more frequently performed in patients whose lymph nodes had an infiltrative appearance (64.3 %) and was the predominant treatment in patients with multiple involved stations (discrete: 60.0 %; infiltrative: 80.4 %). Distant metastasis with/without local progression was found in 50.4 %, 50.0 %, and 36.8 % of patients in the CRT, surgery + perioperative therapy, and surgery alone groups, respectively. The respective 3-year OS and DFS/PFS rates (median values) were as follows: surgery + perioperative therapy—61.9 % (not reached) and 37.1 % (22.4 months; DFS); CRT group—42.2 % (31.9 months) and 26.8 % (12.0 months; PFS); surgery alone group—37.7 % (26.5 months) and 28.7 % (12.6 months; DFS).&lt;br&gt;
Conclusion: This study has illuminated the real-world decision rules for choosing between surgical and non-surgical approaches in patients with Stage IIIA-N2 NSCLC. Our landmark data could support treatment decision making for using immune checkpoint inhibitors and targeted therapy for driver oncogenes in the perioperative therapy era.
</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Non-small cell lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Adjuvant therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Neoadjuvant therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chemoradiotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Observational study</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Retrospective study</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2075-4418</Issn>
      <Volume>15</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Review Article: Diagnostic Paradigm Shift in Spine Surgery</ArticleTitle>
    <FirstPage LZero="delete">594</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Aras Efe</FirstName>
        <LastName>Levent</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chetan</FirstName>
        <LastName>Kumawat</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Christian</FirstName>
        <LastName>Heng</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Salamalikis</FirstName>
        <LastName>Nikolaos</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kajetan</FirstName>
        <LastName>Latka</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiyoshi</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Komatsubara</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Arataki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Shinohara</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Uotani</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Meticulous clinical examination is essential for spinal disorders to utilize the diagnostic methods and technologies that strongly support physicians and enhance clinical practice. A significant change in the approach to diagnosing spinal disorders has occurred in the last three decades, which has enhanced a more nuanced understanding of spine pathology. Traditional radiographic methods such as conventional and functional X-rays and CT scans are still the first line in the diagnosis of spinal disorders due to their low cost and accessibility. As more advanced imaging technologies become increasingly available worldwide, there is a constantly increasing trend in MRI scans for detecting spinal pathologies and making treatment decisions. Not only do MRI scans have superior diagnostic capabilities, but they also assist surgeons in performing meticulous preoperative planning, making them currently the most widely used diagnostic tool for spinal disorders. Positron Emission Tomography (PET) can help detect inflammatory lesions, infections, and tumors. Other advanced diagnostic tools such as CT/MRI fusion image, Functional Magnetic Resonance Imaging (fMRI), Upright and Kinetic MRI, magnetic resonance spectroscopy (MRS), diffusion-weighted imaging (DWI), and diffusion tensor imaging (DTI) could play an important role when it comes to detecting more special pathologies. However, some technical difficulties in the daily praxis and their high costs act as obstacles to their further spread. Integrating artificial intelligence and advancements in data analytics and virtual reality promises to enhance spinal procedures’ precision, safety, and efficacy. As these technologies continue to develop, they will play a critical role in transforming spinal surgery. This paradigm shift emphasizes the importance of continuous innovation and adaptability in improving the diagnosis and treatment of spinal disorders.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">diagnosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">spine surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">innovative technique</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MRI</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">myelography</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Microbiology Society</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0022-1317</Issn>
      <Volume>106</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Summary of taxonomy changes ratified by the International Committee on Taxonomy of Viruses (ICTV) from the Animal dsRNA and ssRNA(−) Viruses Subcommittee, 2025</ArticleTitle>
    <FirstPage LZero="delete">002112</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Holly R.</FirstName>
        <LastName>Hughes</LastName>
        <Affiliation>Centers for Disease Control and Prevention</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Matthew J.</FirstName>
        <LastName>Ballinger</LastName>
        <Affiliation>Biological Sciences, Mississippi State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yiming</FirstName>
        <LastName>Bao</LastName>
        <Affiliation>National Genomics Data Center, China National Center for Bioinformation; Beijing Institute of Genomics, Chinese Academy of Sciences; University of Chinese Academy of Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nicolas</FirstName>
        <LastName>Bejerman</LastName>
        <Affiliation>Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and Instituto Nacional de Tecnología Agropecuaria (INTA)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kim R.</FirstName>
        <LastName>Blasdell</LastName>
        <Affiliation>CSIRO Health and Biosecurity</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Thomas</FirstName>
        <LastName>Briese</LastName>
        <Affiliation>Center for Infection and Immunity, and Department of Epidemiology, Mailman School of Public Health, Columbia University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Julia</FirstName>
        <LastName>Brignone</LastName>
        <Affiliation>Instituto Nacional de Enfermedades Virales Humanas Dr. Julio I. Maiztegui. INEVH -ANLIS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jean Paul</FirstName>
        <LastName>Carrera</LastName>
        <Affiliation>Instituto Conmemorativo Gorgas de Estudios de la Salud</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lander</FirstName>
        <LastName>De Coninck</LastName>
        <Affiliation>Division of Clinical and Epidemiological Virology, KU Leuven</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">William Marciel</FirstName>
        <LastName>de Souza</LastName>
        <Affiliation>Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Humberto</FirstName>
        <LastName>Debat</LastName>
        <Affiliation>Instituto Nacional de Tecnología Agropecuaria (INTA)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ralf G.</FirstName>
        <LastName>Dietzgen</LastName>
        <Affiliation>QAAFI, The University of Queensland</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ralf</FirstName>
        <LastName>Dürrwald</LastName>
        <Affiliation>Robert Koch Institut</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mert</FirstName>
        <LastName>Erdin</LastName>
        <Affiliation>Department of Virology, University of Helsinki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Anthony R.</FirstName>
        <LastName>Fooks</LastName>
        <Affiliation>Animal and Plant Health Agency (APHA)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kristian M.</FirstName>
        <LastName>Forbes</LastName>
        <Affiliation>Department of Biological Sciences, University of Arkansas</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Juliana</FirstName>
        <LastName>Freitas-Astúa</LastName>
        <Affiliation>Embrapa Cassava and Fruits</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jorge B.</FirstName>
        <LastName>Garcia</LastName>
        <Affiliation>Instituto Nacional de Enfermedades Virales Humanas Dr. Julio I. Maiztegui. INEVH -ANLIS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jemma L.</FirstName>
        <LastName>Geoghegan</LastName>
        <Affiliation>Department of Microbiology and Immunology, University of Otago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rebecca M.</FirstName>
        <LastName>Grimwood</LastName>
        <Affiliation>Department of Microbiology and Immunology, University of Otago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayuki</FirstName>
        <LastName>Horie</LastName>
        <Affiliation>Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Timothy H.</FirstName>
        <LastName>Hyndman</LastName>
        <Affiliation>School of Veterinary Medicine, Murdoch University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reimar</FirstName>
        <LastName>Johne</LastName>
        <Affiliation>German Federal Institute for Risk Assessment</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">John D.</FirstName>
        <LastName>Klena</LastName>
        <Affiliation>Viral Special Pathogens Branch, The Centers for Disease Control and Prevention</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eugene V.</FirstName>
        <LastName>Koonin</LastName>
        <Affiliation>Computational Biology Branch, Division of Intramural Research National Library of Medicine, National Institutes of Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Alexei Y.</FirstName>
        <LastName>Kostygov</LastName>
        <Affiliation>University of Ostrava</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mart</FirstName>
        <LastName>Krupovic</LastName>
        <Affiliation>Institut Pasteur, Université Paris Cité, CNRS UMR6047, Archaeal Virology Unit</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jens H.</FirstName>
        <LastName>Kuhn</LastName>
        <Affiliation>Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michael</FirstName>
        <LastName>Letko</LastName>
        <Affiliation>Paul G. Allen School for Global Health, Washington State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun-Min</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Institute of Plant Virology, Ningbo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yiyun</FirstName>
        <LastName>Liu</LastName>
        <Affiliation>National Genomics Data Center, China National Center for Bioinformation; Beijing Institute of Genomics, Chinese Academy of Sciences; University of Chinese Academy of Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maria Laura</FirstName>
        <LastName>Martin</LastName>
        <Affiliation>Instituto Nacional de Enfermedades Virales Humanas Dr. Julio I. Maiztegui. INEVH -ANLIS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nathaniel</FirstName>
        <LastName>Mull</LastName>
        <Affiliation>Department of Natural Sciences, Shawnee State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yael</FirstName>
        <LastName>Nazar</LastName>
        <Affiliation>Instituto Nacional de Enfermedades Virales Humanas Dr. Julio I. Maiztegui. INEVH -ANLIS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norbert</FirstName>
        <LastName>Nowotny</LastName>
        <Affiliation>College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Márcio Roberto Teixeira</FirstName>
        <LastName>Nunes</LastName>
        <Affiliation>Universidade Federal do Pará</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Arnfinn Lodden</FirstName>
        <LastName>Økland</LastName>
        <Affiliation>Pharmaq Analytiq</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dennis</FirstName>
        <LastName>Rubbenstroth</LastName>
        <Affiliation>Institute of Diagnostic Virology, Friedrich-Loeffler-Institut</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Brandy J.</FirstName>
        <LastName>Russell</LastName>
        <Affiliation>Centers for Disease Control and Prevention</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eric</FirstName>
        <LastName>Schott</LastName>
        <Affiliation>Institute of Marine and Environmental Technology, University of Maryland Center for Environmental Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Stephanie</FirstName>
        <LastName>Seifert</LastName>
        <Affiliation>Paul G. Allen School for Global Health, Washington State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Carina</FirstName>
        <LastName>Sen</LastName>
        <Affiliation>Instituto Nacional de Enfermedades Virales Humanas Dr. Julio I. Maiztegui. INEVH -ANLIS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Elizabeth</FirstName>
        <LastName>Shedroff</LastName>
        <Affiliation>Viral Special Pathogens Branch, The Centers for Disease Control and Prevention</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tarja</FirstName>
        <LastName>Sironen</LastName>
        <Affiliation>Department of Virology, University of Helsinki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teemu</FirstName>
        <LastName>Smura</LastName>
        <Affiliation>Department of Virology, University of Helsinki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Camila Prestes Dos Santos</FirstName>
        <LastName>Tavares</LastName>
        <Affiliation>Integrated Group of Aquaculture and Environmental Studies, Federal University of Paraná</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Robert B.</FirstName>
        <LastName>Tesh</LastName>
        <Affiliation>Department of Pathology, The University of Texas Medical Branch</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natasha L.</FirstName>
        <LastName>Tilston</LastName>
        <Affiliation>Department of Microbiology and Immunology, Indiana University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noël</FirstName>
        <LastName>Tordo</LastName>
        <Affiliation>Institut Pasteur</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nikos</FirstName>
        <LastName>Vasilakis</LastName>
        <Affiliation>Department of Pathology, The University of Texas Medical Branch</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Peter J.</FirstName>
        <LastName>Walker</LastName>
        <Affiliation>University of Queensland</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fei</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Wuhan Institute of Virology, Chinese Academy of Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Anna E.</FirstName>
        <LastName>Whitfield</LastName>
        <Affiliation>North Carolina State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shannon L.M.</FirstName>
        <LastName>Whitmer</LastName>
        <Affiliation>Viral Special Pathogens Branch, The Centers for Disease Control and Prevention</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuri I.</FirstName>
        <LastName>Wolf</LastName>
        <Affiliation>Computational Biology Branch, Division of Intramural Research National Library of Medicine, National Institutes of Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Han</FirstName>
        <LastName>Xia</LastName>
        <Affiliation>Wuhan Institute of Virology, Chinese Academy of Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gong-Yin</FirstName>
        <LastName>Ye</LastName>
        <Affiliation>Institute of Insect Sciences, Zhejiang University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zhuangxin</FirstName>
        <LastName>Ye</LastName>
        <Affiliation>Institute of Plant Virology, Ningbo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vyacheslav</FirstName>
        <LastName>Yurchenko</LastName>
        <Affiliation>University of Ostrava</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mingli</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Department of Pathobiology and Population Sciences, Royal Veterinary College</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>RNA viruses are ubiquitous in the environment and are important pathogens of humans, animals and plants. In 2024, the International Committee on Taxonomy of Viruses Animal dsRNA and ssRNA(−) Viruses Subcommittee submitted 18 taxonomic proposals for consideration. These proposals expanded the known virosphere by classifying 9 new genera and 88 species for newly detected virus genomes. Of note, newly established species expand the large family of Rhabdoviridae to 580 species. A new species in the family Arenaviridae includes a virus detected in Antarctic fish with a unique split nucleoprotein ORF. Additionally, four new species were established for historically isolated viruses with previously unsequenced genomes. Furthermore, three species were abolished due to incomplete genome sequence information, and one family was moved from being unassigned in the phylum Negarnaviricota into a subphylum and order. Herein, we summarize the 18 ratified taxonomic proposals and the general features of the current taxonomy, thereby supporting public and animal health responses.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Microbiology Society</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0022-1317</Issn>
      <Volume>106</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Summary of taxonomy changes ratified by the International Committee on Taxonomy of Viruses from the Plant Viruses Subcommittee, 2025</ArticleTitle>
    <FirstPage LZero="delete">002114</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Luisa</FirstName>
        <LastName>Rubino</LastName>
        <Affiliation>Istituto per la Protezione Sostenibile delle Piante, CNR</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Peter</FirstName>
        <LastName>Abrahamian</LastName>
        <Affiliation>USDA-ARS, BARC, National Germplasm Resources Laboratory</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wenxia</FirstName>
        <LastName>An</LastName>
        <Affiliation>Liaoning Key Laboratory of Urban Integrated Pest Management and Ecological Security, Shenyang University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miguel A.</FirstName>
        <LastName>Aranda</LastName>
        <Affiliation>Centro de Edafología y Biología Aplicada del Segura-CSIC</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">José T.</FirstName>
        <LastName>Ascencio-Ibañez</LastName>
        <Affiliation>Department of Molecular and Structural Biochemistry, North Carolina State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nicolas</FirstName>
        <LastName>Bejerman</LastName>
        <Affiliation>Unidad de Fitopatología y Modelización Agrícola (UFYMA) INTA-CONICET</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Arnaud G.</FirstName>
        <LastName>Blouin</LastName>
        <Affiliation>Plant Protection Department</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Thierry</FirstName>
        <LastName>Candresse</LastName>
        <Affiliation>UMR 1332 Biologie du Fruit et Pathologie, University of Bordeaux, INRAE</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomas</FirstName>
        <LastName>Canto</LastName>
        <Affiliation>Margarita Salas Center for Biological Research (CIB-CSIC) Spanish Council for Scientific Research (CSIC)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mengji</FirstName>
        <LastName>Cao</LastName>
        <Affiliation>National Citrus Engineering and Technology Research Center, Integrative Science Center of Germplasm Creation in Western China (CHONGQING) Science City, Citrus Research Institute, Southwest University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">John P.</FirstName>
        <LastName>Carr</LastName>
        <Affiliation>Department of Plant Sciences, University of Cambridge</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Won Kyong</FirstName>
        <LastName>Cho</LastName>
        <Affiliation>Agriculture and Life Sciences Research Institute, Kangwon National University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fiona</FirstName>
        <LastName>Constable</LastName>
        <Affiliation>Agriculture Victoria Research, Department of Energy, Environment and Climate Action and School of Applied Systems Biology, La Trobe University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Indranil</FirstName>
        <LastName>Dasgupta</LastName>
        <Affiliation>University of Delhi South Campu</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Humberto</FirstName>
        <LastName>Debat</LastName>
        <Affiliation>Unidad de Fitopatología y Modelización Agrícola (UFYMA) INTA-CONICET</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ralf G.</FirstName>
        <LastName>Dietzgen</LastName>
        <Affiliation>Queensland Alliance for Agriculture and Food Innovation, The University of Queensland</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michele</FirstName>
        <LastName>Digiaro</LastName>
        <Affiliation>CIHEAM, Istituto Agronomico Mediterraneo of Bari</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Livia</FirstName>
        <LastName>Donaire</LastName>
        <Affiliation>Centro de Edafología y Biología Aplicada del Segura-CSIC</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toufic</FirstName>
        <LastName>Elbeaino</LastName>
        <Affiliation>CIHEAM, Istituto Agronomico Mediterraneo of Bari</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Denis</FirstName>
        <LastName>Fargette</LastName>
        <Affiliation>Virus South Data</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fiona</FirstName>
        <LastName>Filardo</LastName>
        <Affiliation>Queensland Department of Primary Industries</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Matthias G.</FirstName>
        <LastName>Fischer</LastName>
        <Affiliation>Max Planck Institute for Marine Microbiology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nuria</FirstName>
        <LastName>Fontdevila</LastName>
        <Affiliation>Plant Protection Department</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Adrian</FirstName>
        <LastName>Fox</LastName>
        <Affiliation>Fera Science Ltd (Fera), York Biotech Campus</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Juliana</FirstName>
        <LastName>Freitas-Astua</LastName>
        <Affiliation>Embrapa Cassava and Fruits, Brazilian Agricultural Research Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Marc</FirstName>
        <LastName>Fuchs</LastName>
        <Affiliation>Plant Pathology, Cornell University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Andrew D.W.</FirstName>
        <LastName>Geering</LastName>
        <Affiliation>Queensland Alliance for Agriculture and Food Innovation, The University of Queensland</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mahan</FirstName>
        <LastName>Ghafari</LastName>
        <Affiliation>Department of Biology, University of Oxford</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Anders</FirstName>
        <LastName>Hafrén</LastName>
        <Affiliation>Swedish University of Agriculture</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">John</FirstName>
        <LastName>Hammond</LastName>
        <Affiliation>USDA-ARS, USNA, Floral and Nursery Plants Research Unit</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rosemarie</FirstName>
        <LastName>Hammond</LastName>
        <Affiliation>USDA-ARS, BARC, Molecular Plant Pathology Laboratory</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Beata</FirstName>
        <LastName>Hasiów-Jaroszewska</LastName>
        <Affiliation>Institute of Plant Protection-NRI</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eugenie</FirstName>
        <LastName>Hebrard</LastName>
        <Affiliation>PHIM Plant Health Institute, University of Montpellier, INRAE, CIRAD, IRD, Institute Agro</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Carmen</FirstName>
        <LastName>Hernández</LastName>
        <Affiliation>Instituto de Biología Molecular y Celular de Plantas (IBMCP), Universitat Politècnica de Valencia-CSIC</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jean-Michel</FirstName>
        <LastName>Hily</LastName>
        <Affiliation>Institut Français de la Vigne et du Vin</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ahmed</FirstName>
        <LastName>Hosseini</LastName>
        <Affiliation>Vali-e-Asr University of Rafsanjan, Department of Plant Protection</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Roger</FirstName>
        <LastName>Hull</LastName>
        <Affiliation>Retired from John Innes Centre</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Alice K.</FirstName>
        <LastName>Inoue-Nagata</LastName>
        <Affiliation>Embrapa Hortaliças</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ramon</FirstName>
        <LastName>Jordan</LastName>
        <Affiliation>USDA-ARS, USNA, Floral and Nursery Plants Research Unit</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jan F.</FirstName>
        <LastName>Kreuze</LastName>
        <Affiliation>International Potato Center (CIP)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mart</FirstName>
        <LastName>Krupovic</LastName>
        <Affiliation>Institut Pasteur, Université Paris Cité, CNRS UMR6047, Archaeal Virology Unit</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Institute for Plant Protection, NARO</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jens H.</FirstName>
        <LastName>Kuhn</LastName>
        <Affiliation>Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Scott</FirstName>
        <LastName>Leisner</LastName>
        <Affiliation>Department of Biological Sciences, University of Toledo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jean-Michel</FirstName>
        <LastName>Lett</LastName>
        <Affiliation>CIRAD, UMR PVBMT</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chengyu</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Liaoning Key Laboratory of Urban Integrated Pest Management and Ecological Security, Shenyang University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fan</FirstName>
        <LastName>Li</LastName>
        <Affiliation>State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Yunnan Agricultural University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun Min</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Institute of Plant Virology, Ningbo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Paola M.</FirstName>
        <LastName>López-Lambertini</LastName>
        <Affiliation>Instituto de Patología Vegetal (IPAVE), INTA, Unidad de Fitopatología y Modelización Agrícola (UFYMA) INTA-CONICET</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Juan J.</FirstName>
        <LastName>Lopez-Moya</LastName>
        <Affiliation>Centre for Research in Agricultural Genomics, CRAG (CSIC-IRTA-UAB-UB)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Francois</FirstName>
        <LastName>Maclot</LastName>
        <Affiliation>UMR 1332 Biologie du Fruit et Pathologie, University of Bordeaux, INRAE</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kristiina</FirstName>
        <LastName>Mäkinen</LastName>
        <Affiliation>Department of Agricultural Sciences, University of Helsinki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Darren</FirstName>
        <LastName>Martin</LastName>
        <Affiliation>Institute of Infectious Disease and Molecular Medicine, University of Cape Town</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sebastien</FirstName>
        <LastName>Massart</LastName>
        <Affiliation>Plant Pathology Laboratory, TERRA Gembloux Agro-Bio Tech, University of Liege</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">W. Allen</FirstName>
        <LastName>Miller</LastName>
        <Affiliation>Department of Plant Pathology, Entomology and Microbiology, Iowa State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Musa</FirstName>
        <LastName>Mohammadi</LastName>
        <Affiliation>Department of Plant Protection, Gorgan University of Agricultural Sciences and Natural Resources</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dimitre</FirstName>
        <LastName>Mollov</LastName>
        <Affiliation>USDA-APHIS, Plant Protection and Quarantine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emmanuelle</FirstName>
        <LastName>Muller</LastName>
        <Affiliation>CIRAD, AGAP Institut; AGAP Institut, University of Montpellier; CIRAD, INRAE</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Nagata</LastName>
        <Affiliation>Instituto de Ciências Biológicas, Universidade de Brasília</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jesús</FirstName>
        <LastName>Navas-Castillo</LastName>
        <Affiliation>Instituto de Hortofruticultura Subtropical y Mediterránea “La Mayora” (IHSM-UMA-CSIC), Consejo Superior de Investigaciones Científicas</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaro</FirstName>
        <LastName>Neriya</LastName>
        <Affiliation>Utsunomiya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Francisco M.</FirstName>
        <LastName>Ochoa-Corona</LastName>
        <Affiliation>Oklahoma State University, Institute for Biosecurity &amp; Microbial Forensics</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazusato</FirstName>
        <LastName>Ohshima</LastName>
        <Affiliation>Saga University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vicente</FirstName>
        <LastName>Pallás</LastName>
        <Affiliation>Instituto de Biología Molecular y Celular de Plantas (IBMCP), Universitat Politècnica de Valencia-CSIC</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hanu</FirstName>
        <LastName>Pappu</LastName>
        <Affiliation>Department of Plant Pathology, Washington State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Karel</FirstName>
        <LastName>Petrzik</LastName>
        <Affiliation>Institute of Plant Molecular Biology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikhail</FirstName>
        <LastName>Pooggin</LastName>
        <Affiliation>PHIM Plant Health Institute, University of Montpellier, INRAE, CIRAD, IRD</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maria Isabella</FirstName>
        <LastName>Prigigallo</LastName>
        <Affiliation>Istituto per la Protezione Sostenibile delle Piante, CNR</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pedro L.</FirstName>
        <LastName>Ramos-González</LastName>
        <Affiliation>Applied Molecular Biology Laboratory, Instituto Biológico de São Paulo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Simone</FirstName>
        <LastName>Ribeiro</LastName>
        <Affiliation>Embrapa Recursos Genéticos e Biotecnologia</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katja R.</FirstName>
        <LastName>Richert-Pöggeler</LastName>
        <Affiliation>Julius Kühn Institute, Federal Research Centre for Cultivated Plants, Institute for Epidemiology and Pathogen Diagnostics</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Philippe</FirstName>
        <LastName>Roumagnac</LastName>
        <Affiliation>CIRAD, UMR PHIM</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Avijit</FirstName>
        <LastName>Roy</LastName>
        <Affiliation>USDA-ARS, BARC, Molecular Plant Pathology Laboratory, Beltsville, MD, USA</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sead</FirstName>
        <LastName>Sabanadzovic</LastName>
        <Affiliation>Department of Agricultural Science and Plant Protection, Mississippi State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dana</FirstName>
        <LastName>Šafářová</LastName>
        <Affiliation>Department of Cell Biology and Genetics, Faculty of Science, Palacký University Olomouc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pasquale</FirstName>
        <LastName>Saldarelli</LastName>
        <Affiliation>Istituto per la Protezione Sostenibile delle Piante, CNR</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hélène</FirstName>
        <LastName>Sanfaçon</LastName>
        <Affiliation>Summerland Research and Development Centre, Agriculture and Agri-Food Canada</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Cecilia</FirstName>
        <LastName>Sarmiento</LastName>
        <Affiliation>Department of Chemistry and Biotechnology, Tallinn University of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahide</FirstName>
        <LastName>Sasaya</LastName>
        <Affiliation>Strategic Planning Headquarters, NARO</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kay</FirstName>
        <LastName>Scheets</LastName>
        <Affiliation>Department of Plant Pathology, Ecology and Evolution, Oklahoma State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Willem E.W.</FirstName>
        <LastName>Schravesande</LastName>
        <Affiliation>Molecular Plant Pathology, University of Amsterdam</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susan</FirstName>
        <LastName>Seal</LastName>
        <Affiliation>Natural Resources Institute, University of Greenwich</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshifumi</FirstName>
        <LastName>Shimomoto</LastName>
        <Affiliation>Kochi Agricultural Research Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Merike</FirstName>
        <LastName>Sõmera</LastName>
        <Affiliation>Department of Chemistry and Biotechnology, Tallinn University of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Livia</FirstName>
        <LastName>Stavolone</LastName>
        <Affiliation>Istituto per la Protezione Sostenibile delle Piante, CNR</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lucy R.</FirstName>
        <LastName>Stewart</LastName>
        <Affiliation>Currently unaffiliated</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pierre-Yves</FirstName>
        <LastName>Teycheney</LastName>
        <Affiliation>CIRAD, UMR PVBMT &amp; UMR PVBMT, Université de la Réunion</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">John E.</FirstName>
        <LastName>Thomas</LastName>
        <Affiliation>Queensland Alliance for Agriculture and Food Innovation, The University of Queensland</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jeremy R.</FirstName>
        <LastName>Thompson</LastName>
        <Affiliation>Plant Health and Environment Laboratory</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Antonio</FirstName>
        <LastName>Tiberini</LastName>
        <Affiliation>Council for Agricultural Research and Economics, Research Centre for Plant Protection and Certification</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Tomitaka</LastName>
        <Affiliation>Institute for Plant Protection, NARO</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ioannis</FirstName>
        <LastName>Tzanetakis</LastName>
        <Affiliation>Department of Entomology and Plant Pathology, Division of Agriculture, University of Arkansas System</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Marie</FirstName>
        <LastName>Umber</LastName>
        <Affiliation>INRAE, UR ASTRO</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Cica</FirstName>
        <LastName>Urbino</LastName>
        <Affiliation>PHIM Plant Health Institute, University of Montpellier, INRAE, CIRAD, IRD, Institute Agro</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Harrold A.</FirstName>
        <LastName>van den Burg</LastName>
        <Affiliation>Molecular Plant Pathology, University of Amsterdam</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">René A.A.</FirstName>
        <LastName>Van der Vlugt</LastName>
        <Affiliation>Wageningen University and Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Arvind</FirstName>
        <LastName>Varsani</LastName>
        <Affiliation>The Biodesign Center for Fundamental and Applied Microbiomics, Center for Evolution and Medicine, School of Life Sciences, Arizona State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Adriaan</FirstName>
        <LastName>Verhage</LastName>
        <Affiliation>Rijk Zwaan Breeding B.V.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dan</FirstName>
        <LastName>Villamor</LastName>
        <Affiliation>Department of Entomology and Plant Pathology, Division of Agriculture, University of Arkansas System</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susanne</FirstName>
        <LastName>von Bargen</LastName>
        <Affiliation>Humboldt-Universität zu Berlin, Thaer-Institute of Agricultural and Horticultural Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Peter J.</FirstName>
        <LastName>Walker</LastName>
        <Affiliation>The University of Queensland</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Thierry</FirstName>
        <LastName>Wetzel</LastName>
        <Affiliation>Dienstleistungszentrum Ländlicher Raum Rheinpfalz</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Anna E.</FirstName>
        <LastName>Whitfield</LastName>
        <Affiliation>North Carolina State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Stephen J.</FirstName>
        <LastName>Wylie</LastName>
        <Affiliation>Food Futures Institute, Murdoch University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Caixia</FirstName>
        <LastName>Yang</LastName>
        <Affiliation>Liaoning Key Laboratory of Urban Integrated Pest Management and Ecological Security, Shenyang University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">F. Murilo</FirstName>
        <LastName>Zerbini</LastName>
        <Affiliation>Dep. de Fitopatologia/BIOAGRO, Universidade Federal de Viçosa</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Song</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>National Citrus Engineering and Technology Research Center, Integrative Science Center of Germplasm Creation in Western China (CHONGQING) Science City, Citrus Research Institute, Southwest University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>In March 2025, following the annual International Committee on Taxonomy of Viruses (ICTV) ratification vote, newly proposed taxa were added to those under the mandate of the Plant Viruses Subcommittee. In brief, 1 new order, 3 new families, 6 new genera, 2 new subgenera and 206 new species were created. Some taxa were reorganized. Genus Cytorhabdovirus in the family Rhabdoviridae was abolished and its taxa were redistributed into three new genera Alphacytorhabdovirus, Betacytorhabdovirus and Gammacytorhabdovirus. Genus Waikavirus in the family Secoviridae was reorganized into two subgenera (Actinidivirus and Ritunrivirus). One family and four previously unaffiliated genera were moved to the newly established order Tombendovirales. Twelve species not assigned to a genus were abolished. To comply with the ICTV mandate of a binomial format for virus species, eight species were renamed. Demarcation criteria in the absence of biological information were defined in the genus Ilarvirus (family Bromoviridae). This article presents the updated taxonomy put forth by the Plant Viruses Subcommittee and ratified by the ICTV.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1467-3045</Issn>
      <Volume>47</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Artificial Intelligence Approach in Machine Learning-Based Modeling and Networking of the Coronavirus Pathogenesis Pathway</ArticleTitle>
    <FirstPage LZero="delete">466</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shihori</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sabina</FirstName>
        <LastName>Quader</LastName>
        <Affiliation>Innovation Centre of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Division of Cellular and Molecular Toxicology, Center for Biological Safety and Research, National Institute of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyoshi Y.</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihisa</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Mechanical Systems Engineering, Graduate School of Systems Design Tokyo Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Surgical Pathology, Kyoto Prefecture University of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Edward J.</FirstName>
        <LastName>Perkins</LastName>
        <Affiliation>US Army Engineer Research and Development Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Horacio</FirstName>
        <LastName>Cabral</LastName>
        <Affiliation>Department of Bioengineering, Graduate School of Engineering, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The coronavirus pathogenesis pathway, which consists of severe acute respiratory syndrome (SARS) coronavirus infection and signaling pathways, including the interferon pathway, the transforming growth factor beta pathway, the mitogen-activated protein kinase pathway, the apoptosis pathway, and the inflammation pathway, is activated upon coronaviral infection. An artificial intelligence approach based on machine learning was utilized to develop models with images of the coronavirus pathogenesis pathway to predict the activation states. Data on coronaviral infection held in a database were analyzed with Ingenuity Pathway Analysis (IPA), a network pathway analysis tool. Data related to SARS coronavirus 2 (SARS-CoV-2) were extracted from more than 100,000 analyses and datasets in the IPA database. A total of 27 analyses, including nine analyses of SARS-CoV-2-infected human-induced pluripotent stem cells (iPSCs) and iPSC-derived cardiomyocytes and fibroblasts, and a total of 22 analyses of SARS-CoV-2-infected lung adenocarcinoma (LUAD), were identified as being related to “human” and “SARS coronavirus 2” in the database. The coronavirus pathogenesis pathway was activated in SARS-CoV-2-infected iPSC-derived cells and LUAD cells. A prediction model was developed in Python 3.11 using images of the coronavirus pathogenesis pathway under different conditions. The prediction model of activation states of the coronavirus pathogenesis pathway may aid in treatment identification.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">artificial intelligence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">coronavirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">coronaviral infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">machine learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pathway analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">predictionmodel</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">molecular network</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">molecular pathway image</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">network analysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>26</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Induced Pluripotent Stem Cells in Cardiomyopathy: Advancing Disease Modeling, Therapeutic Development, and Regenerative Therapy</ArticleTitle>
    <FirstPage LZero="delete">4984</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Quan Duy</FirstName>
        <LastName>Vo</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukihiro</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Akagi</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Yuasa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cardiomyopathies are a heterogeneous group of heart muscle diseases that can lead to heart failure, arrhythmias, and sudden cardiac death. Traditional animal models and in vitro systems have limitations in replicating the complex pathology of human cardiomyopathies. Induced pluripotent stem cells (iPSCs) offer a transformative platform by enabling the generation of patient-specific cardiomyocytes, thus opening new avenues for disease modeling, drug discovery, and regenerative therapy. This process involves reprogramming somatic cells into iPSCs and subsequently differentiating them into functional cardiomyocytes, which can be characterized using techniques such as electrophysiology, contractility assays, and gene expression profiling. iPSC-derived cardiomyocyte (iPSC-CM) platforms are also being explored for drug screening and personalized medicine, including high-throughput testing for cardiotoxicity and the identification of patient-tailored therapies. While iPSC-CMs already serve as valuable models for understanding disease mechanisms and screening drugs, ongoing advances in maturation and bioengineering are bringing iPSC-based therapies closer to clinical application. Furthermore, the integration of multi-omics approaches and artificial intelligence (AI) is enhancing the predictive power of iPSC models. iPSC-based technologies are paving the way for a new era of personalized cardiology, with the potential to revolutionize the management of cardiomyopathies through patient-specific insights and regenerative strategies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">induced pluripotent stem cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cardiomyopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">disease modeling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">drug screening</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">regenerative therapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2076-2615</Issn>
      <Volume>15</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Canine c-kit Novel Mutation Isolated from a Gastrointestinal Stromal Tumor (GIST) Retains the Ability to Form Dimers but Lacks Autophosphorylation</ArticleTitle>
    <FirstPage LZero="delete">1444</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Shimakawa</LastName>
        <Affiliation>Laboratory of Veterinary Hygiene, School of Veterinary Science, Nippon Veterinary and Life Science University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">So</FirstName>
        <LastName>Doge</LastName>
        <Affiliation>Laboratory of Veterinary Pathology, School of Veterinary Science, Nippon Veterinary and Life Science University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Michishita</LastName>
        <Affiliation>Laboratory of Veterinary Pathology, School of Veterinary Science, Nippon Veterinary and Life Science University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eri</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Laboratory of Veterinary Hygiene, School of Veterinary Science, Nippon Veterinary and Life Science University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Tajima</LastName>
        <Affiliation>Laboratory of Veterinary Pharmacology, School of Veterinary Science, Nippon Veterinary and Life Science University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Laboratory of Veterinary Reproduction, School of Veterinary Science, Nippon Veterinary and Life Science University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Bonkobara</LastName>
        <Affiliation>Laboratory of Veterinary Clinical Pathology, School of Veterinary Science, Nippon Veterinary and Life Science University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masami</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Laboratory of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Ochiai</LastName>
        <Affiliation>Laboratory of Veterinary Hygiene, School of Veterinary Science, Nippon Veterinary and Life Science University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshikazu</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Laboratory of Veterinary Hygiene, School of Veterinary Science, Nippon Veterinary and Life Science University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors that develop in the gastrointestinal tract; KIT mutations are present in both canine and human GISTs. In this study, genomic DNA was extracted from formalin-fixed paraffin-embedded (FFPE) sections of 55 canine GIST cases, and mutation searches were performed for exons 8, 9, and 11. The results revealed novel mutations, A434T and F436S, in exon 8. In contrast to the A434T mutation without functional changes, the F436S mutant retained its dimerization ability, but lost its phosphorylation function and attenuated downstream Akt signaling, which is reflected in wound healing and migration activities. A comparison of the subcellular localization of WT KIT and the F436S mutant revealed no differences. In silico simulations indicated that the F436S mutation alters the structure of the near-membrane region and that its effects may extend to the transmembrane and intracellular domains compared to the WT. F436S is a point mutation that affects the entire molecule because co-mutation with the F436S mutation and the known autophosphorylation mutation reduces the autophosphorylation abilities.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">autophosphorylation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">canine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">c-kit</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">GIST</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">KIT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">loss-of-function mutation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Six-Year Remission With No Relapse After Four-Time Weekly Rituximab Only for Bilateral Ocular Adnexal Follicular Lymphoma</ArticleTitle>
    <FirstPage LZero="delete">e88945</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, and Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Division of Transfusion and Cell Therapy, Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Follicular lymphoma mostly takes an indolent course, and thus, observation with watchful waiting is a main therapeutic strategy. Recent long-term studies suggest earlier treatment with rituximab monotherapy may benefit patients by delaying the need for treatment in the later phase of exacerbation. In this study, we reported a patient with bilateral orbital follicular lymphoma who received four-time weekly rituximab monotherapy as an induction therapy only and maintained the remission for 5 years with no treatment. The patient was a 51-year-old woman who developed a right upper orbital mass and was diagnosed with follicular lymphoma grade 1 by the excisional biopsy. Two years later, at the age of 53 years, she developed a left lacrimal gland mass and underwent excision. The pathological diagnosis was follicular lymphoma grade 1. She did not have any other systemic lesions by fluorodeoxyglucose positron emission tomography. At the age of 54 years, she developed a new mass on the nasal side of the right orbit and underwent weekly rituximab monotherapy (375 mg/m2) four times a month, leading to the reduction of the mass in 3 months. Two high uptake sites on the temporal and nasal side of the right superior orbit by fluorodeoxyglucose positron emission tomography disappeared one year later at the age of 55 years. She was followed with no treatment for 6 years until the age of 60 years at the latest visit. In case of a local orbital relapse, local radiotherapy would be the standard, but rituximab monotherapy as an induction therapy only was chosen in the present patient. Rituximab monotherapy in place of local radiotherapy would be a treatment option for orbital follicular lymphoma.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">claustrophobia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">extranodal marginal zone b-cell lymphoma mucosa-associated lymphoid tissue (malt) type</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fluorodeoxyglucose positron emission tomography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">follicular lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">magnetic resonance imaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mucosaassociated lymphoid tissue (malt) lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ocular adnexa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">orbital mass</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rituximab</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1068-9265</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tumor Microvessels with Specific Morphology as a Prognostic Factor in Esophageal Squamous Cell Carcinoma</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hnin Thida</FirstName>
        <LastName>Tun</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seitaro</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyoshi</FirstName>
        <LastName>Kunitomo</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Angiogenesis is essential for tumor progression. Microvessel density (MVD) is a widely used histological method to assess angiogenesis using immunostained sections, but its prognostic significance in esophageal cancer remains controversial. Recently, the evaluation of microvascular architecture has gained importance as a method to assess tumor aggressiveness. The present study aimed to identify the histological characteristics of tumor microvessels that are associated with the aggressiveness of esophageal squamous cell carcinoma.&lt;br&gt;
Patients and Methods A total of 108 esophageal squamous cell carcinoma tissues were immunohistochemically stained with blood vessel markers and angiogenesis-related markers, including CD31, alpha smooth muscle actin, vascular endothelial growth factor A (VEGF-A), CD206, and D2-40. MVD, microvessel pericyte coverage index (MPI), and tumor vascular morphology were evaluated by microscopy.&lt;br&gt;
Results MVD was significantly associated with patient outcomes, whereas neither MPI nor VEGF-A expression throughout the tumor showed a significant correlation. In addition, the presence of blood vessels encircling clusters of tumor cells, termed C-shaped microvessels, and excessively branching microvessels, termed X-shaped microvessels, was significantly associated with poor prognosis. These vessel types were also correlated with clinicopathological parameters, including deeper invasion of the primary tumor, presence of lymph node metastasis, advanced pathological stage, and distant metastasis. Focal VEGF-A immunoexpression in tumor cells was higher in areas containing C-shaped or X-shaped microvessels compared with areas lacking these vessel morphologies.&lt;br&gt;
Conclusions The data suggest that tumor microvessels with specific morphologies (C-shaped and X-shaped microvessels) may serve as a promising prognostic factor in esophageal squamous cell carcinoma.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Esophageal neoplasms</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Angiogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Microvessel density</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pericytes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">VEGF-A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immunohistochemistry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Prognosis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2198-3844</Issn>
      <Volume>12</Volume>
      <Issue>18</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cryo-EM Analysis of a Tri-Heme Cytochrome-Associated RC-LH1 Complex from the Marine Photoheterotrophic Bacterium Dinoroseobacter Shibae</ArticleTitle>
    <FirstPage LZero="delete">2413456</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Weiwei</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>College of Life Sciences, Zhejiang University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yanting</FirstName>
        <LastName>Liu</LastName>
        <Affiliation>State Key Laboratory of Marine Environmental Science, College of Ocean and Earth Sciences, Xiamen University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jiayi</FirstName>
        <LastName>Gu</LastName>
        <Affiliation>College of Life Sciences, Zhejiang University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shaoya</FirstName>
        <LastName>An</LastName>
        <Affiliation>Department of Pathology of Sir Run Run Shaw Hospital, Department of Biophysics, Zhejiang University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Cheng</FirstName>
        <LastName>Ma</LastName>
        <Affiliation>Department of Pathology of Sir Run Run Shaw Hospital, Department of Biophysics, Zhejiang University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haichun</FirstName>
        <LastName>Gao</LastName>
        <Affiliation>College of Life Sciences, Zhejiang University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nianzhi</FirstName>
        <LastName>Jiao</LastName>
        <Affiliation>State Key Laboratory of Marine Environmental Science, College of Ocean and Earth Sciences, Xiamen University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jian‐Ren</FirstName>
        <LastName>Shen</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, and Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">John Thomas</FirstName>
        <LastName>Beatty</LastName>
        <Affiliation>Department of Microbiology &amp; Immunology, University of British Columbia</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michal</FirstName>
        <LastName>Koblížek</LastName>
        <Affiliation>Laboratory of Anoxygenic Phototrophs, Institute of Microbiology, Czech Academy of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xing</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Department of Pathology of Sir Run Run Shaw Hospital, Department of Biophysics, Zhejiang University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Qiang</FirstName>
        <LastName>Zheng</LastName>
        <Affiliation>State Key Laboratory of Marine Environmental Science, College of Ocean and Earth Sciences, Xiamen University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jing‐Hua</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>College of Life Sciences, Zhejiang University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The reaction center-light harvesting 1 (RC-LH1) complex converts solar energy into electrical energy, driving the initiation of photosynthesis. The authors present a cryo-electron microscopy structure of the RC-LH1 isolated from a marine photoheterotrophic bacterium Dinoroseobacter shibae. The RC comprises four subunits, including a three-heme cytochrome (Cyt) c protein, and is surrounded by a closed LH ring composed of 17 pairs of antenna subunits. Notably, a novel subunit with an N-terminal “helix-turn-helix” motif embedded in the gap between the RC and the LH ring is identified. The purified RC-LH1 complex exhibits high stability in solutions containing Mg2+ or Ca2+. The periplasmic Cyt c2 is predicted to bind at the junction between the Cyt subunit and the membrane plane, enabling electron transfer from Cyt c2 to the proximal heme of the tri-heme Cyt, and subsequently to the special pair of bacteriochlorophylls. These findings provide structural insights into the efficient energy and electron transfer processes within a distinct type of RC-LH1, and shed light on evolutionary adaptations of photosynthesis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">energy transfer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">photoheterotrophic bacteria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">photosynthesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">reaction center</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">structure</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>International Institute of Anticancer Research</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1109-6535</Issn>
      <Volume>22</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>C1orf50 Drives Malignant Melanoma Progression Through the Regulation of Stemness</ArticleTitle>
    <FirstPage LZero="delete">510</FirstPage>
    <LastPage>524</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">YUSUKE</FirstName>
        <LastName>OTANI</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MASAKI</FirstName>
        <LastName>MAEKAWA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">ATSUSHI</FirstName>
        <LastName>TANAKA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TIRSO</FirstName>
        <LastName>PEÑA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">VANESSA D.</FirstName>
        <LastName>CHIN</LastName>
        <Affiliation>UMass Chan Medical School, UMass Memorial Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">ANNA</FirstName>
        <LastName>ROGACHEVSKAYA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SHINICHI</FirstName>
        <LastName>TOYOOKA</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MICHAEL H.</FirstName>
        <LastName>ROEHRL</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">ATSUSHI</FirstName>
        <LastName>FUJIMURA</LastName>
        <Affiliation>Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Aim: Recent advancements in omics analysis have significantly enhanced our understanding of the molecular pathology of malignant melanoma, leading to the development of novel therapeutic strategies that target specific vulnerabilities within the disease. Despite these improvements, the factors contributing to the poor prognosis of patients with malignant melanoma remain incompletely understood. The aim of this study was to investigate the role of C1orf50 (Chromosome 1 open reading frame 50), a gene previously of unknown function, as a prognostic biomarker in melanoma.&lt;br&gt;
Materials and Methods: We performed comprehensive transcriptome data analysis and subsequent functional validation of the human Skin Cutaneous Melanoma project from The Cancer Genome Atlas (TCGA).&lt;br&gt;
Results: Elevated expression levels of C1orf50 correlated with worse survival outcomes. Mechanistically, we revealed that C1orf50 plays a significant role in the regulation of cell cycle processes and cancer cell stemness, providing a potential avenue for novel therapeutic interventions in melanoma.&lt;br&gt;
Conclusion: This study is the first to identify C1orf50 as a prognostic biomarker in melanoma. The clinical relevance of our results sheds light on the importance of further investigation into the biological mechanisms underpinning C1orf50’s impact on melanoma progression and patient prognosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">C1orf50</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">melanoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cancer stem cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">YAP/TAZ</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Managing Persistent Pupillary Membranes With Surgery or Medication: A Report of Three Cases</ArticleTitle>
    <FirstPage LZero="delete">e86695</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Division of Healthcare Science, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The persistent pupillary membrane, as a congenital anomaly, is a remnant of a network of feeding blood vessels for the lens of the eye, called tunica vasculosa lentis. This study reports three patients with persistent pupillary membrane in both eyes who presented in different situations and were managed differently to achieve better vision. The first child (Case 1) who had been seen initially at the age of two years complained of severe photophobia even though he had good visual acuity, and hence, he and his family chose surgical resection of the pupillary membrane in both eyes at the age of six years just before the admission to an elementary school. He did not develop any surgical complications, such as cataract and glaucoma, and maintained the visual acuity in decimals of 1.2 in both eyes at the age of 17 years.&lt;br&gt;
The second child (Case 2), who was seen first at the age of one month, had persistent pupillary membranes in both eyes, together with Peters' anomaly in the left eye. The iris process adhesion to the corneal inner surface was visualized later by optical coherence tomography. She wore full-correction glasses and obtained the visual acuity of 0.7 in the right eye, so she had no problem studying at an elementary school. She used topical 1% atropine once a week in both eyes to maintain pupillary dilation and also used 0.5% timolol and 1% brinzolamide as pressure-lowering eye drops in the left eye with Peters' anomaly.&lt;br&gt;
The third patient (Case 3) with persistent pupillary membranes in both eyes complained of vision problems for the first time at the age of 49 years when she developed cataract. Surgical resection of the pupillary membrane was done in the initial phase of cataract surgery with intraocular lens implantation in both eyes. At surgical resection of the pupillary membrane, a safe and efficient way was to cut the root of the pupillary membrane on the iris surface with scissors, and then the isolated tissues of the pupillary membrane were pulled out with forceps from the side port at the corneal limbus. Pathological examinations of the excised tissues showed blood vessels with red blood cells in the lumen. In such a rare congenital disease as the persistent pupillary membrane, a case-based approach to choose a better option in different conditions from individual to individual is still required to have a better vision in learning at school and in daily working life.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anterior segment dysgenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cataract</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">forceps</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">optical coherence tomography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">persistent pupillary membrane</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peters anomaly</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">resection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">scissors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vitrectomy cutter</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Whole-Eye Radiation for the Local Control of Choroidal Lymphoma in Primary Central Nervous System Lymphoma: A 14-Year Case Study</ArticleTitle>
    <FirstPage LZero="delete">e85680</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomofumi</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>Department of Internal Medicine, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kotaro</FirstName>
        <LastName>Yoshio</LastName>
        <Affiliation>Department of Radiology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirotake</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Pathology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken-ichi</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Hematology and Oncology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Involved-site radiation therapy is effective for curative and palliative treatments of cancers, including lymphoma. This case study describes the use of whole-eye radiation for primary intraocular lymphoma occurring during primary central nervous system lymphoma. The patient, a 68-year-old man, developed personality changes and apathy two weeks after cataract surgery combined with vitrectomy for vitreous opacity in the left eye. Magnetic resonance imaging revealed a mass lesion in the left frontal lobe, and biopsy by craniotomy confirmed diffuse large B-cell lymphoma. He underwent chemotherapy using rituximab combined with high-dose methotrexate and high-dose cytarabine in association with intrathecal methotrexate and cytarabine injections, leading to complete remission. At age 75, he noticed forgetfulness, and fluorodeoxyglucose positron emission tomography and magnetic resonance imaging revealed a relapse of lymphoma in the splenium of the corpus callosum. He underwent chemotherapy using rituximab combined with high-dose methotrexate, followed by monthly rituximab monotherapy for one year and then rituximab monotherapy every two months for one year. He maintained complete remission with no treatment until age 78, when he developed subretinal choroidal lesions in the left eye and underwent whole-eye radiation at 40 Gy. One year later, he developed subretinal choroidal lesions in the right eye and underwent whole-eye radiation at 40 Gy. At age 81, he had lower limb weakness with disorientation. Magnetic resonance imaging showed a relapse of lymphoma in the right frontal to temporal lobe. The brain lesions showed a marked response to four weeks of oral tirabrutinib as a salvage therapy, but the lesions regrew, and the patient died seven months later. Throughout the treatment, he maintained a visual acuity of 0.7 (decimal scale) in both eyes. In conclusion, whole-eye radiation should be considered as a treatment option for the local control of active intraocular lymphoma, especially choroidal lesions, for patients with primary central nervous system lymphoma with no active brain lesions and without systemic treatment.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">brain biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bruton tyrosine kinase (btk) inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">diffuse large b-cell lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fluorodeoxyglucose positron emission tomography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">primary central nervous system lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">primary intraocular (vitreoretinal) lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiation therapy (radiotherapy)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tirabrutinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">whole-eye radiation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elmer Press, Inc.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1923-4155</Issn>
      <Volume>16</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Nephronophthisis and Retinitis Pigmentosa (Senior-Loken Syndrome) After Living-Donor Kidney Transplantation: Twelve-Year Follow-Up in a Young Woman</ArticleTitle>
    <FirstPage LZero="delete">164</FirstPage>
    <LastPage>173</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Onishi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Morinaga</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Senior-Loken syndrome is a hereditary ciliopathy with recessive trait that manifests as nephronophthisis and retinitis pigmentosa. This report described an 18-year-old woman who was referred to a University Hospital to set up a treatment plan for chronic renal failure of an unknown cause. She had experienced nocturnal polyurea from the age of 12 years and was found to have an elevated level of serum creatinine at 3 mg/dL at the age of 15 years. She underwent renal biopsy at a hometown regional hospital which showed global glomerulosclerosis in six of the 13 glomeruli examined, renal tubular dilation in irregular shape, and marked interstitial fibrosis with lymphocytic infiltration. At the age of 19 years, she received a living-donor kidney transplant from her 46-year-old father as a preemptive therapy. At surgery, biopsy of the father’s donor kidney showed two glomeruli with global sclerosis out of 24 glomeruli examined, in association with minimal interstitial fibrosis and lymphocytic infiltration. She began to have extended-release tacrolimus 4 mg daily and mycophenolate mofetil 1,000 mg daily. According to the standard protocol, she underwent biopsy of the transplanted donor kidney to reveal interstitial fibrosis and lymphocytic infiltration, in addition to no sign of rejection and no glomerular deposition of immunoglobulins and complements, both 4 weeks and 14 months after the kidney transplantation. At the age of 23 years, 4 years after the kidney transplantation, she was, for the first time, diagnosed retinitis pigmentosa, and hence, Senior-Loken syndrome. She was followed up in the stable condition with basal doses of tacrolimus 5 mg daily, mycophenolate mofetil 1,000 mg daily, and prednisolone 5 mg daily up until now in 12 years after the kidney transplantation. The interstitial fibrosis with lymphocytic infiltration in the donor kidney might be a milder presentation of the disease with recessive inheritance.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Retinitis pigmentosa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nephronophthisis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Senior-Loken syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Kidney transplantation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Living donor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Kidney biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pathology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Computed tomography scan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Ciliopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Optical coherence tomography</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Detailed Ophthalmic and Pathological Features of Choroidal Metastasis From Breast Cancer: A Case Series of Five Patients</ArticleTitle>
    <FirstPage LZero="delete">e83484</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Division of Healthcare Science, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadahiko</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Muraoka</LastName>
        <Affiliation>Department of Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyoshi</FirstName>
        <LastName>Doihara</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Breast cancer causes choroidal metastases on rare occasions. This study presented the eye manifestations of choroidal metastases from breast cancer and their response to treatments in detail as well as their pathological correlation in five patients. The patients' age at the diagnosis of breast cancer ranged from 24 to 69 years (median: 37 years). The time from the diagnosis of breast cancer to the detection of metastases was concurrent in one patient, two years later in three patients, and six years later in the other patient. The time from the detection of systemic metastases to the detection of choroidal metastases was the same in one patient, while it ranged from one to seven years later in four patients. Choroidal metastases were in the unilateral eye of four patients, whereas they were in both eyes of one patient. Choroidal metastases manifested as one or a few nodular or flat choroidal lesions with serous retinal detachment. As for the treatment of choroidal metastases, enucleation of the right eye was chosen based on the patient's wish as well as the family's wish in the earliest patient when cancer notification was not the norm in Japan. In the other four patients, whole-eye radiation was performed to reduce the choroidal metastatic lesions. As regards the prognosis, which was available in four patients, three patients died within one year from the diagnosis of choroidal metastases, while one patient died one year and eight months later. Regarding the pathology of breast cancer, which was available in four patients, immunostaining of the preserved enucleated eye in the earliest patient revealed that breast cancer cells in the choroidal metastatic lesion were positive for estrogen receptor and negative for progesterone receptor and human epidermal growth factor receptor 2 (HER2). Invasive ductal carcinoma in two patients was positive for estrogen receptor and negative for HER2, while invasive ductal carcinoma in the other patient was triple-negative for estrogen receptor, progesterone receptor, and HER2 with a high Ki-67 index. In conclusion, the prognosis for life was poor in patients with breast cancer who developed choroidal metastases. Choroidal metastatic lesions showed a response to whole-eye radiation to improve the quality of vision at the end of life. Vision-related symptoms should be monitored in the course of chemotherapy for systemic metastases. </Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">breast cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">choroidal metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">estrogen receptor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">her2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immunostaining</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">invasive ductal carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ki-67</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">progesterone receptor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0361-8609</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Midori Filiz</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoka</FirstName>
        <LastName>Haratake</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asami</FirstName>
        <LastName>Nishikori</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Remi</FirstName>
        <LastName>Sumiyoshi</LastName>
        <Affiliation>The Research Program for Intractable Disease by Ministry of Health, Labor and Welfare, Castleman Disease, TAFRO and Related Ddisease Research Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Ujiie</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuri</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Koga</LastName>
        <Affiliation>The Research Program for Intractable Disease by Ministry of Health, Labor and Welfare, Castleman Disease, TAFRO and Related Ddisease Research Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Ueki</LastName>
        <Affiliation>School of Information and Data Sciences, Nagasaki University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dorottya</FirstName>
        <LastName>Laczko</LastName>
        <Affiliation>Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eric</FirstName>
        <LastName>Oksenhendler</LastName>
        <Affiliation>Department of Clinical Immunology, Hôpital Saint-Louis</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David C.</FirstName>
        <LastName>Fajgenbaum</LastName>
        <Affiliation>Center for Cytokine Storm Treatment and Laboratory, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Frits</FirstName>
        <LastName>van Rhee</LastName>
        <Affiliation>Myeloma Center, University of Arkansas for Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Kawakami</LastName>
        <Affiliation>The Research Program for Intractable Disease by Ministry of Health, Labor and Welfare, Castleman Disease, TAFRO and Related Ddisease Research Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuharu</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder classified into three recognized clinical subtypes—idiopathic plasmacytic lymphadenopathy (IPL), TAFRO, and NOS. Although clinical criteria are available for subtyping, diagnostically challenging cases with overlapping histopathological features highlight the need for an improved classification system integrating clinical and histopathological findings. We aimed to develop an objective histopathological subtyping system for iMCD that closely correlates with the clinical subtypes. Excisional lymph node specimens from 94 Japanese iMCD patients (54 IPL, 28 TAFRO, 12 NOS) were analyzed for five key histopathological parameters: germinal center (GC) status, plasmacytosis, vascularity, hemosiderin deposition, and “whirlpool” vessel formation in GC. Using hierarchical clustering, we visualized subgroups and developed a machine learning-based decision tree to differentiate the clinical subtypes and validated it in an external cohort of 12 patients with iMCD. Hierarchical cluster analysis separated the IPL and TAFRO cases into mutually exclusive clusters, whereas the NOS cases were interspersed between them. Decision tree modeling identified plasmacytosis, vascularity, and whirlpool vessel formation as key features distinguishing IPL from TAFRO, achieving 91% and 92% accuracy in the training and test sets, respectively. External validation correctly classified all IPL and TAFRO cases, confirming the reproducibility of the system. Our histopathological classification system closely aligns with the clinical subtypes, offering a more precise approach to iMCD subtyping. It may enhance diagnostic accuracy, guide clinical decision-making for predicting treatment response in challenging cases, and improve patient selection for future research. Further validation of its versatility and clinical utility is required.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">clinical subtype</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">histopathological criteria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">idiopathic multicentric castleman disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lymphoproliferative disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">machine-learning</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1999-4915</Issn>
      <Volume>16</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Metatranscriptomic Sequencing of Sheath Blight-Associated Isolates of Rhizoctonia solani Revealed Multi-Infection by Diverse Groups of RNA Viruses</ArticleTitle>
    <FirstPage LZero="delete">1152</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Michael Louie R.</FirstName>
        <LastName>Urzo</LastName>
        <Affiliation>Microbiology Division, Institute of Biological Sciences, College of Arts and Sciences, University of the Philippines Los Baños</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Timothy D.</FirstName>
        <LastName>Guinto</LastName>
        <Affiliation>Microbiology Division, Institute of Biological Sciences, College of Arts and Sciences, University of the Philippines Los Baños</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ana</FirstName>
        <LastName>Eusebio-Cope</LastName>
        <Affiliation>Fit-for-Future Genetic Resources Unit, Rice Breeding Innovations Department, International Rice Research Institute (IRRI), University of the Philippines Los Baños</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bernard O.</FirstName>
        <LastName>Budot</LastName>
        <Affiliation>Institute of Weed Science, Entomology, and Plant Pathology, College of Agriculture and Food Science, University of the Philippines Los Baños</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mary Jeanie T.</FirstName>
        <LastName>Yanoria</LastName>
        <Affiliation>Traits for Challenged Environments Unit, Rice Breeding Innovations Department, International Rice Research Institute (IRRI), University of the Philippines Los Baños</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gilda B.</FirstName>
        <LastName>Jonson</LastName>
        <Affiliation>Traits for Challenged Environments Unit, Rice Breeding Innovations Department, International Rice Research Institute (IRRI), University of the Philippines Los Baños</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Arakawa</LastName>
        <Affiliation>Faculty of Agriculture, Meijo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Plant-Microbe Interactions Group, Institute of Plant Science and Resources (IPSR), Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiro</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Plant-Microbe Interactions Group, Institute of Plant Science and Resources (IPSR), Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Rice sheath blight, caused by the soil-borne fungus Rhizoctonia solani (teleomorph: Thanatephorus cucumeris, Basidiomycota), is one of the most devastating phytopathogenic fungal diseases and causes yield loss. Here, we report on a very high prevalence (100%) of potential virus-associated double-stranded RNA (dsRNA) elements for a collection of 39 fungal strains of R. solani from the rice sheath blight samples from at least four major rice-growing areas in the Philippines and a reference isolate from the International Rice Research Institute, showing different colony phenotypes. Their dsRNA profiles suggested the presence of multiple viral infections among these Philippine R. solani populations. Using next-generation sequencing, the viral sequences of the three representative R. solani strains (Ilo-Rs-6, Tar-Rs-3, and Tar-Rs-5) from different rice-growing areas revealed the presence of at least 36 viruses or virus-like agents, with the Tar-Rs-3 strain harboring the largest number of viruses (at least 20 in total). These mycoviruses or their candidates are believed to have single-stranded RNA or dsRNA genomes and they belong to or are associated with the orders Martellivirales, Hepelivirales, Durnavirales, Cryppavirales, Ourlivirales, and Ghabrivirales based on their coding-complete RNA-dependent RNA polymerase sequences. The complete genome sequences of two novel RNA viruses belonging to the proposed family Phlegiviridae and family Mitoviridae were determined.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Rhizoctonia solani</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dsRNA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mycovirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">RNA virus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">metatranscriptome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0893-3952</Issn>
      <Volume>38</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Involvement of PI3K–Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease–Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly and Not Otherwise Specified Subtypes</ArticleTitle>
    <FirstPage LZero="delete">100782</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomoka</FirstName>
        <LastName>Haratake</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Midori Filiz</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asami</FirstName>
        <LastName>Nishikori</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michael V.</FirstName>
        <LastName>Gonzalez</LastName>
        <Affiliation>Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">You Cheng</FirstName>
        <LastName>Lai</LastName>
        <Affiliation>Department of Medical Biotechnology and Laboratory Science, Chang Gung University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sayaka</FirstName>
        <LastName>Ochi</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manaka</FirstName>
        <LastName>Tsunoda</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David C.</FirstName>
        <LastName>Fajgenbaum</LastName>
        <Affiliation>Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Frits</FirstName>
        <LastName>van Rhee</LastName>
        <Affiliation>Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuji</FirstName>
        <LastName>Momose</LastName>
        <Affiliation>Department of Pathology, Saitama Medical Center, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuharu</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Idiopathic multicentric Castleman disease is a rare lymphoproliferative disorder that is clinically classified into idiopathic plasmacytic lymphadenopathy (IPL); thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO); and not otherwise specified (NOS). Although each subtype shows varying degrees of hypervascularity, no statistical data on the degree of vascularization have been reported. Additionally, the mechanisms underlying vascularization in each clinical subtype are poorly understood. Here, we aimed to clarify these mechanisms by evaluating the histopathological characteristics of each clinical subtype across 37 patients and performing a whole-transcriptome analysis focusing on angiogenesis-related gene expression. Histologically, TAFRO and NOS exhibited a significantly higher degree of vascularization than IPL (IPL vs TAFRO, P &lt; .001; IPL vs NOS, P = .002). In addition, the germinal centers (GCs) were significantly more atrophic in TAFRO than in IPL. In TAFRO and NOS, “whirlpool vessels” in GCs were seen in most cases (TAFRO, 9/9, 100%; NOS, 6/8, 75%) but not in IPL (IPL vs TAFRO, P &lt; .001; IPL vs NOS, P = .007). Likewise, immunostaining for Ets-related gene revealed higher levels in endothelial cells of GCs in TAFRO than in IPL (P = .014), and TAFRO and NOS were associated with a significantly higher number of endothelial cells in interfollicular areas compared with that in IPL (TAFRO vs IPL, P &lt; .001; NOS vs IPL, P = .002). Gene expression analysis revealed that the PI3K–Akt signaling pathway was significantly enriched in the TAFRO and NOS (TAFRO/NOS) groups. This pathway, which may be activated by vascular endothelial growth factor A and some integrins, is known to affect angiogenesis by increasing vascular permeability, which may explain the clinical manifestations of anasarca and/or fluid retention in TAFRO/NOS. These results suggest that the PI3K–Akt pathway plays an important role in the pathogenesis of TAFRO/NOS.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">idiopathic multicentric Castleman disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">integrin subunit alpha 5</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">PI3K–Akt signaling pathway</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">platelet-derived growth factor receptor beta</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vascular endothelial growth factor A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vascularity</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Case of Chromophobe Renal Cell Carcinoma Metastasizing to the Cervical Lymph Nodes after Long-term Follow-up</ArticleTitle>
    <FirstPage LZero="delete">213</FirstPage>
    <LastPage>219</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Otolaryngology, Chugoku Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Otolaryngology, Chugoku Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kanao</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Nephrology and Urological Surgery, Chugoku Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Narutaka</FirstName>
        <LastName>Katsuya</LastName>
        <Affiliation>Department of Molecular Pathology, Graduate School of Medical Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Molecular Pathology, Graduate School of Medical Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Hamamoto</LastName>
        <Affiliation>Department of Otolaryngology and Head and Neck Surgery, Hiroshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Tahara</LastName>
        <Affiliation>Department of Otolaryngology and Head and Neck Surgery, Hiroshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsutomu</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Otolaryngology and Head and Neck Surgery, Hiroshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachio</FirstName>
        <LastName>Takeno</LastName>
        <Affiliation>Department of Otolaryngology and Head and Neck Surgery, Hiroshima University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/68730</ArticleId>
    </ArticleIdList>
    <Abstract>Renal cell carcinoma (RCC) can metastasize hematogenously and recur after a long dormancy. Chromophobe RCC metastasized to the cervical lymph nodes 10 years after the primary resection in a woman who underwent nephrectomy for RCC (T1aN0M0 stage I). Metastatic RCC diagnosis was confirmed by aspiration. The lymph node mass was resected, and the tumor cells matched chromophobe RCC metastasis. No adjuvant therapy was administered due to the lack of evidence regarding adjuvant therapy for chromophobe RCC. Long-term surveillance is crucial in RCC because of the possibility of late metastasis. We reviewed the clinical aspects and literature on metastatic cervical RCC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cervical lymph node metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">late recurrence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">head and neck</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Continuous Stimulation with Glycolaldehyde-derived Advanced Glycation End Product Reduces Aggrecan and COL2A1 Production via RAGE in Human OUMS-27 Chondrosarcoma Cells</ArticleTitle>
    <FirstPage LZero="delete">157</FirstPage>
    <LastPage>166</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Omer Faruk</FirstName>
        <LastName>Hatipoglu</LastName>
        <Affiliation>Department of Pharmacology, Faculty of Medicine, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Nishinaka</LastName>
        <Affiliation>Department of Pharmacology, Faculty of Medicine, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kursat Oguz</FirstName>
        <LastName>Yaykasli</LastName>
        <Affiliation>Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuji</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Pharmacology, School of Pharmacy, Shujitsu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Pharmacology, School of Pharmacy, Shujitsu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Toyomura</LastName>
        <Affiliation>Department of Pharmacology, School of Pharmacy, Shujitsu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Nishibori</LastName>
        <Affiliation>Department of Translational Research &amp; Dug Development, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Hirohata</LastName>
        <Affiliation>Department of Medical Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideo</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Pharmacology, Faculty of Medicine, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidenori</FirstName>
        <LastName>Wake</LastName>
        <Affiliation>Department of Pharmacology, Faculty of Medicine, Kindai University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/68723</ArticleId>
    </ArticleIdList>
    <Abstract>Chondrocytes are responsible for the production of extracellular matrix (ECM) components such as collagen type II alpha-1 (COL2A1) and aggrecan, which are loosely distributed in articular cartilage. Chondrocyte dysfunction has been implicated in the pathogenesis of rheumatic diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA). With age, advanced glycation end products (AGEs) accumulate in all tissues and body fluids, including cartilage and synovial fluid, causing and accelerating pathological changes associated with chronic diseases such as OA. Glycolaldehyde-derived AGE (AGE3), which is toxic to a variety of cell types, have a stronger effect on cartilage compared with other AGEs. To understand the long-term effects of AGE3 on cartilage, we stimulated a human chondrosarcoma cell line (OUMS-27), which exhibits a chondrocytic phenotype, with 10 μg/ml AGE3 for 4 weeks. As a result, the expressions of COL2A1 and aggrecan were significantly downregulated in the OUMS-27 cells without inducing cell death, but the expressions of proteases that play an important role in cartilage destruction were not affected. Inhibition of the receptor for advanced glycation end products (RAGE) suppressed the AGE3-induced reduction in cartilage component production, suggesting the involvement of RAGE in the action of AGE3.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">advanced glycation end product</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cartilage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">collagen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aggrecan</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Immunometabolic Regulation of Innate Immunity in Systemic Lupus Erythematosus</ArticleTitle>
    <FirstPage LZero="delete">147</FirstPage>
    <LastPage>155</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Haruki</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Review</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/68722</ArticleId>
    </ArticleIdList>
    <Abstract>Pathogens or their components can induce long-lasting changes in the behavior of innate immune cells, a process analogous to “training” for future threats or environmental adaptation. However, such training can sometimes have unintended consequences, such as the development of autoimmunity. Systemic lupus erythematosus (SLE) is a chronic and heterogeneous autoimmune disease characterized by the production of autoantibodies and progressive organ damage. Innate immunity plays a central role in its pathogenesis, contributing through impaired clearance of apoptotic cells, excessive type I interferon production, and dysregulated formation of neutrophil extracellular traps. Recent studies have revealed that metabolites and nucleic acids derived from mitochondria, a crucial energy production site, directly regulate type I interferon and anti-inflammatory cytokine production. These insights have fueled interest in targeting metabolic pathways as a novel therapeutic approach for SLE, offering promise for improving long-term patient outcomes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">systemic lupus erythematosus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">interferon</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tricarboxylic acid cycle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">innate immune memory</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">trained immunity</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1464-6722</Issn>
      <Volume>26</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Genomic Islands of Pseudomonas syringae pv. tabaci 6605: Identification of PtaGI-1 as a Pathogenicity Island With Effector Genes and a Tabtoxin Cluster</ArticleTitle>
    <FirstPage LZero="delete">e70087</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kotomi</FirstName>
        <LastName>Kunishi</LastName>
        <Affiliation>Faculty of Agriculture,Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidenori</FirstName>
        <LastName>Matsui</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanami</FirstName>
        <LastName>Sakata</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiteru</FirstName>
        <LastName>Noutoshi</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Ichinose</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Genomic islands (GIs) are 20-500 kb DNA regions that are thought to be acquired by horizontal gene transfer. GIs that confer pathogenicity and environmental adaptation have been reported in Pseudomonas species; however, GIs that enhance bacterial virulence have not. Here, we identified 110 kb and 103 kb GIs in P. syringae pv. tabaci 6605 (Pta6605), the causative agent of tobacco wildfire disease, which has the ability to produce tabtoxin as a phytotoxin. These GIs are partially homologous to known genomic islands in Pseudomonas aeruginosa and P. syringae pv. phaseolicola and were designated PtaGI-1 and PtaGI-2. Both PtaGIs conserve core genes, whereas each GI possesses different accessory genes. PtaGI-1 contains a tabtoxin biosynthetic gene cluster and three type III effector genes among its accessory genes, whereas PtaGI-2 also contains homologous genes to hsvABC, pathogenicity-related genes in Erwinia amylovora. Inoculation revealed that the PtaGI-1 mutant, but not the PtaGI-2 mutant, lost the ability to biosynthesise tabtoxin and to cause disease. Therefore, PtaGI-1 is thought to be a pathogenicity island. Both PtaGI-1 and PtaGI-2 have a pseudogene of tRNALys on the left border and an intact tRNALys gene on the right border. In a colony of Pta6605, both GIs can be excised at tRNALys, and PtaGI-1 and PtaGI-2 exist in a circular form. These results indicate that tabtoxin biosynthesis genes in PtaGI-1 are required for disease development, and PtaGI-1 is necessary for Pta6605 virulence.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">horizontal gene transfer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">integrative and conjugative elements</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pathogenicity island</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pseudomonas syringae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tabtoxin</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6694</Issn>
      <Volume>17</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impacts of Dental Follicle Cells and Periodontal Ligament Cells on the Bone Invasion of Well-Differentiated Oral Squamous Cell Carcinoma</ArticleTitle>
    <FirstPage LZero="delete">1559</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Anqi</FirstName>
        <LastName>Chang</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyofumi</FirstName>
        <LastName>Takabatake</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tianyan</FirstName>
        <LastName>Piao</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuma</FirstName>
        <LastName>Arashima</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Htoo Shwe</FirstName>
        <LastName>Eain</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yamin</FirstName>
        <LastName>Soe</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zin Zin</FirstName>
        <LastName>Min</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Oral squamous cell carcinoma (OSCC) frequently invades the jawbone, leading to diagnostic and therapeutic challenges. While tumor-bone interactions have been studied, the specific roles of dental follicle cells (DFCs) and periodontal ligament cells (PDLCs) in OSCC-associated bone resorption remain unclear. This study aimed to compare the effects of DFCs and PDLCs on OSCC-induced bone invasion and elucidate the underlying mechanisms. Methods: Primary human DFCs and PDLCs were isolated from extracted third molars and characterized by Giemsa and immunofluorescence staining. An in vitro co-culture system and an in vivo xenograft mouse model were established using the HSC-2 OSCC cell line. Tumor invasion and osteoclast activation were assessed by hematoxylin and eosin (HE) and tartrate-resistant acid phosphatase (TRAP) staining. Immunohistochemical analysis was performed to evaluate the expression of receptor activator of NF-kappa B ligand (RANKL) and parathyroid hormone-related peptide (PTHrP). Results: DFCs significantly enhanced OSCC-induced bone resorption by promoting osteoclastogenesis and upregulating RANKL and PTHrP expression. In contrast, PDLCs suppressed RANKL expression and partially modulated PTHrP levels, thereby reducing osteoclast activity. Conclusions: DFCs and PDLCs exert opposite regulatory effects on OSCC-associated bone destruction. These findings underscore the importance of stromal heterogeneity and highlight the therapeutic potential of targeting specific stromal-tumor interactions to mitigate bone-invasive OSCC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">oral squamous cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dental follicle cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontal ligament cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bone invasion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">receptor activator of NF-kappa B ligand</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">parathyroid hormone-related peptide</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0340-7004</Issn>
      <Volume>74</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>HIF-PH inhibitors induce pseudohypoxia in T cells and suppress the growth of microsatellite stable colorectal cancer by enhancing antitumor immune responses</ArticleTitle>
    <FirstPage LZero="delete">192</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuehua</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuze</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miao</FirstName>
        <LastName>Tian</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teizo</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Recent studies have revealed that CD8+ T cells can be activated via genetic upregulation of HIF-1 alpha, thereby augmenting antitumor effector functions. HIF-1 alpha upregulation can be attained by inhibiting HIF-prolyl hydroxylase (HIF-PH) under normoxic conditions, termed pseudohypoxia. This study investigated whether pseudohypoxia induced by HIF-PH inhibitors suppresses Microsatellite stable (MSS) colorectal cancer (CRC) by affecting tumor immune response.&lt;br&gt;
Methods The HIF-PH inhibitors Roxadustat and Vadadustat were utilized in this study. In vitro, we assessed the effects of HIF-PH inhibitors on human and murine colon cancer cell lines (SW480, HT29, Colon26) and murine T cells. In vivo experiments were performed with mice bearing Colon26 tumors to evaluate the effect of these inhibitors on tumor immune responses. Tumor and spleen samples were analyzed using immunohistochemistry, RT-qPCR, and flow cytometry to elucidate potential mechanisms.&lt;br&gt;
Results HIF-PH inhibitors demonstrated antitumor effects in vivo but not in vitro. These inhibitors enhanced the tumor immune response by increasing the infiltration of CD8+ and CD4+ tumor-infiltrating lymphocytes (TILs). HIF-PH inhibitors induced IL-2 production in splenic and intratumoral CD4+ T cells, promoting T cell proliferation, differentiation, and immune responses. Roxadustat synergistically enhanced the efficacy of anti-PD-1 antibody for MSS cancer by increasing the recruitment of TILs and augmenting effector-like CD8+ T cells.&lt;br&gt;
Conclusion Pseudohypoxia induced by HIF-PH inhibitors activates antitumor immune responses, at least in part, through the induction of IL-2 secretion from CD4+ T cells in the spleen and tumor microenvironment, thereby enhancing immune efficacy against MSS CRC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Microsatellite stable</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hypoxia-inducible factor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune checkpoint inhibitors</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1464-6722</Issn>
      <Volume>26</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pseudomonas syringae pv. tabaci 6605 Requires Seven Type III Effectors to Infect Nicotiana benthamiana</ArticleTitle>
    <FirstPage LZero="delete">e70091</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Kuroe</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachi</FirstName>
        <LastName>Kashihara</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanami</FirstName>
        <LastName>Sakata</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikihiro</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiteru</FirstName>
        <LastName>Noutoshi</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Ichinose</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidenori</FirstName>
        <LastName>Matsui</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Type III effectors (T3Es), virulence factors injected into plant cells via the type III secretion system (T3SS), play essential roles in the infection of host plants. Pseudomonas syringae pv. tabaci 6605 (Pta 6605) is the causal agent of wildfire disease in tobacco and harbours at least 22 T3Es in its genome. However, the specific T3Es required by Pta 6605 to infect Nicotiana benthamiana remain unidentified. In this study, we investigated the T3Es that contribute to Pta 6605 infection of N. benthamiana. We constructed Pta 6605 poly-T3E-deficient mutants (Pta DxE) and inoculated them into N. benthamiana. Flood assay, which mimics natural opening-based entry, showed that mutant strains lacking 14-22 T3Es, namely, Pta D14E-D22E mutants, exhibited reduced disease symptoms. By contrast, infiltration inoculation, which involves direct injection into leaves, showed that the Pta D14E to Pta D20E mutants developed disease symptoms. Notably, the Pta D20E, containing AvrE1 and HopM1, induced weak but observable symptoms upon infiltration inoculation. Conversely, no symptoms were observed in either the flood assay or infiltration inoculation for Pta D21E and Pta D22E. Taken together, these findings indicate that the many T3Es such as AvrPto4/AvrPtoB, HopW1/HopAE1, and HopM1/AvrE1 in Pta 6605 collectively contribute to invasion through natural openings and symptom development in N. benthamiana. This study provides the basis for understanding virulence in the host by identifying the minimum T3E repertoire required by Pta 6605 to infect N. benthamiana.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">poly T3E mutant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">type III effector</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">type III secretion system</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>64</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Characteristics of Early Gastric Cancer in a Patient with a History of Helicobacter pylori Infection and No History of Eradication Therapy</ArticleTitle>
    <FirstPage LZero="delete">343</FirstPage>
    <LastPage>350</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sakiko</FirstName>
        <LastName>Kuraoka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoko</FirstName>
        <LastName>Ino</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Satomi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyasu</FirstName>
        <LastName>Kono</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiro</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective The characteristics of gastric cancer in patients with atrophic mucosa and no apparent history of Helicobacter pylori eradication have not been thoroughly investigated. Therefore, this study examined the clinicopathological characteristics of gastric cancer in these patients.&lt;br&gt;
Methods We retrospectively examined the endoscopic and pathological characteristics of gastric cancer in patients who underwent endoscopic submucosal dissection.&lt;br&gt;
Patients We divided the patients into 2 groups: those with gastric atrophy and no history of eradication (group A; n=102) and those with a history of eradication (group B; n=161). In group A, patients were further divided into mild atrophy (group C) and severe atrophy (group D) groups, while group B was further divided into those who underwent eradication treatment &gt;5 years ago (group E) and those who underwent eradication 1-5 years ago (group F).&lt;br&gt;
Results Group A comprised significantly older individuals (75±8.0 vs. 71±7.5 years old, p&lt;0.001) with a higher frequency of elevated gastric cancer than group B (32.4% vs. 17.4%, p=0.006). Compared with group E, group A was older and had a greater incidence of elevated gastric cancer. The incidence of gastric cancer in the U or M region was lower in group C than in group D.&lt;br&gt;
Conclusion Gastric cancer in patients with gastric atrophy and no history of eradication was associated with an older age and higher frequency of elevated-type morphology than in those with a history of eradication.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">autoimmune gastritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">eradication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Helicobacter pylori</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2397-9070</Issn>
      <Volume>9</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Frequency and Characteristics of Gastrointestinal Diseases in Patients With Neurofibromatosis</ArticleTitle>
    <FirstPage LZero="delete">e70151</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Manami</FirstName>
        <LastName>Honda</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Yamasaki</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakiko</FirstName>
        <LastName>Hiraoka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiro</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy,Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Aim: Patients with neurofibromatosis (NF) frequently experience gastrointestinal symptoms, but the specific characteristics of these lesions are not well understood.&lt;br&gt;
Methods: To investigate the prevalence and nature of gastrointestinal diseases in this population, we analyzed the gastrointestinal lesions identified through endoscopic examinations in patients with NF.&lt;br&gt;
Results: We included 225 patients with NF type 1 (NF1) and 15 with NF type 2 (NF2). None of the NF2 patients underwent endoscopy. Among the NF1 patients, 27 received endoscopies, and 13 (59%) had gastrointestinal lesions. These 13 patients were predominantly male (10 males and three females), with a median age of 53 years (range: 19-76 years). The identified lesions included colorectal polyps (n = 6), gastrointestinal stromal tumors ([GIST], n = 4), subepithelial lesions (n = 3), gastric fundic gland polyps (n = 3), diffuse intestinal ganglioneuromatosis (n = 2), esophageal polyps (n = 2), a Schwann cell hamartoma (n = 1), esophageal cancer (n = 1), and a gastric hyperplastic polyp (n = 1). All GISTs and one case of diffuse intestinal ganglioneuromatosis were surgically resected. Interestingly, six out of 13 patients were asymptomatic. Additionally, all patients who required surgery were 40 years of age or older.&lt;br&gt;
Conclusions: These findings suggest that routine endoscopic examinations, along with imaging techniques like computed tomography and magnetic resonance imaging, could be beneficial for the early detection of gastrointestinal lesions in NF1 patients aged 40 and above.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">colonoscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophagogastroduodenoscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastrointestinal neoplasms</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastrointestinal stromal tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neurofibromatosis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical Outcomes of Neoadjuvant Paclitaxel/Cisplatin/Gemcitabine Compared with Gemcitabine/Cisplatin for Muscle-Invasive Bladder Cancer</ArticleTitle>
    <FirstPage LZero="delete">81</FirstPage>
    <LastPage>92</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuji</FirstName>
        <LastName>Tsugawa</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuma</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Edamura</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Ebara</LastName>
        <Affiliation>Department of Urology, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/68646</ArticleId>
    </ArticleIdList>
    <Abstract>We retrospectively evaluated the oncologic outcomes of paclitaxel, cisplatin, and gemcitabine (PCG) with those of gemcitabine and cisplatin (GC) as neoadjuvant chemotherapy in muscle-invasive bladder cancer (MIBC) patients. The primary outcome was efficacy: pathological complete response (pCR), ypT0N0; and pathological objective response (pOR), ypT0N0, ≤ ypT1N0, or ypT0N1. Secondary outcomes included overall survival (OS), recurrence-free survival (RFS), predictive factors for pOR, OS, and RFS, and hematologic adverse events (AEs). Among 113 patients treated (PCG, n=28; GC, n=85), similar pOR and pCR rates were achieved by the groups (pOR: PCG, 57.1% vs. GC, 49. 4%; p=0.52; pCR: PCG, 39.3% vs. GC, 29.4%; p=0.36). No significant differences were observed in OS (p=1.0) or RFS (p=0.20). Multivariate logistic regression analysis showed that hydronephrosis (odds ratio [OR] 0.32, 95%CI: 0.11-0.92) and clinical node-positive status (cN+) (OR 0.22, 95%CI: 0.050-0.99) were significantly associated with a decreased probability of pOR. On multivariate Cox regression analyses, pOR achievement was associated with improved OS (hazard ratio [HR] 0.23, 95%CI: 0.10-0.56) and RFS (HR 0.30, 95%CI: 0.13-0.67). There were no significant between-group differences in the incidence of grade ≥ 3 hematologic AEs or dose-reduction required, but the PCG group had a higher incidence of grade 4 neutropenia.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">urothelial carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">paclitaxel</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cisplatin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gemcitabine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neoadjuvant</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1880-6546</Issn>
      <Volume>75</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Changes in adrenoceptor expression level contribute to the cellular plasticity of glioblastoma cells</ArticleTitle>
    <FirstPage LZero="delete">100016</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yutaro</FirstName>
        <LastName>Asaka</LastName>
        <Affiliation>Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Masumoto</LastName>
        <Affiliation>Division of Health Administration and Promotion, Department of Social Medicine, Faculty of Medicine, Tottori University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuhito</FirstName>
        <LastName>Uneda</LastName>
        <Affiliation>Department of Neurosurgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vanessa D.</FirstName>
        <LastName>Chin</LastName>
        <Affiliation>UMass Chan Medical School, UMass Memorial Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tirso</FirstName>
        <LastName>Pena</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruyoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuto</FirstName>
        <LastName>Itano</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruhiko</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rongsheng</FirstName>
        <LastName>Huang</LastName>
        <Affiliation>Department of Trauma Orthopedics, The Second Hospital of Dalian Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Fujimura</LastName>
        <Affiliation>Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Glioblastoma cells are known to regulate their cellular plasticity in response to their surrounding microenvironment, but it is not fully understood what factors contribute to the cells' changing plasticity. Here, we found that glioblastoma cells alter the expression level of adrenoreceptors depending on their differentiation stage. Catecholamines are abundant in the central nervous system, and we found that noradrenaline, in particular, enhances the stemness of glioblastoma cells and promotes the dedifferentiation potential of already differentiated glioblastoma cells. Antagonist and RNAi experiments revealed that signaling through alpha 1D-adrenoreceptor is important for noradrenaline action on glioblastoma cells. We also found that high alpha 1Dadrenoreceptor expression was associated with poor prognosis in patients with gliomas. These data suggest that glioblastoma cells increase the expression level of their own adrenoreceptors to alter the surrounding tumor microenvironment favorably for survival. We believe that our findings will contribute to the development of new therapeutic strategies for glioblastoma.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Adrenoceptors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Glioma stem-like cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Differentiated glioma cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Noradrenaline</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cellular plasticity</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Bilateral Scleritis and Neutrophilic Dermatosis With Cytogenetic Chromosomal Aberrancy Related to Pyoderma Gangrenosum: A Case Report of a 20-Year Follow-Up</ArticleTitle>
    <FirstPage LZero="delete">e82348</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noboru</FirstName>
        <LastName>Asada</LastName>
        <Affiliation>Department of Hematology and Oncology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikako</FirstName>
        <LastName>Obika</LastName>
        <Affiliation>Department of General Internal Medicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryotaro</FirstName>
        <LastName>Omichi</LastName>
        <Affiliation>Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiji</FirstName>
        <LastName>Iwatsuki</LastName>
        <Affiliation>Department of Dermatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pyoderma gangrenosum is a non-infectious autoimmune disease with skin plaques and ulcers in the entity of neutrophilic dermatosis and may have a background of myelodysplastic syndromes. This study reported a 20-year follow-up of a patient with pyoderma gangrenosum and scleritis who showed chromosomal aberrancy from the initial phase and later in the course developed thrombocythemia. A 51-year-old man presented with widespread indurated erythematous plaques with scaling and pustules on the forehead, bilateral eyelids, and nasal bridge, in addition to nodular scleritis in the left eye and ulcer formation of the plaques in the lower legs. Skin biopsy revealed massive dermal infiltration mainly with neutrophils in the absence of neutrophilic vasculitis. Suspected of myelodysplastic syndromes, bone marrow biopsy was normal, while chromosomal aberrancy, 46, XY, del (20) (q11q13.3), was detected. In the diagnosis of neutrophilic dermatosis, probably of pyoderma gangrenosum, he began to have oral prednisolone 20 mg daily and colchicine 1 mg daily, leading to the subsidence of skin lesions. Four months later, he developed nodular scleritis in the right eye and began to use topical 0.1% betamethasone in both eyes. He was stable with only prednisolone 12.5 mg daily until the age of 55.5 years, when he showed an increase of serum lactate dehydrogenase. The bone marrow aspirate disclosed neither blast cell increase nor atypical cells. The same chromosomal aberrancy was repeatedly detected. One year later, he developed breathing difficulty and underwent tracheostomy. Laryngeal lesion biopsy disclosed squamous cell papilloma with human papillomavirus-6. At 60 years old, he showed marginal corneal infiltration in the left eye, and at 61 years old, hypopyon in the right eye. Platelets tended to increase up to 1000 × 103/µL, and bone marrow examinations were recommended but refused by the patient. At the latest follow-up at 71 years old, he was ambulatory in health and stable with a tracheostomy cannula. In conclusion, pyoderma gangrenosum with scleritis occurred in an undetermined hematological malignancy with chromosomal aberrancy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">corneal infiltration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hypopyon</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">myelodysplastic syndromes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neutrophilic dermatosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peripheral keratitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pyoderma gangrenosum</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">scleritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sweet syndrome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2075-4418</Issn>
      <Volume>15</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Improving Diagnostic Performance for Head and Neck Tumors with Simple Diffusion Kurtosis Imaging and Machine Learning Bi-Parameter Analysis</ArticleTitle>
    <FirstPage LZero="delete">790</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Suzuka</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Radiological Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihide</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Fukumura</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Nakamitsu</LastName>
        <Affiliation>Radiological Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wlla E.</FirstName>
        <LastName>Al-Hammad</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Radiological Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yudai</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Radiological Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masataka</FirstName>
        <LastName>Oita</LastName>
        <Affiliation>Graduate School of Interdisciplinary Sciences and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Irfan</FirstName>
        <LastName>Sugianto</LastName>
        <Affiliation>Department of Oral Radiology, Faculty of Dentistry, Hasanuddin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Majd</FirstName>
        <LastName>Barham</LastName>
        <Affiliation>Department of Dentistry and Dental Surgery, College of Medicine and Health Sciences, An-Najah National University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nouha</FirstName>
        <LastName>Tekiki</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nurul N.</FirstName>
        <LastName>Kamaruddin</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miki</FirstName>
        <LastName>Hisatomi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Yanagi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Asaumi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Mean kurtosis (MK) values in simple diffusion kurtosis imaging (SDI)-a type of diffusion kurtosis imaging (DKI)-have been reported to be useful in the diagnosis of head and neck malignancies, for which pre-processing with smoothing filters has been reported to improve the diagnostic accuracy. Multi-parameter analysis using DKI in combination with other image types has recently been reported to improve the diagnostic performance. The purpose of this study was to evaluate the usefulness of machine learning (ML)-based multi-parameter analysis using the MK and apparent diffusion coefficient (ADC) values-which can be acquired simultaneously through SDI-for the differential diagnosis of benign and malignant head and neck tumors, which is important for determining the treatment strategy, as well as examining the usefulness of filter pre-processing. Methods: A total of 32 pathologically diagnosed head and neck tumors were included in the study, and a Gaussian filter was used for image pre-processing. MK and ADC values were extracted from pixels within the tumor area and used as explanatory variables. Five ML algorithms were used to create models for the prediction of tumor status (benign or malignant), which were evaluated through ROC analysis. Results: Bi-parameter analysis with gradient boosting achieved the best diagnostic performance, with an AUC of 0.81. Conclusions: The usefulness of bi-parameter analysis with ML methods for the differential diagnosis of benign and malignant head and neck tumors using SDI data were demonstrated.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">head and neck tumors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mean kurtosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">simple diffusion kurtosis imaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">magnetic resonance imaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">apparent diffusion coefficient value</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">diffusion kurtosis imaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">machine learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bi-parameter analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gradient boosting</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">differential diagnosis of benign and malignant</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Natural Course From Primary Intraocular Lymphoma to Brain Lymphoma in Four Years According to Patient's Choice</ArticleTitle>
    <FirstPage LZero="delete">e81476</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Department of Neurological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shotaro</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Department of Internal Medicine, Kurashiki Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken-ichi</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Hematology and Oncology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Primary intraocular lymphoma or vitreoretinal lymphoma is a rare entity of diffuse large B-cell lymphoma that presents vitreous opacity and retinal and choroidal infiltration. Primary central nervous system lymphoma would occur previously, later, or concurrently with respect to primary intraocular lymphoma. This study reported a 72-year-old patient with a pathological diagnosis of primary intraocular lymphoma who developed central nervous system lymphoma four years later in the course of no treatment. She presented with a four-year history of blurred vision in both eyes after cataract surgeries. Three weeks previously, she underwent a vitrectomy in the left eye at a clinic, and measurements of the vitreous fluid showed a high level of interleukin-10 at 5739 pg/mL, in contrast with interleukin-6 at 142 pg/mL. Cytology of the vitreous fluid was class III on the Papanicolaou classification. Head magnetic resonance imaging detected nothing abnormal. She underwent vitrectomy in the right eye as a diagnostic procedure to show large cells in the vitreous which were positive for CD20 and Ki-67 and negative for CD3, leading to a pathological diagnosis of large B-cell lymphoma. Prophylactic chemotherapy with high-dose methotrexate was recommended as a therapeutic option, but she chose observation since she did not have any eye or systemic symptoms. In the follow-up every three months by an oncologist and an ophthalmologist, she did not have any symptoms, and serum levels of soluble interleukin-2 receptor were in the normal range at each visit. She was well for four years until the age of 76 years when she fell and hit her head, and an emergency head computed tomography scan showed a mass in the left occipital lobe. Magnetic resonance imaging demonstrated a well-defined circular mass in the left occipital lobe with a hyperintense signal in the T2-weighted fluid-attenuated inversion recovery (FLAIR) image and diffusion-weighted image. Fluorodeoxyglucose positron emission tomography showed no abnormal uptake systemically, except for the left occipital lesion. She underwent a brain biopsy by craniotomy to pathologically prove diffuse large B-cell lymphoma. She was recommended to receive first-line chemotherapy as the standard treatment but chose observation with no treatment and died of brain lymphoma nine months later. This case happened to illustrate a natural course of primary intraocular lymphoma which proceeded to central nervous system lymphoma four years later.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">brain biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cell block pathology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">diffuse large b-cell lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">natural course</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">primary central nervous system lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">primary intraocular (vitreoretinal) lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vitrectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vitreous opacity</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Association for Cancer Research (AACR)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0008-5472</Issn>
      <Volume>85</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy</ArticleTitle>
    <FirstPage LZero="delete">1082</FirstPage>
    <LastPage>1096</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Kemmotsu</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiaki</FirstName>
        <LastName>Mukohara</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Magari</LastName>
        <Affiliation>Applied Cell Biology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ai</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Medical Protein Engineering, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Youki</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takamasa</FirstName>
        <LastName>Ishino</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Nagasaki</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kota</FirstName>
        <LastName>Tachibana</LastName>
        <Affiliation>Department of Dermatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Department of Neurological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Neurological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery, Breast and Endocrinological Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Isamu</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Brain metastasis is a poor prognostic factor in patients with cancer. Despite showing efficacy in many extracranial tumors, immunotherapy with anti–PD-1 mAb or anti–CTLA4 mAb seems to be less effective against intracranial tumors. Promisingly, recent clinical studies have reported that combination therapy with anti–PD-1 and anti–CTLA4 mAbs has a potent antitumor effect on brain metastasis, highlighting the need to elucidate the detailed mechanisms controlling the intracranial tumor microenvironment (TME) to develop effective immunotherapeutic strategies. In this study, we analyzed the tumor-infiltrating lymphocytes in murine models of brain metastasis that responded to anti–CTLA4 and anti–PD-1 mAbs. Activated CD4+ T follicular helper (TFH) cells with high CTLA4 expression characteristically infiltrated the intracranial TME, which were activated by combination anti–CTLA4 and anti–PD-1 treatment. The loss of TFH cells suppressed the additive effect of CTLA4 blockade on anti–PD-1 mAb. B-cell–activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) produced by abundant myeloid cells, particularly CD80hiCD206lo proinflammatory M1-like macrophages, in the intracranial TME induced B-cell and TFH-cell infiltration and activation. Furthermore, the intracranial TME of patients with non–small cell lung cancer featured TFH- and B-cell infiltration as tertiary lymphoid structures. Together, these findings provide insights into the immune cell cross-talk in the intracranial TME that facilitates an additive antitumor effect of CTLA4 blockade with anti–PD-1 treatment, supporting the potential of a combination immunotherapeutic strategy for brain metastases.&lt;br&gt;
Significance: B-cell and CD4+ T follicular helper cell activation via BAFF/APRIL from abundant myeloid cells in the intracranial tumor microenvironment enables a combinatorial effect of CTLA4 and PD-1 blockade in brain metastases.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>ScienceMatters</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2297-8240</Issn>
      <Volume>2</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2016</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>S-nitrosylation of laforin inhibits its phosphatase activity and is implicated in Lafora disease</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Rikako</FirstName>
        <LastName>Toyota</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuko</FirstName>
        <LastName>Honjo</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University; Research Institute for Radiation Biology and Medicine, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Risa</FirstName>
        <LastName>Imajo</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University; Research Institute for Radiation Biology and Medicine, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayano</FirstName>
        <LastName>Satoh</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University; Research Institute for Radiation Biology and Medicine, Hiroshima University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Recently, the relation between S-nitrosylation by nitric oxide (NO), which is over�produced under pathological conditions and neurodegenerative diseases, includingAlzheimer’s and Parkinson’s diseases, has become a focus of attention. Although mostcases of Parkinson’s disease are known to be caused by mutations in the Parkin gene, arecent finding has indicated that S-nitrosylation of Parkin affects its enzymatic activityand leads to the Parkinsonian phenotype. Therefore, it is important to understand thefunction of S-nitrosylated proteins in the pathogenesis of neurodegenerative diseases.Lafora disease (LD, OMIM 254780) is a neurodegenerative disease characterized by theaccumulation of insoluble glucans called Lafora bodies (LBs). LD is caused by mutationsin genes that encode the glucan phosphatase, Laforin, or the E3 ubiquitin ligase, Malin.In this study, we hypothesized that LD may be caused by S-nitrosylation of Laforin,which is similar to the finding that Parkinson’s disease is caused by S-nitrosylation ofParkin. To test this hypothesis, we first determined whether Laforin was S-nitrosylatedusing a biotin switch assay, and compared the three main functions of unmodified andS-nitrosylated Laforin, namely glucan- and Malin-binding activity and phosphataseactivity. Furthermore, we examined whether the numbers of LBs were changed byNO in the cells expressing wild-type Laforin. Here, we report for the first time thatS-nitrosylation of Laforin inhibited its phosphatase activity and that LB formation wasincreased by an NO donor. Our results suggest a possible hypothesis for LD pathogenesis; that is, the decrease in phosphatase activity of Laforin by S-nitrosylation leads toincreased LB formation. Therefore, LD may be caused not only by mutations in theLaforin or Malin genes, but also by the S-nitrosylation of Laforin.
</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">S-Nitrosylation Of Laforin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Post-Translational Modification </Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nitrosylation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Phosphatase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Glucan-Binding</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Nature Portfolio</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Changes of leucine-rich alpha 2 glycoprotein could be a marker of changes of endoscopic and histologic activity of ulcerative colitis</ArticleTitle>
    <FirstPage LZero="delete">5248</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Aoyama</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakiko</FirstName>
        <LastName>Hiraoka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Yasutomi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Inokuchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Takei</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoko</FirstName>
        <LastName>Igawa</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Takahara</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junki</FirstName>
        <LastName>Toyosawa</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Yamasaki</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Kinugasa</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Gastroenterology, Graduate School of Medicine, Chiba University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Gastroenterology, Japanese Red Cross Society Himeji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Leucine-rich alpha 2 glycoprotein (LRG) is one of the serum biomarkers for disease activity of ulcerative colitis (UC). We focused on the correlation between the changes of LRG and the changes of endoscopic and histologic activity of UC, in comparison to the changes of fecal calprotectin (Fcal), fecal immunochemical test (FIT), and C-reactive protein (CRP). Seventy-nine patients with two or more colonoscopies were enrolled, and 123 paired colonoscopies and 121 paired biopsies were examined. With regard to the change of endoscopic/histologic activity between the preceding and subsequent colonoscopy, there was improvement (n = 29/45), unchanging (n = 63/36), and worsening (n = 31/40). The correlations between the changes of marker levels and endoscopic/histologic activity were Fcal; r = 0.50/0.39 and FIT; r = 0.41/0.40, LRG; r = 0.42/0.40 and CRP; r = 0.22/0.17. Furthermore, when the correlation between the changes of LRG levels and the changes of endoscopic/histological activity was compared with those of other markers, the correlation of LRG tended to be superior to those of CRP (CRP vs. LRG; p = 0.08/0.01). LRG is equivalent to fecal markers and superior to CRP, when inferring changes in disease activity of UC based on changes in its level.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Ulcerative colitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Leucine-rich alpha 2 glycoprotein</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Biomarker</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0361-8609</Issn>
      <Volume>96</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2021</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease</ArticleTitle>
    <FirstPage LZero="delete">1241</FirstPage>
    <LastPage>1252</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David C.</FirstName>
        <LastName>Fajgenbaum</LastName>
        <Affiliation>Center for Cytokine Storm Treatment &amp; Laboratory, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sheila K.</FirstName>
        <LastName>Pierson</LastName>
        <Affiliation>Center for Cytokine Storm Treatment &amp; Laboratory, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Iwaki</LastName>
        <Affiliation>Hematology/Respiratory Medicine, Kanazawa University Graduate School of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asami</FirstName>
        <LastName>Nishikori</LastName>
        <Affiliation>Division of Pathophysiology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuhiro</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Rheumatology, Kanazawa University Graduate School of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pathology, Tokai University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Izutsu</LastName>
        <Affiliation>Department of Hematology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kengo</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Midori Filiz</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Yoshizaki</LastName>
        <Affiliation>Department of Organic Fine Chemicals, Institute of Scientific and Industrial Research, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eric</FirstName>
        <LastName>Oksenhendler</LastName>
        <Affiliation>Department of Clinical Immunology, Hôpital Saint-Louis</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Frits</FirstName>
        <LastName>van Rhee</LastName>
        <Affiliation>Myeloma Center, University of Arkansas for Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuharu</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Division of Pathophysiology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly (TAFRO) syndrome is a heterogeneous entity manifesting with a constellation of symptoms described above that can occur in the context of idiopathic multicentric Castleman disease (iMCD) as well as infectious diseases, malignancies, and rheumatologic disorders. So, iMCD-TAFRO is an aggressive subtype of iMCD with TAFRO syndrome and often hyper-vascularized lymph nodes. Since we proposed diagnostic criteria of iMCD-TAFRO in 2016, we have accumulated new insights on the disorder and additional cases have been reported worldwide. In this systematic review and cohort analysis, we established and validated a definition for iMCD-TAFRO. First, we searched PubMed and Japan Medical Abstracts Society databases using the keyword “TAFRO” to extract cases. Patients with possible systemic autoimmune diseases and hematologic malignancies were excluded. Our search identified 54 cases from 50 articles. We classified cases into three categories: (1) iMCD-TAFRO (TAFRO syndrome with lymph node histopathology consistent with iMCD), (2) possible iMCD-TAFRO (TAFRO syndrome with no lymph node biopsy performed and no other co-morbidities), and (3) TAFRO without iMCD or other co-morbidities (TAFRO syndrome with lymph node histopathology not consistent with iMCD or other comorbidities). Based on the findings, we propose an international definition requiring four clinical criteria (thrombocytopenia, anasarca, fever/hyperinflammatory status, organomegaly), renal dysfunction or characteristic bone marrow findings, and lymph node features consistent with iMCD. The definition was validated with an external cohort (the ACCELERATE Natural History Registry). The present international definition will facilitate a more precise and comprehensive approach to the diagnosis of iMCD-TAFRO.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society for Lymphoreticular Tissue Research</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1346-4280</Issn>
      <Volume>64</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Atypical lymphoplasmacytic and immunoblastic proliferation: A Systematic Review</ArticleTitle>
    <FirstPage LZero="delete">97</FirstPage>
    <LastPage>106</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Midori Filiz</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Medicine, John A. Burns School of Medicine, University of Hawai’i</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Takaoka</LastName>
        <Affiliation>Department of Medicine, John A. Burns School of Medicine, University of Hawai’i</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sharina</FirstName>
        <LastName>Macapagal</LastName>
        <Affiliation>Department of Medicine, John A. Burns School of Medicine, University of Hawai’i</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chalothorn</FirstName>
        <LastName>Wannaphut</LastName>
        <Affiliation>Department of Medicine, John A. Burns School of Medicine, University of Hawai’i</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asami</FirstName>
        <LastName>Nishikori</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroko</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Pathology, Chugoku Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Medicine, John A. Burns School of Medicine, University of Hawai’i</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuharu</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Atypical lymphoplasmacytic and immunoblastic proliferation (ALPIBP) was first reported in 1984 as characteristic histological findings in lymph nodes associated with autoimmune diseases, but it has not been clearly defined to date. To summarize the histological characteristics and clinical diagnoses associated with ALPIBP, we searched MEDLINE and EMBASE for all peer-reviewed articles using keywords including “atypical lymphoplasmacytic and immunoblastic lymphadenopathy” from their inception to December 27, 2023. We also summarized the courses of three cases with a pathological diagnosis of ALPIBP. Nine articles with 52 cases were included. Among the total of 55 cases, including the three from our institution, the median age of the cases was 63.5 years with a female predominance (69.5%). Lymphadenopathy was generalized in 65.6% and regional in 34.4% of cases. RA (24.4%), SLE (24.4%), and autoimmune hemolytic anemia (20.0%), were common clinical diagnoses. A combination of cytotoxic chemotherapy was used in 15.6% of cases due to the suspicion of malignancy. Nodal T-follicular helper cell lymphoma, angioimmunoblastic type, methotrexate-associated lymphoproliferative disorders, and IgG4-related diseases were listed as important diseases that need to be pathologically differentiated from ALPIBP. This review summarizes the current understanding of the characteristics of ALPIBP. Given that underrecognition of ALPIBP could lead to overdiagnosis of hematological malignancy and unnecessary treatment, increased awareness of the condition in pathologists and clinicians is crucial.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">systematic review</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">atypical lymphoplasmacytic and immunoblastic proliferation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">IgG4-related disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">angioimmunoblastic T-cell lymphoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Presumed Autoimmune Keratitis in Both Eyes Without Systemic Manifestations: A 40-Year Course of a Patient With Corneal Infiltrates and Melt</ArticleTitle>
    <FirstPage LZero="delete">e79852</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Peripheral corneal infiltration, corneal ulcer, and melt are recognized complications linked to systemic immunological diseases, such as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. These manifestations, which occur in isolation, might be autoimmune keratitis but are difficult to prove underlying immunological abnormalities. This report described a patient with presumed autoimmune keratitis who repeatedly presented corneal infiltration and perforation in both eyes even after penetrating keratoplasty. The 68-year-old patient with a stable condition of keratoconjunctivitis sicca, in a 28-year follow-up, abruptly developed mild infiltrates in the corneal center of the right eye and white dense infiltrates in the peripheral and central cornea of the left eye. He was treated with topical 0.1% betamethasone eye drops and oral prednisolone tapering from 30 mg daily. The patient underwent cataract surgeries in both eyes 10 months after the onset of corneal infiltration and subsequently underwent penetrating keratoplasty in both eyes due to abrupt corneal perforation in the left eye 14 months after the onset of corneal infiltration. Six months post-keratoplasty, he experienced a recurrence of infiltrates in the corneal grafts in both eyes, leading to corneal leukoma in the left eye. The corneal graft in the right eye maintained its integrity with relatively mild opacity until approximately 3.5 years post-keratoplasty, when he abruptly developed white dense infiltration of both the corneal graft and his own peripheral cornea at the age of 73. In response to oral prednisolone tapered from 15 mg daily, the corneal infiltration in the right eye resolved but resulted in graft failure. Since he did not exhibit systemic symptoms and signs throughout the course, the repeat episodes of infiltration in both his own cornea and the corneal graft would be the manifestations of autoimmune keratitis. The entity of autoimmune keratitis in isolation would be beneficial to establish a therapeutic strategy for long-term immunosuppression in light of a risk for steroid side effects and a high rate of corneal graft failure.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">autoimmune keratitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">corneal graft</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">corneal infiltration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">corneal melt</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">penetrating keratoplasty</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0309-0167</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Kikuchi‐Fujimoto disease: investigating comprehensive clinicopathological features and risk factors for recurrence</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Midori Filiz</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikako</FirstName>
        <LastName>Sakao</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Kurokawa</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asami</FirstName>
        <LastName>Nishikori</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuharu</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aims: Kikuchi-Fujimoto disease (KFD) is a rare disease that typically manifests with fever and cervical lymphadenopathy. Little is known about the risk factors associated with recurrence and their correlation with clinicopathologic features.&lt;br&gt;
Methods and Results: We analysed 112 patients with KFD, predominantly female (61/112, 54.5%), with an average age of 29.4 years. The incidence was higher in males up to the age of 20 and higher in females from their 30s onwards. Of the 70 patients with follow-up data, 23% experienced recurrence. Recurrence was associated with lower C4 levels (P = 0.038) and higher antinuclear antibody (ANA) rates (P = 0.007) compared to transient disease. The mean duration of symptoms was 71.5 days. Lymph node histology in 98 cases (excluding 14 needle biopsy specimens) was classified into three patterns: proliferative (n = 75, 77%), necrotizing (n = 22, 22%), and xanthomatous (n = 1, 1%). The necrotizing pattern associated with significantly enlarged lymph nodes (P = 0.047) and a longer symptom duration (P = 0.009) than the proliferating pattern. The number of CD4-positive lymphocytes was significantly lower in the necrotizing type than in the proliferative type (P &lt; 0.001).&lt;br&gt;
Conclusion: These results indicated that low C4 levels and positive ANA were associated with KFD recurrence. Although the aetiology of KFD remains elusive, given that some cases develop autoimmune disease, the results suggest that patients with recurrent KFD represent an intermediate status between those with transient KFD and those with overt autoimmune disease. The comprehensive clinicopathological findings of this study may be useful for elucidating its pathogenesis and predicting the clinical course.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">histiocytic necrotizing lymphadenitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">histological subtypes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Kikuchi-Fujimoto disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">necrotizing type</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">proliferating type</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">recurrent</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">xanthomatous type</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1865-7257</Issn>
      <Volume>18</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A case of pancreatic ductal adenocarcinoma growing within the pancreatic duct mimicking an intraductal tubulopapillary neoplasm</ArticleTitle>
    <FirstPage LZero="delete">376</FirstPage>
    <LastPage>382</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mayu</FirstName>
        <LastName>Uka</LastName>
        <Affiliation>Department of Radiology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Department of Pathology, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Tsutsumi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Horiguchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We herein report a case of pancreatic ductal adenocarcinoma (PDAC) that developed within the pancreatic duct and was initially diagnosed as an intraductal tubulopapillary neoplasm (ITPN). A 76-year-old man presented with weight loss and main pancreatic duct dilation. The imaging studies revealed a 30-mm hypovascular tumor within the main duct of the pancreatic head. An endoscopic examination with a biopsy revealed high-grade atypical epithelial cells with immunostaining patterns suggestive of ITPN. Following robot-assisted pancreaticoduodenectomy, postoperative pathology revealed conflicting features: nodular/cribriform infiltrations typical of ITPN and non-lobular replacement with scattered infiltrations characteristic of PDAC. A comprehensive genomic profiling test detected KRAS and TP53 mutations, leading to the final diagnosis of PDAC (fT3N1aM0, stage IIB). The patient received adjuvant S-1 chemotherapy and remained recurrence-free for 15 months post-surgery. This case highlights the diagnostic challenges of differentiating intraductal pancreatic tumors and demonstrates the utility of integrating genetic testing with conventional diagnostic modalities for an accurate diagnosis and appropriate treatment selection.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Pancreatic intraductal neoplasms</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pancreatic carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Intraductal tubulopapillary neoplasm</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Genetic testing</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0340-7004</Issn>
      <Volume>74</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone</ArticleTitle>
    <FirstPage LZero="delete">96</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomohiko</FirstName>
        <LastName>Yagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shohei</FirstName>
        <LastName>Nogi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuki</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Yoshimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kanto</FirstName>
        <LastName>Suemori</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Nagai</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuto</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Kakiuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Departments of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background The mechanisms by which neutrophils acquire pro-tumor properties remain poorly understood. In pancreatic cancer, cancer-associated fibroblasts (CAFs) may interact with neutrophils, directing them to promote tumor progression.&lt;br&gt;
Methods To validate the association between CAFs and neutrophils, the localization of neutrophils was examined in clinically resected pancreatic cancer specimens. CAFs were produced by culturing in cancer-conditioned media, and the effects of these CAFs on neutrophils were examined. In vitro migration and invasion assays assess the effect of CAF-activated neutrophils on cancer cells. The factors secreted by the activated neutrophils were also explored. Finally, pirfenidone (PFD) was tested to determine whether it could suppress the pro-tumor functions of activated neutrophils.&lt;br&gt;
Results In pancreatic cancer specimens, neutrophils tended to co-localize with IL-6-positive CAFs. Neutrophils co-cultured with CAFs increased migratory capacity and prolonged life span. CAF-affected neutrophils enhance the migratory and invasive activities of pancreatic cancer cells. IL-8 is the most upregulated cytokine secreted by the neutrophils. PFD suppresses IL-8 secretion from CAF-stimulated neutrophils and mitigates the malignant traits of pancreatic cancer cells.&lt;br&gt;
Conclusion CAFs activate neutrophils and enhance the malignant phenotype of pancreatic cancer. The interactions between cancer cells, CAFs, and neutrophils can be disrupted by PFD, highlighting a potential therapeutic approach.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cancer-associated fibroblasts</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Neutrophil</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Anti-fibrotic agent</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pirfenidone</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Endothelial Cell Polarity in Health and Disease</ArticleTitle>
    <FirstPage LZero="delete">1</FirstPage>
    <LastPage>7</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Moe</FirstName>
        <LastName>Thiha</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Hikita</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Review</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/68353</ArticleId>
    </ArticleIdList>
    <Abstract>Endothelial cell polarity is fundamental to the organization and function of blood vessels, influencing processes such as angiogenesis, vascular stability, and response to shear stress. This review elaborates on the molecular mechanisms that regulate endothelial cell polarity, focusing on key players like the PAR polarity complex and Rho family GTPases. These pathways coordinate the front–rear, apical–basal and planar polarity of endothelial cells, which are essential for the proper formation and maintenance of vascular structures. In health, endothelial polarity ensures not only the orderly development of blood vessels, with tip cells adopting distinct polarities during angiogenesis, but also ensures proper vascular integrity and function. In disease states, however, disruptions in polarity contribute to pathologies such as coronary artery disease, where altered planar polarity exacerbates atherosclerosis, and cancer, where disrupted polarity in tumor vasculature leads to abnormal vessel growth and function. Understanding cell polarity and its disruption is fundamental not only to comprehending how cells interact with their microenvironment and organize themselves into complex, organ-specific tissues but also to developing novel, targeted, and therapeutic strategies for a range of diseases, from cardiovascular disorders to malignancies, ultimately improving patient outcomes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">blood vessel</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endothelial cell</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cell polarity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">atherosclerosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Proceedings of the National Academy of Sciences</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0027-8424</Issn>
      <Volume>121</Volume>
      <Issue>35</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity</ArticleTitle>
    <FirstPage LZero="delete">e2320189121</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fumiaki</FirstName>
        <LastName>Mukohara</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuma</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takamasa</FirstName>
        <LastName>Ishino</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Inozume</LastName>
        <Affiliation>Department of Dermatology, Chiba University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Nagasaki</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Youki</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Suzawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihide</FirstName>
        <LastName>Ueno</LastName>
        <Affiliation>Division of Cellular Signaling, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsushige</FirstName>
        <LastName>Kawase</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Saeki</LastName>
        <Affiliation>Department of Dermatology, Chiba University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shusuke</FirstName>
        <LastName>Kawashima</LastName>
        <Affiliation>Department of Dermatology, Chiba University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuo</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>KOTAI Biotechnologies, Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Dermatology, Chiba University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Honobe-Tabuchi</LastName>
        <Affiliation>Department of Dermatology, University of Yamanashi</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroko</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Dansako</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuyoshi</FirstName>
        <LastName>Kawamura</LastName>
        <Affiliation>Department of Dermatology, University of Yamanashi</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaka</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Honda</LastName>
        <Affiliation>Department of Pathology, Tokyo Women's Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Mano</LastName>
        <Affiliation>Division of Cellular Signaling, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahito</FirstName>
        <LastName>Kawazu</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Immune checkpoint inhibitors (ICIs) exert clinical efficacy against various types of cancers by reinvigorating exhausted CD8+ T cells that can expand and directly attack cancer cells (cancer-specific T cells) among tumor-infiltrating lymphocytes (TILs). Although some reports have identified somatic mutations in TILs, their effect on antitumor immunity remains unclear. In this study, we successfully established 18 cancer-specific T cell clones, which have an exhaustion phenotype, from the TILs of four patients with melanoma. We conducted whole-genome sequencing for these T cell clones and identified various somatic mutations in them with high clonality. Among the somatic mutations, an SH2D2A loss-of-function frameshift mutation and TNFAIP3 deletion could activate T cell effector functions in vitro. Furthermore, we generated CD8+ T cell–specific Tnfaip3 knockout mice and showed that Tnfaip3 function loss in CD8+ T cell increased antitumor immunity, leading to remarkable response to PD-1 blockade in vivo. In addition, we analyzed bulk CD3+ T cells from TILs in additional 12 patients and identified an SH2D2A mutation in one patient through amplicon sequencing. These findings suggest that somatic mutations in TILs can affect antitumor immunity and suggest unique biomarkers and therapeutic targets.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cancer immunology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">somatic mutation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">T cell</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor-infiltrating lymphocytes</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Nature Portfolio</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Novel treatment strategy targeting interleukin-6 induced by cancer associated fibroblasts for peritoneal metastasis of gastric cancer</ArticleTitle>
    <FirstPage LZero="delete">3267</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ema</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Okura</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Une</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Nishiwaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Ohtsuka</LastName>
        <Affiliation>Laboratory of Fundamental Oncology, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rieko</FirstName>
        <LastName>Ohki</LastName>
        <Affiliation>Laboratory of Fundamental Oncology, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cancer-associated fibroblasts (CAFs) are a crucial component in the tumor microenvironment (TME) of peritoneal metastasis (PM), where they contribute to tumor progression and metastasis via secretion of interleukin-6 (IL-6). Here, we investigated the role of IL-6 in PM of gastric cancer (GC) and assessed whether anti-IL-6 receptor antibody (anti-IL-6R Ab) could inhibit PM of GC. We conducted immunohistochemical analysis of IL-6 and alpha-smooth muscle (alpha-SMA) expressions in clinical samples of GC and PM, and investigated the interactions between CAFs and GC cells in vitro. Anti-tumor effects of anti-IL-6R Ab on PM of GC were investigated in an orthotopic murine PM model. IL-6 expression was significantly correlated with alpha-SMA expression in clinical samples of GC, and higher IL-6 expression in the primary tumor was associated with poor prognosis of GC. Higher IL-6 and alpha-SMA expressions were also observed in PM of GC. In vitro, differentiation of fibroblasts into CAFs and chemoresistance were observed in GC cells cocultured with fibroblasts. Anti-IL-6R Ab inhibited the progression of PM in GC cells cocultured with fibroblasts in the orthotopic mouse model but could not inhibit the progression of PM consisting of GC cells alone. IL-6 expression in the TME was associated with poor prognosis of GC, and CAFs were associated with establishment and progression of PM via IL-6. Anti-IL-6R Ab could inhibit PM of GC by the blockade of IL-6 secreted by CAFs, which suggests its therapeutic potential for PM of GC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Peritoneal metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gastric cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Interleukin-6</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cancer-associated fibroblasts</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Interleukin-6 receptor antibody</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Nature Portfolio</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Nomogram models for predicting outcomes in thyroid cancer patients with distant metastasis receiving 131iodine therapy</ArticleTitle>
    <FirstPage LZero="delete">2486</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shui</FirstName>
        <LastName>Jin</LastName>
        <Affiliation>Department of Nuclear Medicine, Zhejiang Cancer Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xuemei</FirstName>
        <LastName>Ye</LastName>
        <Affiliation>Department of Nuclear Medicine, Zhejiang Cancer Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ting</FirstName>
        <LastName>Ye</LastName>
        <Affiliation>Department of Nuclear Medicine, Zhejiang Cancer Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xinyu</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Nuclear Medicine, Faculty of Medicine, University of Augsburg</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jianfeng</FirstName>
        <LastName>Ji</LastName>
        <Affiliation>Department of Nuclear Medicine, Zhejiang Cancer Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jinyu</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Medical records and statistics office, Zhejiang Cancer Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xin</FirstName>
        <LastName>Zhu</LastName>
        <Affiliation>Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Zhejiang Cancer Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xiaochun</FirstName>
        <LastName>Mao</LastName>
        <Affiliation>Department of Thyroid Surgery, Zhejiang Cancer Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Heqing</FirstName>
        <LastName>Yi</LastName>
        <Affiliation>Department of Nuclear Medicine, Zhejiang Cancer Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study aimed to establish and validate prognostic nomogram models for patients who underwent I-131 therapy for thyroid cancer with distant metastases. The cohort was divided into training (70%) and validation (30%) sets for nomogram development. Univariate and multivariate Cox regression analyses were used to identify independent predictors for overall survival (OS) and progression-free survival (PFS). Nomograms were developed based on these predictors, and Kaplan-Meier curves were constructed for validation. Among 451 patients who were screened, 412 met the inclusion criteria and were followed-up for a median duration of 65.2 months. The training and validation sets included 288 and 124 patients, respectively. Pathological type, first I-131 administrated activity, and lesion I-131 uptake in lesions were independent predictors for PFS. For OS, predictors included gender, age, metastasis site, first I-131 administrated activity, I-131 uptake, pulmonary lesion size, and stimulated thyroglobulin levels. These predictors were used to construct nomograms for predicting PFS and OS. Low-risk patients had significantly longer PFS and OS compared to high-risk patients, with 10-year PFS rates of 81.1% vs. 51.9% and 10-year OS rates of 86.2% vs. 37.4%. These may aid individualized prognostic assessment and clinical decision-making, especially in determining the prescribed activity for the first I-131 treatment.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">131iodine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Activity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Distant metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Iodine radioisotopes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Thyroid cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2090-6447</Issn>
      <Volume>2025</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Case of an Oral Elastofibromatous Lesion: A Clinicopathological Analysis With a Literature Review</ArticleTitle>
    <FirstPage LZero="delete">5556176</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sawako</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Masui</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyoichi</FirstName>
        <LastName>Obata</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoya</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Furuki</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoko</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pathology, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Elastofibromatous changes of the oral mucosa, such as an elastofibroma (EF) or an elastofibromatous lesion (EFL), are not well recognized, and the second such case in Japan is reported. A 72-year-old man wearing a complete maxillary denture presented with a small nodule on the hard palate. Histopathological examination showed abundant fibrous tissue with numerous elastic fibers on Elastica van Gieson (EvG) staining. The diagnosis of an oral EFL was made. In the review of oral EF and EFL, no cases with recurrence were identified, but such lesions may resemble neoplastic lesions macroscopically. Accurate diagnosis using EvG stain is needed to recognize oral EFs and EFLs.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">elastofibroma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oral elastofibromatous lesion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oral mucosa</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2077-0383</Issn>
      <Volume>13</Volume>
      <Issue>23</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical Characteristics of Persistent Hypophosphatasemia Uncovered in Adult Patients: A Retrospective Study at a Japanese Tertiary Hospital</ArticleTitle>
    <FirstPage LZero="delete">7078</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Furukawa</LastName>
        <Affiliation>Department of Laboratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihito</FirstName>
        <LastName>Higashikage</LastName>
        <Affiliation>Department of Laboratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Hypophosphatasemia is often overlooked despite its potential to indicate underlying pathologies. The aim of this study was to determine the prevalence of persistent hypophosphatasemia in a large, urban, multi-specialty hospital population and characterize the clinical and laboratory findings in adult patients with this condition. Methods: In this retrospective observational study, the results of 424,434 alkaline phosphatase (ALP) tests in 50,136 patients aged &gt;= 18 years that were performed at Okayama University Hospital between July 2020 and October 2023 were analyzed. Persistent hypophosphatasemia was defined as consistently low ALP levels (&lt;= 40 IU/L) for 28 days with a minimum recorded level of &lt;= 35 IU/L. Results: Persistent hypophosphatasemia was detected in 273 patients (0.54% of the tested patients), and the patients with persistent hypophosphatasemia included a higher proportion of females (72.5% vs. 52.9% in the people without persistent hypophosphatasemia; chi-squared test, p &lt; 0.01) and had a younger median age (51 years vs. 63 years; Mann-Whitney U test, p &lt; 0.01) than those in the overall tested population. The common causes of persistent hypophosphatasemia were cancer (30%), glucocorticoid use (21%), and immunosuppressants (16%). Notably, 38 patients (14%) had no apparent cause for low ALP values. These patients were categorized on the basis of their clinical characteristics, with some patients presenting symptoms potentially related to adult hypophosphatasia. Conclusions: This study provides prevalence and insights into the causes and characteristics of persistent hypophosphatasemia in a Japanese tertiary care setting. While most cases were associated with known causes, patients with unexplained hypophosphatasemia and symptoms such as chronic pain, muscle weakness, and general fatigue could have adult hypophosphatasia. In such cases, comprehensive evaluation and further investigation for hypophosphatasia should be considered. Persistent hypophosphatasemia of undetermined etiology could be a crucial initial step in diagnostic algorithms for this condition.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">chronic fatigue syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chronic pain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hypophosphatasemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">alkaline phosphatase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hypophosphatasia</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>63</Volume>
      <Issue>21</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Endoscopic and Histological Gastritis in University Students with Helicobacter pylori Infection</ArticleTitle>
    <FirstPage LZero="delete">2875</FirstPage>
    <LastPage>2884</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shotaro</FirstName>
        <LastName>Okanoue</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Sakae</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Yokota</LastName>
        <Affiliation>Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Obayashi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Abe</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyasu</FirstName>
        <LastName>Kono</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromitsu</FirstName>
        <LastName>Kanzaki</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiro</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yanai</LastName>
        <Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective Although the characteristics of Helicobacter pylori infection have been extensively reported, there is a lack of consensus regarding its characteristics in young adults. The present study examined the endoscopic and histological characteristics of young adults who underwent eradication therapy for H. pylori infection.&lt;br&gt;
Methods We examined the H. pylori infection status of first-year students at Okayama University School of Medicine and Dentistry between 2014 and 2020. A total of 152 (6.8%) students who were positive for H. pylori antibody or pepsinogen tests were enrolled in the study. Among them, 107 students underwent endoscopy, and their biopsy samples were investigated. Seventy-five students were diagnosed with H. pylori infections.&lt;br&gt;
Results Of 75 H. pylori-positive patients, 57 (76.0%) had endoscopic atrophic gastritis, and 42 (56.0%) had histological atrophy. A few patients had severe atrophic gastritis. All 65 patients who underwent an eradication assessment were successfully treated. After successful eradication, 26 patients underwent endoscopic follow-up. The mean follow-up period was 32.9 months. A histological evaluation revealed that gastric antrum atrophy had subsided in 11 of 14 patients, and atrophy in the lesser curvature of the gastric body had subsided in 7 of 8 patients.&lt;br&gt;
Conclusion More than half of young adults with H. pylori infection had atrophic gastritis. We found mild atrophy in young adults, which subsided shortly after eradication treatment. This study provides a foundation for future studies to evaluate the validity of eradication therapy in preventing gastric cancer in patients.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">atrophic gastritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Helicobacter pylori</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">young adults</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">eradication</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0006-4971</Issn>
      <Volume>145</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Oral Inflammation and Microbiome Dysbiosis Exacerbate Chronic Graft-versus-host Disease</ArticleTitle>
    <FirstPage LZero="delete">881</FirstPage>
    <LastPage>896</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yui</FirstName>
        <LastName>Kambara</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyoshi</FirstName>
        <LastName>Gotoh</LastName>
        <Affiliation>Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuma</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Microbiology and Genetics, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mari</FirstName>
        <LastName>Kunihiro</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Oyama</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiki</FirstName>
        <LastName>Terao</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayame</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Division of Hospital Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daniel</FirstName>
        <LastName>Peltier</LastName>
        <Affiliation>Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, Herman B Wells Center for Pediatric Research, Simon Cancer Center, Indiana University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Seike</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisakazu</FirstName>
        <LastName>Nishimori</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noboru</FirstName>
        <LastName>Asada</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Division of Blood Transfusion, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken-ichi</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Soga</LastName>
        <Affiliation>Division of Hospital Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pavan</FirstName>
        <LastName>Reddy</LastName>
        <Affiliation>Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maeda</FirstName>
        <LastName>Yoshinobu</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The oral microbiota, second in abundance to the gut, is implicated in chronic systemic diseases, but its specific role in graft-versus-host disease (GVHD) pathogenesis has been unclear. Our study finds that mucositis-induced oral dysbiosis in patients after hematopoietic cell transplantation (HCT) associated with increased chronic GVHD (cGVHD), even in patients receiving posttransplant cyclophosphamide. In murine HCT models, oral dysbiosis caused by bilateral molar ligatures exacerbated cGVHD and increased bacterial load in the oral cavity and gut, with Enterococcaceae significantly increasing in both organs. In this model, the migration of Enterococcaceae to cervical lymph nodes both before and after transplantation activated antigen-presenting cells, thereby promoting the expansion of donor-derived inflammatory T cells. Based on these results, we hypothesize that pathogenic bacteria increase in the oral cavity might not only exacerbate local inflammation but also enhance systemic inflammation throughout the HCT course. Additionally, these bacteria translocated to the gut and formed ectopic colonies, further amplifying systemic inflammation. Furthermore, interventions targeting the oral microbiome mitigated murine cGVHD. Collectively, our findings highlight the importance of oral dysbiosis in cGVHD and suggest that modulation of the oral microbiome during transplantation may be an effective approach for preventing or treating cGVHD.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1053-2498</Issn>
      <Volume>44</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Loss of Nr4a1 ameliorates endothelial cell injury and vascular leakage in lung transplantation from circulatory-death donor</ArticleTitle>
    <FirstPage LZero="delete">249</FirstPage>
    <LastPage>260</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Kawana</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikio</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohisa</FirstName>
        <LastName>Sakaue</LastName>
        <Affiliation>Department of Cardiovascular and Thoracic Surgery, Ehime University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of Surgery, Division of Cardiovascular and Thoracic Surgery, Duke University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruki</FirstName>
        <LastName>Choshi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaroh</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Ohtani</LastName>
        <Affiliation>Department of Cell Growth and Tumor Regulation, Proteo-Science Center (PROS), Ehime University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiichiro</FirstName>
        <LastName>Sugimoto</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Ischemia-reperfusion injury (IRI) stands as a major trigger for primary graft dysfunction (PGD) in lung transplantation (LTx). Especially in LTx from donation after cardiac death (DCD), effective control of IRI following warm ischemia (WIRI) is crucial to prevent PGD. This study aimed to identify the key factors affecting WIRI in LTx from DCD.&lt;br&gt;
Methods: Previously reported RNA-sequencing dataset of lung WIRI was reanalyzed to identify nuclear receptor subfamily 4 group A member 1 (NR4A1) as the immediate early gene for WIRI. Dynamics of NR4A1 expression were verified using a mouse hilar clamp model. To investigate the role of NR4A1 in WIRI, a mouse model of LTx from DCD was established using Nr4a1 knockout (Nr4a1−/−) mice.&lt;br&gt;
Results: NR4A1 was located around vascular cells, and its protein levels in the lungs increased rapidly and transiently during WIRI. LTｘ from Nr4a1−/− donors significantly improved pulmonary graft function compared to wild-type donors. Histological analysis showed decreased microvascular endothelial cell death, neutrophil infiltration, and albumin leakage. Evans blue permeability assay demonstrated maintained pulmonary microvascular barrier integrity in grafts from Nr4a1−/− donors, correlating with diminished pulmonary edema. However, NR4A1 did not significantly affect the inflammatory response during WIRI, and IRI was not suppressed when a wild-type donor lung was transplanted into the Nr4a1−/− recipient.&lt;br&gt;
Conclusions: Donor NR4A1 plays a specialized role in the positive regulation of endothelial cell injury and microvascular hyperpermeability. These findings demonstrate the potential of targeting NR4A1 interventions to alleviate PGD and improve outcomes in LTx from DCD.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">lung transplantation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ischemia-reperfusion injury</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">donation after circulatory death</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nuclear receptor subfamily 4 group A member 1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endothelial cell</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-321X</Issn>
      <Volume>31</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cryptococcal prostatitis in an immunocompromised patient with tocilizumab and glucocorticoid therapy: A case report</ArticleTitle>
    <FirstPage LZero="delete">102494</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Oguni</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuhito</FirstName>
        <LastName>Suyama</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshia</FirstName>
        <LastName>Miyawaki</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sawako</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Iio</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cryptococcus prostatitis is an uncommon manifestation of cryptococcal infection that occurs mostly in immunocompromised patients. Tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, has been associated with an increased risk of cryptococcal infections. However, there have been no documented cases of cryptococcal prostatitis in patients receiving tocilizumab therapy. We report a case of cryptococcal prostatitis in a 72-year-old man treated with glucocorticoids and tocilizumab for giant cell arteritis and granulomatosis with polyangiitis. The patient presented dysuria and his serum level of prostate-specific antigen was elevated. Magnetic resonance imaging revealed a prostate mass, and a prostate biopsy was performed, leading to a pathologic diagnosis of cryptococcal prostatitis. Fungal cultures for blood and urine were negative, while the cryptococcal antigen for both serum and urine showed positive results. There were no particular findings in the pulmonary and central nervous systems. The patient was successfully treated with oral fluconazole (400 mg/day) and was discharged. Although cryptococcal prostatitis is a rare entity, clinicians should note that an immunosuppressed patient may develop such a difficult-to-diagnose disease.
</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cryptococcosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fluconazole</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Glucocorticoids</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Prostatitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tocilizumab</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2050-0904</Issn>
      <Volume>13</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Eyelid Spindle Cell Lipoma: Case Report and Review of Three Patients in Literature</ArticleTitle>
    <FirstPage LZero="delete">e70097</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Plastic and Reconstructive Surgery, Kousei Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasumasa</FirstName>
        <LastName>Monobe</LastName>
        <Affiliation>Department of Pathology, General Medical Center, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A 39-year-old woman presented a saucer-shaped mass in the left upper eyelid and underwent the extirpation at local anesthesia. Pathologically, collagen fibers, capillaries, small vessels, and CD34-positive spindle cells were dispersed among mature adipose tissues, indicative of spindle cell lipoma. Long-lasting cyst-like eyelid masses would be usually dermoid cysts, and spindle cell lipoma would be listed as a rare pathological diagnosis in differential diagnoses of cyst-like lesions in the upper and lower eyelid.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CD34</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">eyelid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">orbital bony edge</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pathology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">spindle cell lipoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Society for Hard Tissue Regenerative Biology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-7649</Issn>
      <Volume>33</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>β-catenin Binds to Gsk-3β in Liquid-Liquid Phase Separation Compartment in HEK293 Cells</ArticleTitle>
    <FirstPage LZero="delete">213</FirstPage>
    <LastPage>218</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mari</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Airi</FirstName>
        <LastName>Tanai</LastName>
        <Affiliation>Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Fukuhara</LastName>
        <Affiliation>Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xinyu</FirstName>
        <LastName>Zheng</LastName>
        <Affiliation>Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Heriati</FirstName>
        <LastName>Sitosari</LastName>
        <Affiliation>Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>The Center for Graduate Medical Education (Dental Division), Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mika</FirstName>
        <LastName>Ikegame</LastName>
        <Affiliation>Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirohiko</FirstName>
        <LastName>Okamura</LastName>
        <Affiliation>Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Liquid-liquid phase separation (LLPS) has emerged as a significant mechanism for cellular organization, impacting various biological processes, including Wnt/β-catenin signaling. This study investigates the role of LLPS in the regulation of β-catenin in HEK293 cells, particularly in response to Wnt3a signaling. Our findings demonstrate that β-catenin is regulated by LLPS, forming spherical droplets indicative of this phenomenon. Fluorescence recovery after photobleaching (FRAP) assays revealed that these droplets exhibit reversible dynamics, further confirming their phase-separated nature. Importantly, treatment with Wnt3a led to an increase in β-catenin levels, while simultaneously reducing the recovery of fluorescence intensity in FRAP experiments, suggesting that enhanced Wnt signaling may stimulate the release of β-catenin from LLPS. Immunoprecipitation studies indicated that β-catenin binds to glycogen synthase kinase 3β (Gsk-3β) within the LLPS state, highlighting a potential regulatory mechanism whereby LLPS facilitates the phosphorylation and subsequent degradation of β-catenin. The addition of 1,6-hexanediol disrupted the β-catenin/Gsk-3β interaction, reinforcing the idea that LLPS plays a critical role in modulating these biochemical interactions. The findings presented in this study suggest that LLPS is not only crucial for the spatial organization of β-catenin but also serves as a regulatory mechanism for its signaling functions in the Wnt pathway. Given the association of aberrant Wnt signaling with various diseases, including cancer and neurodegenerative disorders, understanding the role of LLPS in this context may provide new insights into therapeutic strategies targeting these pathological conditions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">β-catenin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gsk-3β</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">LLPS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Wnt</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2210-2612</Issn>
      <Volume>126</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Laparoscopic resection for oesophageal duplication cyst: A case report</ArticleTitle>
    <FirstPage LZero="delete">110572</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Hamazaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kento</FirstName>
        <LastName>Kawasaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Oesophageal duplication cyst is a congenital malformation and rare tumour, clinically manifesting as dysphagia, epigastric pain, or respiratory distress. Duplicate cysts associated with abscess formation or mediastinal penetration and malignancies have been reported, necessitating surgical resection. &lt;br&gt;
Presentation of case: A 55-year-old woman had chest discomfort for 1 year. Preoperative imaging, including computed tomography (CT), upper gastrointestinal endoscopy, and endoscopic ultrasound, revealed a tumour extending from the anterior wall to the lesser curvature of the near the oesophagogastric junction (OGJ) and a suspected mural nodule within the tumour. Contrast-enhanced CT revealed a cystic nodule on the wall of the lesser curvature of the OGJ, with an unclear boundary between the cystic nodule and the oesophageal wall. Magnetic resonance imaging showed an isointense signal on T1-weighted imaging and hyperintensity on T2weighted imaging. Laparoscopic lower oesophagectomy and proximal gastrectomy with lymph node dissection were performed to the confirm mucinous cyst. Pathological findings revealed a cystic lesion in the muscularis propria of the OGJ filled with mucinous components and lined with multilayered columnar epithelial cells. The cyst was diagnosed as a duplicate without malignancy. &lt;br&gt;
Discussion: Since the border between the cyst and the oesophageal walls was unclear, and the cyst potentially contained a malignant component, instead of cystectomy, lower oesophagectomy and proximal gastrectomy with lymph node dissection were performed with oesophagogastric anastomosis using the double-flap technique, tailored specifically for OGJ cancer. &lt;br&gt;
Conclusions: Oesophageal duplication cysts are rare. Lower oesophagectomy and proximal gastrectomy are selective surgical approaches for cyst duplication at the OGJ.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Oesophageal duplication cyst</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Laparoscopic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lower oesophagectomy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elmer Press, Inc.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1923-4155</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Local Control of Conjunctival Malignant Melanoma by Proton Beam Therapy in a Patient With No Metastasis in Six Years From in Situ to Nodular Lesions</ArticleTitle>
    <FirstPage LZero="delete">28</FirstPage>
    <LastPage>36</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Regenerative and Reconstructive Medicine (Ophthalmology), Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Ogata</LastName>
        <Affiliation>Department of Radiology, Proton Beam Center, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Waki</LastName>
        <Affiliation>Department of Radiology, Proton Beam Center, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kota</FirstName>
        <LastName>Tachibana</LastName>
        <Affiliation>Department of Dermatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fuji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Adachi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Yamasaki</LastName>
        <Affiliation>Department of Dermatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Conjunctival malignant melanoma is extremely rare, with no standard of care established at moment. Here we report a 65-year-old woman, as a hepatitis B virus (HBV) carrier, who presented concurrently a liver mass and lower bulbar conjunctival pigmented lesions in the right eye. Needle liver biopsy and excisional conjunctival biopsy showed hepatocellular carcinoma and conjunctival malignant melanoma in situ, respectively. The priority was given to segmental liver resection for hepatocellular carcinoma after transcatheter arterial chemoembolization. In 1 year, she underwent second and third resection of bulbar conjunctival pigmented lesions, and the pathological examinations constantly showed melanoma in situ. In the course, she showed gradual widening of pigmented lesions to upper bulbar conjunctiva and lower palpebral conjunctiva and lower eyelid. About 2.5 years from the initial visit, the lower eyelid lesion was resected for a genomic DNA-based test of BRAF mutations which turned out to be absent, and then, she began to have intravenous anti-programmed cell death-1 (PD-1), nivolumab every 3 or 4 weeks. She developed iritis in the right eye with conjunctival melanoma as an immune-related adverse event, 3 months after the beginning of nivolumab, and so she used daily topical 0.1% betamethasone eye drops to control the intraocular inflammation. She showed no metastasis in 6 years of follow-up, but later in the course, 5 years from the initial visit, she developed abruptly a non-pigmented nodular lesion on the temporal side of the bulbar conjunctiva along the corneal limbus, accompanied by two pigmented nodular lesions in the upper and lower eyelids in a few months. She thus, underwent proton beam therapy toward the conjunctival melanoma and achieved the successful local control. Proton beam therapy is a treatment option in place of orbital exenteration, and multidisciplinary team collaboration is desirable to achieve better cosmetic and functional outcomes in conjunctival malignant melanoma.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Ocular surface</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Conjunctiva</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Malignant melanoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proton beam therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nivolumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">PD-1 inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune checkpoint inhibitor</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>78</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Treatment of Tenosynovial Giant Cell Tumor of the Cervical Spine with Postoperative Anti-RANKL Antibody (Denosumab) Administration</ArticleTitle>
    <FirstPage LZero="delete">469</FirstPage>
    <LastPage>474</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Nagase</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Sasada</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Ayada</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hayato</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>Sugahara</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinao</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Yasuhara</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/67877</ArticleId>
    </ArticleIdList>
    <Abstract>Tenosynovial giant cell tumor (TGCT) is a fibrous histiocytic tumor originating in the synovial membrane. While cervical TGCT may not be considered a common diagnosis preoperatively because it is relatively rare, it has a high recurrence rate and should be considered. Total resection is preferable, but it can be challenging due to the risk of damaging the vertebral artery. Denosumab has shown effectiveness as a postoperative treatment for osteolytic bone lesion. Denosumab administration coupled with close follow-up might offer an effective postoperative treatment option for unresectable TGCT with bone invasion.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">tenosynovial giant cell tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bone tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">spine</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>78</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Traumatic Neuroma Arising from Surgical Trauma during Conversion from Laparoscopic to Open Cholecystectomy</ArticleTitle>
    <FirstPage LZero="delete">459</FirstPage>
    <LastPage>464</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyasu</FirstName>
        <LastName>Tabuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rika</FirstName>
        <LastName>Yoshimatsu</LastName>
        <Affiliation>Department of Radiology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Okabayashi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/67872</ArticleId>
    </ArticleIdList>
    <Abstract>Traumatic neuroma is an abnormal proliferation of injured nerves resulting from trauma or surgery. We present a case of traumatic neuroma arising in the cystic duct after cholecystectomy. A 66-year-old man was referred to our department due to a biliary tumor. He had undergone cholecystectomy 20 years prior. Cholangioscopy showed an elevated lesion covered with smooth mucosa. Histological examination revealed normal bile duct mucosa. Although benign disease was suspected, the possibilities of malignant disease could not be excluded. Extrahepatic bile duct resection was planned to include intraoperative rapid-freezing of a biopsy specimen followed by histopathological examination. These intraoperative histology results showed proliferation of nerve and fibrous tissue only, resulting in the diagnosis of traumatic neuroma, so no lymph nodes were removed. To avoid excessive surgical intervention, histopathological examination of an intraoperative rapid-frozen biopsy specimen may be important for diagnosing traumatic neuroma.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">traumatic neuroma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">biliary stricture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cholecystectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cholangiography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intraoperative rapid-frozen biopsy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>78</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Case of Radiation-Induced Angiosarcoma after Breast-Conserving Surgery with Hypofractionated Radiotherapy in a Japanese Patient</ArticleTitle>
    <FirstPage LZero="delete">453</FirstPage>
    <LastPage>458</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yujiro</FirstName>
        <LastName>Kawata</LastName>
        <Affiliation>Department of Radiology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Radiology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoji</FirstName>
        <LastName>Tokiya</LastName>
        <Affiliation>Department of Radiology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Matsuno</LastName>
        <Affiliation>Department of Pathology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Dermatology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naruto</FirstName>
        <LastName>Taira</LastName>
        <Affiliation>Department of Breast and Thyroid Surgery, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kuniaki</FirstName>
        <LastName>Katsui</LastName>
        <Affiliation>Department of Radiology, Kawasaki Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/67871</ArticleId>
    </ArticleIdList>
    <Abstract>Radiation-induced angiosarcoma (RIAS) is a rare, late adverse event of radiotherapy comprising approximately half of all radiation-induced sarcomas. It has a relatively short latency period and generally unfavorable prognosis. This study presents a case of RIAS that developed 5 years and 11 months after the completion of hypofractionated radiotherapy (42.56 Gy/16 fractions) following partial mastectomy. The patient was diagnosed with RIAS 10 months after the onset of skin redness. She underwent skin tumor resection, followed by paclitaxel, then pazopanib administration, but no radiotherapy. At 6 years and 2 months after surgery, no RIAS recurrence has been detected.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">breast cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hypofractionated radiotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiation-induced angiosarcoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>78</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Risk Factors for Gangrenous Cholecystitis and the Outcomes of Early Cholecystectomy: A Retrospective Study of a Single-Center City General Hospital</ArticleTitle>
    <FirstPage LZero="delete">439</FirstPage>
    <LastPage>447</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mampei</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Surgery, Sasebo City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Surgery, Sasebo City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yorihisa</FirstName>
        <LastName>Sumida</LastName>
        <Affiliation>Department of Surgery, Sasebo City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoto</FirstName>
        <LastName>Yamazaki</LastName>
        <Affiliation>Department of Surgery, Sasebo City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Department of Surgery, Sasebo City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Fukuda</LastName>
        <Affiliation>Department of Surgery, Sasebo City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Hisanaga</LastName>
        <Affiliation>Department of Surgery, Sasebo City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koki</FirstName>
        <LastName>Wakata</LastName>
        <Affiliation>Department of Surgery, Sasebo City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Surgery, Sasebo City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Eguchi</LastName>
        <Affiliation>Department of Surgery, Nagasaki University Graduate School of Biomedical Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/67869</ArticleId>
    </ArticleIdList>
    <Abstract>Gangrenous cholecystitis (GC) is classified as moderate acute cholecystitis according to the Tokyo Guidelines from 2018 (TG18). We evaluated the risk factors for GC and the outcomes of early cholecystectomy. A total of 136 patients who underwent emergency cholecystectomy for acute cholecystitis were retrospectively analyzed; 58 of these patients (42.6%) were diagnosed with GC (GC group) based on our retrospective pathologic diagnosis. We comparatively evaluated the patient backgrounds and surgical outcomes between the GC group and non-GC group. The GC group was significantly older and included more hypertensive patients than the non-GC group. The GC group was prescribed more antibiotics as initial treatment than the non-GC group, and they had more days between onset and surgery. The preoperative white blood cell count and C-reactive protein values were significantly higher in the GC group than in the non-GC group, and these values were predictive factors for GC. Cholecystectomy required a longer operation time and caused greater blood loss in the GC group. The GC group also had longer hospitalization times than the non-GC group; however, no significant differences were observed in terms of postoperative complications. In conclusion, gangrenous changes should be assessed when diagnosing cholecystitis, and appropriate treatment, such as surgery or drainage, should be undertaken.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">gangrenous</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cholecystitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">acute cholecystitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">laparoscopic cholecystectomy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1340-6868</Issn>
      <Volume>32</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The role of C1orf50 in breast cancer progression and prognosis</ArticleTitle>
    <FirstPage LZero="delete">292</FirstPage>
    <LastPage>305</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Maekawa</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tirso</FirstName>
        <LastName>Peña</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Anna</FirstName>
        <LastName>Rogachevskaya</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruhiko</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuto</FirstName>
        <LastName>Itano</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruyoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyoshi</FirstName>
        <LastName>Doihara</LastName>
        <Affiliation>Department of General Surgery, Kawasaki Medical School General Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michael H.</FirstName>
        <LastName>Roehrl</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Fujimura</LastName>
        <Affiliation>Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Although the prognosis of breast cancer has significantly improved compared to other types of cancer, there are still some patients who expire due to recurrence or metastasis. Therefore, it is necessary to develop a method to identify patients with poor prognosis at the early stages of cancer. In the process of discovering new prognostic markers from genes of unknown function, we found that the expression of C1orf50 determines the prognosis of breast cancer patients, especially for those with Luminal A breast cancer. This study aims to elucidate the molecular role of C1orf50 in breast cancer progression. Bioinformatic analyses of the breast cancer dataset of TCGA, and in vitro analyses, reveal the molecular pathways influenced by C1orf50 expression. C1orf50 knockdown suppressed the cell cycle of breast cancer cells and weakened their ability to maintain the undifferentiated state and self-renewal capacity. Interestingly, upregulation of C1orf50 increased sensitivity to CDK4/6 inhibition. In addition, C1orf50 was found to be more abundant in breast cancer cells than in normal breast epithelium, suggesting C1orf50’s involvement in breast cancer pathogenesis. Furthermore, the mRNA expression level of C1orf50 was positively correlated with the expression of PD-L1 and its related factors. These results suggest that C1orf50 promotes breast cancer progression through cell cycle upregulation, maintenance of cancer stemness, and immune evasion mechanisms. Our study uncovers the biological functions of C1orf50 in Luminal breast cancer progression, a finding not previously reported in any type of cancer.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">C1orf50</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Luminal A breast cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cell cycle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune evasion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">YAP/TAZ</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2192-3183</Issn>
      <Volume>14</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Successful immunotherapy with ipilimumab and nivolumab in a patient with pulmonary sclerosing pneumocytoma</ArticleTitle>
    <FirstPage LZero="delete">60</FirstPage>
    <LastPage>63</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yumi</FirstName>
        <LastName>Inukai-Motokura</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Baba</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Takeguchi</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mari</FirstName>
        <LastName>Uno</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Ayada</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pulmonary sclerosing pneumocytoma (PSP) is a rare form of lung cancer that occasionally presents with lymph node and extrapulmonary metastases, and multiple lesions. The treatment of metastatic PSP remains undefined. This study reports the case of a 48-year-old female patient diagnosed with PSP following surgical intervention for a solitary nodule in the left lower lobe. Four years later, recurrence occurred in the left hilar and mediastinal lymph nodes, necessitating an additional resection. Concurrently, sacral metastases developed and required palliative radiotherapy. Genetic analysis identified an AKT1 E17K mutation, characteristic of PSP, and absence of programmed cell death ligand 1 (PD-L1) expression in the tumor. Two years post-recurrence, the tumor recurred in the left mammary gland and mediastinal lymph nodes. Combination immunotherapy with ipilimumab and nivolumab yielded a significantly positive response in this metastatic PSP case. This is the first reported case of successful treatment of multiple distant metastatic PSP with ipilimumab and nivolumab, following the failure of various local treatments. Further case series are warranted to validate the efficacy of immunotherapy in metastatic PSP.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Pulmonary sclerosing pneumocytoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Ipilimumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nivolumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Programmed cell death ligand 1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Case report</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2090-6447</Issn>
      <Volume>2024</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Rare Case of Multiple Myeloma Identified Following the Diagnosis of Amyloidosis of the Tongue</ArticleTitle>
    <FirstPage LZero="delete">8836103</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hideka</FirstName>
        <LastName>Kanemoto</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyoichi</FirstName>
        <LastName>Obata</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Kadoya</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kisho</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kunisada</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mayumi</FirstName>
        <LastName>Yao</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ibaragi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Amyloidosis is a disease in which amyloid protein is deposited in organs and tissues, resulting in functional impairment. Amyloidosis occurs in 12%-30% of patients with multiple myeloma, but in rare cases, amyloidosis may precede the diagnosis of multiple myeloma. Our patient was a 76-year-old Japanese male on dialysis. Multiple nodules accompanied by ulcers were observed on his tongue. He had no subjective symptoms or clinical findings associated with multiple myeloma. The histopathological findings suggested amyloidosis. We suspected both systemic and localized amyloidosis and performed a comprehensive systemic examination. Since the patient had been on dialysis for only a short period of time (similar to 3 months), dialysis-related amyloidosis was ruled out. After blood and urine tests, a diagnosis of multiple myeloma was made. Chemotherapy treatment was started, but the patient's multiple myeloma could not be suppressed and the tongue amyloidosis worsened, leading to his death 2 years and 2 months after the initial diagnosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>16</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Axillary Reactive Lymphoid Hyperplasia, Likely Due to Unicentric Castleman Disease, and the Concurrent Presence of Orbital Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: A Six-Year Follow-Up Study</ArticleTitle>
    <FirstPage LZero="delete">e73775</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fuji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Department of Hematology and Oncology, Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Castleman disease is a lymphadenopathy of unknown cause at a single site, which is designated as unicentric Castleman disease, or at multiple sites designated as multicentric Castleman disease. We present a patient who showed axillary reactive lymphoid hyperplasia, likely due to unicentric Castleman disease, and orbital extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma in a six-year follow-up. A 76-year-old man had a painless left axillary mass for an unknown period and also left complete blepharoptosis with no other systemic symptoms. Suspected of lymphoma, iliac bone marrow biopsy showed no anomalous cells, and positron emission tomography demonstrated abnormal uptake at the left axilla and in the left superior anterior orbit. Incisional biopsy of the left axillary mass demonstrated hyperplastic lymphoid follicles with an atrophic germinal center and prominent small vessels in the follicular center, indicative of unicentric Castleman disease. One year later, annual follow-up positron emission tomography disclosed a high uptake site, next to the previously-identified cyst, in the pancreatic body. Trans-gastric fine needle pancreatic biopsy proved adenocarcinoma and he underwent subtotal stomach-preserving pancreaticoduodenectomy with jejunal anastomosis. He was well for six months after the surgery and thus, underwent resection of the left orbital lesion at 78 years old. The pathology of the orbital lesion showed ambiguous nodular structure with massive infiltration with CD20-positive medium-sized lymphoid cells which were κ monotype in immunoglobulin light chain restriction, indicative of MALT lymphoma. In the four-year period of the COVID-19 pandemic, he was healthy and followed with no treatment until the age of 82 years when he underwent radiation (46 Gy) to the left axillary lesion which did not regress. He then underwent eyelid levator muscle plication for left blepharoptosis since the left orbital lesion remained unpalpable. The six-year follow-up showed that concurrent and independent orbital MALT lymphoma and axillary reactive lymphoid hyperplasia, likely due to unicentric Castleman disease, were both stable. The present case illustrates how important it is to make pathological diagnoses in different anatomical lesions after the initial diagnosis of Castleman disease.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">blepharoptosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">castleman disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue (malt) lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pancreatic cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">reactive lymphoid hyperplasia</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1433-7398</Issn>
      <Volume>42</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tectal glioma: clinical, radiological, and pathological features, and the importance of molecular analysis</ArticleTitle>
    <FirstPage LZero="delete">1</FirstPage>
    <LastPage>11</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryoji</FirstName>
        <LastName>Imoto</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichiro</FirstName>
        <LastName>Hirano</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Kemmotsu</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuki</FirstName>
        <LastName>Suruga</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Mizuta</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhito</FirstName>
        <LastName>Kegoya</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Umeda</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Madoka</FirstName>
        <LastName>Hokama</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Washio</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yanai</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaishi</FirstName>
        <LastName>Satomi</LastName>
        <Affiliation>Department of Pathology, Kyorin University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Ichimura</LastName>
        <Affiliation>Department of Brain Disease Translational Research, Juntendo University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Isao</FirstName>
        <LastName>Date</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Tectal glioma (TG) is a rare lower grade glioma (LrGG) that occurs in the tectum, mainly affecting children. TG shares pathological similarities with pilocytic astrocytoma (PA), but recent genetic analyses have revealed distinct features, such as alterations in KRAS and BRAF. We conducted a retrospective review of cases clinically diagnosed as TG and treated at our institute between January 2005 and March 2023. Six cases were identified and the median age was 30.5 years. Four patients underwent biopsy and two patients underwent tumor resection. Histological diagnoses included three cases of PA, one case of astrocytoma, and two cases of high-grade glioma. The integrated diagnosis, according to the fifth edition of the World Health Organization Classification of Tumours of the central nervous system, included two cases of PA and one case each of diffuse high-grade glioma; diffuse midline glioma H3 K27-altered; glioblastoma; and circumscribed astrocytic glioma. Among the three patients who underwent molecular evaluation, two had KRAS mutation and one had H3-3A K27M mutation. Our results demonstrate the diverse histological and molecular characteristics of TG distinct from other LrGGs. Given the heterogeneous pathological background and the risk of pathological progression in TG, we emphasize the importance of comprehensive diagnosis, including molecular evaluation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Tectal glioma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lower grade glioma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">KRAS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">H3 K27M</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Molecular analysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society for Lymphoreticular Tissue Research</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1346-4280</Issn>
      <Volume>64</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease</ArticleTitle>
    <FirstPage LZero="delete">297</FirstPage>
    <LastPage>306</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Asami</FirstName>
        <LastName>Nishikori</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Midori Filiz</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Chijimatsu</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Himawari</FirstName>
        <LastName>Ueta</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">You Cheng</FirstName>
        <LastName>Lai</LastName>
        <Affiliation>Department of Medical Biotechnology and Laboratory Science, Chang Gung University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuri</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yudai</FirstName>
        <LastName>Takeda</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sayaka</FirstName>
        <LastName>Ochi</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoka</FirstName>
        <LastName>Haratake</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pathology, Tokai University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuji</FirstName>
        <LastName>Momose</LastName>
        <Affiliation>Department of Pathology, Saitama Medical Center, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuharu</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Idiopathic multicentric Castleman disease (iMCD) is a type of Castleman disease unrelated to the Kaposi sarcoma-associated herpesvirus/human herpesvirus type 8 (KSHV/HHV8) infection. Presently, iMCD is classified into iMCD-IPL (idiopathic plasmacytic lymphadenopathy), iMCD-TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), and iMCD-NOS (not otherwise specified). The most common treatment for iMCD is using IL-6 inhibitors; however, some patients resist IL-6 inhibitors, especially for iMCD-TAFRO/NOS. Nevertheless, since serum IL-6 levels are not significantly different between the iMCD-IPL and iMCD-TAFRO/NOS cases, cytokines other than IL-6 may be responsible for the differences in pathogenesis. Herein, we performed a transcriptome analysis of cytokine storm-related genes and examined the differences between iMCD-IPL and iMCD-TAFRO/NOS. The results demonstrated that counts per million of STAT2, IL1R1, IL1RAP, IL33, TAFAIP1, and VEGFA (P &lt; 0.001); STAT3, JAK2, MAPK8, IL17RA, IL18, TAFAIP2, TAFAIP3, PDGFA, VEGFC, CXCL10, CCL4, and CXCL13 (P &lt; 0.01); and STAT1, STAT6, JAK1, MAPK1, MAPK3, MAPK6, MAPK7, MAPK9, MAPK10, MAPK11, MAPK12, MAPK14, NFKB1, NFKBIA, NFKBIB, NFKBIZ, MTOR, IL10RB, IL12RB2, IL18BP, TAFAIP6, TNFAIP8L1, TNFAIP8L3, CSF2RBP1, PDGFB, PDGFC, and CXCL9 (P &lt; 0.05) were significantly increased in iMCD-TAFRO/NOS. Particularly, upregulated IL33 expression was demonstrated for the first time in iMCD-TAFRO/NOS. Thus, inflammatory signaling, such as JAK-STAT and MAPK, may be enhanced in iMCD-TAFRO/NOS and may be a cytokine storm.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">idiopathic multicentric Castleman disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cytokine storm</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transcriptome analysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0021-5155</Issn>
      <Volume>68</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Epiretinal membrane: an overview and update</ArticleTitle>
    <FirstPage LZero="delete">603</FirstPage>
    <LastPage>613</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Matoba</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Epiretinal membrane (ERM) is a frequently diagnosed macular disease associated with aging, characterized by a fibrous membrane forming on the internal limiting membrane (ILM) and leading to visual dysfunctions such as metamorphopsia. Various hypotheses regarding the pathology of metamorphopsia have been proposed; however, the complete pathophysiologic mechanism underlying ERM remains unclear. Optical coherence tomography (OCT) provides detailed images enabling precise diagnosis and characterization of ERM, with several recent studies using the latest OCT imaging techniques. Surgical removal of ERM is the only treatment option; however, criteria for surgical intervention are not established, complicating the decision-making processes. Furthermore, the debate on whether simultaneous peeling of the ILM during ERM surgery enhances outcomes or poses unnecessary risks is ongoing, with no definite conclusion having yet been reached. This review also focuses on epiretinal proliferation, which is different from ERM and is characteristic of lamellar macular hole (LMH). Recently, diagnostic criteria for LMH and related diseases were proposed. Reports on effective surgical procedures for LMH exist, although more research is needed to confirm the long-term outcomes. Thus, this review article aims to provide an overview and updated knowledge of ERM, LMH, and related diseases.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">En face imaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Epiretinal membrane</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Epiretinal proliferation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Internal limiting membrane</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lamellar macular hole</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>78</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Occult Nesidioblastosis Detected by 111In-Pentetreotide Single-Photon Emission Computed Tomography</ArticleTitle>
    <FirstPage LZero="delete">423</FirstPage>
    <LastPage>428</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Gastroenteorlogical Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyasu</FirstName>
        <LastName>Tabuchi</LastName>
        <Affiliation>Department of Gastroenteorlogical Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rika</FirstName>
        <LastName>Yoshimatsu</LastName>
        <Affiliation>Department of Radiology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ai</FirstName>
        <LastName>Hishida</LastName>
        <Affiliation>Department of Endocrinology and Metabolism, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Okabayashi</LastName>
        <Affiliation>Department of Gastroenteorlogical Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/67667</ArticleId>
    </ArticleIdList>
    <Abstract>Nesidioblastosis, also known as persistent hyperinsulinemic hypoglycemia, is usually observed in children and infants, although more recently adult-onset nesidioblastosis has also been described. We present a case of nesidioblastosis in a 78-year-old man that was detected by 111In-pentetreotide single photon emission computed tomography (SPECT/CT). The patient was transferred to our hospital’s emergency department in a hypoglycemic coma. Dynamic enhanced CT could detect no lesion in the pancreas, but an 111In-pentetreotide SPECT/CT scan performed after a similar episode four weeks later showed increased focal uptake at the head of the pancreas. The results of a selective arterial calcium injection test were negative. After careful consideration and discussion among colleagues, surgical intervention was selected, and a pancreaticoduodenectomy was performed. On histology, there were elevated numbers of Langerhans islets in the pancreatic head, and the islets themselves appeared enlarged. Hypertrophic β-cells comprised the majority, but α-cells, δ-cells and pancreatic polypeptide were also detected in the islets. Based on the histopathological results and repeated hyperinsulinemic hypoglycemic crises, the patient was finally diagnosed with adult-onset nesidioblastosis. He had no hypoglycemic symptoms during outpatient follow-up examination. Since 111In-pentetreotide SPECT/CT may be able to detect nesidioblastosis, clinicians should consider this relatively new-modality examination when encountering such cases.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">111In-pentetreotide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nesidioblastosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">single-photon emission computed tomography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hyperinsulinemic hypoglycemia</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society of Clinical Oncology (ASCO)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2473-4284</Issn>
      <Volume>8</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Response to Imatinib in a Patient With Gastric Adenocarcinoma With KIT Q556_K558 In-Frame Deletion: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e2400228</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunio</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Medical Oncology, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Midori</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Pathology, Kagawa Prefectural Central Hospital,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoko</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pathology, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Ayada</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Makimoto</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Ichihara</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuko</FirstName>
        <LastName>Okita</LastName>
        <Affiliation>Research Management Division, Clinical Research Support Office, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Tabata</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Nature Portfolio</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>14</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effectiveness of data-augmentation on deep learning in evaluating rapid on-site cytopathology at endoscopic ultrasound-guided fine needle aspiration</ArticleTitle>
    <FirstPage LZero="delete">22441</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taisuke</FirstName>
        <LastName>Obata</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Matsumi</FirstName>
        <LastName>Akihiro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosaku</FirstName>
        <LastName>Morimoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Terasawa</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuhiro</FirstName>
        <LastName>Yamazaki</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Horiguchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Tsutsumi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironari</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ten</FirstName>
        <LastName>Cho</LastName>
        <Affiliation>Business Strategy Division, Ryobi Systems Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayoshi</FirstName>
        <LastName>Tanimoto</LastName>
        <Affiliation>Business Strategy Division, Ryobi Systems Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akimitsu</FirstName>
        <LastName>Ohto</LastName>
        <Affiliation>Business Strategy Division, Ryobi Systems Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiro</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Rapid on-site cytopathology evaluation (ROSE) has been considered an effective method to increase the diagnostic ability of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA); however, ROSE is unavailable in most institutes worldwide due to the shortage of cytopathologists. To overcome this situation, we created an artificial intelligence (AI)-based system (the ROSE-AI system), which was trained with the augmented data to evaluate the slide images acquired by EUS-FNA. This study aimed to clarify the effects of such data-augmentation on establishing an effective ROSE-AI system by comparing the efficacy of various data-augmentation techniques. The ROSE-AI system was trained with increased data obtained by the various data-augmentation techniques, including geometric transformation, color space transformation, and kernel filtering. By performing five-fold cross-validation, we compared the efficacy of each data-augmentation technique on the increasing diagnostic abilities of the ROSE-AI system. We collected 4059 divided EUS-FNA slide images from 36 patients with pancreatic cancer and nine patients with non-pancreatic cancer. The diagnostic ability of the ROSE-AI system without data augmentation had a sensitivity, specificity, and accuracy of 87.5%, 79.7%, and 83.7%, respectively. While, some data-augmentation techniques decreased diagnostic ability, the ROSE-AI system trained only with the augmented data using the geometric transformation technique had the highest diagnostic accuracy (88.2%). We successfully developed a prototype ROSE-AI system with high diagnostic ability. Each data-augmentation technique may have various compatibilities with AI-mediated diagnostics, and the geometric transformation was the most effective for the ROSE-AI system.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>16</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Presumed Choroidopathy of IgG4-Related Disease Discovered During 16-Year Follow-Up of a Patient With Polycystic Kidney Disease</ArticleTitle>
    <FirstPage LZero="delete">e70865</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Nephrology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Immunoglobulin G4 (IgG4)-related disease is characterized by infiltration with IgG4-producing plasma cells in different organs and the elevation of serum IgG4. We present a patient with polycystic kidney disease in long-term follow-up who developed bilateral lacrimal gland enlargement and presumed IgG4-related choroidopathy at different time points. A 45-year-old woman developed bilateral upper eyelid swelling. Head MRI showed bilateral lacrimal gland enlargement, and the resection on both sides revealed foci of infiltration with lymphocytes and plasma cells in bilateral lacrimal glands. The IgG4-immunostaining did not satisfy the diagnostic criteria. She had been taking oral valsartan 40 mg daily for hypertension with polycystic kidney disease.&lt;br&gt;
&lt;br&gt;
The patient was well until the age of 49 years, when she noticed yellowish vision in the right eye compared to the left eye. The right eye showed multiple yellowish spotty lesions in the deep retina to choroid with a mildly hyperemic optic disc, while the left eye showed the normal fundus. No inflammation was noted in the anterior segments of both eyes. Fundus angiography demonstrated early-phase no-filling with late-phase leakage by fluorescein dye and both early-phase and late-phase no-filling by indocyanine green dye, leading to the diagnosis of acute posterior multifocal placoid pigment epitheliopathy (APMPPE). She began to have oral prednisolone tapered from 30 mg daily and discontinued in a year. At the age of 52 years, she switched to candesartan 8 mg daily and began to have tolvaptan (a selective competitive vasopressin receptor 2 (V2) antagonist) 90 mg daily for polycystic kidney disease with liver cysts. At that time, the lesions in the right eye had mild degeneration.&lt;br&gt;
&lt;br&gt;
The patient was followed once a year ophthalmologically to maintain good vision. At 57 years, serum IgG4, which was measured for the first time on suspicion of IgG4-related disease, was elevated to 269.6 mg/dL. In the following four years to the latest visit at 61 years, she kept stable but high levels of serum IgG4 around 300 mg/dL. Serum IgG4 measurement is helpful to make a clinical diagnosis and, hence, a clinical decision since the spectrum of IgG4-related disease remains obscure.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">acute posterior multifocal placoid pigment epitheliopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">choroidopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">uveitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lacrimal gland tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">igg4-related disease</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>BMC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1472-6831</Issn>
      <Volume>24</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Histological differences related to autophagy in the minor salivary gland between primary and secondary types of Sjögren's syndrome</ArticleTitle>
    <FirstPage LZero="delete">1099</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hitomi</FirstName>
        <LastName>Ono-Minagi</LastName>
        <Affiliation>Department of Cytology and Histology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsutomu</FirstName>
        <LastName>Nohno</LastName>
        <Affiliation>Department of Cytology and Histology, Okayama University Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyofumi</FirstName>
        <LastName>Takabatake</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Katsuyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohta</FirstName>
        <LastName>Miyawaki</LastName>
        <Affiliation>Division of Precision Medicine, Kyushu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ibaragi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Iida</LastName>
        <Affiliation>Department of Oral and Maxillofacial Reconstructive Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Yoshino</LastName>
        <Affiliation>Department of Pathology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayoshi</FirstName>
        <LastName>Sakai</LastName>
        <Affiliation>Department of Rehabilitation for Orofacial Disorders, Osaka University Graduate School of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyo</FirstName>
        <LastName>Ohuchi</LastName>
        <Affiliation>Department of Cytology and Histology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Some forms of Sjögren’s syndrome (SS) follow a clinical course accompanied by systemic symptoms caused by lymphocyte infiltration and proliferation in the liver, kidneys, and other organs. To better understand the clinical outcomes of SS, here we used minor salivary gland tissues from patients and examine their molecular, biological, and pathological characteristics. A retrospective study was performed, combining clinical data and formalin-fixed paraffin-embedded (FFPE) samples from female patients over 60 years of age who underwent biopsies at Okayama University Hospital. We employed direct digital RNA counting with nCounter® and multiplex immunofluorescence analysis with a PhenoCycler™ on the labial gland biopsies. We compared FFPE samples from SS patients who presented with other connective tissue diseases (secondary SS) with those from stable SS patients with symptoms restricted to the exocrine glands (primary SS). Secondary SS tissues showed enhanced epithelial damage and lymphocytic infiltration accompanied by elevated expression of autophagy marker genes in the immune cells of the labial glands. The close intercellular distance between helper T cells and B cells positive for autophagy-associated molecules suggests accelerated autophagy in these lymphocytes and potential B cell activation by helper T cells. These findings indicate that examination of FFPE samples from labial gland biopsies can be an effective tool for evaluating molecular histological differences between secondary and primary SS through multiplexed analysis of gene expression and tissue imaging.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Autoimmune disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Xerostomia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Multiplex immunostaining</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Spatial analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Autophagy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1996-1944</Issn>
      <Volume>17</Volume>
      <Issue>17</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Antibacterial Dental Adhesive Containing Cetylpyridinium Chloride Montmorillonite</ArticleTitle>
    <FirstPage LZero="delete">4368</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of Oral Health Sciences, BIOMAT, KU Leuven</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichi</FirstName>
        <LastName>Nakamori</LastName>
        <Affiliation>Department of Advanced Prosthodontics, Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chenmin</FirstName>
        <LastName>Yao</LastName>
        <Affiliation>Department of Oral Health Sciences, BIOMAT, KU Leuven</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mohammed H.</FirstName>
        <LastName>Ahmed</LastName>
        <Affiliation>Department of Oral Health Sciences, BIOMAT, KU Leuven</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Benjamin</FirstName>
        <LastName>Mercelis</LastName>
        <Affiliation>Department of Oral Health Sciences, BIOMAT, KU Leuven</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Nagaoka</LastName>
        <Affiliation>Advanced Research Center for Oral and Craniofacial Science, Okayama University Dental School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukinori</FirstName>
        <LastName>Maruo</LastName>
        <Affiliation>Department of Prosthodontics, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Biomaterials and Bioengineering, Faculty of Dental Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiko</FirstName>
        <LastName>Abe</LastName>
        <Affiliation>Department of Advanced Prosthodontics, Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Meerbeek, Bart</FirstName>
        <LastName>Van Meerbeek</LastName>
        <Affiliation>Department of Oral Health Sciences, BIOMAT, KU Leuven</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kumiko</FirstName>
        <LastName>Yoshihara</LastName>
        <Affiliation>Department of Pathology &amp; Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Oral bacteria cause tooth caries and periodontal disease. Much research is being conducted to prevent both major oral diseases by rendering dental materials' antimicrobial potential. However, such antimicrobial materials are regarded as 'combination' products and face high hurdles for regulatory approval. We loaded inorganic montmorillonite with the antimicrobial agent cetylpyridinium chloride, referred to below as 'CPC-Mont'. CPC-Mont particles in a 1, 3 and 5 wt% concentration were added to the considered gold-standard self-etch adhesive Clearfil SE Bond 2 ('CSE2'; Kuraray Noritake) to render its antibacterial potential (CSE2 without CPC-Mont served as control). Besides measuring (immediate) bonding effectiveness and (aged) bond durability to dentin, the antibacterial activity against S. mutans and the polymerization-conversion rate was assessed. Immediate and aged bond strength was not affected by 1 and 3 wt% CPC-Mont addition, while 5 wt% CPC-Mont significantly lowered bond strength and bond durability. The higher the concentration of the antimicrobial material added, the stronger the antimicrobial activity. Polymerization conversion was not affected by the CPC-Mont addition in any of the three concentrations. Hence, adding 3 wt% CPC-Mont to the two-step self-etch adhesive rendered additional antimicrobial potential on top of its primary bonding function.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">dental adhesive</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antibacterial agent</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dentin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">degree of conversion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">micro tensile bond strength</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">scanning microscopy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1345-2630</Issn>
      <Volume>90</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Morphogenesis and adaptive strategies for infection in plant pathogenic fungi</ArticleTitle>
    <FirstPage LZero="delete">371</FirstPage>
    <LastPage>373</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fumi</FirstName>
        <LastName>Fukada</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1996-1944</Issn>
      <Volume>17</Volume>
      <Issue>16</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effect of Scaffold Geometrical Structure on Macrophage Polarization during Bone Regeneration Using Honeycomb Tricalcium Phosphate</ArticleTitle>
    <FirstPage LZero="delete">4108</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kiyofumi</FirstName>
        <LastName>Takabatake</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetsugu</FirstName>
        <LastName>Tsujigiwa</LastName>
        <Affiliation>Department of Life Science, Faculty of Science, Okayama University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Anqi</FirstName>
        <LastName>Chang</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tianyan</FirstName>
        <LastName>Piao</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasunori</FirstName>
        <LastName>Inada</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuma</FirstName>
        <LastName>Arashima</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Morimatsu</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The polarization balance of M1/M2 macrophages with different functions is important in osteogenesis and bone repair processes. In a previous study, we succeeded in developing honeycomb tricalcium phosphate (TCP), which is a cylindrical scaffold with a honeycomb arrangement of straight pores, and we demonstrated that TCP with 300 and 500 mu m pore diameters (300TCP and 500TCP) induced bone formation within the pores. However, the details of the influence of macrophage polarization on bone formation using engineered biomaterials, especially with respect to the geometric structure of the artificial biomaterials, are unknown. In this study, we examined whether differences in bone tissue formation due to differences in TCP geometry were due to the polarity of the assembling macrophages. Immunohistochemistry for IBA-1, iNOS, and CD163 single staining was performed. The 300TCP showed a marked infiltration of iNOS-positive cells, which are thought to be M1 macrophages, during the osteogenesis process, while no involvement of CD163-positive cells, which are thought to be M2 macrophages, was observed in the TCP pores. In addition, 500TCP showed a clustering of iNOS-positive cells and CD163-positive cells at 2 weeks, suggesting the involvement of M2 macrophages in the formation of bone tissue in the TCP pores. In conclusion, we demonstrated for the first time that the geometrical structure of the artificial biomaterial, i.e., the pore size of honeycomb TCP, affects the polarization of M1/2 macrophages and bone tissue formation in TCP pores.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">honeycomb TCP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bone formation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">macrophages</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">polarization</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>78</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Middle-Ear Salivary Gland Choristoma with Congenital, Single-Sided Hearing Loss</ArticleTitle>
    <FirstPage LZero="delete">349</FirstPage>
    <LastPage>355</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Tominaga</LastName>
        <Affiliation>Department of Otolaryngology, Head and Neck Surgery, Hiroshima City, Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Sugaya</LastName>
        <Affiliation>Department of Otolaryngology, Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Kariya</LastName>
        <Affiliation>Department of Otolaryngology, Head and Neck Surgery, Kawasaki Medical School Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aiko</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Otolaryngology, Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Department of Otolaryngology, Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizuo</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Otolaryngology, Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/67554</ArticleId>
    </ArticleIdList>
    <Abstract>Middle-ear salivary gland choristoma (SGCh) is a rare, benign tumor that causes conductive hearing loss owing to middle-ear morphological abnormalities. Early diagnosis is challenging, and surgical resection is indispensable for a definitive diagnosis. We report the case of a 3-year-old boy diagnosed with middle-ear SGCh during the follow-up period for left-sided hearing loss discovered at newborn hearing screening (NHS). Long-term follow-up after the NHS result, subsequent computed tomography/magnetic resonance imaging, and surgical resection led to its relatively early diagnosis and treatment.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">middle-ear salivary gland choristoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">middle-ear morphological abnormalities</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">newborn hearing screening</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">unilateral hearing loss</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">surgical resection</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>78</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pneumocephalus with Inverted Papilloma in the Frontoethmoidal Sinus: Case Report and Literature Review</ArticleTitle>
    <FirstPage LZero="delete">337</FirstPage>
    <LastPage>343</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Seiichiro</FirstName>
        <LastName>Makihara</LastName>
        <Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Uraguchi</LastName>
        <Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sawako</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aiko</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Ikemachi</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Ota</LastName>
        <Affiliation>Department of Plastic and Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Plastic and Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shotaro</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Munechika</FirstName>
        <LastName>Tsumura</LastName>
        <Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiya</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Neurosurgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiari</FirstName>
        <LastName>Umakoshi</LastName>
        <Affiliation>Department of Neurosurgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Hirashita</LastName>
        <Affiliation>Department of Neurosurgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizuo</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/67550</ArticleId>
    </ArticleIdList>
    <Abstract>Here, we describe the unique case of a pneumocephalus originating from an inverted papilloma (IP) in the frontoethmoidal sinus. A 71-year-old man with diabetes presented with headaches and altered consciousness. Imaging revealed the pneumocephalus together with bone destruction in the left frontal sinus. He underwent simultaneous endoscopic endonasal and transcranial surgery using an ORBEYE exoscope. Pathological diagnosis of the tumor confirmed IP. Post-surgery, the pneumocephalus was significantly resolved and the squamous cell carcinoma antigen level, which had been elevated, decreased. This case underscores the importance of a multidisciplinary approach and innovative surgical methods in treating complex sinonasal pathologies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">pneumocephalus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">inverted papilloma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">frontoethmoidal sinus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endoscopic endonasal and transcranial surgery</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>78</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Rare Subglottic Pleomorphic Adenoma: Magnetic Resonance Findings</ArticleTitle>
    <FirstPage LZero="delete">331</FirstPage>
    <LastPage>335</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Chieko</FirstName>
        <LastName>Furukawa</LastName>
        <Affiliation>Department of Otolaryngology Head and Neck Surgery, Japanese Red Cross Society Himeji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyasu</FirstName>
        <LastName>Tachibana</LastName>
        <Affiliation>Department of Otolaryngology Head and Neck Surgery, Japanese Red Cross Society Himeji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuji</FirstName>
        <LastName>Nobuhisa</LastName>
        <Affiliation>Department of Surgery, Japanese Red Cross Society Himeji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Kanie</LastName>
        <Affiliation>Department of Radiology, Japanese Red Cross Society Himeji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoji</FirstName>
        <LastName>Wani</LastName>
        <Affiliation>Department of Pathology, Japanese Red Cross Society Himeji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun-Ya</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Otolaryngology Head and Neck Surgery, Japanese Red Cross Society Himeji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akifumi</FirstName>
        <LastName>Kariya</LastName>
        <Affiliation>Department of Otolaryngology Head and Neck Surgery, Japanese Red Cross Society Himeji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asuka</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Otolaryngology Head and Neck Surgery, Japanese Red Cross Society Himeji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Iichiro</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Surgery, Japanese Red Cross Society Himeji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Naoi</LastName>
        <Affiliation>Department of Otolaryngology Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizuo</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Otolaryngology Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/67549</ArticleId>
    </ArticleIdList>
    <Abstract>No previous study has published magnetic resonance imaging (MRI) findings for a subglottic pleomorphic adenoma. Here, we describe the case of a 62-year-old man with a subglottic pleomorphic adenoma. Endoscopic findings revealed a smooth-surfaced tumor arising from the subglottic posterior wall. MRI revealed the lesion as an isointense region on T1-weighted images, which was homogeneously enhanced. This lesion showed a heterogeneously hyperintense region on T2-weighted images. Diffusion-weighted imaging (DWI) showed slightly high intensity in the same area, with a normal or only slightly high apparent diffusion coefficient (ADC). Laryngomicrosurgery was performed for transoral excision of the subglottic tumor, resulting in a postsurgical diagnosis of pleomorphic adenoma.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">subglottis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pleomorphic adenoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MRI</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transoral surgery</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2577-171X</Issn>
      <Volume>6</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2023</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A case of mucosal-associated lymphoid tissue lymphoma of the urachus</ArticleTitle>
    <FirstPage LZero="delete">253</FirstPage>
    <LastPage>256</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazuma</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Haisa</LastName>
        <Affiliation>Department of Urology, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Kajihara</LastName>
        <Affiliation>Department of Urology, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuji</FirstName>
        <LastName>Tsugawa</LastName>
        <Affiliation>Department of Urology, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Urology, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Sako</LastName>
        <Affiliation>Department of Urology, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Murao</LastName>
        <Affiliation>Department of Urology, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Ebara</LastName>
        <Affiliation>Department of Urology, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Urachus carcinoma is a rare malignancy with an aggressive potential and a poor prognosis, and evidence is limited for its diagnosis and treatment.&lt;br&gt;
Case presentation: A 75-year-old man underwent fluorodeoxyglucose positron emission tomography/computed tomography for staging prostate cancer, and a mass (standardized uptake value max 9.5) was observed on the outside of the urinary bladder dome. T2-weighted magnetic resonance imaging showed the urachus and a low-intensity tumor, which suggested a malignant tumor. We suspected urachal carcinoma and performed total resection of the urachus and partial cystectomy. Pathological examination revealed mucosa-associated lymphoid tissue lymphoma with cells positive for CD20 and negative for CD3, CD5, and cyclin D1. After the surgery, no recurrence has been observed for more than 2 years.&lt;br&gt;
Conclusion: We encountered an extremely rare case of mucosa-associated lymphoid tissue lymphoma of the urachus. Surgical resection of the tumor provided an accurate diagnosis and good disease control.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bladder cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">malignant lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MALT lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">urachal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">urachal remnant</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Nature Portfolio</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>14</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Training high-performance deep learning classifier for diagnosis in oral cytology using diverse annotations</ArticleTitle>
    <FirstPage LZero="delete">17591</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Sukegawa</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Futa</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Electrical, Electronic and Computer Engineering, Faculty of Engineering, Gifu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Department of Electrical, Electronic and Computer Engineering, Faculty of Engineering, Gifu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takanaga</FirstName>
        <LastName>Ochiai</LastName>
        <Affiliation>Division of Oral Pathogenesis and Disease Control, Department of Oral Pathology, Asahi University School of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsumitsu</FirstName>
        <LastName>Shimada</LastName>
        <Affiliation>Department of Oral Pathology, Graduate School of Oral Medicine, Matsumoto Dental University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Electrical, Electronic and Computer Engineering, Faculty of Engineering, Gifu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Taki</LastName>
        <Affiliation>Department of Electrical, Electronic and Computer Engineering, Faculty of Engineering, Gifu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumi</FirstName>
        <LastName>Nakai</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kagawa University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakai</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kagawa University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Ishihama</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kagawa University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Miyazaki</LastName>
        <Affiliation>Stony Brook Cancer Center, Stony Brook University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Department of Oral Pathology, Graduate School of Oral Medicine, Matsumoto Dental University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minoru</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kagawa University Faculty of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The uncertainty of true labels in medical images hinders diagnosis owing to the variability across professionals when applying deep learning models. We used deep learning to obtain an optimal convolutional neural network (CNN) by adequately annotating data for oral exfoliative cytology considering labels from multiple oral pathologists. Six whole-slide images were processed using QuPath for segmenting them into tiles. The images were labeled by three oral pathologists, resulting in 14,535 images with the corresponding pathologists' annotations. Data from three pathologists who provided the same diagnosis were labeled as ground truth (GT) and used for testing. We investigated six models trained using the annotations of (1) pathologist A, (2) pathologist B, (3) pathologist C, (4) GT, (5) majority voting, and (6) a probabilistic model. We divided the test by cross-validation per slide dataset and examined the classification performance of the CNN with a ResNet50 baseline. Statistical evaluation was performed repeatedly and independently using every slide 10 times as test data. For the area under the curve, three cases showed the highest values (0.861, 0.955, and 0.991) for the probabilistic model. Regarding accuracy, two cases showed the highest values (0.988 and 0.967). For the models using the pathologists and GT annotations, many slides showed very low accuracy and large variations across tests. Hence, the classifier trained with probabilistic labels provided the optimal CNN for oral exfoliative cytology considering diagnoses from multiple pathologists. These results may lead to trusted medical artificial intelligence solutions that reflect diverse diagnoses of various professionals.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Deep learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oral cytology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Classification</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Convolutional neural network</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Probabilistic labeling</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1471-2415</Issn>
      <Volume>24</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pathological findings in enucleated eyes of patients with neurofibromatosis type 1: report of a case with 15-year follow-up and review of 14 patients in the literature</ArticleTitle>
    <FirstPage LZero="delete">341</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaya</FirstName>
        <LastName>Seno</LastName>
        <Affiliation>Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeki</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Neurological Surgery, General Medical Center, Kawasaki Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Backgrounds Iris nodules are frequently noted as clinical manifestations of neurofibromatosis type 1 but the other intraocular manifestations are rare. The purpose of this study is to present a patient with a phthisic eye who underwent enucleation for a cosmetic reason after 15-year follow-up and also to review 14 patients with enucleation described in the literature.&lt;br&gt;
Case presentation A 17-year-old man with neurofibromatosis type 1 from infancy underwent the enucleation of phthisic left eye and also had the resection of eyelid subcutaneous mass lesions on the left side for a cosmetic reason. He had undergone four-time preceding surgeries for eyelid and orbital mass reduction on the left side in childhood and had developed total retinal detachment 10 years previously. Pathologically, the enucleated eye showed massive retinal gliosis positive for both S-100 and glial fibrillary acidic protein (GFAP) in the area with involvement of the detached retinal neuronal layer, together with a more fibrotic lesion along the choroid which were, in contrast, negative for both S-100 and GFAP. The choroid, ciliary body, and iris did not show apparent neurofibroma while episcleral neurofibroma was present.&lt;br&gt;
Literature review In review of enucleated eyes of 14 patients in the literature, buphthalmic eyes with early-onset glaucoma on the unilateral side was clinically diagnosed in 9 patients who frequently showed varying extent of hemifacial neurofibromatosis which involved the eyelid and orbit on the same side. Pathologically, neurofibromas in varying extent were found in the choroid of 12 patients. One patient showed choroidal malignant melanoma on the left side and fusiform enlargement of the optic nerve on the right side suspected of optic nerve glioma. The phthisic eye in another patient showed massive retinal gliosis similar to the present patient.&lt;br&gt;
Conclusions In summary of the 15 patients with neurofibromatosis type 1, including the present patient, buphthalmic or phthisic eyes with no vision were enucleated for cosmetic reasons and showed choroidal neurofibroma in most patients and massive retinal gliosis in two patients including the present patient.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Neurofibromatosis type 1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Enucleation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Eye</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pathology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Massive retinal gliosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Choroidal neurofibroma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Phthisis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Buphthalmos</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Malignant melanoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cosmetic surgery</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elmer Press, Inc.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1923-4155</Issn>
      <Volume>15</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Anterior Uveitis After Discontinuation of Janus Kinase Inhibitor, Ruxolitinib</ArticleTitle>
    <FirstPage LZero="delete">208</FirstPage>
    <LastPage>214</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoto</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Internal Medicine, Kaneda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasumasa</FirstName>
        <LastName>Monobe</LastName>
        <Affiliation>Department of Pathology, General Medical Center, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Primary myelofibrosis shows widespread fibrosis in the bone marrow and is part of myeloproliferative neoplasms in which gene mutations in hematopoietic stem cells lead to abnormal clonal expansion of one or more lineage of myeloid and erythroid cells and megakaryocytes. Janus kinase (JAK) inhibitors are the main therapeutic regimen for primary myelofibrosis which harbors gene mutations, resulting in continuous activation of JAK-STAT signaling pathway. Since JAK inhibitors modulate immunological state, the administration would have a potential for uveitis. A 67-year-old patient presented with weight loss of 10 kg in the past 2 years after his retirement. He showed normocytic anemia with anisocytosis and abnormal shape, as well as hepatosplenomegaly. Suspected of hematological malignancy, bone marrow biopsy led to the diagnosis of primary myelofibrosis (grade 2) with bizarre megakaryocytes and relative maintenance of myeloid and erythroid lineage. He started to have blood transfusion. Genomic DNA analysis of the peripheral blood showed a pathogenic variant in the exon 9 of calreticulin (CALR) gene while pathogenic variants in Janus kinase-2 (JAK2), and myeloproliferative leukemia virus oncogene (MPL) were absent. He began to have oral ruxolitinib 10 mg daily at the timepoint of 5 months after the initial visit and the dose was increased to 20 mg daily 8 months later but was discontinued further 4 months later because he showed the limited effect of ruxolitinib. He had blood transfusion every week or every 2 weeks in the following 2 months until he noticed blurred vision in the right eye. The right eye showed thick fibrin membrane formation in the anterior chamber in front of the pupil which prevented the fundus from visualization. The left eye showed no inflammation and optic nerve atrophy, sequel to tuberculous meningitis in childhood. The patient started to use 0.1% betamethasone six times daily and 1% atropine once daily as eye drops. A week later, fibrin membrane disappeared and the pupillary area with total iris posterior synechia was visible in the right eye. He regained the vision in the right eye and did not show relapse of uveitis only with topical 0.1% betamethasone. Uveitis might be related with the administration and discontinuation of ruxolitinib.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Janus kinase inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Ruxolitinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Anemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Myelofibrosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Anterior uveitis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2397-9070</Issn>
      <Volume>8</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Rare case of rectal carcinoid with synchronous primary carcinoid tumors of the lung misdiagnosed as lung metastases</ArticleTitle>
    <FirstPage LZero="delete">e70003</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rhohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A 68-year-old woman was referred to our hospital for rectal surgery after a pathological diagnosis of rectal carcinoid with venous invasion following endoscopic submucosal dissection of a 5 mm-sized submucosal tumor in the lower rectum. Chest CT showed nodules in the left upper lobe and right lower lobe, but positron emission tomography and somatostatin receptor scintigraphy showed no hyperaccumulation in the lung nodules. CT-guided needle biopsy was performed on the nodular lesion in the left upper lobe, which showed focal growth of tumor cells with a high N/C ratio and positive synaptophysin, leading to a diagnosis of pulmonary metastasis of rectal carcinoid. Since the patient was asymptomatic and did not wish to undergo surgery or chemotherapy, she was followed up strictly with sufficient informed consent. Three years have passed since the diagnosis, and there is no tendency for the lung metastasis to increase, and no other new lesions have been observed. The disease had not progressed and remained stable. Therefore, immunohistological analysis of the lung biopsy specimen was performed again, which was positive for TTF-1 and negative for CDX2. Consequently, the diagnosis was changed to primary lung carcinoid tumors, and the patient remains under follow-up with no disease progression.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">lung metastases</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neuroendocrine tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rectal carcinoid</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6694</Issn>
      <Volume>16</Volume>
      <Issue>13</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficacy of Cisplatin-CXCR4 Antagonist Combination Therapy in Oral Cancer</ArticleTitle>
    <FirstPage LZero="delete">2326</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Saori</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Preliminary Examination Room, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yamin</FirstName>
        <LastName>Soe</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Htoo Shwe</FirstName>
        <LastName>Eain</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Sanou</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyofumi</FirstName>
        <LastName>Takabatake</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Takeshita</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miki</FirstName>
        <LastName>Hisatomi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Asaumi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Yanagi</LastName>
        <Affiliation>Preliminary Examination Room, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cisplatin is a platinum-based compound that is widely used for treating inoperable oral squamous cell carcinoma (OSCC) in Japan; however, resistance to cisplatin presents a challenge and innovative approaches are required. We aimed to investigate the therapeutic potential of targeting the chemokine receptor CXCR4, which is involved in angiogenesis and tumor progression, using the CXCR4 inhibitor AMD3100, in combination with cisplatin. AMD3100 induced necrosis and bleeding in OSCC xenografts by inhibiting angiogenesis. We investigated the combined ability of AMD3100 plus cisplatin to enhance the antitumor effect in cisplatin-resistant OSCC. An MTS assay identified HSC-2 cells as cisplatin-resistant cells in vitro. Mice treated with the cisplatin-AMD combination exhibited the most significant reduction in tumor volume, accompanied by extensive hemorrhage and necrosis. Histological examination indicated thin and short tumor vessels in the AMD and cisplatin–AMD groups. These results indicated that cisplatin and AMD3100 had synergistic antitumor effects, highlighting their potential for vascular therapy of refractory OSCC. Antitumor vascular therapy using cisplatin combined with a CXCR4 inhibitor provides a novel strategy for addressing cisplatin-resistant OSCC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">oral squamous cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CXCR4</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cisplatin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antitumor vascular therapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
</ArticleSet>
